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Missing data are common in longitudinal clinical trials.  Rubin described three different missing 
data mechanisms based on the level of dependence between the missing data process and the 
measurement process.  These are missing completely at random (MCAR), missing at random 
(MAR) and missing not at random (MNAR).  Data are MCAR when the probability of dropout 
is independent of both observed and unobserved data.  Data are MAR when the probability of 
data being missing does not depend on the unobserved data, conditional on the observed data.  
When neither MCAR nor MAR is valid, data are MNAR. 
 
The aim of this thesis is to discuss statistical methodology required for analysing missing 
outcome data and provide valid statistical methods for the MAR, MCAR and MNAR scenarios.  
This thesis does not focus on data analysis where covariate data are missing.  Under MCAR 
complete and available case analyses are valid.  When data are MAR multiple imputation, 
likelihood-based models, inverse probability weighting and Bayesian models are valid.  When 
data are MNAR pattern-mixture, selection and shared-parameter models are valid.  These 
methods are illustrated by an in depth analysis of two data sets with missing data. 
 
The first data set is the SAPiT trial an open label, randomised controlled trial in HIV-
tuberculosis co-infected patients.  Patients were randomised to three arms; each initiating 
antiretroviral therapy at a different time.  CD4+ count, an indication of HIV progression, was 
measured at baseline and every 6 months for 24 months.  The primary question was whether 
CD4+ count trajectory over time differed for the three treatment arms.  The assumption that 
missing data are MCAR was not supported by the observed data.  We performed a range of 
sensitivity analyses under both MAR and MNAR assumptions.   
 
The second data set is a placebo-controlled, randomised clinical trial conducted for 8 weeks to 
determine the effectiveness of hypericum or sertraline in reducing depression, measured by the 
Hamilton depression scale.  The trial randomised 340 participants, with 28% lost to follow-up 
before Week 8.  We performed a sensitivity analysis under different assumptions about the 
missing data process.  The missing data mechanism was not MCAR.  Under MAR assumptions, 
some of the sensitivity analyses found no difference between either of the treatment arms and 
placebo, while some found a significant difference between sertraline and placebo, but not 
between hypericum and placebo.  This re-analysis contributed to the literature around the 
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The statistical analysis of longitudinal data in a clinical trial often has the unavoidable problem of 
missing data.  This poses the question of how one should deal with the missing data in the 
statistical analysis.  It is vital to apply a correct statistical analysis that deals with the missing data 
to arrive at reliable and unbiased conclusions. This thesis discusses methods of dealing with 
missing data and provides an in-depth analysis of two longitudinal data sets which have missing 
data.  In the following paragraph the specific aims of the thesis are set out.   
1.1 Aim of the thesis 
The aim of this thesis is to show how available missing data methods can be used in an appropriate 
statistical analysis of a real life clinical trial, with missing data.  We will show how statistical 
methodology can be used to analyse missing outcome data and provide valid statistical methods for 
missing completely at random (MCAR), missing at random (MAR) and missing not at random 
(MNAR) scenarios.  This thesis does not focus on scenarios where covariate data are missing, but 
rather on the analysis when outcome data are missing.   
 
Missing data is a vast topic in statistics.  It is not possible to describe every method that could be 
used in the analysis of missing data.  There are valid methods that are not discussed in this thesis, 
for example propensity scores (Horton and Kleinman, 2007) and instrumental variables.  The 
intention is to discuss some of the most useful methods that could be applied in mainstream 
statistical analysis using standard statistical software.   
 
      Chapter 1 
2 
  
This thesis gives a broad overview of missing data methods, with a more in depth focus on pattern-
mixture models.  Frequentist, likelihood and Bayesian methods are used.  The methodology for 
calculating the variance of estimates when combining estimates from pattern-mixture models will 
be extended to include the case where there are three or four patterns of missing data using the 
delta method (Section 3.3.2.1).  This methodology has been published for two categories, and this 
thesis includes the extension to three and four categories, which follows directly from the two 
category case.  These derivations form a new contribution to the application of well-known theory 
related to the calculation of the variance of the parameter estimates in pattern-mixture models, 
using the delta method.  
 
The thesis contributes to promoting good practice in two ways.  It tries to discourage the use of 
suboptimal methodology and promotes the use of appropriate methodology and emphasises proper 
sensitivity analysis.  
 
Throughout the thesis all statistical analyses are done using SAS, with the exception of the 
Bayesian analyses that were done using OpenBUGS.  A further aim of the thesis is to show that 
appropriate statistical methodology can be applied using standard statistical software.  Most of the 
statistical methods used can also be applied in many other software packages, such as STATA, R, 
MLwiN and SPSS.  The objective of the thesis is not to list all statistical software that can be used 
or to contrast implementation using different software packages, but to show that it can be done in 
one of these.  SAS is used for the analysis in this study because it is still regarded as the industry 
standard in clinical trial data analysis and is widely used.  SAS can also fit Bayesian models, but 
OpenBUGS was used to fit the Bayesian models, since it is regarded as the standard software for 
Bayesian analysis.   
 
This is a thesis in the field of applied statistics.  The statistical methods used in the thesis are not 
new or original and have been developed previously by other authors.  The original contribution of 
the thesis lies in showing that these methods can be applied validly in the analysis of a clinical trial 
using standard statistical software.  In addition, the sensitivity analysis juxtaposing several methods 
is a unique application to the two data sets presented.  In the analysis in Chapter 6 the application 
of correct methods when data are incomplete leads to a different conclusion than what was 
previously found with methods that did not take missing data into account.  This leads to a different 
conclusion about the effectiveness of St John’s Wort from the conclusion previously published.  





The application of the theory to both data sets is made more complicated by the fact that there are 
three treatment arms.  Most applications in the literature only discuss the two arm case.  This thesis 
also shows how some problems unique to this application that are not addressed in methodological 
discussions can be addressed.  For example, the application of the delta method in Section 3.3.2.1 
was done in detail because only the application for two dropout categories was available in the 
literature.   
 
This thesis focuses on continuous, normally distributed outcome data only.  The challenges raised 
by missing data are similar for categorical and non-normal data.  The mathematics and some 
implementations differ and as such this was regarded to be outside the scope of this thesis.   
 
1.2 What is a clinical trial? 
A clinical trial is a prospective study comparing the effect and value of an intervention against a 
control in humans.  Each participant is followed forward from a well-defined point, which is called 
baseline.  The participants are directly observed and an intervention is applied to all participants in 
a standardised manner.  A clinical trial includes a control group, which does not receive the 
intervention against which the intervention group is compared.  The investigator does not have 
control over what each individual participant actually does.  The investigator can only encourage 
participants to follow certain procedures.  Since it may be impossible to have pure intervention and 
control groups in the presence of everything people choose to do, an investigator may only be able 
to compare intervention strategies (Friedman, Furberg, & DeMets, 1998). 
 
The ideal clinical trial is randomised and double blinded.  Randomisation is the process by which 
each participant has the same chance of being assigned to either intervention or control.  Chance 
underlies the allocation process.  Neither the participant, nor the investigator, should know what the 
assignment will be at the time the participant decides to enter the study.  Randomisation is the best 
method for achieving comparability between treatment arms and is the basis for statistical inference 
(Friedman et al., 1998). 
 
Double-blinding means that the investigator and participant are blinded, or masked, to the identity 
of the assigned intervention.  Several other aspects of a trial can also be blinded, namely the 
assessment, classification and evaluation of response variables.  The goal of blinding is to prevent 
bias during the data collection process (Friedman et al., 1998). 
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1.3 What are missing data? 
In a trial context missing data are data that was intended to be collected, but were not collected.  
There are different causes for missing data and different amounts of missing data.  Some causes of 
missing data are by design and some are by chance (Horton & Kleinman, 2007).  Some sources of 
missing data affect all data for a specific participant, other sources affect specific items only 
(Committee for medicinal products for human use, [CHMP], 2010).  For example, a specific 
reading could be missing because a machine broke or a specimen got lost or all data for a particular 
visit could be missing because the participant did not attend the visit (Carpenter & Kenward, 2007).  
Some variables are not collected on all participants and some participants may decline to provide 
some information (Horton & Kleinman, 2007). 
 
Two occurrences of missing data can be distinguished: 
1. Intermittent missing data: A participant missed one visit, but attended at least one 
subsequent follow-up visit. 
2. Withdrawal (also called dropout):  A participant had no further visits after a certain time 
point (Carpenter & Kenward, 2007).  This could happen because the participant refused to 
continue further in the study (CHMP, 2010). 
 
Dropouts in a clinical trial may be for treatment related reasons, for example a participant dropping 
out because of intolerability of the treatment or due to a lack of a drug effect (National Research 
Council, 2010).  Dropout can also be unrelated to treatment.  This can be caused by the participant 
moving away or if the participant developed an unrelated illness that required stopping the study 
treatment (Gould, 1980).  Dropout can lead to bias in the analysis of a clinical trial if the 
participants who dropped out are systematically different from those who did not (Hogan, Roy, & 
Korkontzelou, 2004).   
1.4 Why missing data matters 
Interpretation of the results of a trial is problematic when the number of missing values is 
substantial (CHMP, 2010).  Bias is one of the main concerns in a clinical trial.  Bias can be defined 
as systematic error or the difference between the true value and the value obtained in the trial, due 
to causes other than sampling error (Friedman et al., 1998).  Missing data are a potential source of 
bias when analysing clinical trials, and this bias is the most important concern resulting from 
missing data.  If participants are excluded, this may influence the comparability of the treatment 
groups or the representativeness of the study sample in relation to the target population.  Both of 




An example of this is where patients who were performing less well on the treatment tended to 
drop out of the study more than patients who performed better on the treatment.  A complete case 
estimation of the trial outcome would then provide a significant overestimate of the true 
performance of the original patients in the trial, because only the patients with favourable clinical 
outcome remained in the trial.   
 
The risk of bias in the estimation of the treatment effect from the observed data depends on the 
relationship between missingness, treatment arm and outcome.  Missing values are not expected to 
lead to bias if they are not related to the real value of the unobserved measurement, for example 
when poor outcomes are no more likely to be missing than good outcomes.  This is illustrated in 
the causal diagram in A) of Figure 1.1.  If the missing observation is related to the real value of the 
outcome (for example poor outcomes are less likely to be observed than good outcomes), this leads 
to bias even if the missing values are not related to treatment (CHMP, 2010).  This situation is 
illustrated in B) of Figure 1.1.  Missing values lead to bias if they are related to both the treatment 
arm and the unobserved outcome variable.  This is pictured in C) in Figure 1.1.   In this case 
missing values could be more likely in one treatment arm, if participants withdrew from the one 
arm since the treatment was not effective (CHMP, 2010).  In Figure 1.1, A) does not lead to bias 
because of missing data, whereas both B) and C) can lead to bias. 
 
A) 












E                                   D 
 
R 
E:  Treatment arm, D: Outcome variable, R:  An indicator of whether or not data are missing 
Arrows indicate a relationship between variables, whereas dotted lines indicate no relationship 
Figure 1.1:  Causal diagrams showing the relationship between treatment arm, 




Several authors test whether missing values are related to treatment by checking whether missing 
values are equally likely in all treatment arms.  Imbalance in participant withdrawal by intervention 
arm is not itself a problem, but could be a possible indicator of other problems (Carpenter & 
Kenward, 2007).  Dropout can differ among treatment groups without invalidating the analysis, if 
the dropout is not related to the outcome.  This is illustrated in D) in Figure 1.1. 
 
It is often difficult to determine whether any relationship between missing values and the 
unobserved outcome is absent (CHMP, 2010).  It is therefore not always possible to know from the 
collected data whether the outcome would be biased. 
 
The extent to which missing data bias results is influenced by many factors.  These include the 
relationship between missingness, treatment assignment and outcome; the type of measure 
employed to quantify the treatment effect and the expected direction of changes over time for 
participants in the trial.  The strategy employed to handle missing values might in itself provide a 
source of bias (CHMP, 2010). 
 
Missing data lead to a loss in precision, even if the data are missing in such a way that conclusions 
are valid, since less data are available to use to make decisions (Carpenter & Kenward, 2007).  
Missing data imply a smaller sample size.  The greater the number of missing values the greater the 
likely reduction in power (CHMP, 2010).   
 
Non-completers may be more likely to have extreme values (either because a very good response 
or a very bad response might lead to loss to follow-up).  The exclusion of the non-completers could 
lead to an underestimate of the variability in the data because participants who remain are often 
more similar and thus artificially narrow the confidence interval for estimation of the treatment 
effect (Carpenter & Kenward, 2007; CHMP, 2010).  Missing data may thus potentially alter 
conclusions.   
 
To draw proper inferences from the trial, dropouts should be included correctly in the analysis.  
The way in which dropouts, especially treatment related dropouts, are included in the analysis can 
influence the conclusions drawn from the trial dramatically (Gould, 1980).  It is important to know 
whether these conclusions are sensitive to the missingness mechanism; as this determines how 
valid the conclusions of the trial are (Carpenter & Kenward, 2007). 
 
The International Conference on Harmonisation of Technical Requirements for Registration of 




“Missing values represent a potential source of bias in a clinical trial.  Hence, every effort 
should be undertaken to fulfil all the requirements of the protocol concerning the collection 
and management of data.  In reality, however, there will almost always be some missing data.  
A trial may be regarded as valid, none the less, provided the methods of dealing with missing 
values are sensible, and particularly if those methods are predefined in the protocol.  
Definition of methods may be refined by updating this aspect in the statistical analysis plan 
during the blind review.  Unfortunately, no universally applicable methods of handling 
missing values can be recommended.  An investigation should be made concerning the 
sensitivity of the results of analysis to the method of handling missing values, especially if the 
number of missing values is substantial.”  (ICH E9 Expert Working Group, 1999) 
 
Analysing missing data correctly versus just dropping it from the analysis increases efficiency and 
decreases bias (Horton & Kleinman, 2007).  Increasingly the importance of considering missing 
data is being acknowledged (CHMP, 2010). 
1.5 Intent to treat (ITT) analysis 
The definition of an ITT analysis is that all participants are analysed as randomised, in the groups 
they were randomised to, whether or not these participants completed the study according to 
protocol or adhered to the treatment they were randomised to.  The E9 guidelines (ICH E9 Expert 
Working Group, 1999) define the ITT population as “The set of participants that is as close as 
possible to the ideal implied by the intention-to-treat principle.  It is derived from the set of all 
randomised participants by minimal and justified elimination of participants.”  The ITT analysis 
has two principles.  The first is that all participants randomised to a treatment arm are included in 
the analysis, even if they drop out, and the second is that participants are analysed according to the 
treatment they were randomised to, and not according to the treatment they actually received (Little 
& Yau, 1996).  The principal advantage of the ITT analysis is that it avoids the selection bias 
introduced by the non-random losses of participants or when participants take a different treatment 
than the one assigned to them and thus preserves the randomisation, providing a basis for a valid 
inference (ICH E9 Expert Working Group, 1999; Little & Yau, 1996).  This is stated by Fleming 
(2011) as “In order to preserve the integrity of randomization, all patients should be followed until 
the complete capture of trial outcomes, even after patients have discontinued randomized treatment 
or initiated other interventions.”  In order to do an ITT analysis as intended, complete follow-up of 
all participants is needed (ICH E9 Expert Working Group, 1999).   
 
The ITT analysis estimates the benefits of a treatment policy relative to control and reflects the 
effectiveness of the treatment policy for the population.  This observed estimate includes the effect 
of the treatment assigned and changes to this treatment over time (National Research Council, 
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2010).  An ITT analysis that includes time off treatment in the analysis evaluates the entire 
intervention, including auxiliary care provided and rescue therapy offered.  It is argued that this is 
most relevant in answering the question about the real life effect of the intervention should it 
become policy (Fleming, 2011).  The ITT analysis asks one specific question, while a patient 
taking his medicine might want to know what the on-treatment efficacy of a treatment is, not just 
the ITT efficacy (Keene, 2011).   
 
With no missing data the ITT analysis includes every participant who was randomised, regardless 
of adherence to the protocol, to estimate the effect of intending to give an intervention.  Thus if 
participants are followed up after they cease to adhere to the intervention protocol, the data needed 
for an ITT analysis is available (Carpenter & Kenward, 2007). 
 
Participants who are lost to follow-up create special problems in the ITT analysis, since potentially 
incomplete profiles would need to be analysed as randomised.  The target estimand of the ITT 
analysis is the as randomised analysis of the hypothetical complete data, if outcomes were available 
for the participants who dropped out (Little & Yau, 1996).  Failure to include these participants in 
the analysis may seriously undermine the ITT approach.  The E9 guidelines mention that 
imputation techniques can be used to compensate for missing data.  The E9 guidelines were written 
long ago before missing data theory was well developed.  The guidelines state:  “Other methods 
employed to ensure the availability of measurements of primary variables for every subject in the 
full analysis set may require some assumptions about the subjects' outcomes or a simpler choice of 
outcome (for example, success/failure).” (ICH E9 Expert Working Group, 1999). 
 
The requirement for an ITT analysis implies that the data analyst needs a response from each 
randomised participant in order to include each randomised participant in the analysis.  The ITT 
analysis intends to analyse the outcome for everyone who entered the trial, even if they do not have 
complete data.  This interpretation of the ITT analysis makes missing data a particularly 
troublesome issue in clinical trials.  The analyst cannot ignore the missing data if he or she wants to 
follow the requirement of an ITT analysis.  
 
In practice, a simplistic imputation method, last observation carried forward (LOCF) is often seen 
as a solution to this problem.  When implementing LOCF every missing value for a participant is 
replaced by the last observation observed before the missing value.  However, several publications 
highlight the problems with LOCF as an analysis technique and this is not regarded as a feasible 
alternative in analysing missing data (Carpenter et al., 2004; Mallinckrodt, Clark, & David, 2001; 
Molenberghs & Kenward, 2007; Molenberghs et al., 2004).  LOCF might inflate the Type I error 
and creates bias in the estimation of mean change from baseline while creating standard errors that 
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are too small (Mallinckrodt et al., 2001).  LOCF has also been shown to force the missing data 
mechanism to be future dependent (Kenward & Molenberghs, 2009).   
 
Missing data also violate the strict ITT principle which requires measurement of all participant 
outcomes regardless of protocol adherence (CHMP, 2010).  With incomplete data there is no 
unequivocal ITT analysis (Carpenter & Kenward, 2007).  Various analyses are possible, as 
discussed later. 
 
1.6 Missing data and per protocol analysis 
The per protocol population is a subset of the ITT population and includes those participants who 
were more compliant to the protocol; patients who completed a pre-specified minimal exposure to 
the treatment regimen (for example, received 80% of all doses), have the primary endpoint variable 
available and have no major protocol violations.  The per protocol analysis maximises the 
opportunity for a new treatment to show efficacy in the analysis.  It also most closely reflects the 
scientific model underlying the protocol.  It is possible that a per protocol analysis could be biased, 
and this is seldom regarded as the primary analysis of a trial (ICH E9 Expert Working Group, 
1999).   
 
In a per protocol analysis non-adherers to the protocol are simply eliminated (Rothman, Greenland, 
& Lash, 2008).  The per protocol analysis regards a participant’s data as effectively missing from 
the time the participant ceased to adhere to the protocol.  The per protocol analysis thus does not 
maintain the comparability of treatment groups that should have been guaranteed by randomisation, 
because it excludes randomly assigned participants on the basis of outcomes after baseline.  The 
answer provided by the per protocol analysis is not applicable to the entire set of eligible patients 
and not interpretable in real life settings (Fleming, 2011).  A per protocol analysis could be 
excluding participants because they do badly on the regimen, since participants doing badly on a 
regimen are more likely to discontinue the regimen and not completing the full treatment regimen, 
thus biasing the results (Keene, 2011).   
 
An “as treated” analysis is defined as a subset of the per protocol analysis, where only participants 
who adhered to the intervention are included (Hulley et al., 2007).  This analysis is based on the 
actual treatment received, rather than the treatment randomised to.  This is subject to bias from 
factors that influence whether a participant in the study adheres to treatment.  One such factor 
could be the treatment itself; since certain treatments might be easier or harder to adhere to than 




Because of the different hypotheses underlying per protocol and ITT analyses, it is not a surprise 
that there will be a difference in the way missing data are handled.  There must be a difference 
between the conditional distributions of the missing data given the observed when addressing the 
ITT and per protocol hypotheses (Carpenter & Kenward, 2007). 
1.7 What is the correct analysis in the face of missing data? 
Before modelling the data it is important for the statistician to take the time, together with the 
investigators, to understand why observations might be missing, using the data (Carpenter & 
Kenward, 2007).  Any data analysis should start with a critical discussion of the number, timing, 
pattern, reason for and implications of missing values.  There is no universally applicable method 
of handling missing values and different approaches may lead to different results (CHMP, 2010).   
 
The CHMP report emphasizes that when proposing a method to handle missing data it is important 
that an analysis is provided which does not have a bias favouring the experimental treatment, this, 
in their words, is a conservative analysis.  This is the main justification they require for selecting a 
particular method.  They do not consider the properties of the method under particular assumptions, 
only whether it provides a conservative estimate of the efficacy of the experimental treatment 
(CHMP, 2010). 
 
This primary focus of the CHMP report is not helpful in many instances.  The document is written 
as a guideline in drug development and drug licensing and in that context the requirement for a 
conservative approach is easy to implement.  Drug manufacturers have a motivation to get new 
drugs on the market and it protects the public to require that drugs can only be shown superior in a 
conservative analysis.  If effectiveness can be shown in the presence of bias against the drug, the 
licensing authority can be certain that the drug is even more effective than claimed by the drug 
manufacturer.  A biased, conservative analysis might also lead to an effective drug not being 
licensed, which is also not in the best interest of the public.  However, many other settings do not 
have such a clear experimental arm against which a conservative analysis should be applied.  For 
example, in public health research, where governments are looking for the best possible treatment 
protocol to implement in state hospitals it is not clear whether a conservative bias would be more 
prudent.  In cost effectiveness analysis of medications already registered, it is also not clear in 
which direction one wants conservative bias to be applied, since there is no clear ‘active’ arm that 
should not be advantaged by any bias.   
 
Trying to perform a conservative analysis is not the solution to analysing missing data.  In the first 
place, it can be argued that a conservative analysis might do as much harm as a liberal analysis by 
keeping an effective treatment from being adopted.  Rather, one should apply an analysis that is 
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valid, neither conservative nor liberal.  Whether an analysis is valid, depends on the assumptions 
one is willing to make regarding the missing data mechanism.  Keene (2011) also argued that it is 
important to aim for the most relevant approach, the one that answers the question you are asking, 
not for the most conservative approach.   
 
There is no universal statistical method to use when data are missing, but there are universal 
principles which apply to every situation.  With missing data extra assumptions are required.  
These assumptions specify the mechanism by which the data became missing and highlights 
differences in the distribution of the data between participants who did and did not complete the 
trial.  It is also necessary to show that the inferences about the intervention are robust to different 
assumptions about the reason for missing data (Carpenter & Kenward, 2007). 
 
Principles for handling missing data highlighted by the panel on handling missing data in clinical 
trials (National Research Council, 2010) are: 
1. Minimise the occurrence of missing data through proper screening of participants, good 
trial conduct and data collection efforts. 
2. A missing value hides a true underlying value.  This true underlying value is important for 
analysis. 
3. Reasons for missing data should be documented, since these reasons can inform the 
assumptions about the missing data mechanism.   
4. The missing data mechanism needs to be assumed and this assumption should be 
transparent. 
5. A statistically valid analysis should be done under the missing data assumption.  This 
analysis should account for sampling variability and uncertainty associated with missing 
observations. 
6. A sensitivity analysis should be done to test the robustness of the analysis.   
1.8 How much missing data are acceptable? 
It is often assumed that the amount of missing data determines whether missing data are biasing 
results.  However, there is no universal rule regarding the maximum number of missing values that 
could be acceptable.  The nature of the outcome variable determines the absolute number of 
missing values.  If the outcome variable is mortality, less missing data are expected than if the 
outcome is difficult to measure.  The length of the trial also determines the amount of missing data.  
The longer the trial the more missing data are to be expected (CHMP, 2010). 
 
It is not only the amount of missing data that determines whether missing data bias results, 
although more missing data certainly raises more suspicion of possible bias than few missing data 
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points.  Rather it is determined by the question, information in the observed data and the reason for 
the missing data.  Context determines whether error will be induced by the missing data.  If an 
event is rare then missing data on few participants can alter the estimated event rates dramatically.  
If the proportion of participants withdrawing varies by intervention arm, estimated intervention 
effects are more likely to be affected than if participants withdraw independently of treatment arm.  
Even if no bias is introduced by missing data, missing data certainly leads to efficiency loss 
(Carpenter & Kenward, 2007).  The anticipated effect size in the study and the likelihood that a 
sensitivity analysis would confirm the findings of the trial also influences the amount of missing 
data that would be deemed acceptable (National Research Council, 2010).   
 
In Chapter 2 we discuss under what circumstances missing data can lead to bias (Carpenter & 
Kenward, 2007).   
1.9 How missing data are currently handled 
Burton and Altman (2004) did a review of the use of missing data methods in 100 cancer 
prognostic studies published in 2002.  Of these 81 had missing data and 32 stated how the missing 
data were analysed; 12 used complete case approach, 23 available case, 6 omitted variables, 4 used 
a missing indicator approach, 3 used ad hoc imputation procedures and one used multiple 
imputation.  They found that missing data were generally handled inadequately and included some 
guidelines for the handling of missing data in their paper.  These included: 
• Description of the completeness of data.  The number of cases with missing data should be 
stated.  The frequency of missingness should be given for every variable.  
• Sufficient detail should be provided on the missing data analysis methods used.   
• Any imputation method used should be referenced.   
• For each analysis the number of cases included should be given.   
• Missing data should also be explored by giving the known reasons for missingness and 
comparing the characteristics of cases with and without missing data. 
 
A review by Wood et al. (2004) showed that the description of missing data and the methods used 
are inadequate.  Horton and Switzer (2005) reviewed 311 papers published between 2004 and 2005 
in the New England Journal of Medicine, only 26 (8%) reported missing data methods.  This means 
there is a disjoint between the theoretical statistical methods available and the practical 
implementation of these methods in applied settings.   
 
A trial should be designed in such a manner that variables are collected on all participants prior to 
withdrawal.  These variables can be collected at baseline and during follow-up and can then be 
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used to predict or describe withdrawal (Carpenter & Kenward, 2007).  The amount of missing data 
and the strategies selected to handle missing data can influence the required sample size, the 
estimate of treatment effect and the confidence with which data can ultimately be interpreted.  How 
to minimise the amount of missing data is a critical issue that must be considered during the design 
of a trial (CHMP, 2010).   
  
The National Research Council (2010) report on missing data discusses ways in which trials could 
be designed in order to minimise the impact of missing data.  Data collection should be 
strengthened.  They emphasise that trial outcome data should be collected for participants who stop 
the study treatment or had protocol non-compliance.  Where possible, outcome data after 
withdrawal should be collected.  The reason for dropout should also be collected (CHMP, 2010).  
They also suggest that outcomes be defined in a manner that is measurable in as many participants 
as possible; this includes the use of composite outcomes such as time to death or worsening of 
disease.  They suggest that study duration be shorter in order to reduce missing data due to attrition.  
Attention should be given to how missing data due to death is to be handled.  It is worth noting 
from their discussion that the handling of missing data is much larger than simply accounting for 
this in the statistical analysis.  Researchers should be proactive in preventing missing data in the 
first place.  It is also important to collect covariate data that is predictive of withdrawal and the 
study outcome, since this improves the adjustments made with incomplete data.  Fleming (2011) 
also stated that the preferred approach to addressing missing data is to prevent it.  He also argues 
that studies should distinguish between non-adherence (not receiving randomised therapy) and non-
retention (not attending study visits).   
 
The CHMP made the following points regarding the handling of missing data (CHMP, 2010), and 
these were reinforced by Carpenter and Kenward (2007): 
1. One should take care in the design and implementation of a trial by minimising the amount 
of missing observations 
2. One should consider how to cope with missing data when drawing up the data analysis 
plan 
3. One should specify in advance the nature and scope of any sensitivity analysis 
4. One should look at the proportion of missing data by time of withdrawal and treatment arm 
 
The panel on handling missing data in clinical trials (National Research Council, 2010) summarises 
points on which guidelines for the handling of missing data in clinical trials agree.  These are 
1. One should plan how missing data will be handled during the design of the study. 
2. Complete data should be collected for all randomised participants, even if they discontinue 
study treatment.  
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3. The CONSORT guidelines (Schulz et al., 2010) should be adhered to. 
4. The use of single imputation methods is criticised. 
5. Emphasis is placed on doing sensitivity analysis, since no single way of handling missing 
data exists.   
 
The issues raised by missing data are wider than the technical details of statistical analysis 
(Carpenter & Kenward, 2007).  There is no best approach for all situations.  The acceptability of an 
approach depends on the assumptions made and whether it is reasonable to make these assumptions 
in the particular case (CHMP, 2010).  Missing data provide a real challenge for the correct analysis 
of clinical trials.  The National Research Council (2010) start their recommendations with: 
“Missing data in clinical trials can seriously undermine the benefits provided by randomization 
into control and treatment groups”.  
 
Mallinckrodt et al. (2003) summarised this as follows: 
“When determining a suitable approach to modelling longitudinal data, it is important to realize 
that no single “best” method currently exists. This implies that an analysis must be individually 
tailored for a given situation. It is, therefore, crucial that the desired attributes of the analysis are 
clear, and that the characteristics of the missing and non-missing data are understood.” 
 
This thesis addresses the analysis of clinical trials when a considerable amount of data are 
incomplete.  However, it should be remembered that the best way to deal with missing data is to 
prevent it from occurring in the first place by conducting the trial well, screening of participants 
and data collection.  The National Research Council (2010) stressed the importance of continuing 
to collect data even when participants are not receiving the study treatment.   
 
The rest of this thesis is structured as follows.  In Chapter 2 we discuss different missing data 
mechanisms and introduce the MCAR, MAR and MNAR terminology of Rubin (1976).  Monotone 
and non-monotone missing data are described and a taxonomy of missing data is given.  In Chapter 
3 different approaches to dealing with missing data are given.  These include the complete case 
analysis, single and multiple imputation, selection models, pattern-mixture models, shared-
parameter models, weighting methods and Bayesian methods.  Likelihood-based methods are 
discussed in detail.   
 
Chapter 4 highlights the importance of sensitivity analyses and describes the principles that should 
be followed when a sensitivity analysis is done.  Chapter 5 introduces the first example data set, the 
SAPiT study.  The study is explained and the data are analysed using the methods discussed in 
Chapter 3.  In Chapter 6 the second example data set, the St John’s Wort trial, is introduced and the 
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data are analysed using the methods discussed in Chapter 3.  This re-analysis of the data provided a 
contribution to the literature around the effectiveness of St John’s Wort because it changed the 
conclusions of the original analysis where missing data were not taken into account.  Chapter 7 




Types of missing data 
 
In a clinical trial either baseline covariates, covariates over time or outcome data can be missing.   
Baseline covariates, which are often included in the statistical analysis, are seldom missing, 
because study staff go to great lengths to collect this data and some variables need to be collected at 
baseline in order to determine the participant’s eligibility, for example age or disease status.  The 
most likely baseline covariates to be missing are laboratory variables and sometimes interview data 
that participants do not want to divulge, such as salary.  Missing date are often only created over 
time when participants do not attend all visits.  Because baseline data are often collected with very 
little missing observations, the focus of the missing data discussion will be on missing outcome 
data and baseline covariates are assumed to be complete.  Missing data in covariates can be 
handled conveniently using multiple imputation, which is discussed in Section 3.2.    
2.1 Notation 
We assume N independent participants in a trial, indicated by i = 1,…,N.  We plan to collect a set 
of n measurements Yij with j = 1,…,n.  Participant is indicated by i and measurement by j.  Because 
of the possibility of missing data, we assume that we have  observations for participant i.  
 
Yij:  Response for ith participant at jth occasion 
Yi =(, … , 	)′ :  Vector of outcomes : Observed component of Yi  : Missing component of Yi 
       Chapter 2 
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 =   (, … , 	)′: Vector of missing data indicators; Rij = 1 if Yij is observed and 0 otherwise  = 1 +  ∑ 	 : Dropout indicator.  If the missing data indicator consists of all  equal to 1 
up to time j and 0 thereafter, then the missing data can be represented by the dropout-time, the first 
time point where the data are missing.   
xi: Vector of covariates for participant i 
tij: The value of time (day, visit, week) for the j
th measurement of participant i 
θ: Parameter vector describing the measurement process; relating the outcomes Y to the covariates 
x : Parameter vector describing missingness process.  θ and ψ may have some parameters in 
common.   : An indicator variable for treatment; 1 if the participant is in the active treatment arm and 0 if the 
participant is in the control arm.  This is constant across time for a given participant 
2.2 Missing data mechanisms 
Rubin (1976) described three different missing data mechanisms.  This taxonomy is based on the 
level of dependence between the missing data process and the measurement process.  These are 
MCAR, MAR and MNAR.  Most subsequent work has used these terms and has built on these 
concepts.  Each is discussed in turn.   
 
Independence across participants is assumed.  The density of the full data is   ( ,  |", , #) = (, , |", , #) . 
This can be factored as 
 $, , %", , #& =  $, %, #& $ %, , #, ",  &. 
 
This factorisation makes it clear that the first factor on the right hand side can be inferred from 
observed data.  By making modelling assumptions the analyst can estimate this distribution from 
the observed data.  The second factor above is the distribution of missing data and cannot be 
inferred from the observed data.  Thus, to analyse the full data model when data are incomplete, the 
analyst has to specify a model for the distribution of the observed data and to combine this with 
assumptions about the missing data.  These assumptions cannot be tested using the observed data.   
2.2.1 Missing completely at random (MCAR) 
When missing data are MCAR the missingness is not related to any factor and is unrelated to any 
inference one wishes to draw.  This means that the probability of dropout is independent of both 




This type of missing data arises when observations are missing because of equipment failure or 
because the staff member who collected the data was ill.  These events are as likely to occur for one 
participant as for another, whatever their disease severity or intervention.  It is as if after 
randomising the participants to intervention we randomly decide who to observe (Carpenter & 
Kenward, 2007).  Participants who drop out of a study for this reason could be considered a 
random sample from the total study population and their characteristics and outcomes are similar to 
that of the study population (CHMP, 2010).  MCAR data implies that  (|#, , ) = (|#, )  
(Horton & Kleinman, 2007; Molenberghs & Kenward, 2007).   
 
When missing data are MCAR, an analysis of those participants who completed the study is valid.  
Important instances of non-likelihood methods such as generalised estimating equations (GEE) are 
also valid.  Validity does not necessarily imply that such methods applied to the completers only 
are also efficient, and there usually are good reasons to include the incompletely observed study 
participants as well. 
 
MCAR is the easiest type of missing data mechanism to deal with.  However, in practice 
missingness is often related to the outcome of interest and thus the data are not MCAR.  There is 
often an association between the probability of having missing data (either participant withdrawal 
or intermittent missing data) and either the intervention, baseline variables such as baseline disease 
status, or the measurement just prior to the missing observation (when data are measured 
longitudinally).  If, for example sicker participants are more likely to have missing data, an analysis 
that assumes MCAR is not sensible.  The convenient assumption of MCAR can thus be made in 
rare circumstances only.  When the MCAR assumption cannot be made, one cannot analyse only 
those participants with complete data (Carpenter & Kenward, 2007). 
 
In spite of what observed data may suggest, one can never be sure that data are MCAR.  
Nevertheless the observed outcome data can rule out MCAR.  We can investigate whether there is 
any relationship between observed outcome data and the occurrence of missing data.  If there is, 
data are not MCAR (Carpenter & Kenward, 2007).  One can test whether data are MCAR against 
the assumption of MAR (Diggle, 2002).  In the simple setting this test reduces to a t-test comparing 
the means of outcome variables for complete and incomplete cases.  Logistic regression can be 
used to identify predictors of dropout or missingness (Carpenter, Pocock, & Lamm, 2002).   
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2.2.2 Missing at random (MAR) 
MAR is a less stringent requirement than MCAR.  Missing data are said to follow a MAR 
mechanism if the probability of non-response can depend on observed data (responses and baseline 
covariates) but conditionally on these does not depend on unobserved responses.  This assumption 
implies that the behaviour of the post dropout observations can be predicted from the observed 
variables and therefore the response can be estimated without bias using the observed data 
exclusively (CHMP, 2010). 
 
The term MAR might be misleading, since missingness is not random and can actually be predicted 
from recorded information, although in a stochastic rather than a deterministic sense.  Missingness 
is, however, random after controlling for the observed covariates (Horton & Kleinman, 2007).  
Another way of looking at this is to say that data are MAR when we can find fully observed 
variables which define groups within which the data are MCAR.  Data are MAR, if, conditional on 
another variable, the data are MCAR (Carpenter & Kenward, 2007). 
 
In the case of MAR data, the statistical distribution of potentially missing data is the same 
(conditionally) for all participants who share the same observed data, whether or not they have 
missing data.  Participants who have missing data share the same conditional statistical behaviour 
in their unobserved future, given their observed past, as those who do not have missing data. In 
other words, the distribution of the endpoint value, given baseline and observed data, for 
participants with missing values is the same as for participants without missing data (Carpenter & 
Kenward, 2007). 
 
MAR data occur, for example, when a participant was doing poorly and the physician decided to 
discontinue participation.  In such a case dropout was related to the outcome of interest, but the 
observed data explained the dropout (Mallinckrodt, Sanger, et al., 2003).  The MAR assumption is 
implausible if missing data are due to some unobserved deterioration, but plausible if missing data 
are simply due to loss to follow-up.  The MAR assumption is more plausible than the MCAR 
assumption (Little & Rubin, 1987; Mallinckrodt, Clark, et al., 2003).   
 
Mathematically MAR data are defined as follows:   ' ( |# ,  , ) = '( |# ,  ()*, )  
(Molenberghs & Kenward, 2007). 
 
Under MAR assumptions analysis of completers only or observed data only is not valid.  The 
marginal average cannot be used.  Imagine that worse health at baseline is associated both with 
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increased risk of withdrawal and poor response to intervention.  In this case, analysing data from 
the participants who remain to the end of the trial gives an over optimistic view of the intervention 
effect (Carpenter & Kenward, 2007).  Under MAR assumptions unweighted GEE is not valid, due 
to its non-likelihood nature.  Likelihood-based analyses, some weighted estimation methods, 
multiple imputation and Bayesian methods are valid, among others (Molenberghs & Kenward, 
2007).   
 
MAR data can be analysed through joint modelling of complete and partially observed response 
data, conditional on fully observed data.  With current methods available to analyse MAR data, 
single or simple imputation of data is not needed.  If outcome data are MCAR conditional on 
treatment alone (i.e. MAR) then including treatment in the model gives a valid treatment estimate 
(Carpenter & Kenward, 2007). 
 
It is argued that a MAR analysis addresses the per protocol hypothesis under which we want to 
estimate the distribution of responses had participants continued to adhere to the protocol.  If we 
assume the data are MAR, sensible estimates of the intervention effect addresses this hypothesis.  
Within each baseline group, for example each treatment group, the distribution of responses is the 
same for observed and unobserved participants.  This assumes that the unobserved participants 
continued with treatment per protocol as the observed participants did.  Under MAR assumptions 
the estimated treatment effect is thus the per protocol treatment effect (Carpenter & Kenward, 
2007).  If no further data are collected when participants are withdrawn from treatment, methods 
that rely on MAR are estimating treatment effect under the condition that everyone remained on 
treatment.  This does not provide a valid estimator of the ITT effect.  If data are collected after 
withdrawal from treatment, this can be used to estimate the ITT effect, assuming MAR (National 
Research Council, 2010).   
 
The process to analyse data where the missing data mechanism is believed to be MAR can be as 
follows:   
1.  Identify a fully observed variable or set of variables whose values predict the occurrence of 
missing data 
2.  Within groups identified by this variable or set of variables, assume data are MCAR.  Within 
these groups sensible estimates can thus be obtained from the observed data 
3.  An overall average estimate is obtained from these separate groups, by averaging the groups and 





Hogan et al (2004) extended the MAR concept to longitudinal data.  They coined the phrase 
sequential MAR (or S-MAR).  The S-MAR assumption is that given ,+, = 1 the future 
responses (- + , … , -). are independent of + conditional on the past.  The difference between the 
MAR and S-MAR assumption is that under MAR, dropout at + can depend on elements of the 
covariates (x variables) and observed responses (Y variables) before, at and after t, while under S-
MAR dropout at time t can depend on elements of the covariates and the observed Y before t or in 
the case of the covariates, at t.   
 
By including a rich set of predictors, the MAR assumption can be made more plausible (Collins, 
Schafer, & Kam, 2001).  If all the predictors of dropout are known and used in a model, then a 
MAR model is adequate.  In the design of a study it is thus important to identify the likely causes 
for dropout and collecting variables that would measure this.  Baseline characteristics and response 
variables over time could be useful.  A study can also be designed so that withdrawal is triggered 
by a response variable deteriorating beyond a specific level (Carpenter et al., 2002).  This is the 
case in the Hypericum perforatum study discussed in Chapter 6 (Hypericum Depression Trial 
Study Group, 2002).   
2.2.3 Missing not at random (MNAR) 
MNAR has several synonyms and is also called not missing at random (NMAR).  Data are MNAR 
if the probability of an observation being missing depends on unobserved measurements, 
conditional on the observed data.  Even given the information about the missingness mechanism in 
the fully observed data, the reason for an observation being missing depends on the unseen value of 
that observation.  The distribution of future observations conditional on past observations differs 
between those who have missing data and those who do not (National Research Council, 2010).  
MNAR is often defined by exclusion; when neither MCAR nor MAR assumptions are valid, data 
are MNAR (Carpenter & Kenward, 2007).  Missingness can depend on unobserved outcomes in 
addition to dependency on observed covariates and outcomes (Molenberghs & Kenward, 2007). 
 
MNAR data in a clinical trial could arise, for example, when a participant had been doing well until 
midway in a trial and was then lost to follow-up, because, after the last observed visit the 
participant relapsed into a worsened condition.  In such an instance dropout was related to the 
outcome of interest, but the observed data did not predict the dropout.  The unobserved data held 
information not foreseen by the observed data.  Missingness due to adverse events are difficult to 
classify as MNAR versus MAR because the relationship to the observed outcome may vary from 
situation to situation.  Missingness due to adverse events are not MNAR, if it was observed that the 
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participant’s condition worsened prior to the dropout but would be MNAR if the participant’s 
condition did not worsen prior to the dropout (Mallinckrodt, Sanger, et al., 2003).   
 
Future observations cannot be predicted without bias by the model.  It is impossible to be certain 
whether there is a relationship between missing values and the observed outcome variable or to 
judge whether the missing data can be adequately predicted from the observed data (CHMP, 2010).  
Ignoring non-random missing data when it is present, means choosing not to model the relationship 
between the unobserved response and dropout.  This means ignoring the fact that dropout indicates 
some deviation in the response.  This effect is then ignored in the estimates of parameters 
(Carpenter et al., 2002).   
 
Valid inference under MNAR requires explicit or implicit use of the missing value mechanism.  In 
practice, we often do not know what it is.  Because MNAR methods require assumptions that 
cannot be validated from the data at hand, a definitive MNAR analysis does not exist (Carpenter & 
Kenward, 2007; Mallinckrodt, Sanger, et al., 2003).  Any analysis of data in the presence of 
MNAR data is assumption driven.  The panel on handling missing data in clinical trials (National 
Research Council, 2010) called this the “central problem of missing data analysis in clinical 
trials”.  Since no definitive analysis exists, sensitivity analysis plays a large role in the analysis of 
missing data assumed to be MNAR (Mallinckrodt, Clark, et al., 2003; Molenberghs & Kenward, 
2007).    
 
The observed data can be used to distinguish between MCAR and MAR, but the observed data 
cannot be used to distinguish between MNAR and MAR (Carpenter et al., 2002; Horton & 
Kleinman, 2007).  This means that one can never rule out MNAR, because in order to do so one 
needs to observe the missing measurements.  The MNAR models in a sensitivity analysis need to 
be selected to generate conclusions bounded by the results of the MAR model and the worst case 
MNAR model.  The sensitivity of conclusions to non-random dropout can be assessed by 
modifying the MAR model to allow for various non-random dropout scenarios and seeing whether 
conclusions vary (Carpenter et al., 2002).  An overall assessment of MAR versus MNAR is not 
possible, because every MNAR model has a unique MAR counterpart, with the same fit as the 
original MNAR model.  This MAR model would also lead to the same predictions of the observed 
data as the MNAR model (Molenberghs et al., 2008).    
 
Most analytic approaches under MNAR are based on models for the joint distribution of the 
outcome variable and the missing data mechanism.  Classifications of different MNAR models are 
based on the factorisation of these joint models.  These missing data models fit in the broader 




The analysis of MNAR data proceeds in two steps.  During the first step the statistical relationship 
between the chance of seeing a variable and its unseen value is described.  During the second step 
we describe how the distribution of the data differs among participants with missing observations 
(Carpenter & Kenward, 2007).  
 
The only way forward in the face of MNAR data is to use auxiliary information and knowledge 
about possible data mechanisms to describe distributions for the missing data or to conduct 
sensitivity analyses to gauge whether conclusions will change when varying assumptions are made 
about the missing data mechanism while assuming MNAR.   
2.2.4 Summary of MCAR, MAR and MNAR 
It is implausible that clinical trial data would be MCAR.  MNAR analyses are difficult to 
implement and interpret and it is difficult to know whether the assumptions made are correct.  
MAR likelihood-based methods seem to be most suited to longitudinal clinical trials data especially 
if covariate information predictive of missingness is collected and conditional analyses can be 
done.  However, this depends on the estimand and the MAR analysis generally answers the per 
protocol question and not the ITT question.  Since it is difficult to rule out the possibility of MNAR 
data, it is suggested that when an MAR analysis is done, MNAR analysis is used to assess 
robustness of the results from the likelihood-based MAR analysis (Mallinckrodt, Sanger, et al., 
2003; Molenberghs & Kenward, 2007).  With missing data it is important to remember that no 
definitive correct analysis exists.  
 
Rubin (1987) argued that, even if data are MNAR, after accounting for the information about the 
missingness mechanism in the observed data, there is relatively little information remaining in the 
unseen data.  This is a further argument for the use of MAR methods. 
2.3 Monotone and non-monotone missing data 
The pattern of missing data can be classified as monotone or non-monotone missing data.  If the 
data matrix can be rearranged so that there is a hierarchy of missingness so that observing a 
particular variable Yt for a participant implies that Yt-1 is observed then missingness is said to be 
monotone.  Simple methods can be used if the pattern is monotone (Horton & Kleinman, 2007). In 
longitudinal data monotone missing data are created when missingness is caused by dropout 
(Molenberghs & Kenward, 2007).  When missingness is caused by participants randomly missing 
some visits and arriving for other visits missingness is non-monotone.  When missingness is non-
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monotone, models for the missingness of one variable may include covariates or previous outcome 
data which also have missing values.   
 
Some of the methods discussed in the chapters that follow can only be applied when missing data 
are monotone, for example weighted GEE and pattern-mixture models under identifying 
restrictions.  This will be discussed in more detail where these methods are described.  It is also 
important to know whether missingness is monotone or non-monotone when choosing the multiple 
imputation method.   
2.4 A taxonomy of missing data  
To appropriately describe missing data issues, it is convenient to adopt a number of interconnected 
but logically independent taxonomic dimensions.  Several have been touched upon already in what 
preceded. 
 
Missing data mechanism 
The missing data mechanism refers to whether data are MCAR, MAR or MNAR, in other words it 
refers to why data are missing.  These were defined and discussed in detail in Section 2.2  
 
Missing data pattern 
This refers to whether data are complete or missing and whether missing data are monotone or non-
monotone.  This has been discussed in Section 2.3. 
 
Missing data frameworks 
Will the data be analysed using a pattern-mixture model, a selection model, or employing a shared-
parameter model?  A selection model factors the joint distribution of the measurement and response 
mechanism into the marginal measurement distribution and the distribution of the missing data, 
conditional on the outcomes.  A pattern-mixture model does the reverse (Kenward & Molenberghs, 
2009).  These are discussed in Chapter 3. 
 
Inferential paradigm 
Three commonly used paradigms exist for statistical inference, namely likelihood, Bayesian and 
frequentist inference.   
 
Ignorability 
Rubin (1976) defined the concept of ignorability in missing data.  This refers to the fact that under 
certain conditions the mechanism generating missing data can be ignored when the interest is in 




In order for missing data to be ignorable in the likelihood setting, the assumption is made that the 
parameters of the missing data mechanism are distinct from the parameters of the sampling model, 
the separability condition (Ibrahim et al., 2005).  When the separability condition holds in a 
likelihood framework or under Bayesian inference, ignorability is equivalent to the union of MAR 
and MCAR.  Frequentist methods such as GEE are generally unbiased only under MCAR, even 
though there are some exceptions (such as restricted maximum likelihood (REML), certain forms 
of profile likelihood, protective estimation methods, etc.).  However, if GEE are weighted using 
weights that depend on the missingness probability, GEE can be used under MAR.  This is what is 
called inverse probability weighting (Carpenter & Kenward, 2007).  When ignorability holds, one 
need not specify the missing data mechanism, but only the full data response model (Daniels & 
Hogan, 2008).   
 
Study population 
Study population defines the study population to which the analysis refers.  These include the ITT, 
per protocol or “as treated” populations.  Some implications of missing data for the ITT population 
were discussed in Section 1.4.   
2.4.1 Summary 
Several approaches to analysing missing data are possible by making selections on the taxonomy 
dimensions discussed in the previous section.  In the case of continuous data, if missingness is non-
monotone, but is dominated by dropout, the question translates to a selection model question.  This 
implies we are interested in the overall treatment effect change over time, not specific to a dropout 
group.  This analysis would make use of all the data; both from complete and incomplete 
sequences.   
 
We return to the conundrum mentioned in Section 1.4: clinical trials generally require an analysis 
by ITT, which is complicated by missing data.  Some methods would be valid if the MAR 
assumption can be made, and the missing data mechanism is ignorable, such as direct likelihood, 
direct Bayesian inference, multiple imputation and inverse probability weighting methods (such as 
weighted estimating equations).  However, these methods address the per protocol hypothesis and 
not the ITT hypothesis.   
 
In Chapter 3 various methods to deal with missing data are discussed.  Most of these methods can 




2.5 The estimand 
The choice of an estimand involves the outcome measure, the population of interest and the time 
over which the analysis is conducted (National Research Council, 2010).  The estimand is that 
quantitative feature which one would like to know from the population, but is only available 
through the inferences drawn from a selected sample from this population.  It is important that the 
estimand be clearly defined, by specifying the outcome measure and the target population of 
interest clearly.   
 
The full analysis set is all participants who met the inclusion and exclusion criteria and were 
randomised.  Ideally, inference for the target population of eligible participants would be drawn 
from the full analysis set (Carpenter & Kenward, 2013).   
 
The estimand one chooses is influenced by whether one wants to determine the efficacy or the 
effectiveness of the intervention.  The efficacy is defined as the effects of the intervention if taken 
as specified in the protocol, in other words the benefit of the drug expected at the endpoint of the 
trial if all participants adhered to the treatment.  Effectiveness, on the other hand, is the effects of 
the treatment observed in the trial, given imperfect adherence and other deviations from the 
protocol (Mallinckrodt et al., 2012).   
 
(Carpenter, Roger, & Kenward, 2013) preferred to introduce the less ambiguous terms ‘de jure’ and 
‘de facto’.  In essence, the de jure hypothesis is the efficacy hypothesis.  The de jure question asks 
what the expected treatment effect would be in the target population if the treatment and control 
were taken as specified in the protocol.  This is also what is sometimes meant under the per 
protocol effect.  Within the context of missing data, this question becomes “If after participants 
were not observed, they continued with the treatment randomised to and adhered to the protocol, 
what would the treatment effect be at the end of the study?” 
 
The de facto question refers to the effectiveness question, namely what effect would be seen in 
practice if this treatment was assigned to the population of eligible patients.  This is what is 
sometimes meant under the ITT question.  In the context of missing data, the de facto question is 
“If we had observed all the participants at the end of the trial, what would the treatment effect have 
been?” (Carpenter et al., 2013). 
 
The following five estimands were listed by the National Research Council (2010) in the context of 




Estimand 1: Differences in outcome improvement at the planned endpoint for all randomised 
participants.  
This estimand compares mean outcomes for participants randomised to the treatment and control 
arms, regardless of what treatment they actually received; the traditional ITT framework.  Data 
after participants stopped using the randomised medication or started using rescue medication are 
included in this analysis.  This answers the de facto question, or the effectiveness hypothesis 
regarding treatment policies relative to control.  The observed difference between the treatment and 
control includes the effect of the treatment randomised to as well as any changes made to the 
participants’ treatment over time, either due to lack of effect or side-effects.  During the drug 
development process causal effects are usually the focus, not treatment policies.  A parallel-group 
randomised trial in which outcome data are collected on all participants, those who adhere to the 
protocol and treatment regimen and those who do not adhere, supports the use of this estimand.  If 
outcome data are not collected after participants drop out or switch from the assigned treatment, 
this estimand is not supported (Mallinckrodt et al., 2012; National Research Council, 2010).   
 
Estimand 2: Difference in outcome improvement in tolerators.  
This estimand compares the mean outcomes for treatment versus control in the subset of 
participants who tolerated and adhered to the treatment.  A design that supports this estimand is a 
study with an active run-in phase used to identify participants who meet tolerability and efficacy 
criteria to continue.  After the run-in phase, participants are randomised to one of the two treatment 
arms.  Drug benefit is assessed only in participants who were selected because they responded 
favourably during the run-in phase (Mallinckrodt et al., 2012; National Research Council, 2010).   
 
Estimand 3: Difference in outcome improvement if all participants tolerated or adhered.  
This estimand assesses the outcome if all participants adhered to the treatment regimen for the 
study duration and did not drop out of the study.  It addresses the de jure (efficacy) hypotheses 
about the causal effects of the treatment randomised to.  Although this is the question one would 
like to answer in a clinical trial, it is unlikely that all participants will adhere.  In real trials when 
using Estimand 3, one should asses the degree of non-adherence and how this may influence the 
treatment benefit observed.  When data are missing, this estimand requires imputation of what 
would have been the outcome if individuals who did not comply had complied (Mallinckrodt et al., 
2012; National Research Council, 2010).   
 
Estimand 4: Difference in areas under the outcome curve during adherence to treatment  
This estimand compares the means of the area under the curve over the duration of protocol 
adherence between the two arms.  This estimand simultaneously quantifies the effect of treatment 
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on both the outcome measure and the duration of tolerability or adherence in all participants.  A 
parallel group randomised trial supports the use of this estimand (National Research Council, 
2010).   
 
Estimand 5: Difference in outcome improvement during adherence to treatment 
This estimand is the difference in mean outcomes as long as participants adhere to the protocol and 
treatment.  This estimand includes both the duration of tolerability or adherence and outcome 
improvement in all participants.  A parallel-group randomised trial supports the use of this 
estimand.  This estimand assesses the de facto hypothesis regarding the randomised treatment.  
Assessing effects only while the drug is taken overestimates effectiveness at the endpoint, if the 
drug is not long acting or does not alter the disease permanently (Mallinckrodt et al., 2012; 
National Research Council, 2010).   
 
Mallinckrodt et al. (2012) also defined a sixth estimand.   
Estimand 6: Difference in outcome improvement in all randomised participants at the 
planned endpoint of the trial attributable to the initially randomised medication.  
This estimand assesses effectiveness or the de facto hypothesis and requires data after withdrawal 
of the randomised study medication until the planned endpoint of the study.  This estimand needs 
to be free from the confounding effects of rescue medication, because inference is to be made on 
the study medication and not the treatment regimen.  While Estimand 3 addresses the de jure 
(efficacy) hypothesis, this estimand addresses the de facto (effectiveness) hypothesis.  Both make 
causal inference regarding the initially randomised treatment in all participants at the planned 
endpoint of the trial.   
 




Approaches to dealing with missing data 
 
When data are incomplete all analyses make assumptions in addition to the assumptions already 
made with complete data.  Although simple analyses are always appealing, simple methods do not 
necessarily make plausible assumptions (Molenberghs & Kenward, 2007).  With high rates of 
missingness results may be problematic to interpret regardless of the analytic methodology used 
(Mallinckrodt, Sanger, et al., 2003).  In order to interpret the results correctly one needs to be clear 
about the assumptions made in the data analysis.  In the discussion of various approaches to 
analysing missing data that follows, the assumptions underlying each of the approaches are 
discussed.   
 
The missing data process could either be of direct interest in the modelling of the data or merely a 
nuisance that needs to be accounted for.  The research question determines whether the missing 
data process is of interest or merely a nuisance.  Dropout, or missing data for other reasons, can 
reflect a clinically meaningful response to treatment which one might want to take into account 
when making inference about the treatment.  
 
A critical discussion of the number, timing, pattern, reason for and possible implications of missing 
values should be included in the final report.  Graphical summaries, like Kaplan-Meier plots, of the 
dropout patterns should be provided so that it can be seen whether there is a differential dropout 
pattern between treatment groups.  Whether participants with and without missing values have 
different characteristics at baseline can contain important information.  The final report should have 
        Chapter 3 
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a discussion on whether the pre-defined analysis is still sensible, with additional sensitivity 
analyses (CHMP, 2010).  
 
A systematic approach for analysing incomplete data could follow the following steps. 
1.  Consider the reason, or mechanism, which caused the data to be missing. 
Take account of all the information about the missingness mechanism in the observed data.  
Determine the probability distribution of the missing data, since this informs the analysis.  Consider 
how the reason for missing a visit depended on the previous visits and the baseline data.  Next 
consider how the missingness mechanism depends on unseen measurements.  This affects the 
probability distribution of the missing data and the estimated intervention effect at the final visit 
(Carpenter & Kenward, 2007). 
 
2. Some assumptions need to be made. 
A missingness mechanism and the distribution of the missing data given observed data need to be 
assumed.  Possible distributions of the missing data given the observed data can be identified.  
Focus on whether the distribution of participants’ unseen observations at later visits, given their 
observations at previous visits and baseline, is different from that seen among the participants who 
have no missing data.  The available data do not have any information about these distributions.  
The validity of the assumption about the distribution of the missing data cannot be verified.  It is 
important to see how different assumptions made about the missing data distribution change the 
conclusions drawn.  The final conclusions are valid if the assumptions made about the missing data 
mechanism and the distribution of missing data was correct.  If these assumptions are wrong, the 
model is wrong and the conclusions drawn using this model are also wrong. 
 
Various methods have been proposed throughout the years for dealing with missing data.  In a 
review paper Horton and Kleinman (2007) list various approaches of dealing with missing data.  
They do not specifically refer to the longitudinal case.  They list the following: complete case 
method, ad hoc methods like LOCF, multiple imputation, likelihood-based approaches, weighting 
methods and Bayesian methods.  We do not discuss ad hoc methods in the rest of this thesis. 
 
3.1 Complete case analysis 
In a complete case analysis only those participants with complete data are analysed.  All 
participants who withdrew or have missing data are excluded.  In a clinical trial context this implies 
an analysis of completers (Horton & Kleinman, 2007; Molenberghs & Kenward, 2007).  The 
advantage of this approach is that it is easy to implement and easy to describe.  Although it seems 
appealing, this approach is inefficient, because not all collected data are used, and has the potential 
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to be biased if the missing data mechanism is MAR or MNAR (Horton & Kleinman, 2007; 
Molenberghs & Kenward, 2007).   
 
When the true missingness mechanism is MCAR this analysis is unbiased and sensible, even if 
inefficient (Carpenter & Kenward, 2007; Molenberghs & Kenward, 2007).  A complete case 
analysis violates the ITT principle, since it does not include all randomised participants, but only 
includes those who have completed the study and have no missing data (CHMP, 2010).  Any 
analysis that violates the ITT principle is open to bias relative to the ITT question, since 
randomisation is not preserved and the comparability of randomised groups, guaranteed by 
randomisation, is lost.  Complete case analysis is done on a subset of participants, those who 
completed, and a different type of participant may be retained in the different treatment arms, for 
example participants not benefiting could drop out of the placebo arm, while participants 
experiencing side effects could drop out of the active arm.  When an ITT question is not the focus 
of the analysis, such as when an as treated or per protocol analysis is done, the above mentioned 
bias is less important.  There are distortions in the mean structure, the variance structure and the 
correlation structure when a complete case analysis is done (Molenberghs & Kenward, 2007).  The 
complete case analysis requires the assumption that the complete cases are a random subsample of 
all cases (Little, 1993).   
 
The bias introduced by complete case analysis depends on the degree of deviation from MCAR, 
how much data are missing and the specific analysis.  Thus, the potential for bias increases if more 
data are missing (Little & Rubin, 2002).   
 
The European Medicines Agency (EMEA) suggested that complete case analysis be used in 
confirmatory trials as a secondary supportive analysis (sensitivity analysis) to illustrate the 
robustness of conclusions (CHMP, 2010).  However the National Research Council (2010) stated 
that these analyses do not have a place in regulatory submissions.  In practice, it is often incorrectly 
used as an easy starting point in any analysis, before more complicated models are fitted.   
 
In a simulation example Ibrahim et al. (2005) showed that if the missing data mechanism depended 
on the outcome a complete case analysis was inefficient and outperformed by maximum likelihood, 
multiple imputation, Bayesian analysis and weighted estimating equation estimates, whether or not 
the distribution of the missing data was correctly specified in these methods.  It seems plausible to 
use the likelihood approach as the easiest approach to handle the missing data problem.  
Technically it is a strong and robust approach.   
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3.2 Single imputation and multiple imputation 
We discussed the inefficient and potentially incorrect way of analysing missing data by throwing 
away the missing data and ignoring missing data and the missing data mechanism in the analysis of 
data, the complete case analysis.  The other extreme is to replace the missing data by creating data.  
This is called imputation.   
 
Longitudinal imputation is done by using data from the same participant at different times, often 
without using data from other participants.  This is in contrast to cross-sectional imputation 
methods where data at a particular time point is used to impute missing data at that time point.   
Different single imputation techniques used with longitudinal data include interpolation (if a value 
at t = 2 is missing, this value is imputed as the value between t = 1 and t = 3), LOCF, ratio 
imputation and regression imputation.  Longitudinal regression imputation is done by fitting a 
linear or other regression model for each participant with a missing value.  This model includes the 
outcome variable as dependent variable and time and other covariates as independent variables.  
The predicted value of the outcome for the time point with a missing value is then imputed.  It is 
believed that these longitudinal imputation methods use more data and provide better imputations 
than cross-sectional methods (Twisk, 2013). 
 
There are various problems with single imputation of data.  In the analysis of observed data we 
allow for the fact that measurements are made with error.  To assume that if data are missing we 
can impute the missing value without error (single value) is illogical.  Another problem is that with 
conditional mean imputation, the imputed data are much less variable than the observed data would 
have been.  Thus analysing the imputed data as observed data leads to an underestimation of 
standard errors and p-values.  The confidence intervals for treatment effects calculated with 
imputed data are thus too narrow and artificially create an impression of precision (Carpenter & 
Kenward, 2007; CHMP, 2010).  
 
Multiple imputation, first suggested by Rubin (1987) overcomes the limitations of single 
imputation.  It involves producing several imputed data sets, each with different imputed values 
from the posterior predictive distribution of the missing data given the observed data.  The analyst 
applies conventional estimation methods to each of these imputed data sets.  In multiple imputation 
an extra step is added after data were imputed.  This additional step is needed to correctly estimate 
the variability of quantities estimated from a completed data set.  Parameter estimates are averaged 
across the analyses of the imputed data sets.  Standard errors are calculated using Rubin’s (1987) 
formula. Multiple imputation provides an approach for accounting for the variability of the 
estimated distribution of the missing data given the observed data.  Multiple imputation does not 
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treat any one set of imputations as the true unobserved values of the missing data (Carpenter & 
Kenward, 2007).    
 
Multiple imputation is done in three steps to estimate incomplete data regression models. 
Step 1.  Plausible values for missing observations are created that reflect uncertainty about the 
missing data models.  These values are used to fill in or impute the missing values, generally 
assuming the missing data process is MAR.  This process is repeated, resulting in the 
creation of a number of, say m, completed data sets.  Taking into account the uncertainty in 
estimating both the relationship between the variables and the residual variability several 
complete data sets are imputed.  These provide a representation of the distribution of the 
missing data given the observed.   
Step 2.  Each of these data sets is analysed using complete data methods.  The data analysis method 
that would have been appropriate had there been no missing data is used for this analysis.   
Step 3.  The results are combined, which allows the uncertainty regarding the imputations to be 
taken into account.  Typically five to ten imputations are created.  These results are unbiased 
and have approximately the correct standard error (Horton & Kleinman, 2007; Molenberghs 
& Kenward, 2007). 
 
In short, imputation processes similar to stochastic regression are run on the same data set multiple 
times.  Each imputed data set is analysed separately and the results are averaged except for the 
standard error term. The standard error is constructed by the within imputation variance of each 
data set as well as the variance between imputed items on each data set. These two variances are 
added together and their square root determines the standard error.  The noise due to residual 
variation, as well as the additional noise due to imputation, is introduced to the regression model. 
 
The repeated imputations in Step 1 are draws from the posterior predictive distribution of the 
missing values under a specific Bayesian model for both the data and the missing data mechanism 
(Rubin, 1996).  Multiple imputation is at heart a Bayesian procedure, but Rubin (1987) provides 
technical conditions under which multiple imputation can be interpreted validly under the 
frequentist paradigm.   
 
For each of the m imputations a point estimate, Q0 1, is computed for the parameter (Q) of interest, 
for i = 1,…,m.  The combined point estimate of this parameter (Q) for multiple imputations is the 
average of the m estimates; each calculated using a complete (imputed) data set.  In a similar 
manner a within-imputation variance, 23, can be calculated as the average of the m variances from 
each of the imputed complete data sets.  A between imputation variance is also calculated as 
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4 = , ∑ (56−58)9 . 
 
The variance estimate of 58 is : =  23 +  ;1 + < 4, 
the sum of the within-imputation component and the between-imputation component (Rubin, 
1987).  The imputation model can include baseline and other variables which are not included in 
the eventual trial analysis (Ibrahim et al., 2005).  Including more variables in the imputation model 
can improve the accuracy of the imputation (Carpenter & Kenward, 2007). 
 
For a single parameter, the ratio of the between-imputation component of variance to the within-
imputation component, defined as  
 =  (1 +  =,)423  
gives the relative increase in variance due to the missing data.  This indicates how the missing data 
increase the uncertainty of the estimates.  One can view this quantity as the cost due to missing data 
(Rubin, 1987).  Interval estimates and significance levels can be obtained using a t distribution with 
center 58  and scale T½ and degrees of freedom  




The two-sided p-value for the null hypothesis  
H0: Q = 0 
is computed by comparing 58:9 
with a t-distribution with v degrees of freedom (Little & Yau, 1996). 
 
If the missingness pattern is monotone, parametric regression methods assuming multivariate 
normality or nonparametric methods that uses propensity scores are appropriate (Rubin, 1987).  If 
the missingness pattern is not monotone a Markov Chain Monte Carlo (MCMC) method is used 
(Schafer, 1997).  Instead of imputing all missing values using the MCMC method, just enough 
missing values can also be imputed to make the imputed data sets monotone and methods 
appropriate for monotone data sets are then used on these imputed monotone data sets.   
 
In the parametric regression method, a regression model is fitted for each variable with missing 
values, with the previous variables as covariates.  Based on the fitted regression coefficients, a new 
regression model is simulated from the posterior predictive distribution of the parameters and is 
used to impute the missing values.  For variable - with missing values a model 
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- =  >? +  >- + >9-9+ . . . + >,-,, + A 
is fitted using observations with observed values for - to -,,.   
 
This model included the regression parameter estimates  >B  = (>B?, >B, . . . , >B,)′ 
And the covariance matrix CD9E 
where E is the matrix derived from the intercept and observed variables. For each imputation, new 
parameters  >∗ = (>∗?, >∗, . . . , >∗(,))′ and C∗9  
are drawn or simulated from the posterior predictive distribution of the parameters.  The missing 
value is then replaced by the value calculated using the parameters and observed or simulated 
previous observations of the outcome variable and a simulated error term (Rubin, 1987; SAS 
Institute Inc., 2004).   
 
The propensity score method generates a propensity score for each missing variable to estimate the 
probability that the observation is missing.  The observations are grouped based on these 
propensity scores and an approximate Bayesian bootstrap imputation is applied to each group 
(Rubin, 1987).   
 
Under the MCMC method one generate multiple imputations using MCMC sampling with a single 
chain that is long enough for the distribution to reach a stationary distribution.  The initial estimates 
for the algorithm are obtained using the expectation maximisation (EM) algorithm and the initial 
estimates for the EM algorithm are generated using a complete case analysis (Molenberghs & 
Verbeke, 2005).  Routinely, a multivariate normal distribution is assumed for continuous data.  A 
general contingency table model is assumed for categorical data.  Schafer (1997) considered a 
specific distribution for a mixture of continuous and discrete outcomes.  Through MCMC one can 
simulate the Bayesian joint posterior distribution of the unknown quantities and obtain estimates of 
the posterior parameters.  During the imputation step the missing values for each observation is 
simulated independently.  The imputation step draws values for  from a conditional 
distribution for |.  Given a complete sample the posterior step simulates the posterior 
population mean vector and covariance matrix.  These new estimates are then used in the next 
imputation step.  The two steps are iterated long enough for the results to be stable, thus creating a 
Markov chain which converges in distribution to G(, H|).  This simulates independent 
draws of the missing values from the posterior distribution.  Various prior distributions can be 
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used, either non-informative priors when no prior information exist, or informative priors where 
appropriate.  
 
Multiple imputation can also be done through multivariate imputation by chained equations 
(MICE), also known as fully conditional specification and sequential regression multivariate 
imputation.  MICE assumes the missing data are MAR given the variables used in the imputation 
process.  Many multiple imputation procedures assume a large joint model for all the variables, for 
example a joint normal distribution.  In the MICE procedure a series of regression models are run 
where each variable with missing data is modelled conditional on the other variables in the 
imputer’s model.  Each variable can be modelled according to its own distribution.  Binary 
variables can be modelled using logistic regression and continuous variables can be modelled using 
linear regression (Azur et al., 2011; White, Royston, & Wood, 2011).   
 
Initially, a single imputation, using mean imputation or simple random sampling, is performed for 
every missing value in the data set (called a place-holder imputation).  These placeholder 
imputations for one variable (variable A) are then set back to missing.  A regression model is then 
fitted with variable A as the dependent variable and the other variables in the imputation model as 
independent variables.  The missing values for variable A are replaced by simulated draws from the 
corresponding posterior predictive distribution of variable A.   When variable A is subsequently 
used as an independent variable in the regression models for other variables, both observed and 
imputed values are used.  This process is repeated for all variables that have missing data and all 
missing values are imputed.  These steps are repeated for a number of cycles, generally 10 to 20, 
with the imputations being updated at each cycle.  At the end of these cycles the final imputations 
are retained, resulting in one imputed data set.  By the end of the cycles, it is important that 
convergence is achieved and the distribution of the parameters governing the imputations become 
stable.  This will avoid dependence on the order in which the variables are imputed.  The 
convergence can be checked by comparing the regression models at subsequent cycles.   This 
process is then repeated to create the m multiple imputed data sets (Azur et al., 2011; White et al., 
2011).   
 
MICE is flexible and can impute many different types of data (binary, ordinal, unordered 
categorical and continuous) because each variable is imputed using its own imputation model.  
Justification of the MICE procedure rested on empirical studies rather than clear theoretical 
rationale.  Fitting a series of conditional distributions may not be consistent with a proper joint 
distribution.  A consequence of incompatible conditional regressions is that the distribution of 
imputed values may depend on the order in which the variables were imputed (Azur et al., 2011; 




When there are relatively few variables needing imputation, the variables are continuous and 
approximately normally distributed (in which case a multivariate normal model would be 
appropriate) a multivariate normal model may be preferable.  Results based on MCMC sampling 
assuming that the data are multivariate normal agree asymptotically with those from MICE when 
all imputation models are linear (Azur et al., 2011; White et al., 2011).  
 
Multiple imputation is said to be proper if it leads to consistent asymptotically normal estimators, 
correct variance estimators and valid tests.  Proper multiple imputation will be multiple imputations 
for which Rubin’s rule yields a consistent asymptotically normal estimator of the unknown 
parameter and a weakly unbiased estimator of the asymptotic variance in sufficiently regular 
models (Rubin, 1987).  Proper multiple imputations are imputations where the values of the 
complete data statistics Q and U created through the multiple imputation are approximately 
unbiased for the complete-data analogues for large m; thus  
E(58I|J, -) =  56  and 
E(23I|J, -) =  2 and 
E(4I|J, -) =  KLM(58I|J, -) 
where B is the variance-covariance matrix (Rubin, 1996).  Rubin (1987) concluded that if 
imputations are drawn from a Bayesian posterior distribution of Ymis under the response mechanism 
and an appropriate model for the data, then in large samples the imputation is proper.   
 
Imputations drawn from a Bayesian predictive distribution are proper when the model used for the 
imputations and the model used for the analysis are compatible.  When 56 or U involves some 
variable, X, then leaving X out of the imputation scheme would result in an improper imputation, 
which would lead to biased estimation and invalid inference.  Variables correlated with the imputed 
outcome and not included in the set of predictors will lead to bias.  At a minimum clustering and 
stratification indicators and sample design weights should be included in the imputation model.  
Therefore the biggest problem with the imputer’s model is excluding variables associated with the 
outcome.  Including too many variables and including unimportant variables can lead to a small 
loss in precision but this is unimportant compared to the increased validity achieved when relevant 
variables are included.  It is therefore recommended that as many variables as possible are included 
in the imputer’s model (Rubin, 1996).  Any variables that will be included in subsequent analyses, 
including interactions, should be included in the imputer’s model.  The imputer’s model can 
include variables that will not be included in the analysis model.  Generally the imputation will be 
proper if all sources of variability and uncertainty are included in the imputed values, including 
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prediction errors of the individual values and errors of estimation in the fitted coefficients of the 
imputation model (White et al., 2011).   
 
Proper multiple imputation requires that the imputed data are drawn from the Bayesian posterior 
distribution where uncertainty about the parameters in the imputation model is properly 
represented, using uninformative priors for the parameters.  Each set of imputed data will be based 
on a different set of model parameters, which are drawn for each imputation from the Bayesian 
posterior (Carpenter & Kenward, 2007).   
 
Multiple imputation can be used with various analysis methods.  It can be used with a cross-
sectional analysis at the endpoint, a selection model, a pattern-mixture model or a shared-parameter 
model (Carpenter & Kenward, 2007; Janssens, Molenberghs, & Kerstens, 2012).  Step 2 in the 
methods above is varied to use the method most appropriate to the problem at hand. 
 
Little and Yau (1996) proposed a method where multiple imputation is used to analyse the data 
according to the ITT principle.  Missing values of the outcome are imputed with multiple 
imputation using a model that conditions on the actual, or assumed, treatments received.  The 
imputed data are then analysed based on the treatment as randomised.  Observed variables that 
improve the imputation should be included in the imputation model even if they are not included in 
the analysis model; in this example actual treatment received is such a variable.   
 
Multiple imputation can be used either in a longitudinal or cross-sectional setting.  Longitudinal 
outcome data can be imputed by regarding the different time points as different variables. For 
example, with three time points, the outcomes at t =1, t=2 and t=3 are included in the imputer’s 
model.  However, the time dependent property of longitudinal data is not taken into account during 
imputation, for example that the observation at t = 1 is before the observation at t = 2.   
 
Several researchers have developed methods to undertake multiple imputation in a longitudinal 
setting.  For example Liu, Taylor, and Belin (2000) implemented a random coefficients model to 
impute incomplete multivariate continuous longitudinal data.  Multivariate repeated measures were 
jointly modelled, a normal model was assumed for time dependent variables in a regression model 
conditional on the time independent variables and time.  Gibbs sampling in which the parameters 
and missing values are drawn iteratively from conditional distributions was used to draw model 
parameters and impute missing observations.  Li, Mehrotra, and Barnard (2006) used a propensity 
score-based multiple imputation method for longitudinal data with binary responses.  The 
imputations are done sequentially over time.  Missing responses at time 2 were imputed first given 
data at time 1, then missing responses at time 3 were imputed given the observed plus imputed data 
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at times 1 and 2, etc.  A propensity score was calculated at each time point with missing data and 
the propensity scores at each time point were used to group participants.  Missing values were then 
imputed separately for each propensity score group to produce a complete data set.  This 
imputation process was then repeated multiple times to create m complete data sets.   
 
Several authors also describe methods for multiple imputation of time dependent covariates in a 
longitudinal setting.  Carrigan et al. (2007) introduced a random intercept into the imputation 
component of the model to incorporate within-participant correlation and take into account the 
longitudinal study design.  Nevalainen, Kenward, and Virtanen (2009) extended an iterative 
procedure, fully conditional specification, to generate values of a time-dependent covariate in the 
repeated measurement setting by being doubly iterative over the follow-up time of individuals.  
These methods were developed to impute covariates but can also be adapted to impute repeated 
outcome variables. 
 
Rubin (1987) argued that only three to ten imputations are needed and five imputations is often 
used as default.  Rubin showed that the efficiency of an estimate based on m imputations is 
approximately (1 +  N), , 
where γ is the rate of missing information.  If the rate of missing information is 30% or lower, five 
imputations provide a 94% efficient estimator.  With 50% missing information, five imputed data 
sets produce a point estimate that is 91% as efficient as one based on an infinite number of 
imputations, and 10 data sets produce a point estimate that is 96% efficient.  With higher rates of 
missing information, more imputations had larger added benefit.  For example, if the rate of 
missing information was 90% then five imputations had 85% efficiency and 20 imputations had 
96% efficiency.   
 
Rubin’s (1987) formula focused on relative efficiency but did not take precision of standard errors 
and other estimates into account.  Both efficiency of the point estimate and precision of estimation 
play a role in the number of imputations needed.  With few imputations the standard error and 
therefore p-values and confidence intervals can be unstable.  Looking at precision of standard 
errors instead of relative efficiency authors have recalculated the number of imputations needed 
and came up with larger numbers than Rubin did.    
 
Graham, Olchowski, and Gilreath (2007) did simulations and found that 20 imputations led to a 
small loss of power with 10-30% missing information.  If missing information was 50%, 40 
imputations were recommended.  Bodner (2008) also illustrated that less than ten imputations led 
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to substantial imprecision in important quantities based on the standard error such as p-values, 
confidence intervals and fractions of missing information.  For example, with 50% missing 
information they recommended that 50 imputations were needed to achieve specified precision at 
95% confidence levels.  White et al. (2011) went further than considering statistical efficiency and 
power.  They were interested in the repeatability of results and considered the Monte Carlo error 
(standard deviation across repeated runs of the same imputation procedure with the same data) of 
the results.  Monte Carlo errors will be smaller with a larger number of imputations.  They derived 
an easy rule of thumb, namely that the number of imputations should at least be larger than the 
percentage of missing data.   
 
With easily available computing resources, there is no reason for a large number of imputations not 
to be used in relatively small data sets.  White et al. (2011) recommend 100 to 500 imputations.  
Taking efficiency, power and precision into account it is recommended that 50 to 100 imputations 
are done.   
 
Multiple imputation gives similar results to likelihood analyses when the imputation model is 
congenial, especially as the number of imputations increases.  Multiple imputation offers 
advantages if covariates are missing, because likelihood analyses in these instances might be 
impracticable.  Where responses only are missing and likelihood analysis is possible, multiple 
imputation adds little advantage (Molenberghs & Kenward, 2007).   
 
Multiple imputation does not aim to create information by simulating values, but it rather tries to 
represent the observed information in a way that enables valid analysis with complete data tools, 
while taking account of increased variability created by missing data. The simulation is only used 
to handle the missing information.  The rest of the information is handled by the complete data 
method (Rubin, 1996).  Over the past decade multiple imputation has become one of the most used 
methods to handle missing data, probably due to its ease of use and versatility. 
3.3 Modelling frameworks 
Any analysis should be based on explicit and understandable assumptions.  Three main frameworks 
exist where approaches to missing data can be developed.  These are selection models, pattern-
mixture models and shared-parameter models.  Each is discussed briefly.   
3.3.1 Selection models 
Selection models require the specification of the full data model and a selection model that 
characterises the probability of data being missing as a function of covariates and the full data 
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(Hogan et al., 2004).  In a selection model, the joint distribution of the ith participant’s outcomes, , and missingness indicators, , is factored as the marginal density of the measurement process 
and the conditional distribution of the missingness process given the measurement model (| ); thus  ( ,  |J , O, ", ) = (|J, ")(| , O, )  
where J is a design matrix for the measurement process and O is a design matrix for the 
missingness mechanism. 
 
It is called a selection model, since  (| , O, )  can be seen as a participant’s selection 
process to continue or leave the study.  Participants are thus selected for dropout by their response.   
A participant’s missing values are selected through a probability model, given their measurements, 
whether observed or not (Molenberghs & Kenward, 2007).   
 
If we assume that the missing data process is MCAR this translates to 
                                      (, |J, O, ", ) = $|J, "&(|O , ). 
If we assume that the missing data process is MAR this factorisation translates to                                         (, |J, O , ", ) = $|J , "&$|, O, &. 
This implies that the marginal model for the observed data only, is required.  The joint likelihood is 
factored into a term including the observed data and θ and a term including the missingness 
indicator and ψ.  The measurement model, $|J, "&, and the missingness model, (|) or $|, O , & can be fitted separately, provided that the separability requirement holds. This 
implies that the parameters, θ and ψ, are functionally independent or distinct of each other 
(Molenberghs & Kenward, 2007).  In that case inference for θ can be drawn from the observed data 
alone.  In the MAR case covariates associated with missingness should be included in the model 
(Carpenter et al., 2002).   
 
If the missingness is assumed to be MNAR, then the joint likelihood cannot be simplified.  Thus, in 
order to find the maximum likelihood estimates, integration is required.  Since this is not possible 
analytically, numerical integration is required to find the maximum.  This can be difficult and time 
consuming.  An EM algorithm or MCMC approach could be considered (Carpenter et al., 2002).  
In a Bayesian framework the missing observations are regarded as parameters and if vague priors 
are used the posterior means could be good approximations of the maximum likelihood estimates. 
The MNAR model has the same structure as the MAR model, with terms relating the missing data 
indicator to the individual’s value of the outcome variable at time j, earlier time points and baseline 




In the special case of dropout, denote the time at which dropout occurs as Di, if no dropout 
occurred, Di = ni + 1.  Diggle and Kenward (1994) combined a multivariate normal model for the 
measurement process, (|J , "), and a logistic regression model for the dropout process, (| , O , ).  Define P = (  , … , ,,)′ as the observed history of participant i up to time Q,,.  The logistic dropout model could be written as  lSTUQVW$ = X%  ≥ X, P,  , &Z =  [? + [ + [9,,. 
 
If [ = 0  then this model refers to the MAR case, since dropout does not depend on the current 
measurement and when [= [9= 0 this model refers to the MCAR case, since dropout does not 
depend on the outcome at all.  The parameter and precision estimates are obtained using maximum 
likelihood.  This involves computationally demanding integration, making this model difficult to 
use.  Two key features of this model determine the identification of parameters:  normality of the 
response distribution and linear dependence between  ]STUQVW$ = X%  ≥ X, P,  , &Z 
and Yij.  It is not possible to evaluate whether the normality assumption holds if data are missing.  
Knowledge of the subject matter is often used to determine whether it is plausible that the data are 
normally distributed (Hogan et al., 2004). 
 
Parametric selection models in a MNAR context raise problems around the identification of 
parameters and sensitivity to assumptions.  These problems can be somewhat alleviated or at least 
illuminated by the use of semi-parametric selection models (National Research Council, 2010).  
Semi-parametric selection models can be constructed by using a parametric model for the missing 
data mechanism and a semi- or non-parametric model for the observed data or the complete data 
distribution. For example Rotnitzky, Robins, and Scharfstein (1998) considered such a non-
likelihood approach and proposed a class of augmented inverse probability weighting estimators, 
an extension of GEE.  When joint estimation of the non-response parameter and the outcome 
measure parameter is difficult, they proposed regarding the nonresponse model parameter as 
known and performing sensitivity analysis to determine how the outcome measure parameter 
changes.  Scharfstein, Rotnitzky, and Robins (1999) extended this by allowing semi-parametric 
nonresponse mechanisms. 
 
Conceptually selection models involve two stages.  These stages are usually performed 
simultaneously.  The first stage is to develop a predictive model for whether or not a participant has 
missing data with variables obtained prior to the missing data (such as at baseline).  This model of 
missingness provides a predicted probability of missingness or propensity for each participant.  
These missingness propensity scores are then used in the second stage longitudinal data model as a 
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covariate to adjust for the potential influence of missing data.  By modelling the missingness 
process, selection models provide valuable information regarding the predictors of missingness.   
 
Different models may be appropriate for the missingness model.  One model could assume that 
observations are missing at certain visits, but the participant may be observed again at the next 
visit.  In this instance the simple model for the response at visit j can be given as:   ]STUQ W$ = 1& =  ̂ + _. 
In other words the log odds of observing participant i at visit j depends on the visit and on the 
response.  This model cannot be fitted alone.  Using numerical integration over the unobserved 
responses, it can be fitted in conjunction with a mixed model for the response.  δ depends on the 
distributional assumptions about the missing data.  If δ = 0, the MAR assumption holds and the 
probability of response does not depend on the missing observations.  A more plausible model 
could also include other covariates and the outcome variable observed at previous visits.  The more 
complicated model could be given as  ]STUQ W$ = 1& =  ̂  + `.# + a-,, +  _ 
(Carpenter & Kenward, 2007). 
 
The above model can accommodate withdrawal by adding 
P$ = 1|,, = 0& =  0 where j >1. 
If withdrawal does not depend on the last observation, but on the pattern of observations 
throughout the trial, one can replace - in the above model with the slope for participant i 
(Carpenter & Kenward, 2007).   
 
Selection models require integration over the missing data.  This can be done using numerical 
integration.  Selection models could have limited practical use, since they require specialised 
numerical routines for maximising the likelihood.  The likelihood could also be flat with respect to 
parameters that characterise the non-MAR selection, leading to numerical instability (Hogan et al., 
2004).     
 
Bayesian models with vague priors can also be used to fit these models, using MCMC methods 
(Carpenter & Kenward, 2007).  Carpenter et al. (2002) suggested that selection models be fitted 
using a Bayesian framework since it is easier to program, quicker to estimate and flexible.  They 
fitted it in BUGS (Spiegelhalter et al., 1995) using non-informative or vague priors.  Using vague 
priors implies that the parameter estimates approximate maximum likelihood estimates.  Within 
BUGS the sensitivity of the model to non-random missingness can be assessed.   
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3.3.2 Pattern-mixture models 
Little (1993, 1994) described a class of models to model the dependence between missing response 
and dropout; calling these pattern-mixture models.  He gave a statistically rigorous treatment of 
random-effects pattern-mixture models for longitudinal data with dropout.  According to Little 
MAR assumptions need not be made; a model can be specified that does not require the missing 
data mechanism to be ignorable.  Participants are divided into groups according to their missing 
data pattern.  This method enables one to assess the degree to which important model terms depend 
on the missing data pattern (Hedeker & Gibbons, 1997).  
 
Pattern-mixture models provide a flexible class of models for data that are not MCAR (Little, 
1993).  Pattern-mixture models are based on the factorisation  
(, |#, ", ) = (| , #, ")(|, #, )                 (Equation 1) 
where the distribution of  is conditioned on .  The pattern-mixture model is based on a 
marginal model for the dropout process and a conditional model for the observed outcome given 
the dropout pattern (Verbeke, Lesaffre, & Spiessens, 2001).  This allows for a different response 
model for each pattern of missing values.  The observed data are a mixture of these weighted by the 
probability of each missing value or dropout pattern (Molenberghs & Kenward, 2007).  The term 
pattern-mixture is derived from this and reflects that the marginal distribution of Y is a mixture of 
distributions (Little, 1993).  If the missing data mechanism is ignorable then the component (|, #, [) gives no information about θ and can be ignored for the likelihood inference.  It can be 
based on the likelihood obtained by integrating missing values out of the density (| , # , ") 
(Little, 1993; Little, 1994).   
 
Define ti, the last occasion at which a measurement was obtained, as Q =  − 1; and ti is the 
realisation of the dropout index Ti.  Then the factorisation of Equation 1 becomes (, Q|#, ", ) = (|Q , #, ")(Q|, #, ). 
Consider a trivariate normal outcome where Ti can take values 1 and 2 for dropouts and 3 for 
completers.  A pattern-mixture model implies a different distribution for each time of dropout, with |Q ~ c [ e (Q) , f ( Q )] (Molenberghs & Kenward, 2007). 
 
Consider the case of a two-arm randomised trial.  For simplification of notation, two dropout 
categories are considered only; either a participant completed the trial or did not complete the trial.  
This can be extended to more patterns.  Let 
YiC : Response for the i
th participant in the control arm 




πC : Probability of withdrawal in the control arm, πC = P(RiC = 0) 
YiI, RiI and πI is defined similarly for the intervention arm 
 
In the control arm, observed responses come from a distribution with mean µC and variance σ
2, 
while unobserved responses, in participants who dropped out, come from a shifted distribution with 
mean µC + δC and variance Cg9 , where δC is the difference in the control arm between the true mean 
of the unobserved data and the true mean of the observed data.  Thus -h| h = 1 ~ ( µh , C9) -h| h = 0 ~ ( µh + _h , Cg9 ) 
For the intervention arm, µ I and δI are defined similarly.  The variances are assumed to be equal in 
the control and intervention arms.  Under this model the average response in the control arm is  
(1-πC) µC + πC (µC + δC). 
The average response in the intervention arm is 
(1-πI) µ I + πI (µ I + δI). 
If δC = δI = 0 then the MAR assumption holds.  The average effect of the intervention is  
∆ = (1-πI)µ I + πI(µ I + δI) – [(1-πC)µC + πC(µC + δC)] = (µ I - µC)+ (δIπI - δCπC) 
The average treatment effect amongst completers, (µ I - µC), can be estimated using the complete 
case analysis.  Therefore the total treatment effect is equal to the treatment effect in completers plus 
the bias due to informative withdrawal (Carpenter & Kenward, 2007).   
 
The assumptions made by the pattern-mixture model are the following: 
• In this example, normality is assumed within pattern.  Non-Gaussian outcomes can also be 
accommodated.   
• The conditional distribution of the outcome is assumed to depend on the dropout time only 
through the dropout pattern.  Outcome is assumed to be independent of dropout within a 
pattern. 
• Intermittent missingness is assumed to be MAR. 
• Variances are assumed to be constant across patterns, but this assumption can be relaxed. 
• Covariate effects are the same for missing and observed data within a dropout pattern (Hogan 
et al., 2004).   
 
White et al. (2007) took a Bayesian approach in a non-longitudinal setting and assumed a prior 
distribution for the informative missingness parameters.  In the control arm the distribution of _h~c(=h , jh9) and in the intervention arm the distribution of _k~c(=k , jh9).  White et al. then 
assume non-informative priors, independent of δ.  The probability of dropout, πI and πC, are 
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estimated by the fraction of dropouts in each of the arms (pI and pC).  The posterior mean and 
variance of the treatment effect is estimated by correcting the complete case estimate taking 
account of the informative dropout.  Let ∆hh = (µ I - µC) and jm(∆6hh)  be the standard error of the 
complete case treatment estimate.  Then the posterior mean is calculated as: ∆6hh + =kGk − =hGh, 
while the posterior variance is given by: 
jm(∆6hh)9 + Gk9jk9 − 2ojhjkGhGk + Gh9jh9 +  (=k9 + jk9) Gk(1 − Gk)k + (=h9 + jh9) Gh(1 − Gh)h  
 
The posterior mean is the mean of the complete case analysis corrected for the prior distribution of 
the means and the observed proportion of drop outs.  The estimate for the posterior variance 
includes the variance for the complete case estimate corrected for uncertainty about δC, δI, pC and pI 
and using the prior variances sC and sI.  The latter terms decrease with sample size.  This method 
inflates the standard error to reflect uncertainty due to missing information.  It is also possible to 
include covariates on which dropout and outcome depend (White et al., 2007).   
 
White et al. (2007) elicited the distribution of possible values of the parameters in the prior 
distributions from experts in the field by obtaining opinions from experts on the difference in true 
means between the observed and unobserved data.  The concept of a correlation was too unfamiliar 
to the experts and information on the correlation between δC and δI could not be elicited.  If no prior 
information is available, a working value of the correlation can be adopted and the value for δ 
which causes the treatment effect to be non-significant is then found.  Zero is a good choice for the 
correlation since this gives the widest confidence intervals.  The plausibility of this value of δ is 
then assessed.  If the reasons why outcomes are missing are recorded it may be appropriate to have 
a different δ parameter for each reason.  Separate δ parameters should be perfectly correlated 
within trial arms; introducing imperfectly correlated δ parameters would erode the systematic 
element and artificially reduce the correction for dropout. 
 
These pattern-mixture models could be implemented with random-effects mixed models.  The steps 
in implementing these models are as follows: 
1. Assign a variable or a set of dummy variables that identify the pattern of the missing data.  
Some patterns of missing data can be grouped together if some groups are small. 
2. Fit a mixed model with the pattern of missing data variable as a main effect and as an 
interaction with other effects in the model. 
3. Derive an overall averaged estimate for the model parameters, averaging over the missing 
data patterns.  Estimates are obtained for the fixed effects separately for completers 
(>Bp) and dropouts (>Bq).  Averaged estimates for these parameters are then equal to 
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>B = rp>Bp + rq>Bq 
where rp and rq represent the population weights for completers and dropouts.  These 
weights can be estimated by the sample proportions.  Estimates of the standard errors can 
be obtained using the delta method (Hogan and Laird 1997) as described in Section 3.3.2.1. 
 
Pattern-mixture models can be used with random-effects models, but can also be used with other 
longitudinal methods that allow for missing data across time, such as structural equation models 
and GEE (Hedeker & Gibbons, 1997).  Hedeker and Gibbons only discussed the implementation 
with mixed models.  
 
Carpenter and Kenward (2007) suggested the use of a pattern-mixture approach implementing 
multiple imputation.  The analysis proposed by White et al. (2007) can be extended to longitudinal 
data by modifying the conditional distribution of the missing data given the observed data under 
MAR after a participant dropped out.  The assumption is made that participants who drop out have 
on average a poorer (or different) response than predicted by MAR.  Let the change in rate of 
decline be denoted by δ.  Then the conditional mean for the first response after withdrawal is 
reduced by δ, the second by 2δ, etc (see Figure 3.1).  The mean and variance of _s for all treatment 
groups l are elicited from experts.  It is assumed to be normally distributed.  The correlation 
between any two treatment arms should also be elicited.   
 
This approach uses multiple imputation as follows:  The MAR assumption is made and m 
imputations are created.  With two treatment groups the following is sampled for each of the k 
imputations:  
tuvu9vw ~c xt__9w , y C9 C9C9 C99 z{ 
For each imputation the first MAR imputed value is decreased by usv ,  the second by 2usv, etc.  
The data sets are then analysed as discussed in Section 3.2 for multiple imputation.  If the time 
between observations is not equal, the multipliers of d can be chosen to reflect the spacing between 
observations. Interim missing observations can be decreased by us or can be left with the MAR 
imputed values.  This is consistent with assuming that interim missing data are different from drop 
out and is truly random, whereas participant drop out is not random.  In the absence of prior 
information one can set _ = _9. 
 
Pattern-mixture models are under-identified and hence over-specified.  If data are missing then 
there are no data to identify the Q|}component of e(Q) or the Q|}column of f(Q).  The data supply 
no information about the parameters of the distribution with missing data (Little, 1993).  Little 
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(1993, 1994) solves this problem by placing restrictions.  The restrictions depend on the missing 
data mechanism assumed and reflect the contextual knowledge of the nature of the mechanism 
creating the missing data.  Inestimable parameters of the incomplete patterns are set equal to 
functions of the parameters describing the distribution of the completers.  Alternative approaches 
for overcoming the under-identification exist (Molenberghs & Kenward, 2007).  Molenberghs and 
Kenward (2007) argue that the under-identification can be seen as an advantage, because it forces 
one to make assumptions transparent.  This serves as a useful starting point for sensitivity analyses.   
 
 
Figure 3.1:  Schematic illustration of increasing the rate of decline by δ after 
withdrawal (Carpenter & Kenward, 2007)  
 
Little (1994) advocated the use of identifying restrictions and listed some.  In the case of monotone 
missing data, with t = 1, …,n dropout patterns, the complete data density for pattern t is given by 
),...,|,...,(),...,(),...,( 1111 tnttttnt yyyyfyyfyyf += . 
The first factor can be identified or modelled from the observed data.  The second factor is not 
identified from the observed data.  Identifying restrictions are applied in order to identify the 
second component.  One can base identification on all patterns for which a given component is 






jsjsst yyyfyyyf ω  
with s = t+1,…,n.  Thus  



















Different choices can be made for sω , leading to different special cases of the above equation.  
The only restriction is that the ~ are non-negative and sum to one (Thijs et al., 2002). 
1. Complete case missing values (CCMV).   
In the complete case missing value approach 1=snω  and all other ω  = 0.  This implies 
that missing information is borrowed from the completers only.  If the model effect for a 
dropout pattern cannot be estimated, the estimated model effect of the fully observed 
pattern will be used.  This method requires a reasonable number of complete cases and can 
be inefficient if the fraction of complete cases is small (Little, 1993). 
2. Neighbouring case missing values (NCMV).   
In this instance 1=ssω  and all other ω = 0 are missing.  Information is borrowed from the 
closest available pattern (Kenward, Molenberghs, & Thijs, 2003).   





















where jα is the fraction of observations in pattern j.  In the absence of an estimate ACMV 
will average over all patterns where the model effect could be estimated.  The average is 
weighted proportional to the number of participants in the pattern.   This is the counterpart 
of MAR in the pattern-mixture model context.  The other two identifying restrictions 
(complete case missing values and neighbouring case missing values) lead to MNAR 
models (Molenberghs & Kenward, 2007; Molenberghs et al., 1998). 
 
Previously three steps in fitting pattern-mixture models with random-effects mixed models were 
given.  Here we give the steps to fit pattern-mixture models using identifying restrictions (Kenward 
et al., 2003; Thijs et al., 2002): 
1. Specify and fit a model to the pattern specific identifiable densities ),...,( 1 nt yyf . 
2. Choose a model for ),...,|( 11 ttt yyyf +  or select an identification method.  This can be 
done in a data independent way by placing a prior on the parameters.  If this is done in a 
data dependent way procedures described in number 4 below can be followed.   
3. Using this model or identification method, the conditional distribution of the unobserved 
outcomes, given the observed ones, ),...,|,...,( 112 ++ tntt yyyyf , is determined.   
4. Inference is now based on the observed quantities using the full distribution specified.  
This could imply integration over the distribution of the unknown quantities.  However, 
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simulation-based approaches such as multiple imputation is often implemented.  The 
multiple imputation is done for the unobserved components, given the observed component 
and the pattern-specific densities.   
5. The multiple imputed data sets are then analysed using proper methods as described in 
Section 3.2, a pattern-mixture model, selection model or any other model would be 
appropriate.  The analysis model does not need to be the same as the imputation model.   
 
Instead of identifying restrictions model simplification can be done to identify the parameters 
(Thijs et al., 2002).  Two types of simplification can be done in fitting pattern-mixture models.  The 
trend can be restricted to functional forms supported by the information available in a pattern.  
These models are fitted by creating a model within each of the patterns separately.  Secondly, the 
parameters can vary across the patterns in a parametric way; for example, it could be assumed that 
the time trend is parallel across patterns.  These models are fitted by treating the pattern as a 
covariate (Hogan & Laird, 1997; Michiels et al., 2002; Thijs et al., 2002).  The available data can 
be used to assess whether such simplifications are supported where data are available.  It is argued 
that these solutions are assumption rich.  If identifying restrictions are used, the assumptions are 
more clearly specified. 
 
Estimation relies on linearity and homoscedasticity of the regression and the missing data 
mechanism is assumed to depend on Yi in an additive manner (Little, 1994).  Maximum likelihood 
methods for selection models require numerical methods, whereas the pattern-mixture models lead 
to maximum likelihood estimates with explicit forms (Little, 1993). 
 
Pattern-mixture models can be used under ITT in a two arm trial of active treatment versus placebo 
by making two assumptions.  The first is that participants who withdraw discontinue treatment and 
the second is that future outcomes given past outcomes are the same for participants who withdraw 
in the active arm as for participants in the placebo group with the same past.  The appropriate 
pattern-mixture model can be constructed by using the estimated model from the placebo group to 
represent the future behaviour of withdrawals from the active group.  This model for the future 
behaviour is the MAR model for all observed data and can be consistently estimated from the 
observed data.  This pattern-mixture model differs only from a likelihood model fitted under MAR 
in its implications for the unobserved behaviour of withdrawals from the active group.  Imputations 
for future outcomes differ between the two models, and this affects the estimated final treatment 
comparisons.  A variety of alternative pattern-mixture models can be constructed to examine the 




Little and Yau (1996) call this model the zero dose model.  They also suggested other applications 
of pattern-mixture models for example the continuing dose and the nearest dose model.  They 
proposed that missing values of the outcome after drop out be imputed with multiple imputation 
using a model that conditions on the actual, or assumed, dose of treatments received after dropout; 
data are thus imputed according to different patterns depending on the actual treatment received, 
leading to sensitivity analyses.  In their study they collected information on the doses received after 
dropout.  In the nearest dose model, cases in the control group are assigned a zero dose after drop 
out and cases in the treatment group are assigned a treatment dose group closest to the actual 
recorded dose after drop out.  The data imputed using the data observed after drop out are then 
analysed based on the treatment as randomised, according to the classical ITT principle.   
 
Pattern-mixture models can be factorised as follows: 
)(),...,|,...,(),...,|(),...,(),,...,( 1121111 tdfyyyyfyyyfyyftdyyf ttntttttttn === +++   
(Kenward et al., 2003).
 
 
Fitting a pattern-mixture model creates some complications.  One pair of treatment contrasts is 
created for each pattern fitted.  One can either fit a stratified analysis, where the null hypothesis 
addresses all the pairwise contrasts simultaneously or one can analyse the marginal effects, for 
example a single marginal treatment contrast (Hogan & Laird, 1997).  Pattern-mixture models do 
not automatically provide estimates and standard errors of marginal quantities of interest, such as 
the overall treatment effect (Thijs et al., 2002).  The marginal contrasts are obtained by weighting 
each of the treatment estimates by the number of participants in the pattern.  The marginal within-
imputed and between-imputed variances are obtained using the delta method (Hogan & Laird, 
1997). The primary analysis usually is the marginal analysis (Kenward et al., 2003).   
 
Pattern-mixture models can also be used to identify which patterns are responsible for a treatment 
effect.  The stratified analysis allows a more detailed consideration of the treatment effect 
(Kenward et al., 2003).   
 
When the marginal distribution of the outcomes is of interest, the mixing over the different dropout 
patterns is needed.  These models often include many parameters and some may be estimated 
inefficiently (Verbeke et al., 2001).  An advantage of pattern-mixture models is that it is regarded 
as more honest than other methods since the untestable assumptions are stated and not implicit.  
The need for assumptions and their implications are more obvious in pattern-mixture models.  
These models could also be computationally easier to execute (Michiels et al., 2002).  With pattern-
mixture modelling one can decide whether or not to model the data beyond the moment of dropout, 
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whereas with selection models this always happens (Thijs et al., 2002).  However, in order to 
estimate the large number of parameters in most pattern-mixture models, each dropout pattern 
needs to occur sufficiently often (Hogan & Laird, 1997).   
 
Pattern-mixture models play a role in sensitivity analyses, because they separate the observed data 
distribution and the predictive distribution of missing data given observed data (National Research 
Council, 2010).   
3.3.2.1 The Delta Method 
The derivation of most of the theory discussed in this overview chapter is available in referenced 
texts and was not repeated here.  However, the formulas for using the delta method to calculate the 
standard errors are not available when there are more than two categories of missing data.  This 
section therefore gives the complete derivation using the delta method where there are three or four 
groups in the pattern-mixture model.  These derivations are done so that variances and parameter 
estimates obtained from standard procedures in standard statistical software can be used to 
calculate the standard error, thus increasing the likelihood that it can be used by practicing applied 
statisticians.  Generalisation to any number of groups is relatively straightforward and can be done 
conveniently using vector and matrix algebra. 
 
The delta method can be applied to calculate the variance when a pattern-mixture model is used.  
This is described for the two and three group example.  The theorem and proof for the univariate 
version of the delta method is given in Casella and Berger (2002), page 243.  The theorem states 
that if H6 is a sequence of random variables that satisfies √$H6 − H& → c(0, C9) 
in distribution, then for a given function T, √VT$H6& − T(H)Z  →  c(0, C9[T.(H)9); 
provided that T.(H) exists and is not 0.   
 
A multivariate version of the delta method was also specified (Casella & Berger, 2002).  Assume 
that  "0 is a p x 1 vector with an asymptotic normal distribution: √("0 − ") → c(, (")), 
where (") is a p × p asymptotic covariance matrix of √0.  For large n, 0 is distributed c(",  (")) or c(", (")), where (") =    (").  Let (") be a vector function of θ, i.e.  (") = (T("), T9("), … , T("))., 
which has a continuous first partial derivative.  Then  
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√ [$T$"0& − T(")Z → c(0, ;() < (") ;() <.). 
 
Hedeker and Gibbons (1997) calculated an overall estimate per treatment arm combining the 
pattern observed in the completers and the pattern observed in the dropouts.  This is done by letting Jp denote the number of completers and Jq denote the number of dropouts. The proportion of 
completers and dropouts are given by rp and rq , respectively, and the parameter estimates in the 
completers and dropouts are denoted by >p and >q. Furthermore, rq = 1 − rp, since rp + rq = 1.  
Now let " =  [rp , >p , >q  . and T() =  rp>p + rq>q. 
The averaged overall estimate is then calculated by replacing the π’s with the proportion of 
participants in the sample in the appropriate group and replacing the β’s with the estimate of the 
parameter in each of the groups.  The authors give a formula for calculating the variance of T() but do not show the derivation of this formula.  It is derived as follows for each of the fixed 
effects.  The superscript denoting the fixed effect is excluded to simplify the formulas. 
 
It follows that Jp~ 4c(, rp  ), and rDp =   ≃ c(rp , (,) )]. 
The variance-covariance matrix of "0 is given by 
E$"0& =  (,) 0 00 KLM(>Bp) 00 0 KLM(>Bq) =
K 0 00 K9 00 0 K. 
Completers and dropouts are assumed to be independent groups.  The function T() can also be 
written as T() = rp>p + (1 − rp)>q, 
giving 
()  = >p −  >q;  () =  rp and () = 1 − rp  . 
 
VVg$0&Z =  [>p − >q , rp , 1 − rp K 0 00 K9 00 0 K 
>p − >qrp1 − rp  
=  [K(>p − >q), rpK9, (1 − rp)K >p − >qrp1 − rp  = K(>p − >q)9 +  rp9 K9 +  (1 − rp)9 K 
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= (>p − >q)9     (,)  + rp9  var(>p) + (1 − rp)9  var(>q). 
 
The estimate of the variance is  var Vg$0&Z = (>Bp − >Bq)9  (,) +  (rDp)9var (>Bp) + (1-rDp)9var (>Bq)                    = (>Bp − >Bq)9    + (rDp)9var (>Bp) + (rDq)9var (>Bq). 
 
The extension of the above to three groups is as follows: 
For three groups, say A, B and C, let the population weights be r, r and rp and r + r + rp = 1, 
so that  rp = 1 − (r + r). 
The vectors of the parameter estimates from the individual models for each of the patterns are ` , `¡ and `h.  Let " = (r, r , > ,>¡, >h) and as in the two group case,  
let T() = r>  + r>¡ + rp>h 
which can also be written as  T() = r>  + r>¡ + [1 − (r + r)>h and 
V(0) =
¢££
£¤var(rD) cov ¡ 0cov ¡ var(rD) 0000
000
var(>B)00




where covª«= cov(π­, π®). 
 
The plausible multinomial assumption is made that the three dropout status groups are independent, 
therefore the covariances between the β’s are 0.  However, the proportions rD and rD are not 
independent and the covariances are not 0 in that case.  The required derivatives are: ()¯  = >  − >h  
 
()°  = >¡ − >h  
 
()¯  = r  
 
()°  = r  
 
()±  = 1 − (r + r ). 
 
VVg$0&Z =  V>B  − >Bh ,  >B¡ − >Bh ,  π­,  π®, ²1 − (π­ + π®)³ZV(θ6) µ¶T(")¶H · 
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= V$>B  − >Bh&KLM(rD) + oSK ¡$ >B¡ − >Bh&, $>B  − >Bh&oSK ¡ + $ >B¡ − >Bh&KLM(rD),
 rKLM$>B &, rKLM$>B¡&, ²1 − (π­ + π®)³KLM$>Bh&Z µ¶T(")¶H · = $>B  − >Bh&9KLM(rD) +  2oSK ¡$>B  − >Bh&$ >B¡ − >Bh& + $ >B¡ − >Bh&9KLM(rD) +  r9KLM$>B & +r9KLM$>B¡& + ²1 − (π­ + π®)³9KLM$>Bh&                (Equation 2) 
 
The variances and covariances in this equation above are equal to cov ¡ = cov¡  = cov(rD, rD) = −rrc  
var(π­) =  r(1 − r)c  
var(π) =  r(1 − r)c  
If oSK ¡, var(rL), var(r¸) are replaced in Equation 2 the variance is estimated by the following: 
KLM VT$"0&Z = (>B  − >Bh)9 rD(1 − rD)c −  2 rDrDc $>B  − >Bh&$>B¡ − >Bh& + (>B¡ − >Bh)9 ∗  ¹(,¹) +  rD9KLM$>B & + rD9KLM$>B¡& + [1 − (rD + rD)9KLM(>Bh). 
 
This formulation of the equation is not in the most natural form to fit the model.  The following 
changes can be made to write the formula in a form that is easier to use.   
 
As above, it follows that: r + r + rp = 1, 
so that  rp = 1 − (r + r) 
and 3̀ = T() = r>  + r>¡ + rp>h 
which can also be written as T() = r>  + r>¡ + [1 − (r + r¡)>h. 
One change is made by defining >¡ = >  + >∆ and >h = >  + >∆9 
with >∆ and >∆9 indicating how groups B and C differ from group A then 
                             T(") = 3̀ = r>  + r>¡ + rp>h                                            = r>  + r(>  + >∆) + [1 − (r +  r)(>  + >∆9)                     = r>  + r>  + r>∆ + >  + >∆9 − r>  − r>∆9 − r>  − r>∆9 = >  + r>∆ + [1 − (r +  r)>∆9 = >  + r>∆ + rp>∆9. 
 









var(>B ) cov(>B , >B∆) cov$>B , >B∆9&cov(>B , >B∆) var(>B∆) 0cov(>B , >B∆9)00
000
var$>B∆9&00
     
0 00 00var(rD)cov(rD , rDp)
0cov(rD , rDp)var(rDp) §̈̈
¨̈© 
;(") < V("0) ;(") <. = 
[1, r , rp , >∆, >∆9 
¢££
££¤
var(>B ) cov(>B , >B∆) cov$>B , >B∆9&cov(>B , >B∆) var(>B∆) 0cov(>B , >B∆9)00
000
var$>B∆9&00
     







= Vvar$>B & + r cov$>B , >B∆& + rp  cov$>B , >B∆9&, cov$>B , >B∆& + r var$>B∆&, cov$>B , >B∆9&+ rp  var$>B∆9&, >∆ var(rD) + >∆9 cov(rD, rDp), >∆cov(rD, rDp)+ >∆9 var(rDp)Z  [1, r , rp , >∆, >∆9. = var$>B & + r cov$>B , >B∆& + rp  cov$>B , >B∆9& +  rcov$>B , >B∆& +  π®9var$>B∆&+ rp  cov$>B , >B∆9& + π½9var$>B∆9& +   >∆9var(rD) + 2>∆9 >∆cov(rD, rDp)+  >∆99var(rDp)                                                                                  var(>B) = var(>B  + r>B∆ +  rp>B∆9) =  var$>B & + var$π® >B∆& +  var$rp>B∆9& + 2cov$>B , r>B∆& + 2cov$r>B∆, rp>B∆9&+ 2cov$>B , rp>B∆9& =  var$>B & + π®9var$>B∆& + r½9var$>B∆9& + 2rcov$>B , >B∆& + 2rrpcov$>B∆, >B∆9&+ 2rpcov$>B , >B∆9& 
 
Since the covariance between >B∆ and >B∆9 is 0, it follows that var(>B) =  var$>B & + π®9var$>B∆& + r½9var$>B∆9& + 2rcov$>B , >B∆& + 2rpcov$>B , >B∆9& 
Combining var(>B) and V(0) gives the following: 
;(") < ¾$0& ;(") <.=var$>B& +  >∆9var(rD) + >∆99var(rDp) + 2>∆9 >∆cov(rD , rDp) 
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= var$>B& +  >∆9 ¿º(,¿º)À + >∆99 ¿Á(,¿Á)À − 2>∆9 >∆ ¿º¿ÁÀ . 
 
This means that the variance can be calculated in standard statistical software such as SAS by 
calculating the variance for >B  using the estimate statement and then adding the contribution to the 
variance made by the other four terms; >B∆ and >B∆9 are available as standard SAS output and π® 
and π½ can be estimated from the sample.  A Wald test statistic for the null hypothesis Â?: > =>9 = ⋯ = 0 is given by  
>∗. t¶T(")¶H w ¾("0) t¶T(")¶H w. >∗  
where >∗ = (>, … , >).  (Thijs et al., 2002). 
 
Extending these methods to four groups follows the same general ideas and is given in Appendix 1.   
3.3.3 Shared-parameter models 
In shared-parameter models, a vector of latent variables or random effects, bi, is included in the 
joint model, where one or more components are shared between both factors in the joint 
distribution.  The latent term or random effects capture dependence between dropout (R) and the 
response process (Y).  The missing data process and the observed measures are independent, 
conditional on a common set of latent variables (random effects).   
 
The joint distribution can be augmented with random effects (,  , )|J , O, Å, ", , Æ), 
where ξ is the parameter vector describing the random effects and M is the covariates describing 
the random effects distribution.  
 
The joint model can be factored either as a selection model or a pattern-mixture model.  The 
selection model factorization is: 
                       (, , )|J , O, Å, ", ) = (|J, ), ")(|, ), O , ) ()|Å, Æ) 
The pattern-mixture model factorization is: (, , )|J, O , Ç, ", , Æ) = (|, ), J, ")(|), O , )()|Å, È) 
(Molenberghs & Kenward, 2007).  A key feature of these models is that they are specified 
conditional on the latent term. 
 
The shared-parameter model assumes MNAR.  MAR implies that the conditional density of  conditional on the complete data, , does not depend on the missing data, while MNAR 
implies that the conditional density of  conditional on the complete data, , depends on the 
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missing data, .  The following argument shows that the typical shared-parameter models are 
MNAR.  The conditional density of   given Y = (, ) is 
$M%, & =  É T(M|¸)T$, %¸&ℎ(¸)u¸É T(, |¸)ℎ(¸)u¸  
=É T$M%¸&ℎ$¸%, &u¸ 
The conditional density depends on  since h(b|, ) depends on .  h(b|, )db 
can be seen as an empirical Bayes posterior distribution, which depends on the entire likelihood, 
including contributions due to both  and  (Albert & Follmann, 2009).   
 
Wu and Carroll (1988) proposed latent variable models in cases such as informative right 
censoring, where a joint model of the continuous response variable and the time to dropout, 
modelled by for example a proportional hazards regression, is developed.  The missingness and 
outcome models are linked because the same random effects are in both models.  The correlations 
between these variables induce dependence between dropout and response.  The latent variable or 
random effect helps to capture or account for individual to individual heterogeneity which is a 
significant feature in clinical trial data.   
 
Wu and Carroll (1988) used a Gaussian random coefficient model combined with a model for time 
to drop out such as logistic or probit regression.  They assumed the full data distribution follows a 
linear random effects model with random intercepts and slopes; where conditional on random 
effects  -+ =  ¸? +  ¸Q + A+ 
where the random effects (¸?, ¸) follow a bivariate normal distribution and A+~ c(0, C9).  The 
hazard of drop-out did not depend directly on the Y’s but on the random effects 
logit(+) =  Ë? + Ë¸? + Ë9¸ 
An individual’s random slope was included as a covariate in the model for the censoring process.  
When the regression coefficient for the random slope is not 0 there is dependence between the 
response and the missing data process.  The conditional joint distribution of Y and R given b is 
structured as f(y|b)f(r|b).  The marginal joint distribution is obtained by integrating against f(b).  
Data from both Y and R are used to model the distribution of b.  The combination of probit and 
Gaussian response allows the integral to be solved.  
 
A key feature of these models is that they are specified conditionally on the random effect term 
with the assumption that repeated measures are independent of dropout times conditional on the 
random effect (Hogan et al., 2004).  This assumption is untestable because the outcome 




In shared-parameter models parameters can be estimated using different methods.  One of these is 
maximum likelihood estimation.  This can be computationally intensive, since it involves 
integrating over the random effects distribution.  In cases where the direct integral cannot be 
calculated, approaches such as Monte Carlo EM or Laplace approximations of the likelihood can 
be used (Albert & Follmann, 2009).     
 
Alternatively non-weighted analyses can be done, where regression models are fitted separately for 
each participant, and the parameter estimates are then averaged over participants.  For example, for 
the linear mixed effects model - =  >? + >Q + >9Ì + >ÌQ + ¸? + ¸Q + A 
we can fit a least squares regression for Y for each participant.  The within group average of the 
slopes provide an unbiased estimate of the mean slope for each group.  To compare two groups one 
can perform a t-test using the individually estimated slopes.  This is unbiased but is inefficient 
compared to shared-parameter models where individual estimates are weighted according to their 
precision.   
 
Lastly shared-parameter models can be approximated using conditional approaches.  This has been 
proposed by Wu and Bailey (1989), who approximated the parameter estimates conditional on 
dropout with constant variance and mean given as a polynomial expression of dropout.  They 
modelled the joint distribution of   and ¸ conditional on , u, and #. $ , )%u,Ì& = T$%), u,#&=$)%u,#&. 
Follmann and Wu (1995) and Albert and Follmann (2000) proposed similar methodology for the 
analysis of binary longitudinal data and repeated count data.   
 
In all three methods, estimated variances of the parameter estimates can be calculated using 
bootstrap methods.  In the maximum likelihood approach asymptotic variances can be obtained by 
the matrix of observed Fisher information (Albert & Follmann, 2009).   
 
Shared-parameter models differ from selection models in how they relate the probability of a 
missing observation and the response process.  Shared-random effects models link the two by 
relating an individual’s propensity to response with propensity to miss a visit, while selection 
models directly model the probability of missing a visit as a function of the response.  These 




3.3.4 Joint modelling of longitudinal data and time to missingness 
Joint modelling of time to event and longitudinal outcomes has been done in various contexts 
(Henderson, Diggle, & Dobson, 2000; Tsiatis & Davidian, 2004; Tsiatis, Degruttola, & Wulfsohn, 
1995).  If the interest of inference is in the association between the endogenous time dependent 
response variable and the survival mechanism the longitudinal and survival processes have to be 
modelled jointly, including parameters that represent their correlation.  Such models couple the 
survival or time to event model with a model for the repeated measurements and allow one to 
incorporate measurement error in the longitudinal variable into the model, which is not possible if 
one simply models the time to event.  Joint modelling has also been used to model longitudinal 
markers as surrogates for survival.  In this context Tsiatis et al. (1995) explored whether CD4+ 
count can be used as a surrogate marker for survival in AIDS patients.   
 
Time to event or survival data is generated by observing participants until an event occurs.  A 
complication with time to event data is that the event does not occur for some participants during 
the follow-up period of the study.  For these participants only the maximum waiting time up to 
which it is known that the event has not occurred is collected.  For all participants a right censored 
time, which is the maximum of follow-up time or the time to occurrence of the event, is recorded 
(Kalbfleisch & Prentice, 2002).   
 
A joint model consists of a survival sub-model and a longitudinal sub-model.  The survival sub-
model is constructed as follows ℎ(Q|ℳ(Q), Î) =  ℎ?(Q)exp [Ò′Î + ^Ó(Q) 
where  ℳ(Q) denotes the history of the true unobserved longitudinal process up to time t Î is a vector of baseline covariates with a corresponding vector of regression coefficients Ò ℎ?(t) is the baseline risk function 
α quantifies the effect of the underlying longitudinal outcome to the risk of an event Ó(Q) denotes the true and unobserved value of the longitudinal outcome at time t.  This is 
different from (Q) which is the observed value of the outcome, contaminated with measurement 
error (Rizopoulos, 2012). 
 
The survival function, which is defined as the probability of event time being beyond some time 
point, t, can be obtained as Ô(Q|ℳ(Q), Î) = exp (− É ℎ?(j)exp [Ò′Î + ^Ó(j)uj+? . 
The survival function depends on the whole covariate history ℳ(Q) and not only on the current 




The hazard function is the probability of an event occurring in the next short period of time, given 
that the event had not occurred up to that time and all the past history.  In the widely used semi-
parametric Cox proportional hazards model the baseline covariates are modelled parametrically 
while the baseline hazard function is modelled non-parametrically with no specific form and is 
considered a nuisance parameter.  It is not possible to simultaneously estimate the baseline hazard 
function and the parameters of interest (Cox, 1972).  Cox (1975) suggested an estimation method 
based on conditional probabilities at the event times, based on maximising the partial likelihood 
which does not depend on the baseline proportional hazard function and only the parameters of 
explanatory variables are estimated.  Thus in a standard survival function the baseline risk function 
is not specified.  However in the joint modelling framework the baseline hazard function, ℎ?(t), has 
to be specified.  Common choices for ℎ?(t) are parametric distributions such as the Weibull or 
Gamma distributions or cubic splines or a piecewise constant model.  These models can be made 
flexible by increasing the number of internal knots and the estimation of standard errors follows 
from asymptotic maximum likelihood theory (Rizopoulos, 2012).      
 
The second component of the joint model is the participant specific longitudinal model that is 
specified using, for example, linear mixed models.  The goal of this model is to reconstruct the 
complete longitudinal history, ℳ(Q), of each participant.  Since Y is the observed outcome, which 
is equal to the true unobserved outcome plus error:   =  = +  A = =  #′` + Õ′) 
where A~c(0, C9), )~ c(0, ) and # is the design vector for the fixed effects β and Õ is the 
design vector for the random effects ) (Rizopoulos, 2012).  Yij is only collected intermittently and 
the modelling is complicated by the fact that the longitudinal measurements are recorded with 
error.  Previous attempts at incorporating the longitudinal model with the time to event model did 
not take this into account (Tsiatis & Davidian, 2004).  Good estimates of ℳ(Q) can only be 
obtained if the time structure in # and Õ is specified correctly.  If participants show non-linear 
longitudinal trajectories, high-dimensional functions of time can be considered, either higher-order 
polynomials or splines (Rizopoulos, 2012).   
 
The assumption is made that the random effects account for both the association between the 
longitudinal process and the survival process, and the correlation between the repeated 
measurements in the longitudinal process.  Thus, we assume conditional independence.  This is 
given as G(, _ , |), H) = G(, _|), H)G( |), H) 
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where  is the observed time to event, and _ is the event indicator (1 if the event was observed 
and 0 if the event was not observed) and H = (H+′, HÖ′, H′)′ where H+ denote the parameters for the 
event time outcome, HÖ denote the parameters for the longitudinal outcome and H denote the 
unique parameters for the random-effects covariance matrix.  The assumption is made that given 
the observed history, the censoring mechanism and the mechanism that generates times of visits are 
independent of the true event times and future measurements.  This means that whether a 
participant arrives for a visit or withdraws depends on observed past longitudinal measurements, 
but not on additional latent participant characteristics associated with disease stage or prognosis.  
The observed data cannot be used to test this assumption (Rizopoulos, 2012; Tsiatis & Davidian, 
2004).   
 
The main estimation method proposed for joint models is maximum likelihood (Henderson et al., 
2000).  An early formulation of joint models included a longitudinal model of participant-specific 
random effects expressed as a linear or more general spline function of time with a parametric 
lognormal time to event model.  They developed an EM algorithm to maximize the log-likelihood, 
which involved intractable integrals over the distribution of ^, assumed to be normally distributed 
(Degruttola & Tu, 1994).  In general, the maximum likelihood estimates are derived as the modes 
of the log-likelihood function corresponding to the joint distribution of the observed outcome.  
Fitting joint models for longitudinal and survival data requires a combination of double numerical 
integration and optimization.  The integral with respect to time in the survival function and the 
integral with respect to the random effects in the score vector do not generally have an analytic 
solution and a numerical approach is usually employed to approximate these integrals in the 
calculations of the log-likelihood and the score vector.  Maximization of the log-likelihood function 
can be achieved using the EM algorithm, Fisher scoring, or the Newton-Raphson algorithm.  The 
observed data score vector can be used to calculate the Hessian matrix and standard errors using an 
approximate observed information matrix.  Fitting joint models are computationally intensive.  
Convergence problems are not uncommon (Rizopoulos, 2012).  Bayesian estimation using MCMC 
techniques has been considered (Chi & Ibrahim, 2006; Wang & Taylor, 2001).  A conditional score 
approach in which the random effects are treated as nuisance parameters was used to develop 
estimating equations that yield asymptotically normal estimators.  In this approach no assumption 
was made regarding the distribution of the random effects (Tsiatis & Davidian, 2001).   
 
The joint models discussed to this point apply mostly to the modelling of time to event taking the 
longitudinal covariates into account.  Joint models can also be used to model incomplete 
longitudinal data.  In this case, the occurrence of an event is defined as the time of dropout, or the 
time when the longitudinal process is discontinued.  Intermittent missing values are treated as 
ignorable and assumed to be MCAR and can be ignored in the likelihood function.  The 
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longitudinal response vector can be divided in an observed and missing part.  ∗ is the true dropout 
time for participant i, while   is the observed dropout time. The dropout mechanism is derived by 
the conditional distribution of the time to dropout given the complete vector of longitudinal 
responses 
G$∗%, , H& =  × G $∗, )%, , H&u¸ 
=  É G $∗%), , , H&G$) %, , H&u¸         
Applying the conditional independence assumption, this becomes 
× G (∗|), H)G$)%, , H&u¸ 
The time to dropout depends on  through the posterior distribution of the random effects G$)%, , H& .  Under the joint model the survival and longitudinal sub-models share the 
same random effects.  Therefore joint models fall under the shared-parameter model discussed in 
Section 3.3.3.  Joint models correspond to a MNAR missing data mechanism.  Under a simple 
random effects structure this missing data mechanism implies, for example, that participants who 
show steep increases in their longitudinal profiles may be more or less likely to drop out 
(Rizopoulos, 2012).   
 
The joint model of the survival and longitudinal sub-models is  ℎ(Q) =  ℎ?(Q)exp [Ò′Î + ^[#.(Q)> + Õ.(Q)). 
There is a connection between the association parameter α and the missing data mechanism.  If 
α = 0 then the missing data mechanism is MCAR.  In this instance ℎ(Q) =  ℎ?(Q)exp [Ò′Î and 
the dropout process does not depend on either the missing or observed longitudinal responses.  
Censoring corresponds to a MAR missing data mechanism because in the formulation of the 
likelihood function of joint models it was assumed that the censoring mechanism depends on the 
observed history but is independent of future unobserved outcomes (Rizopoulos, 2012).    
 
If α = 0 the parameters in the two sub-models are distinct and their corresponding parameters can 
be estimated separately.  Under a full likelihood approach, the estimated parameters derived from 
maximizing the log-likelihood of the longitudinal process will also be valid under a MAR missing 
data mechanism where the dropout depends on the observed responses only.  An advantage of 
shared-parameter models is that these models can handle both intermittent missingness and 
monotone missingness.  Many of the pattern-mixture and selection models have difficulty handling 




Sensitivity analysis within this framework consists of fitting several joint models where different 
alterations are made in the survival sub-model.  Alternative parameterization of the longitudinal 
marker can also be considered.   
3.4 Likelihood-based approach 
Likelihood-based analysis is a viable approach when analysing incomplete longitudinal data when 
the MAR assumption is plausible.  All available cases are used in a likelihood-based way using 
ignorability theory.  Ignorability has been defined in Section 2.4; and means that the mild 
separability assumption is made that the parameters of the missing data mechanism are distinct 
from the parameters of the sampling model.  This implies that the mechanism generating missing 
data can be ignored when the interest is in inference about the measurement process, without 
biasing the analysis.  Ignoring the missing data mechanism assumes there is no scientific interest in 
the missing data mechanism.   
 
The following desirable properties are associated with maximum likelihood analyses when the 
assumptions are met: consistency, asymptotic efficiency and asymptotic normality, under broadly 
applicable regularity conditions.  Consistency implies that the estimates are progressively less 
biased and less variable given a large sample.  Asymptotic efficiency implies that the estimates 
have minimum standard errors and asymptotic normality enables the user to use normal 
approximations when calculating confidence intervals and p-values.  These desirable properties are 
all large sample approximations (Allison, 2009).   
 
Likelihood-based approaches use a parametric model to formulate a statistical mechanism for the 
missing data and base inference on the likelihood function of the incomplete data.  The objective is 
to draw inference about a parameter, θ, in a model  (|H) for the response data that is not fully 
observed.  Under the MAR assumption, θ and the missing data model are functionally independent 
and missing data can be treated as ignorable.  In this case inference is drawn about θ without 
having to specify a model that relates the missing data process to the Y or X (National Research 
Council, 2010).  Information from the non-missing data is used to provide information about the 
missing data.  Missing data are not imputed (Mallinckrodt, Clark, et al., 2003).   
 
In the absence of missing data, likelihood-based methods entail the maximization of the full data 
likelihood. When data are incomplete this likelihood is replaced by the observed data likelihood, 
where the individual likelihoods are integrated over the missing values,  ∏ É  (Ù®Ú, Û1Ú, |", Ü)d. 
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Under ignorability and MCAR or MAR missingness, the integral can be rewritten as an integral 
over the missing values and the distribution of the missing data mechanism (under a selection 
model).  This simplifies the integral tremendously.   
 
If the MAR assumption holds, ignorability is assumed and the sample is relatively large, maximum 
likelihood theory can be used to estimate θ.  Under regularity conditions H6 has a normal 
distribution with mean θ and variance estimated by the inverse of the observed information matrix ,$H6& or using bootstrap methods (Kenward & Molenberghs, 1998; National Research Council, 
2010).   
 
Sometimes numerical approximation is needed to maximize the likelihood.  The EM algorithm, a 
general-purpose iterative algorithm, can be used for calculating maximum likelihood estimates in 
these instances (Dempster, Laird, & Rubin, 1977; Horton & Kleinman, 2007; Little & Rubin, 2002; 
Molenberghs & Kenward, 2007). 
 
Likelihood-based estimation adjusts data in terms of the conditional expectation of the unobserved 
measurements given the observed measurements.  Thus a likelihood-based ignorable analysis 
accommodates information on a participant with post-randomisation outcomes, even with missing 
data.  An ignorable likelihood is therefore consistent with the ITT analysis, provided that the 
treatment compliance is the same for those who drop out and those who remain in the study 
(Molenberghs & Kenward, 2007; Molenberghs et al., 2004).  Likelihood-based methods are easy to 
implement because no data manipulation is required to accommodate the missing data.  
 
If data sets have no missing data, the estimate of the mean in a saturated means multivariate normal 
model does not depend on the specification of the variance matrix.  However, with missing data, 
the inference of the mean depends on the specification of the variance matrix (National Research 
Council, 2010).   
 
Likelihood-based methods treat longitudinal data as clustered data that are temporally aligned, 
assuming that the missing data are orthogonal to the missingness process given observed data, 
regardless of where the dropout occurs.  Under MAR the likelihood-based approach requires 
correct specification of the full data model (Hogan et al., 2004).  
 
One application of direct likelihood methods is through mixed models.  A mixed model is a model 
that includes both fixed and random effects.  The most common random effects model is the 
generalised linear mixed model which combines concepts from generalised linear models and 
linear mixed models (Molenberghs & Kenward, 2007).  Generalised linear mixed models assume a 
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random component, the components of Y, which is independent from each other and follows some 
distribution with constant variance of errors; a systematic component, a linear prediction using the 
covariates and β; and a link function between the random and systematic components.  This 
generalises and extends linear models by allowing the distribution of the systematic component to 
be from an exponential family other than the normal distribution and the link function can become 
any monotonic differentiable function.  Classical linear models assume a Gaussian distribution for 
the components of Y and the identity function as a link function (McCullagh & Nelder, 1989).   
 
If  is the ni-dimensional vector of all measurements for participant i, then -  can be modelled 
using, for example, a random intercept and slope model as - = (>? + ¸?) + (> + ¸)Q +  >9 + >Q + A               (Equation 3) ) = (¸?, ¸).~ c(0, Ý), Þ~c(0, f), ), … , )  and Þ, … , Þ are independent, where  is the treatment group and Q is a time variable.    
  
The components in ` = (>?, >, >9, >)′  are fixed effects and the components in bi are random 
effects (Molenberghs & Kenward, 2007).  The fixed effect of greatest interest in clinical trials is 
generally treatment allocation.  Additional fixed effects such as baseline covariates, demographic 
data or site can also be included (Mallinckrodt, Sanger, et al., 2003).  The participants in a study 
are thought of as representative of a larger population of participants, therefore, the effects specific 
to an individual, bi, are treated as random effects (Hedeker & Mermelstein, 2007).   
 
The random effects approach is based on the assumption that for every participant the response can 
be modelled by a linear regression model with participant specific regression coefficients.  These 
analyses use likelihood-based estimates and participant specific effects and correlations between 
the repeated measurements are modelled via the within participant error correlation structure  
(Mallinckrodt, Sanger, et al., 2003).  The random participant effects included in the model account 
for the correlation between the repeated measures of a participant.  These random effects reflect the 
change of each participant over time and explain the correlational structure of the longitudinal data.  
They indicate the degree of variation per participant that exist in the population (Hedeker & 
Mermelstein, 2007). 
 
The error terms are assumed to be normally distributed and independent conditional on the random 
individual-specific effects, bi.  This model represents the measurement of Y as a function of time, 
at the individual and population levels.  The overall population intercept is given by β0, the random 
slope for participant i is given by bi0, and β1 is the overall population slope (the effect of time).  The 
intercept parameters indicate the starting point and the slope parameters indicate the degree of 
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change over time.  The population intercept and slope parameters represent the trend for the 
population and the individual parameters show how the individual differs from the population 
trend.  Equation 3 includes a time by treatment interaction and can also be expanded to include 
other interactions, higher order polynomials or time varying coefficients (Hedeker & Mermelstein, 
2007).   
 
Random-effects models are useful in the longitudinal setting because participants are not required 
to be measured on the same number of time points (the number of data points per individual is not 
assumed to be balanced) and time is treated as a continuous variable.  Participants with incomplete 
data or designs where follow-up times are not uniform across participants can thus be included.  
The  vector and the Xi and Zi matrices carry the i subscript, thus no assumption of complete data 
on the response across time points is made (Hedeker & Gibbons, 1997; Hedeker & Mermelstein, 
2007).  The change in the response variable for each participant can be estimated.  The advantage 
of these mixed models is that the predictors of both intra-individual (within-participant) and inter-
individual (between-participants) variation can be assessed (Hedeker & Mermelstein, 2007).   
 
The model assumes that the available data for a participant represents that participant’s deviation 
from the average trend observed for the whole sample.  The model estimates the participant’s trend 
across time on the basis of the observed data for the participant and the time trend estimated for the 
whole sample, adjusted for covariates (Hedeker & Gibbons, 1997).   
 
Mixed effects models consider the unique attributes of each participant.  Responses of individual 
participants are allowed to vary and to be correlated over time.  Information from the observed 
outcomes of a participant can be used to provide information about the unobserved outcomes.  All 
available data are used to compensate for the data missing on a particular participant (Mallinckrodt, 
Sanger, et al., 2003). 
 
Estimation and inference is based on maximum likelihood.  To determine the significance of model 
parameters, large sample variances and covariances of the maximum likelihood estimates are 
obtained.  This is used to construct confidence intervals and conduct Wald tests for the model 
parameters (Hedeker & Gibbons, 1997).  In general no analytic solution exists and numerical 
maximisation routines are used.  In practice often REML estimation is used (Laird & Ware, 1982).  
This leads to smaller bias in the estimation of the variance component than maximum likelihood 
(Molenberghs & Kenward, 2007) because the method accounts for degrees of freedom lost in 




When the interest is on inference on the fixed effects β, t and F distributions can be used.  The 
denominator degrees of freedom are estimated with the method of Kenward and Roger (1997).  
When interest lies in inference for some of the variance components classical Wald, likelihood 
ratio and score tests can be used.  If the interest lies in the random effects empirical Bayesian 
estimation methods can be used (Molenberghs & Kenward, 2007).  Inference is based on the 
conditional distribution for  which is obtained by integrating out the random effects.  The 
resulting likelihood for the joint distribution is maximised in the presence of N integrals over the q-
dimensional random effects.   
 
In order to fit a mixed effects linear model to a data set with missing data, a few assumptions are 
needed.  The assumptions made include: 
1. Because a normal outcome is assumed, multivariate normality ought to apply. 
2. To avoid overly restrictive, unverifiable assumptions, it is sensible to select a saturated 
means model that include time, treatment and time by treatment interaction.  In the same 
spirit, an unstructured variance-covariance matrix reduces the risk of model 
misspecification and, consequently, incorrect inferences.   
3. The joint statistical behaviour of the unobserved measurements from an individual who 
drops out is assumed to be the same as that of an individual who does not drop out who 
shares the same history (previous measurements, including baseline) and the same 
covariates (including treatment group).  If dropout means stopping treatment the assumption 
that these two groups behave the same is not true (Kenward, 2006). 
 
The choice of the structure of the covariance matrix influences the point estimates when the data 
are incomplete.  An unstructured covariance matrix is often the appropriate first choice.  Carpenter 
and Kenward (2007) showed that using the unstructured covariance matrix does not lead to a 
noticeable loss of power if the sample size is not very small.  A different covariance matrix can 
also be used in each treatment group. 
 
Why does direct likelihood, via mixed models, provide a valid analysis when data are incomplete?  
It takes into account the expectation of the missing measurements, given the observed 
measurements and is valid and unbiased under MAR (Molenberghs & Kenward, 2007).  It can be 
thought of as aiming to estimate the treatment effect that would have been observed if all 
participants had continued on treatment for the full study duration (CHMP, 2010).  The CHMP also 
believe that these methods would overestimate the treatment effect of effective interventions, thus 
biasing results in favour of the treatment effect and should only be used when missing data are 
negligible.  Mallinckrodt et al. (2003) showed that mixed model analysis was robust to the presence 
of MNAR data.  Thus this method is appropriate to use with MCAR and MAR data, and could, in 
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some circumstances be appropriate with MNAR data.  In some settings a biased MAR analysis will 
be less biased than a MCAR analysis. 
 
Likelihood-based methods work in the context of missing data by adjusting the least square means 
for a participant at times after drop out.  The magnitude of the adjustment is determined by the 
within participant correlation and by the participant’s deviation from the group mean.  The 
uncertainty in the adjustment is determined by the amount of data contributing to the group mean, 
the amount of data on the participant and the within-participant correlation (Mallinckrodt, Clark, et 
al., 2003).  
 
Although mixed effects analysis uses all data collected on participants who completed and did not 
complete the study treatment, if data were only collected while participants were on treatment then 
the analysis estimates what would have happened if all participants with missing data had stayed in 
the study and completed treatment.  This is not a strict ITT analysis, since it does not account for 
withdrawal from treatment.  Continuing follow-up and data collection after discontinuation of 
treatment could alleviate this problem.  However, as long as there are missing data off treatment, 
the likelihood-based methods will represent an analysis on treatment more closely than a strict ITT 
analysis (Keene, 2011).  
 
Likelihood-based methods are the easiest methods to use and can be applied with most standard 
software, without much knowledge of missing data analysis.  These methods should be encouraged, 
while understanding that they may not provide a strict ITT analysis, if treatment compliance of 
those who drop out is not the same as compliance of those who remain.   
3.5 Weighting methods 
If data are MAR a missingness weight can be assigned to the complete cases.  This implies that the 
probability of being observed is a function of the variables measured (National Research Council, 
2010).  In this approach, also called inverse probability weighting, a model for the probability of 
missingness is fitted, and the inverse of these probabilities are used as weights for the complete 
case (Horton & Kleinman, 2007; Molenberghs & Kenward, 2007).  Weighting by the inverse of the 
probability of being observed means that participants who were observed but had low probability 
of being observed, are given more weight and as such also represent the unobserved participants.  
This way, the complete cases are used to estimate parameters that are valid for both the complete 
cases and missing cases.  
 
This is explained by starting with the univariate case.  In the univariate case inverse probability 
weighting is done by assigning sampling weights to the complete cases.  For example, in a survey, 
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if only some observations are observed a weighted average, where each observed observation is 
weighted by the inverse of the probability of response, would be unbiased, whereas the unweighted 
average would not be unbiased.   
 
This idea is applied to regression with missing observations.  If all values of the covariate are 
observed, then the true population parameter values will have an expected value of 0.  This is 
called a consistent parameter estimate.  If some of the covariates are missing then the parameter 
estimates are no longer consistent and the expected value of the estimating equations is no longer 0.  
If each covariate is observed with probability r, then weighting by 	 creates estimating equations 
with expectation 0 and consistent parameter estimates.  Often r is estimated using logistic 
regression, after which a weighted regression will be performed with weights 
	 (Carpenter, 
Kenward, & Vansteelandt, 2006).   
 
For example, an inverse probability weighting estimate of the mean is computed by first fitting a 
model for the probability of being observed; r( , ") =  W(R = 1|#, "). 
An indicator of whether an observation was observed is regressed against observed characteristics 
of the participant.  The mean of Y is then estimated using the weighted average, the average of the 
observed Y weighted inversely by the probability of being observed.  
à̂ =  1 â r$#, H6&  
The correlation structure should ideally be the independence working correlation structure and 
standard errors can be estimated using bootstrap methods (National Research Council, 2010).   
 
Considering longitudinal data with repeated measures, when there is no missing data repeated 
measures regression models can be fitted using GEE.  For repeated measures with missing data 
GEE does not produce consistent and valid estimates unless the missingness is MCAR because 
regression estimation depend strongly on the assumed correlation structure.  Weighted GEE can be 
used when the missingness mechanism is MAR and monotone.  Echoing the ideas already 
discussed in the univariate case, the weight is obtained from the inverse probability of a participant 
being observed at that particular measurement occasion, given that the participant is still in the 
study, covariates and previous measurements on the response variable (Molenberghs & Kenward, 
2007).  The probability that participant i, who is still in the study at time t – 1, will be observed at 
time t is λ1|.  The probability that participant i is still in the study is calculated using cumulative 
conditional probabilities;  
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At t = 0: ä? = 1 
at t = 1: r = ä 
at t = 2, r9 = ää9 
at t = 3, r = ää9ä 
Additional assumptions underlying inverse probability weighting are that there are no covariate 
profiles where Y could not be observed.  The possible values of missing responses are the same as 
the possible values of observed responses.  Thus missing values cannot be imputed outside the 
range of observed values (National Research Council, 2010). 
 
The procedure to use inverse probability weighting is as follows: Ensure that the missing data 
follow a monotone pattern.  Additional information on covariates collected should be included 
when the probability of observing data is modelled.  Calculate the probability that the outcome is 
observed.  Fit the regression that would have been fitted had all data been fully observed, but 
weight individual contributions to the model by the inverse of the probability of being observed 
(Carpenter et al., 2006; National Research Council, 2010).   
 
Given a large sample and MAR missingness, the inverse probability weighted GEE yields unbiased 
estimates when the probability of observing data is correctly specified.  A disadvantage of this 
method is that the model for the probability of being observed has to be correctly specified for the 
estimator to be unbiased.  If the probabilities are calculated incorrectly the observations are not 
weighted correctly and will not represent the missing data.  The parameter estimates are inefficient 
relative to likelihood-based estimates (National Research Council, 2010).   
 
Observations with very small probability of being observed will have large inverse weights.  These 
observations will then dominate the method and lead to instabilities and high variance in small 
samples.  The augmented inverse probability weighting estimator improves on this, since the 
variance is not as high when individual weights are high.  Strata can be created based on the 
predicted probability of being complete.  Respondents are then weighted by the inverse of the 
response rate in these strata.  This can be controlled by choosing strata that limit the size of the 
weights, thereby controlling the variance.  The theoretical justification of this method is based on 
large-sample arguments and it may not hold in small samples (National Research Council, 2010). 
 
Weighted estimating equations are robust, since it does not depend on knowledge of the 
distribution of the unobserved data, and the estimates are consistent and asymptotically normal.  It 
can be applied in settings where other approaches are difficult to apply.  Other methods may be 
optimal when the distributional assumptions are correct, but they may not be desirable when the 
assumptions are violated.  The estimates are also potentially inefficient, since it uses only data from 
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completers (Ibrahim et al., 2005).  In addition to the methods that use data from completers, Robins 
et al (1994; Robins, Rotnitzky, & Zhao, 1995) and others (Carpenter et al., 2006; Vansteelandt, 
Carpenter, & Kenward, 2010) extended the methods by including incomplete cases in the 
calculation of the weights.  This improved efficiency.   
 
Augmented inverse probability weighting estimators are obtained by adding to the inverse 
probability weighting estimating functions an augmentation term that depends on unknown 
functions of the observed data.  In this way the augmented inverse probability weighting GEE 
procedure does not use information from complete cases only.  If these functions are appropriately 
chosen, it leads to efficiency.  
 
The augmented inverse probability weighting estimator of µ = E(-v) is: à̂=  ∑ å	æÖ	æ	(ç	æ;0) +  ∑ é å	æ	$ç	æ;0& − 1ê T(v, , Ì) , 
where v = 1 if -v is observed and 0 if -v is not observed.  The observed history at time k is 
denoted as v,, r(ëv; H) = W(v = 1|v,θ) is the probability that a participant remained in the 
study to time k and T(v, , Ì) is a function of the observed history up to k-1 (National Research 
Council, 2010).   
 
The first term in this estimator is the inverse probability weighting estimator of µ, which weights 
the observed measurements.  The second term is the augmented term added and has mean 0 
because the expectation of v is r$v; H6&, so that this is still a consistent estimator.  This term 
includes information on both fully observed participants and participants with missing values.  The 
variance will be determined by T(ëv, , J) which can be chosen to minimise the variance.  The 
precise form for this expression is not known, but it can be estimated using participants with 
observed outcomes.  If g is correct, then the augmented inverse probability weighting estimator is 
more efficient than the standard inverse probability weighting estimator (Molenberghs & Kenward, 
2007; National Research Council, 2010).  Robins and Rotnitzky (1995) described the calculation of 
this function.  Thus augmented inverse probability weighting estimators are obtained by 
augmenting the estimating function with a term that depends on a function of the observed data.  If 
these functions are chosen correctly the efficiency of the standard weighted GEE can be improved.   
 
Double robust estimation combines inverse probability weighting with regression modelling.  Each 
observation is weighted equal to the inverse of the probability of being observed to create pseudo-
populations of complete and incomplete participants that represent what would have happened to 
the population under those two conditions.  Maximum likelihood regression or GEE is conducted 
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within these pseudo-populations adjusting for confounders and variables of interest.  An estimator 
is doubly robust if it is consistent when either a model for the probability of being observed or a 
model for the distribution of the complete data is correctly specified or if both are correctly 
specified.  Because one cannot know whether the model for missingness is correctly specified, this 
is a highly desirable property (Molenberghs & Kenward, 2007; Vansteelandt et al., 2010).   
 
Such a model can be obtained by replacing the observed value in the substantive model with the 
fitted value of a generalised linear model analysis of the outcome on background characteristics 
fitted to the responders using the weights 1/r.  The doubly robust nature of the estimator can be 
seen as follows.  When the imputation model is correctly specified, the misspecification of the 
weights does not influence the expected value of the estimator.  The estimator can be written as a 
set of equations including a product of the model residuals and the weights, and since the expected 
value of the model residuals is 0, the term would be 0, regardless of the weights and therefore gives 
an unbiased estimator.  If the weights are correctly calculated (the response model is correctly 
specified), then misspecification of the imputation model does not affect the validity of the doubly 
robust estimator because the weighted least squares estimator satisfies 1 â r -

 = 1 â r =∗(J)

  
where =∗(J) is the fitted value for participant i.  If the weights are correctly specified then å		 has 
an expected value of 1.  This implies that =∗(J) = - in expectation (Vansteelandt et al., 2010).   
 
A doubly robust estimator offers the advantage over standard inverse probability estimators or 
likelihood-based estimators that there are two chances to make correct inference.  These methods 
do assume that the substantive model is correctly specified.  The doubly robust estimators are less 
efficient than maximum likelihood estimators when the likelihood is correctly specified, but they 
are more robust to incorrect specification of the model.  Doubly robust estimators can be difficult 
to construct, or might not even exist in some instances (Bang & Robins, 2005; Robins et al., 1994).  
These methods assume a MAR missingness mechanism (Vansteelandt et al., 2010). 
 
The standard errors cannot be calculated using standard methods, because with inverse probability 
weighting the standard errors ignore the imprecision of the estimated weights.  One solution is to 
calculate the standard errors using bootstrap techniques.  Bootstrap may not perform well when 
some individuals are oversampled in some of the bootstrap samples.  An alternative is to consider 
sandwich estimators.  These may not perform well with larger weights because they are based on 
large sample approximations that might not hold when some individuals have large weights 
(Vansteelandt et al., 2010).   
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3.6 Bayesian approaches 
Ibrahim et al. (2005) argued that maximum likelihood and multiple imputation have Bayesian 
connections.  Multiple imputation was originally derived from a Bayesian framework where the 
sampling in the imputation step is done from the posterior distribution of interest.  Maximum 
likelihood can be viewed as a large-sample Bayesian method, with non-informative priors.   
 
Bayesian approaches have also been applied more generally in the analysis of missing data.  This is 
done by specifying priors on all the parameters and specifying distributions for the missing 
covariates (Horton & Kleinman, 2007).  The missing data are then sampled from their conditional 
distribution via the Gibbs sampler.  The Gibbs sampler is an algorithm that involves sampling a 
Markov chain where the kernel is the product of the sequentially updated full conditional 
distributions of the parameters and the stationary distribution is the posterior distribution (Geman 
& Geman, 1984).  Fully Bayesian methods are powerful and general methods for dealing with 
missing data since existing Bayesian methods can be adapted for dealing with missing data.   
 
In classical, frequentist statistical analysis parameters are regarded to be fixed non-random 
quantities.  Probability statements made concern the data observed.  In Bayesian analysis the 
parameters are treated as realisations of random variables.  Probability statements are then made 
about the model parameters and not about the data.  Bayesian analyses have three components; the 
prior distribution, the likelihood and the posterior distribution.  The prior distribution reflects the 
distribution of the parameters before the data are seen; thus expressing uncertainty about the 
parameters prior to seeing the data.  The likelihood gives the distribution of the observed data.  
This is the same distribution that would be used in classical frequentist inference.  The posterior 
distribution uses Bayes’ Theorem to combine information from the prior distribution and the 
likelihood.  The posterior distribution expresses uncertainty about the unknown parameters after 
seeing the data.  In ignorable methods the posterior distribution is G(H|) ∝ G(H)í(H|), with G(H) the prior distribution and í(H|) the full data likelihood.  Thus the Bayesian inference is 
done by specifying a model, specifying prior distributions for the parameters of the model, and then 
updating the prior information on the parameters using the model specified and the data observed 
to obtain the posterior distribution of the parameters.  Our assumptions about the missing data can 
thus be made explicit through the prior distributions (Daniels & Hogan, 2008).   
 
Bayesian inference distinguishes between observable quantities, the data, and unobservable 
quantities, such as the statistical parameters and the missing data.  The unobserved quantities have 
an associated probability distribution.  Thus Bayesian methods are a natural way of handling 
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missing data because a probability distribution is estimated for each missing value.  This also 
allows for uncertainty to be captured.  Missing data are treated as unknown parameters.   
 
Prior distributions quantify a priori knowledge about the parameter(s).  An informative prior is a 
prior that contains information through a probability distribution.  The prior distribution can come 
either from previous studies, historical information or expert opinion.  If this is not available a 
vague prior can be used if no information is available.  These are called non-informative priors.  
Specifying the prior is important and can influence the results.  The Bayesian approach allows 
assumptions about non-identified parameters to be formalised through prior distributions (Daniels 
& Hogan, 2008).  The sensitivity of the results to the prior used should always be explored. 
 
To conduct the fully Bayesian analysis on the observed data a posteriori the following steps are 
followed: 
1. The distribution of the data containing the missing data is specified. 
2. The joint prior distribution is specified. 
3. Sample from the posterior using simulations methods like the Gibbs sampler (Ibrahim et 
al., 2005). 
 
With complete data, when informative priors are used, information from the prior is combined with 
information from the data to create the posterior.  For example in the case of the normal linear 
regression model, the posterior mean of β is a weighted average of the ordinary least square 
estimator and the prior mean.  The weights depend on the data and the prior variance.  The strength 
and informativeness of the prior is determined by the prior variance.  With incomplete data some 
information only derives from the prior (Daniels & Hogan, 2008).   
 
It is not easy to derive the parameters of the prior distribution from experts.  One suggestion is to 
rather ask experts to predict future data or data patterns and to use this to model the data and derive 
parameters from these models.  This is done because it is easier for experts to visualise data than to 
visualise parameters (Daniels & Hogan, 2008).   
 
When there are incomplete data, a prior belief is assigned to the distribution of the missing data 
points.  The prior is assumed to be independent of the data.  If covariates are observed and only the 
response has missing data, one need not assign a missingness model, provided the missing data 
mechanism is ignorable.  There is no fundamental distinction in the handling of missing data and 
unknown parameters within the Bayesian framework.  The missing data are then treated as 
additional unknown parameters and the imputation of the missing outcome variables is unnecessary 
for a valid inference about the model parameters.  If imputation of the missing data is needed, 
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values can be generated from the posterior predictive distribution.  However, if the assumption that 
the missing data mechanism is ignorable cannot be made, then we need to specify a response model 
of missingness.  If covariates are missing an imputation model for the missing data is required.  All 
that is needed is the specification of the appropriate joint model for the observed and missing data 
and model parameters.  Posterior samples of the model parameters and missing values are then 
generated in the usual way using MCMC (Mason et al., 2012).  
 
The posterior distribution is the basis of Bayesian inference, but for complex models the integration 
is not possible analytically.  MCMC is done by sampling from the joint posterior distribution in 
cases where analytical integration is not possible (Gilks, Richardson, & Spiegelhalter, 1996).  
Sound inference based on MCMC methods requires that the Markov chain being simulated has 
achieved steady state or converged.  Convergence is checked by running multiple chains with 
different starting points and checking whether the chains converge to the same point.   
 
Inference based on serially correlated MCMC draws is less precise than if the draws were 
independent.  In Bayesian analysis assessing the fit of the model includes checking for sensitivity 
of the analysis to the prior specified, or conflict between the prior and the data observed.  Posterior 
predictive model checking is also done, in which the simulated data from the posterior predictive 
distribution is compared to the observed data.  If the model fits well the simulated data should be 
similar to the observed data (Gelman et al., 2004).  The Deviance Information Criterion (DIC) can 
be used to compare models in a similar way as the Akaike Information Criterion, with smaller 
values indicating better model fit.  It gives a measure of model fit, that is penalised for model 
complexity (Spiegelhalter et al., 2002).  When data are incomplete the DIC is based on the fit of the 
joint model (, |H, [) to the observed data (Yobs and R).  The DIC indicates how consistent the 
modelling assumptions are with the observed data, but cannot provide information about the fit to 
the data that was not observed (Daniels & Hogan, 2008).   
 
Bayesian analysis provides a flexible way to model MNAR data, using a selection model 
factorisation of a joint model, consisting of a model of interest and a model of missingness.  The 
results are not robust to incorrect specification of the various parts of the joint model.   
 
The advantage of Bayesian modelling is that it provides a model based approach to missing data, 
which is theoretically sound.  Uncertainty can be modelled.  These models also have the ability to 
incorporate realistic assumptions about the reasons for missing data.   
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3.7 Death as a cause of missing data 
One of the more difficult issues in the analysis of longitudinal data is how to handle death as a 
cause of dropout and thus a cause of missing data.  Little has been written about addressing missing 
data when deaths occur during follow-up and is related to the outcome of interest.  The National 
Research Council (2010) recommended that one define the estimand carefully; for example as 
outcomes in those who would remain alive on either treatment.  This estimand applies to a sub-
group that cannot necessarily be identified.   
 
Most methods for the analysis of data after dropout assume that participants who drop out could 
have been measured after their dropout time.  Random-effects models or multiple imputation may 
impute data beyond dropout; this is not plausible if drop out was caused by death (Hogan et al., 
2004).  A possible way to approach this is to draw inferences about the sub-population of 
participants who would survive (Robins, Greenland, & Hu, 1999; Rubin & Frangakis, 1999).   
 
Regression models can be used to describe the relationship between predictors and the longitudinal 
response, but survival influences whether the longitudinal response will be observed at later visits.  
Thus if one modelled longitudinal data truncated by death, the model will explicitly or implicitly 
also include survival.  Kurland et al. (2009) discuss several modelling options for longitudinal data 
truncated by death.  These methods answer different scientific questions and also have different 
estimands.   
 
The first type of methods models the outcome unconditional on survival.  These models are 
appropriate if deaths do not occur or are independent of the response process or do not result in 
truncation.  When these conditions are not met, the unconditional distribution averages (|j) 
over the survival function (j), where Ô represents the survival time for participant i.  These 
unconditional models are usually not the correct model to use when there is imbalance due to death 
(Kurland et al., 2009).  Mixed effects models are an example of these and may impute data beyond 
death.   
 
A second direction one could take is through models that are fully conditional on death.  Only 
participants who survived are analysed, or those who survived are analysed separately from those 
who did not survive.  One way to do a fully conditional analysis is with pattern-mixture models, 
where outcome is modelled separately for groups defined by the survival time.  These models can 
model the individual trajectories correctly, but they use future survival time to model earlier 
outcomes.  Principal stratification as described by Frangakis and Rubin (2002) can also be used, 
where causal effects are estimated for principal strata as defined by the potential survival outcome.  
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These models describe the causal treatment effect for each stratum.  Terminal decline models are a 
third fully conditional option.  These models include only the participants who died during the 
study and the analysis counts backwards from death (Kurland et al., 2009).   
 
The third direction one could take is to use partly conditional models.  These can be fitted by 
conditioning the expected value of the response at time tij on the participant being alive at time tij.  
Partly conditional regression models correct the shortcoming that data are imputed after death by 
methods that model the correlation structure of longitudinal data, by assuming independence 
among the longitudinal responses.  These models then fit regression models conditional on being 
alive and describe the outcome variables among the dynamic cohort of surviving participants 
(Kurland et al., 2009).   
 
The last method to handle missing data created by death is to fit a joint model of both the outcome 
and survival.  A joint model of the probability of being alive and healthy is created.  Joint models 
were discussed in detail in Section 3.3.4. 
 
Dufouil, Brayne, and Clayton (2004) argued that death and dropout refer to two different kinds of 
loss to follow-up and should not simply be combined in analysis.  They also distinguished between 
a mortal and immortal cohort.  In an immortal cohort, all participants are observed at all time 
points.  Analyses based on likelihood give correct results when the missing observations are MAR, 
but full probability modelling of participant-specific response profiles does not readily 
accommodate different treatment of death and drop-out.  Marginal modelling approaches, such as 
GEE, can accommodate this; however GEE is only valid under MCAR.  Inverse probability 
weighting methods can solve this problem, and weighted GEE is valid under MAR.   
 
Dufouil et al. (2004) suggested imputing values for drop outs and allowing participants who died to 
be removed from the study.  They assumed that the mortality rate following drop-out was the same 
as the mortality rate for participants remaining in the study.  They defined r+ as the probability 
that participant I, seen at time t – 1 and still alive at time t, will drop out at time t.  Using ideas from 
inverse probability weighting they fit a logistic regression using data from the survivors at each 
wave to model r+ and then use double decrement life table models to calculate the weights for 
inverse probability weighting.  They then simulate imputation of missing data for participants who 
dropped out, but not for those who died.  This analysis assumes that following drop out the 
distribution of outcome in surviving participants mirrors that in participants remaining in the study, 
conditional on observed data.  If the interest is to predict the longitudinal outcome in living 
participants, then the mortal cohort analysis is appropriate.  This method can only be used with 
monotone missing data.   
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3.8 Concluding points 
Several methods to analyse longitudinal data when data are incomplete were discussed in this 
chapter.  These methods require assumptions made about the distribution of the missing data, often 
the conditional distribution of the missing data given the observed data, or the mechanism that 
created the missing data.  The resulting conclusions can be sensitive to the assumptions made 
(Ibrahim et al., 2005; Molenberghs & Kenward, 2007; National Research Council, 2010).  The 
validity of these assumptions can, however, not be tested using the available data. 
 
The various methods discussed all have advantages and disadvantages.  The mechanism creating 
the missing data (MCAR, MAR, MNAR) determines to a large extent which of the analysis 
methods are appropriate in any specific instance.  If the missing data mechanism is MCAR almost 
any method would be appropriate, LOCF being a counterexample.  The complete case analysis is 
only unbiased if the data are MCAR.  Under MAR, inverse probability weighting, likelihood-based 
approaches, Bayesian methods and multiple data imputation are used and valid, given some 
assumptions.  Under MNAR conditions selection models, pattern-mixture models and shared-
parameter models are used. 
 
The parameters estimated using a pattern-mixture model, selection model or shared-parameter 
model cannot be compared directly.  This is because θ in a selection model represents a marginal 
effect, in a pattern-mixture model it represents an effect conditional on missing data and in a 
shared-parameter model it measures an effect conditional on a latent variable.  However, the 
estimate obtained from a pattern-mixture model can be averaged to obtain a marginal estimate, 
which is comparable to a selection model estimate.  
 
Methods that do not assume MAR widen confidence or credible intervals because they inflate the 
standard error to reflect the uncertainty created by the missing data (White et al., 2007).  Certain 
methods are almost never appropriate.  These include single imputation methods, such as LOCF.  
The analysis of a clinical trial should account for the uncertainty created by missing data.  The 
significant tests should have valid type I error rates and standard errors should be calculated 
appropriately.  This is accomplished through multiple imputing, inverse probability weighting, 
Bayesian methods and maximum likelihood methods.   
 
Likelihood-based estimation in an incomplete multivariate setting involves adjustment in terms of 
the conditional expectation of the unobserved measurements given the observed ones.  This is 
therefore a proper way to use the available post randomisation outcomes, even when some data are 
missing (Molenberghs & Kenward, 2007).  Mallinckrodt et al. (2003) proposed that likelihood-
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based mixed effects models are the appropriate choice for the primary analysis; since these 
resolved the problems posed to the greatest extent.  However, the mean structure and the variance-
covariance structure need to be correctly modelled. 
 
Regulatory agencies used to ask for a single, pre-specified primary analysis.  This is difficult to 
implement with incomplete data and several sensitivity analyses.  MNAR methods are not simple, 
and in a sensitivity analysis context do not lead to a single analysis, nor is it easy to pre-specify.  
Ignorable likelihood-based mixed-effects analyses are consistent with the need for a simple, pre-
specified analysis, based on the ITT principle, provided that the treatment compliance is the same 
for those who drop out and those who remain in the study and data are collected after drop out.  It 
may not be feasible to collect data after drop out and information on treatment compliance may not 
be available in those who dropped out (Mallinckrodt, Clark, et al., 2003).  Any particular MNAR 
model leads to a set of conclusions if the assumptions about the dropout mechanism were true.  
Since these assumptions cannot be tested, any particular model could not be the definitive 
conclusion of a trial (Molenberghs & Kenward, 2007).  This has changed over the years and now 
regulators may want reassurance that inference is robust to departures from the assumptions of the 
primary analysis.  This can be done with sensitivity analysis (Carpenter et al., 2013).   
 
We did not consider incomplete time-to-event data.  The standard approach to dealing with missing 
data in these studies is to censor the participant at the last time where data were observed.  The 
assumption underlying this is that censoring is non-informative, or MAR.  This assumption is 
probably valid for participants who reach the scheduled end of study without experiencing the 
event under study.  This assumption is not appropriate for participants who leave the study early, 
either due to a competing event or withdrawal from the study.  Including a withdrawn participant as 
censored in a time to event analysis is regarded as following the ITT principle.  In reality in order 
to follow the ITT principle, one might need to assume that participants who withdraw early from 
the study are not MAR, but have informative censoring.  These methods are not as well developed 





With incomplete data there is no definitive correct analysis of the data; especially not when missing 
data are MNAR.  In addition, the data cannot be used to verify any of the assumptions made about 
the missing data mechanism, since this is not contained in the observed data.  This point was made 
throughout the previous chapters and is often highlighted by various authors (Carpenter & 
Kenward, 2007; Mallinckrodt, Clark, et al., 2003; Molenberghs & Kenward, 2007).  Because the 
data include no information about the missing data process and the non-identified parameters, a 
sensitivity analysis should be done over a range of different values of the parameters (Daniels & 
Hogan, 2000).  Sensitivity analyses should play a central role in the analysis of incomplete data. 
 
Recommendation 15 of the National Research Council (2010) states: “Sensitivity analyses should 
be part of the primary reporting of findings from clinical trials. Examining sensitivity to the 
assumptions about the missing data mechanism should be a mandatory component of reporting.” 
 
There are many approaches to sensitivity analyses.  These include adding sensitivity parameters to 
models, investigating local influence, incorporating prior belief, fitting different models, such as 
pattern-mixture models and selection models.   
 
4.1 Definition of sensitivity analysis 
The CHMP (2010) defined sensitivity analyses as a set of analyses where the missing data are 
handled in a different way in each analysis.  They argued that it should be presented to support the 
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main analysis.  Beunckens et al. (2009) adapted a pragmatic definition of a sensitivity analysis as 
an analysis in which several statistical models are considered simultaneously and/or where a 
statistical model is further scrutinised using specialised tools, such as diagnostic measures.  White 
et al. (2007) described sensitivity analyses as follows:  Instead of using the complete case analysis 
at the final endpoint (assuming MCAR within randomised groups) the intervention effect should be 
estimated assuming MAR (using an appropriate mixed model or multiple imputation).  The 
sensitivity of the MAR analysis to informative missingness should then be investigated rather than 
exploring the sensitivity of the MCAR analysis to informative missingness.  During this process a 
range of conclusions, rather than a single conclusion, is obtained.  This provides insight into the 
sensitivity to the assumptions made (Thijs et al., 2002).  Daniels and Hogan (2008) defined 
sensitivity analyses as the assessment of sensitivity of model-based inferences to assumptions that 
cannot be verified or checked with the data.  In the missing data setting, this refers to inferences 
around the full data distribution.   
 
Janssens et al. (2012) noted that sensitivity could refer to different concepts.  It could refer to 
varying the parameter of interest, ways of data analysis, assumptions about the data, assumptions 
about the missing data or different analysis populations.  In the sensitivity analysis they performed 
the way in which the data were analysed, the model specification, the class of model (selection, 
parameter or multiple imputation), assumptions about the data and assumptions about the missing 
data (MAR versus MNAR) were varied.   
 
Thus although there seems to be consensus about the need for and importance of sensitivity 
analysis, there is not much consensus about exactly what is defined as a sensitivity analysis.   
4.2 Guiding principles for sensitivity analysis 
Several guidance for sensitivity analyses were suggested by various authors.  Carpenter and 
Kenward (2007) gave the following guiding principles for sensitivity analyses.   
1. The sensitivity analyses should be pre-defined, and address the impact of clinically 
plausible departures from MAR.  The specification of the sensitivity analyses should be 
part of the trial planning process.  Opinions should be collected on the differences between 
responders and non-responders from experts in the field. 
2. The sensitivity analyses should be transparent to non-statisticians, most notably the 
investigators and regulators. 
3. The statistical methods employed should be applicable to a wide range of settings. 
4. Technically simple methods are often used because it is argued that these methods are less 
complicated.  The assumptions behind these simple methods could sometimes be 
unrealistic or complicated to understand.  It should therefore not be assumed that a 
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technically simple method is transparent.  More complicated methods with simple and 
transparent assumptions are favoured over technically simple methods with opaque 
assumptions. 
5. It is important to vary the assumptions about the missing data mechanism rather than to 
simply vary the statistical methods or models used.  Different methods that make the same 
assumption about the underlying and unobserved missing data mechanism could lead to the 
same conclusion, without providing a true sensitivity analysis.  The appropriate techniques 
should be used to analyse the data under each of the alternative assumptions. 
 
The CHMP (2010) suggested the following: 
1. Certain types of missing data should be treated as MNAR.   
2. Multiple imputation methods should be used to incorporate a pattern-mixture approach. 
3. The impact different model settings have on the results should be compared. 
4. Retrieved dropout data could be utilised.   
5. A worst case analysis should be done. 
6. A responder analysis should be done where all missing data are treated as failures and 
another analysis should be done where missing data due to certain reasons are treated as 
failures and missing data due to other reasons are treated as successes.   
 
Some of the suggestions by the CHMP seem to violate the fifth guiding principle of Carpenter and 
Kenward (2007) as given above, since these methods focus on changing the methodology or model, 
rather than varying the assumptions made in the analysis.   
 
A distinction can be made in sensitivity analysis between two different analyses; one tests 
assumption sensitivity and one tests parameter sensitivity.  For assumption sensitivity, alternative 
models are fitted by changing the key assumptions; including assumptions about the model of the 
missingness and the distributional assumptions of the full data model.  Parameter sensitivity 
involves running the base model with the parameters controlling the extent of the departure from 
MAR in a plausible range.  Within the selection model paradigm, a strategy is to consider various 
dependencies of the missing data process on the outcomes and/or covariates.   
4.3 The role of MAR and MNAR models in sensitivity analyses 
Various plausible MNAR models could be fitted in a sensitivity analysis (Molenberghs & 
Kenward, 2007).  Or one can assess how a collection of MNAR models differ from the set of 




Molenberghs et al. (2004) suggested that a sensitivity analysis is a good compromise between 
fitting only a MNAR model and ignoring MNAR models completely.  Such an analysis could 
explore the dependence of the results on departures from MAR assumptions.  The aim of sensitivity 
analysis is to explore plausible departures from MAR and whether this changes the conclusions, 
rather than to confirm that a specific MNAR model is correct (Carpenter & Kenward, 2007). 
 
Carpenter et al. (2002) suggested that a sensitivity analysis should consist of building an ‘envelope 
of conclusions’ bounded by the results of the MAR model and the worst case MNAR model.  The 
selection of a worst case model should depend on scientific judgement.  There is no use in 
assuming worst case implausible outcomes.  The sensitivity of the conclusions to non-random 
missingness should be assessed by modifying the MAR model to allow for various plausible 
MNAR scenarios.  The conclusions are then examined to see whether they vary.   
 
In a similar vein Beunckens et al. (2009) suggested that a selected number of plausible MAR 
models be fitted, or that a preferred (primary) analysis is supplemented with a number of 
variations.  If the conclusions are stable across all the models it provides an indication that the 
results are robust to inherently untestable assumptions about the missingness mechanism. 
4.4 Pattern-mixture models in sensitivity analysis 
Daniels and Hogan (2000) parameterised the pattern-mixture model in a manner that allowed 
sensitivity analyses to be formulated in terms of between-pattern differences in means and 
variances.  The sensitivity analysis then follows by varying non-identified parameters directly, 
allowing examination of all specifications along a continuum.  They considered the special case 
where  = (, … , )′ 
and only  is missing (Little & Wang, 1996).  An identifying restriction is  p$ %í⋆, & = (í⋆ + ä) 
where L is a 1 × n-1 matrix and ⋆=(, … , ,,).  Different values of L and λ characterise 
assumptions about the pattern specific regression of  on , … , ,,.   
 
The advantage of this method for sensitivity analysis is that it constrains marginal means, variances 
and covariances.  It makes explicit the dependence of the missing data mechanism on -.  The non-
identified parameters in a pattern are estimated using data from within the pattern.  Parameters 
already identified are not dependent on λ.  The data offer no information that can be used to 
estimate λ, but sensitivity analyses can be done by varying λ through the range of plausible values 




The pattern-mixture model is then rewritten in terms of between-pattern location and scale changes.  
This provides a useful framework for imposing model constraints and interpreting them and 
conducting sensitivity analyses.  This is an easier way to communicate the sensitivity analyses to 
non-statisticians.  It may be easier to formulate the constraints based on, for example, the 
differences in outcome between those who dropped out and those who completed the study than in 
terms of missing data mechanisms.  Another advantage is that this method makes explicit all non-
identified parameters.  The non-identified parameters for patterns with incomplete data are 
functions of the fully identified parameters in the complete pattern through additive terms.  Using 
these location-scale parameterisations reduces the sensitivity analyses to a series of complete data 
problems.  The model is fully identified by fixing these components characterising the differences 
between completers and dropouts (Daniels & Hogan, 2000).   
 
In order to draw inferences about the marginal mean over all patterns of missing data information 
about the marginal variance is needed.  Sensitivity analyses based on the unidentified components 
of the variance and location parameters can be done based on the assumed differences between 
unobserved data within a pattern relative to patterns with more complete data.  The non-identified 
components of these parameters can be varied without affecting the already identified components.  
The marginal distribution of the observed data can be held fixed while examining different non-
ignorable missing data mechanisms.  Sensitivity analyses are then done by comparing inference 
about the difference in treatment arms at different combinations of the unknown components in the 
parameters (Daniels & Hogan, 2000).   
 
Pattern-mixture models offer an advantage over selection models when sensitivity analyses are 
done, since the assumptions are explicit (Verbeke et al., 2001).  Special attention should be given to 
the ACMV restriction in pattern-mixture models since this model represents the MAR counterpart 
in other types of models.  Complete case (CCMV) and neighbouring value missing (NCMV) value 
restrictions represent the extremes for the ~ vector.  It thus makes sense to regard the results found 
with these two methods as the ranges between which the results are likely to fall (Thijs et al., 
2002).   
 
Pattern-mixture models can be factorised as (, |# , ", [) = $| , #, "&$|,  , #, "&(|, #, ) 
This parameterisation splits the full data model into a factor with identified and factors with non-
identified components.  It is easy to identify the sensitivity parameter(s) from here.  If a pattern-
mixture model is used, the general model allows the missing data to be MNAR, with MAR as a 
special case.  The sensitivity parameters are then defined such that the degree of departure from 
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MAR is quantified by the sensitivity parameters.  These parameters are non-identified and the fit of 
the model to the observed data does not differ when different values for the sensitivity parameter 
are assumed.  In most situations the models have a large number of sensitivity parameters.  It is 
often necessary to reduce these parameters by making some assumptions.  Care should be taken 
when choosing the prior distributions for the missing value mechanism and the parameter space 
over which the sensitivity parameters are varied (Daniels & Hogan, 2008).   
 
Thijs et al (2002) also considered sensitivity analysis within the context of pattern-mixture models 
by using three distinct strategies to fit the models.  The first strategy was to use identifying 
restrictions, the second was to fit a model for each pattern of missing data and the third was to fit a 
single model with pattern as covariate.  The results obtained with these strategies were then 
contrasted to get a range of conclusions.  The sensitivity analysis was therefore conducted by 
determining whether results change under the different assumptions made by these models. 
 
If a pattern-mixture model is fitted, the choice of the different patterns could be subjective and it 
might be important to check the robustness of the findings if different patterns are chosen 
(Molenberghs & Kenward, 2007).  
4.5 Bayesian methods in sensitivity analysis 
In the context of Bayesian analysis, a sensitivity parameter is defined as a parameter created 
through a reparameterisation of the full data parameters such that the sensitivity parameter is a non-
constant function of the parameters of the extrapolation distribution and the fit of the model to the 
observed data is not affected by the sensitivity parameter.  When the sensitivity parameters are 
fixed, the full data model is identified.  The sensitivity parameters are used to quantify beliefs about 
the missing data mechanism.  This is done by fixing their values at constants, examining inference 
across a range of constants, or by assigning a prior distribution (Daniels & Hogan, 2008).   
 
A challenge when using prior distributions or even parameters during sensitivity analyses is to 
make the priors understandable and transparent to subject matter experts interpreting the model-
based inferences or to make them amenable to incorporation of external information (Daniels & 
Hogan, 2008; Scharfstein et al., 1999).  Sensitivity analysis is done by looking at a specific model 
for the full-data distribution where some of the parameter(s) are sensitivity parameters as defined 
above.  The sensitivity parameters are informed by prior distributions that characterise assumptions 




Some principles for the reparameterisation of the models for sensitivity analyses are: 
1.  Parameterise the model in terms of a sensitivity parameter that satisfies the definition of a 
sensitivity parameter given two paragraphs above.  Thus assumptions about the missing 
data mechanism are fully encoded by prior distributions.  One can move through all full-
data models with MNAR missingness by varying the value of the sensitivity parameters.  
Changing the value of the sensitivity parameter does not affect the observed data likelihood 
and the fit to the observed data.   
2. The prior distribution of the sensitivity parameter should reflect the uncertainty about the 
missing data assumptions and other non-identifiable aspects of the model. The prior 
distribution for the sensitivity parameter can be informed by external information, such as 
expert opinion.  Uncertainty about these assumptions can be incorporated through Bayesian 
priors.   
3. The full-data models should be centered at MAR, such that the MAR assumption coincides 
with a specific point of the sensitivity parameters.  Then the effect of the missing data 
assumptions can be viewed in terms of departures from MAR (Daniels & Hogan, 2008).   
4.6 Global and local sensitivity 
Sensitivity analysis can also be performed on the level of individual observations.  One tries to find 
observations that make the conclusions more in line with a MNAR model.  Two techniques that 
allows for this are global and local influence.  The method of local influence detects observations 
with a large influence on the model of interest or the missingness model parameters.  Local 
influence changes, for example, the missingness process for one observation from MAR to MNAR.  
Global influence is based on case deletion, or occasionally a measurement deletion approach.  It is 
based on the difference in log-likelihood between the model that is fitted to the entire data set and 
the data set where one participant is removed (Beunckens et al., 2009; Molenberghs & Kenward, 
2007).  Local and global influence are related to, but different from, each other. 
4.7 Uncertainty region 
Most sensitivity analyses are ad hoc.  One attempt to create a systematic tool for sensitivity 
analysis is the interval of uncertainty, a region of possible values of a parameter that is consistent 
with the data (Beunckens et al., 2009; Molenberghs, Kenward, & Goetghebeur, 2001; Vansteelandt 
et al., 2006).  This region depends on the data, both observed and missing, and on the model fitted.  
The region of ignorance, which is created due to the incompleteness of the data, is added to the 
measure of imprecision, created by the sampling uncertainty, to create the region of uncertainty.  




Strong 95% uncertainty intervals are designed to cover all values in the ignorance region itself 
simultaneously with 95% probability.  This strong uncertainty region is calculated by adding the 
standard 100(1-α) % confidence limits to the estimated ignorance limits.  That is [ïð, ïñ = [>Bs − ò¼  se(>Bs  ), >Bô − ò¼  se(>Bô) 
where ïð and ïñ are the lower and upper limits of the strong uncertainty region, >Bs and >Bô are the 
lower and upper limits of the estimated ignorance limits and õ/9 is the 100(1-α/2)th percentile of 
the standard normal distribution.  Weak 95% uncertainty intervals are designed to have expected 
95% overlap with the ignorance region and can be constructed as  [ïð, ïñ = [>Bs − ò∗¼  se(>Bs  ), >Bô − ò∗¼  se(>Bô) 
where ò∗¼  solves the equation 
^ =  se$>Bs& + se$>Bô&>ô −  >s × ÷( + øI? õ∗9 )u +  ù 
where ÷(.) is the standard normal density function.  The correction term ù is so small that it can be 
set as 0 without affecting the accuracy.  A solution for ò∗¼  can only be found by substituting >Bs, >Bô, se$>Bs& and se$>Bô& with consistent estimators (Vansteelandt et al., 2006).    
 
The largest possible set of identifiable parameters is selected.  All remaining parameters are then 
regarded as sensitivity parameters. Values are chosen for the sensitivity parameters and the 
identifiable parameters are estimated using the most appropriate model.  If this is done for all 
possible values of the sensitivity parameter, a region of estimates is obtained.  Thus the combined 
effects of imprecision and ignorance are captured in the region of uncertainty.  Details regarding 




SAPiT study data analysis 
The study of missing data was motivated by the analysis of the secondary objectives of the SAPiT 
(Starting Antiretroviral therapy at three Points in Tuberculosis) clinical trial (Abdool Karim et al., 
2010).  In Section 5.1 we describe the design and published results of the SAPiT trial.  Section 5.2 
continues with a description of the missing data in the trial.  We then analyse the data using MCAR 
methods in Section 5.3, MAR methods in Section 5.4 and MNAR methods in Section 5.5.  We 
conclude the chapter by contrasting these analyses and drawing a conclusion regarding the 
findings. 
5.1 The SAPiT study 
5.1.1 Background to the study 
It is estimated that in 2010 there were about 34 million human immunodeficiency virus (HIV) 
infected people worldwide (Joint United Nations Programme on HIV/AIDS (UNAIDS), 2010) and 
8.7 million new tuberculosis cases in 2011, 13% of these co-infected with HIV (World Health 
Organization, 2012).  In Africa, 46% of tuberculosis patients tested for HIV, were found to be HIV-
positive (World Health Organization, 2012).  Globally, an estimated 380 000 HIV infected persons 
died due to tuberculosis in 2009 (Joint United Nations Programme on HIV/AIDS (UNAIDS), 
2010).  Tuberculosis is the most common presenting opportunistic infection in HIV infected 
individuals (Churchyard et al., 2000), and is the most common cause of mortality in acquired 
immune deficiency syndrome (AIDS) patients in developing countries (Mukadi, Maher, & Harries, 
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2001). In the presence of HIV, tuberculosis is associated with substantially higher case fatality 
rates, even with effective tuberculosis chemotherapy (Schluger, 1999). 
 
Tuberculosis is the most common notified cause of death in South Africa (Health Systems Trust, 
2008).  In 2011, South Africa had an estimated 5.6 million people infected with HIV (Joint United 
Nations Programme on HIV/AIDS UNAIDS, 2012) and 401 048 reported tuberculosis cases in 
2010 (Day, Gray, & Budgell, 2012), of whom approximately 53% were dually infected with 
tuberculosis and HIV (South African Department of Health, 2007).  The World Health 
Organisation (WHO) estimates that 60% of tested tuberculosis patients in South Africa were HIV 
positive in 2010 (World Health Organisation, 2011).  In this setting, routine HIV testing in 
tuberculosis patients is an important path for entry into HIV treatment programs.  
 
Prior to the SAPiT study there was no clinical trial data to guide the timing of antiretroviral therapy 
initiation in tuberculosis patients.  The timing of antiretroviral therapy initiation in tuberculosis 
patients was variable, depending on clinician judgement.  Available guidelines were based on 
observational data and expert opinion (National Department of Health, 2004).  The WHO 
guidelines (World Health Organisation, 2003) urged integrated treatment of HIV and tuberculosis, 
but clinicians often deferred HIV treatment in tuberculosis-HIV co-infected patients because of 
numerous concerns.  These included drug interactions between rifampicin and some classes of 
antiretroviral therapy (Piscitelli & Gallicano, 2001), additive side effects and toxicities (Girardi et 
al., 2001) and a high pill burden. 
 
The aim of the SAPiT trial was to determine the optimal time to initiate antiretroviral therapy in 
patients on tuberculosis treatment and the primary outcome was mortality (Abdool Karim et al., 
2010). 
5.1.2 Methods 
The SAPiT trial (protocol number: CAPRISA 003) was an open label, randomised controlled trial 
comparing three treatment strategies of antiretroviral therapy initiation in HIV-tuberculosis co-
infected patients.  Participants were randomised to one of three arms: 
1. Early integrated treatment arm:  antiretroviral therapy initiated within 4 weeks of starting 
tuberculosis treatment 
2. Late integrated treatment arm:  antiretroviral therapy initiated within 4 weeks of completing 
the intensive phase of tuberculosis treatment, which happens approximately 2 months after 
the initiation of tuberculosis therapy 
3. Sequential treatment arm:  antiretroviral therapy initiated within 4 weeks of completing 




The trial was conducted at the CAPRISA eThekwini tuberculosis-HIV clinic, which adjoins the 
Prince Cyril Zulu Communicable Disease Centre, one of the largest out-patient tuberculosis 
facilities in South Africa.  From 28 June 2005 to 11 July 2008, HIV positive tuberculosis infected 
patients, who were 18 years or older were recruited from the Prince Cyril Zulu Communicable 
Disease Clinic. To qualify for inclusion in the trial, participants had to be initiated on the standard 
tuberculosis treatment regimens, as stipulated in the South African National Tuberculosis Control 
Programme guidelines (Department of Health, 2004), had to have a CD4+ count below 500 
cells/mm3 at screening and had to have no clinical contra-indications to initiation of antiretroviral 
therapy.  Female participants were required to agree to use contraception while on efavirenz.  After 
providing informed consent, qualifying tuberculosis-HIV co-infected patients were enrolled and 
randomised to one of the three treatment arms in a 1:1:1 ratio in permuted blocks of six or nine 
with no stratification, using sealed envelopes.  Trial arm assignment was concealed until after 
randomisation, but thereafter both the participants and the clinic staff were aware of participant arm 
assignment.   
 
According to the South African National Tuberculosis Control Programme Guidelines (Department 
of Health, 2004) the first episode of tuberculosis is treated with a fixed drug combination of 
rifampicin, isoniazid, ethambutol and pyrazinamide for a 2-month intensive phase.  Thereafter, the 
4-month continuation phase comprises a fixed-drug combination of isoniazid and rifampicin.  
Patients with a history of tuberculosis receive a 60-day intensive phase which includes 
streptomycin, followed by a 100-day continuation phase.  The Prince Cyril Zulu Communicable 
Disease Centre offers clinic-based directly observed therapy.  Some patients did not attend the 
clinic daily for directly observed therapy.   
 
Participants were scheduled to visit the clinic monthly for 24 months.  At these visits antiretroviral 
therapy was dispensed and clinical status was monitored.  CD4+ count was measured using the 
FACS Calibur flow cytometer (Becton Dickinson, Franklin Lakes New Jersey, United States of 
America).  HIV RNA was measured using the Roche Cobas Amplicor HIV-1 Monitor v1.5.  CD4+ 
count and HIV RNA viral load were measured at screening, randomisation and every 6 months 
thereafter.   
5.1.3 Primary and secondary endpoints of the SAPiT trial 
The primary endpoint of the trial was all cause mortality.  During an interim analysis of the data it 
was found that initiation of antiretroviral therapy during tuberculosis treatment (arms 1 and 2 
combined) in patients with sputum tuberculosis and HIV co-infection with CD4+ counts <500 
cells/mm3 reduced mortality by 56% (95% confidence interval [CI]: 21% to 75%, p = 0.003).  
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Mortality in patients with integrated HIV and tuberculosis treatment was 5.4 per 100 person-years, 
while it was 12.1 per 100 person-years in patients when initiation of antiretroviral therapy was 
delayed until completion of tuberculosis treatment (Abdool Karim et al., 2010).   
 
The population, demographic data and primary endpoint of mortality have been analysed and 
reported previously for interim data (Abdool Karim et al., 2010) and for complete data in the first 
two arms (Abdool Karim et al., 2011).  It was shown that there was a significant difference in 
mortality between the treatment arms.  At the time of the interim analysis, overall 8.1% of the 
participants in the study had died.  In addition to the high mortality, loss to follow-up was also high 
with 18.4% of participants being terminated or lost to follow-up at the time of the analysis.  This 
was fairly evenly spread between the study arms.  
 
Secondary endpoints included tolerability, toxicity, CD4+ counts, HIV RNA viral load, 
tuberculosis outcomes and immune reconstitution inflammatory syndrome (IRIS).  Tolerability was 
defined as study initiated treatment interruptions in the pharmacy records.  Toxicity was assessed 
by a clinical checklist and standard laboratory assessments for haematological, hepatic and renal 
abnormalities.  IRIS was defined as a paradoxical deterioration in clinical status after antiretroviral 
therapy initiation without another attributable cause.  One of the secondary endpoints was to 
compare HIV-outcomes in terms of CD4+ count and HIV RNA viral load at 6, 12, 18 and 24 
months post randomisation and to investigate the difference between the treatment arms in 
variations in longitudinal CD4+ count.   
 
CD4+ cells are a type of white blood cells (lymphocyte) that fight infection.  The CD4+ count 
measures the number of CD4+ cells in a certain volume of blood.  HIV infects CD4+ T-cells and 
causes immunosuppression in the human host; this is measured as a low CD4+ count.  The CD4+ 
count is an indication of the level of immunopathology caused by the HIV infection and is a crude 
representation of the damage done to the immune system by HIV infection.  Thus CD4+ counts are 
used clinically as a measure of disease progression and effectiveness of antiretroviral therapy (Gray 
et al., 2010).  CD4+ cell count is a useful surrogate marker of treatment effects and effectiveness 
(Daniels & Hughes, 1997).  Normal CD4+ counts range between 600 and 1500 cells/mm3 in adults 
(BARC laboratory reference ranges).  This is much reduced during HIV infection.  In 2010 the 
South African treatment guidelines required that antiretroviral treatment be started when a patient’s 
CD4+ count was below 200 cells/mm3  
 
The objective of this chapter is to analyse the secondary outcome of CD4+ count profiles over time 
in the three arms.  The goal is to characterise the changes in CD4+ count over time as a function of 
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treatment arm, in order to determine whether integrated HIV and tuberculosis treatment improved 
or worsened HIV outcomes.   
 
The high mortality, combined with the even higher loss to follow-up rate suggested that the 
secondary objective of CD4+ count could not be analysed without taking missing data into account, 
since about a quarter of participants did not complete the study and did not have CD4+ counts past 
12 months post randomisation.  It is possible that dropout is related to CD4+ count.  It is plausible 
that the unobserved (because they are missing) CD4+ counts among those who dropped out are 
lower than those who continue follow-up, even after adjusting for observed CD4+ counts and other 
covariates.  The goal of this analysis was to analyse the secondary objective of CD4+ count in a 
valid way, while taking missing data into account.  This analysis included the entire 24 months of 
follow-up per participant in the SAPiT trial.  The primary endpoint was CD4+ count at 6, 12, 18 
and 24 months. 
5.1.4 Statistical notation 
The statistical notation was introduced in Section 2.1.  It was adapted for this data set as follows:  
We assume N independent participants, indicated by i = 1, …,N.  The CD4+ count outcome for the 
i
th participant at jth occasion is given by -.  Treatment is indicated by the two variables ú and í.  
If the ith participant is in the early integrated treatment arm, then ú = 1, else ú = 0.  If the ith 
participant is in the late integrated treatment arm, then í = 1, else í = 0.  A participant i 
belonging to the sequential treatment arm will thus have ú =  í = 0.  The sequential arm is 
therefore the reference group.  tij is the time point for the i
th participant at the jth occasion, and can 
take the values 0, 6, 12, 18 and 24 months.  When dropout is defined as a binary variable, we 
indicate dropout by .  If participant i dropped out, then  = 1, if participant i did not drop out 
then  = 0.  In some models dropout was not defined as a binary variable.  In those instances it is 
described where the model is given.   
 
5.2 Patterns of missing data  
It is important to understand and try to explain why data are missing using the data collected.  The 
number of missing data points and the reasons for having missing data are provided in Table 5.1.  
Most of the participants lost to follow-up were lost within the first year, and after 12 months only a 
few additional participants had missing values.  Treatment arm seemed to be related to whether 
data were missing, with missing data being more prevalent as antiretroviral initiation was delayed 
(exact Cochran-Armitage trend test , p = 0.01).  This test compares the number of participants in 
pattern 1 in Table 5.2 in the three treatment arms.  The trend investigated went from early 
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integrated treatment arm (immediate antiretroviral therapy), to late integrated treatment arm 
(antiretroviral therapy at the end of the intensive phase) to sequential treatment arm (antiretroviral 
therapy after tuberculosis treatment).  The early integrated treatment arm had fewer missing values 
than the other two treatment arms.  Participants were also lost to follow-up earlier in the later 
treatment arms.  More than one third of participants, 37.9%, were lost to follow-up by 24 months.  
Overall, 28% (69/243) of the missing data at 24 months were caused by deaths.  Mortality had been 
shown to be related to treatment arm (Abdool Karim et al., 2010), thus any analysis of CD4+ count 
at 24 months could be biased if the issue of missing data were not properly taken into account.   
 
Table 5.1:  Number of participants attending each 6-monthly evaluation 
 Early integrated 
treatment arm 
N = 214 
Late integrated 
treatment arm 
N = 215 
Sequential   
treatment arm 
N = 213 
 N Number missing 
(%) 
N Number missing 
(%) 
N Number missing 
(%) 
Number with CD4+ count at       
  6 months 173 41 (19.2%) 159 56 (26.0%) 154 59 (27.7%) 
  12 months 160 54 (25.2%) 150 65 (30.2%) 128 85 (39.9%) 
  18 months 152 62 (29.0%) 143 72 (33.5%) 123 90 (42.3%) 
  24 months 145 69 (32.2%) 131 84 (39.1%) 123 90 (42.3%) 
Number of participants dead at      
  6 months 10 ` 5  12  
  12 months 13  12  32  
  18 months 14  15  35  
  24 months 17  17  35  
Reasons not attending 6 month visit     
  Lost to follow-up 21  38  31  
  Dead 10 ` 5  12  
  Terminated 6  5  5  
  Attended later visits, 
missed the 6 month visit 
4  8  11  
Reasons not attending 12 month visit     
  Lost to follow-up 25  37  36  
  Dead 13  12  32  
  Terminated 13  15  10  
  Attended later visits, 
missed the 12 month visit 
3  1  7  
Reasons not attending 18 month visit     
  Lost to follow-up 27  35  35  
  Dead 13  15  35  
  Terminated 17  19  14  
  Attended later visits, 
missed the 18 month visit 
5  3  6  
Reasons not attending 24 month visit     
  Lost to follow-up 0  2  0  
  Dead 17  17  35  
  Terminated 52  65  55  
Participants are regarded as lost to follow-up when they have not attended clinic visits for three months.  Attempts are made to locate 
participants who do not attend visits.  These attempts are repeated at intervals until study end.  Sometimes a participant is regarded as 
lost to follow-up at a visit and is later found to have died subsequent to being lost to follow-up.  These participants are classified as lost 




The different patterns of missing data and the number of participants in each of these patterns are 
given in Table 5.2.  Most participants completed the study.  The missing data pattern with the most 
participants was pattern 5, where participants had baseline data only.   
 
Table 5.2:  Patterns of missing data in each of the treatment arms 

















N = 215 




N = 213 
1 X X X X X 137 (64.0%) 122 (56.7%) 108 (50.7%) 
2 X X X X  8 (3.7%) 12 (5.6%) 5 (2.4%) 
3 X X X   8 (3.7%) 6 (2.8%) 5 (2.4%) 
4 X X    14 (6.5%) 16 (7.4%) 30 (14.1%) 
5 X     37 (17.3) 48 (22.3%) 48 (22.5%) 
6 X Completers, with some interim 
missing data 
X 8 (3.7%) 9 (4.2%) 15 (7.0%) 
7 X Did not complete, with interim 
missing data 
 2 (0.9%) 2 (0.9%) 2 (0.9%) 
X:  Indicates data present 
 
 
Figure 5.1:  Sample medians of CD4+ counts at each 6 monthly visit.   
The solid dots represent the medians for participants who did not drop out before the subsequent 
CD4+ measurement.  The diamonds represent the medians of participants who dropped out before 




Although the observed data cannot give information about the unobserved missing data, there is an 
indication that dropout in this study is not MCAR.  Figure 5.1 gives the observed median CD4+ 
count at each of the time points for the participants who dropped out at the subsequent visit and for 
those who did not drop out at the subsequent visit.  At baseline median CD4+ count was similar for 
those who dropped out and those who did not.  However, at 6 and 12 months the median CD4+ 
count of those who dropped out at the subsequent visit was lower than for those who did not drop 
out.  At 18 months the median CD4+ counts of those who dropped out was higher than for those 
who did not drop out.  This is an interesting phenomenon.  A possible reason is that by 18 months 
participants have improved sufficiently to be less likely to drop out due to ill health.  It is also 
possible that participants who are likely to drop out due to lower CD4+ counts have already done 
so by 18 months.  These theories cannot be validated using the available data.  It should also be 
borne in mind that there were only 29 participants who dropped out after 18 months.  The median 
for those who dropped out was therefore less stable and more variable.  The fact that participants 
with lower median CD4+ count are more likely to drop out at the earlier visits suggests that 
dropout depends at least on observed CD4+ count, and implies that model-based means could be 
different from observed means.   
 
At 6 months there was a significant difference between the CD4+ counts of participants who 
missed the 12 month visit and those who did not miss this visit.  The median CD4+ count at 6 
months was 198 (interquartile range [IQR]: 65 to 301) cells/mm3 in participants who missed their 
12 month visit and 212 (IQR: 117 to 350) cells/mm3 in participants who attended the 12 month 
visit (median difference = -14, Wilcoxon p = 0.049).   
 
At 12 months there was not a significant difference between the CD4+ counts of participants who 
missed the 18 month visit and those who did not miss this visit.  The median CD4+ count at 12 
months was 239 (IQR: 163 to 381) cells/mm3 in participants who missed their 18 month visit and 
289 (IQR: 182 to 431) cells/mm3 in participants who attended the 18 month visit (median 
difference = -50, Wilcoxon p = 0.15).   
 
Carpenter and Kenward (2007) suggested that logistic regression and/or survival analysis be used 
to determine key independent variables associated with withdrawal.  We used logistic regression to 
identify variables associated with missing CD4+ count at each of the 6-monthly visits.  Baseline 
variables believed by the clinical staff to be related to tuberculosis and HIV outcomes were used in 




Table 5.3: Variables associated with missing a visit, results of logistic regression, 
modelling the probability of withdrawing 
 Missed visit Univariate Multivariate 
 N (%) Odds Ratio  
(95% CI) 
p-value Odds Ratio  
(95% CI) 
p-value 
Variables associated with missing the 6 month visit    
Arm (ref sequential)  59/213 (27.7) 1.00  1.00  
- Early treatment arm 41/214 (19.2) 0.62 (0.39 to 0.97) 0.04 0.61 (0.38 to 0.97) 0.04 
- Late treatment arm 56/215 (26.1) 0.92 (0.60 to 1.41) 0.70 0.93 (0.60 to 1.43) 0.72 
Gender (ref male) 86/319 (27.0) 1.00  1.00  
- Female 70/323 (21.7) 0.75 (0.52 to 1.08) 0.12 0.64 (0.44 to 0.94) 0.02 
Age - 0.97 (0.95 to 0.99) 0.01 0.96 (0.94 to 0.98) 0.001 
WHO status (ref = Stage 4) 150/604 (24.8) 1.00  1.00  
- Stage 3 6/38 (15.8) 1.76 (0.72 to 4.30) 0.21 1.69 (0.54 to 5.28) 0.37 
CD4+ count at baseline  
(50 cell/mm3  increments) 
- 1.06 (0.99 to 1.14) 0.12 1.05 (0.98 to 1.14) 0.16 
Extra pulmonary tuberculosis 148/599 (24.7) 1.00  1.00  
- Yes 8/43 (18.6) 0.70 (0.32 to 1.54) 0.37 1.11 (0.39 to 3.09) 0.85 
Log viral load at baseline  - 0.83 (0.67 to 1.02) 0.08 0.83 (0.66 to 1.05)  0.12 
History of tuberculosis 96/428 (22.4) 1.00  1.00  
- Yes 60/214 (28.0) 1.35 (0.93 to 1.96) 0.12 1.47 (1.00 to 2.17) 0.05 
Multidrug resistant tuberculosis 151/624 (24.2) 1.00  1.00  
- Yes 5/18 (27.8) 1.21 (0.42 to 3.43) 0.73 1.35 (0.44 to 4.09) 0.60 
Variables associated with missing the 12 month visit for those not lost to follow-up at the 6 month visit 
Arm (ref sequential)  37/165 (22.4) 1.00  1.00  
- Early treatment arm 17/177 (9.6) 0.37 (0.20 to 0.68) 0.002 0.47 (0.24 to 0.93) 0.03 
- Late treatment arm 17/167 (10.2) 0.39 (0.21 to 0.73)  0.003 0.47 (0.24 to 0.92) 0.03 
Gender (ref male) 34/241 (14.1) 1.00  1.00  
- Female 37/268 (13.8) 0.98 (0.59 to 1.61) 0.92 0.90 (0.52 to 1.58) 0.72 
Age - 0.97 (0.93 to 1.00) 0.03 0.96 (0.92 to 1.00) 0.03 
WHO status (ref = Stage 4) 8/33 (24.2) 1.00  1.00  
- Stage 3 63/476 (13.2) 0.48 (0.21 to 1.10) 0.08 0.81 (0.18 to 3.55) 0.78 
CD4+ count at baseline  
(50 cell/mm3 increments) 
- 1.00 (0.90 to 1.11) 0.98 1.06 (0.92 to 1.23) 0.42 
Extra pulmonary tuberculosis 62/473 (13.1) 1.00  1.00  
- Yes 9/36 (25.0) 2.21 (0.99 to 4.92) 0.05 0.65 (0.16 to 2.72) 0.56 
Log viral load at baseline  - 1.22 (0.89 to 1.67) 0.21 1.22 (0.85 to 1.75) 0.28 
History of tuberculosis 51/294 (14.8) 1.00  1.00  
- Yes 20/164 (12.2) 1.80 (0.46 to 1.39) 0.43 0.86 (0.48 to 1.57) 0.63 
Multidrug resistant tuberculosis 66/495 (97.3) 1.00  1.00  
- Yes 5/14 (35.7) 3.61 (1.17 to 11.1) 0.03 2.87 (0.78 to 10.56) 0.11 
CD4+ count at 6 months  
(ref > 200 cell/mm3) 
33/254 (13.0) 1.00  1.00  
- < 50 cell/mm3   13/41 (31.7) 3.11 (1.47 to 6.60) 0.006 2.28 (0.78 to 6.65) 0.13 
- - 50 – 200 cell/mm3   21/191 (11.0) 0.83 (0.46 to 1.48) 0.03 0.86 (0.41 to 1.79) 0.68 
- -missing 4/23 (17.4) 1.41 (0.45 to 4.40) 0.96 1.25 (0.37 to 4.26) 0.72 
Variables associated with missing the 18 month visit for those not loss to follow-up at 12 months 
Arm (ref sequential)  12/135 (8.9) 1.00  1.00  
- Early treatment arm 12/163 (7.4) 0.82 (0.35 to 1.88) 0.63 1.17 (0.47 to 2.90) 0.74 
- Late treatment arm 8/151 (5.3) 0.57 (0.23 to 1.45) 0.24 0.73 (0.28 to 1.96) 0.54 
Gender (ref male) 15/211 (7.1) 1.00  1.00  
- Female 17/238 (7.1) 1.01 (0.49 to 2.07) 0.99 0.86 (0.39 to 1.89) 0.70 
Age - 0.95 (0.91 to 1.00) 0.047 0.95 (0.90 to 1.00) 0.05 
WHO status (ref = Stage 4) 1/25 (4.0) 1.00  1.00  
- Stage 3 31/424 (7.3) 1.89 (0.25 to 14.46) 0.54 0.83 (0.07 to 10.58) 0.89 
CD4+ count at baseline  
(50 cell/mm3  increments) 
- 0.97 (0.82 to 1.13) 0.67 1.03 (0.86 to 1.25) 0.73 
Extra pulmonary tuberculosis 31/422 (7.4) 1.00  1.00  
- Yes 1/27 (3.7) 0.49 (0.06 to 3.70) 0.49 2.42 (0.19 to 30.04) 0.49 
Log viral load at baseline  - 0.72 (0.48 to 1.08) 0.11 0.59 (0.36 to 0.95) 0.03 
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Table 5.3: Variables associated with missing a visit, results of logistic regression, 
modelling the probability of withdrawing 
 Missed visit Univariate Multivariate 
 N (%) Odds Ratio  
(95% CI) 
p-value Odds Ratio  
(95% CI) 
p-value 
History of tuberculosis 19/299 (6.4) 1.00  1.00  
- Yes 13/150 (8.7) 1.40 (0.67 to 2.92) 0.37 1.29 (0.60 to 2.81) 0.51 
Multidrug resistant tuberculosis 32/440 (7.3)     
- Yes 0/9 (0) Not calculated  Not calculated        
CD4+ count at 12 months 
(ref > 200 cell/mm3) 
17/307 (5.5) 1.00  1.00  
-  < 50 cell/mm3   4/13 (30.8) 7.58 (2.11 to 27.1) 0.002 9.68 (2.07 to 45.27) 0.004 
- 50 – 200 cell/mm3   8/118 (6.8) 1.24 (0.52 to 2.96) 0.63 1.57 (0.57 to 4.37) 0.38 
- Missing 3/11 (27.3) 6.40 (1.56 to 26.3) 0.01 4.66 (1.04 to 20.99) 0.04 
Variables associated with missing the 24 month visit for those not loss to follow-up at 18 months 
Arm (ref sequential)  6/129 (4.7) 1.00  1.00  
- Early treatment arm 12/157 (7.6) 1.70 (0.62 to 4.65) 0.30 2.14 (0.74 to 6.18) 0.16 
- Late treatment arm 15/146 (10.3) 2.35 (0.88 to 6.24) 0.09 2.69 (0.96 to 7.53) 0.06 
Gender (ref male) 21/201 (10.5) 1.00  1.00  
- Female 12/231 (5.2) 0.47 (0.23 to 0.98) 0.04 0.45 (0.21 to 1.00) 0.05 
Age - 1.01 (0.97 to 1.05) 0.81 1.00 (0.96 to 1.05) 0.90 
WHO status (ref = Stage 4) 0/24 (0)     
- Stage 3 33/408 (8.1) Not calculated  Not calculated  
CD4+ count at baseline  








1.26 (1.08 to 1.47) 
 
0.004 
Extra pulmonary tuberculosis 30/405 (7.4) 1.00  1.00  
- Yes 3/27 (11.1) 1.56 (0.45 to 5.49) 0.49 0.59 (0.15 to 2.31) 0.45 
Log viral load at baseline  - 0.81 (0.53 to 1.22) 0.30 0.94 (0.60 to 1.49) 0.81 
History of tuberculosis 25/288 (8.7) 1.00  1.00  
- Yes 8/144 (5.6) 0.62 (0.27 to 1.41) 0.25 0.57 (0.24 to 1.36) 0.20 
Multidrug resistant tuberculosis 33/423 (7.8)     
- Yes 0/9 (0) Not calculated  Not calculated  
CD4+ count <50 cell/mm3  at 








- Yes 3/35 (8.6) 1.15 (0.33 to 3.97) 0.78 2.79 (0.67 to 11.67) 0.16 
Missed any visit prior to 24 
months 
25/392 (6.4) 1.00  1.00  
- Yes 8/40 (20.0) 3.67 (1.53 to 8.80) 0.004 3.81 (1.47 to 9.84) 0.006 
Shaded cells indicate significant variables 
Baseline variables believed by the clinical staff to be related to tuberculosis and HIV outcomes were included in this analysis.   
 
Some variables were associated with having missing data (Table 5.3).  Missing data at Month 6 
were associated with treatment arm (early compared to sequential treatment arm: Odds ratio [OR] = 
0.62) and age (OR = 0.97) in the univariate analysis and with treatment arm (OR = 0.61), gender 
(OR = 0.64), age (OR = 0.96) and history of tuberculosis (OR = 1.47) in the multivariate case.  The 
variables indicative of disease status were not the variables that predicted having missing data.  
Missing data at Month 12 were associated with treatment arm (early compared to sequential 
treatment arm: OR = 0.37; late compared to sequential treatment arm: OR = 0.39), age (OR = 
0.97), CD4+ count at Month 6 (CD4+ count < 50: OR = 3.11, CD4 count 50-200: OR = 0.83), 
extra pulmonary tuberculosis (OR = 2.21), and having multidrug resistant tuberculosis (OR = 3.61) 
in the univariate analysis and with treatment arm (early compared to sequential treatment arm: OR 
= 0.47; late compared to sequential treatment arm: OR = 0.47) and age (0.96) in the multivariate 
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analysis.  In the univariate analysis some variables related to disease status were predictive of 
missing data.  Missing data at Month 18 were associated with age (OR = 0.95), CD4+ count at 
Month 12 <50 cell/mm3 (OR = 7.58) or missing CD4+ count (OR = 6.40) in the univariate analysis 
and with age (OR = 0.95), viral load (OR = 9.68) and CD4+ count < 50 cell/mm3 (OR = 9.68) or 
missing CD4+ count (OR = 4.66) in the multivariate analysis.  Missing data at Month 24 were 
associated with gender (OR = 0.47 and 0.45, respectively), CD4+ count at baseline (OR = 1.21 and 
1.26, respectively) and having had a previous missed visit (OR = 3.67 and 3.81, respectively) in 
both the univariate and multivariate analyses.   
 
Since the occurrence of missing data was associated with baseline data and previous CD4+ count 
measurements the data could not be assumed to be MCAR and data analysis that made the 
assumption of MCAR data would be biased and give incorrect results.  It was not possible to rule 
out that the data were MNAR using the observed data only, since the definition of MNAR 
depended on unobserved observations.  We therefore made the assumption that the CD4+ count 
data in the SAPiT study were either MAR or MNAR. 
 
The SAPiT study had three treatment arms.  Having more than two treatment arms raised the 
question whether all three arms should be compared or whether two treatments at a time should be 
analysed in a pairwise comparison.  This choice influences the p-value if a linear mixed model is 
used since model based smoothing of the covariance structure takes place either on two or three 
arms.  Efficiency can be gained by using all arms.  Risk of misspecification can be reduced by 
assuming a treatment arm specific covariance matrix and treatment arm specific mean evolution 
(Molenberghs & Kenward, 2007; Molenberghs et al., 2004).  We decided to include all three arms, 
since the scientific interest was in determining which of the three time points of antiretroviral 
therapy initiation resulted in the best HIV endpoints, and to possibly combine two arms if we found 
no difference between the two arms, while comparing those two to the third arm.  At the start of the 
study, it was not clear that any of these arms would be the natural comparator arm.  A different 
decision could have been made if we were comparing two active treatments and a placebo arm.  In 
that case, it might make sense to compare each of the active treatment arms in a pairwise fashion 
with the placebo arm.   
 
The CD4+ count data were not normally distributed.  A square root transformation of CD4+ count 
produced a normal distribution, therefore modelling was done and p-values were calculated using 
square root transformed CD4+ count throughout.  Graphs and reported summary statistics are given 
in the original scale, because clinical researchers find it difficult to interpret square root 
transformed CD4+ counts and the applied medical statistician can communicate results more 
clearly to colleagues using actual CD4+ counts instead of square root transformed CD4+ counts.  
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The Chapter would flow better and be less confusing if all graphs, summaries and tables were done 
using the square root of CD4+ count.  We have however decided that the ability to communicate to 
clinical researchers was more important and include CD4+ counts in the original scale as much as 
possible.   
 
The mean profiles did not follow a linear trend over time.  A linear model was fitted by including 
both a term for time and a quadratic term for time.  In all models fitted, the quadratic time effect 
was statistically significant. 
 
In this clinical trial the objective is to estimate the effect of treatment assignment on clinical 
outcomes over all randomised individuals regardless of what treatment participants actually 
received.  This is Estimand 1 described in the National Research Council report (2010).  This 
clinical trial was conducted to determine what the treatment policy should be for patients co-
infected with tuberculosis and HIV and not to test whether the drugs worked, since these were all 
licensed drugs.  We were interested in identifying an appropriate public health policy regarding the 
time of initiation of antiretroviral treatment, therefore the traditional ITT analysis, or the de facto 
hypothesis is the most appropriate.  
 
This estimand can be obtained in a parallel-group randomised trial in which outcome data are 
collected on all participants, regardless of whether the study treatment is received.  However, 
CD4+ count measurements cannot be collected for participants who do not attend visits.  We will 
perform a range of sensitivity analyses and state whether we were able to obtain Estimand 1 in each 
instance.  The estimator defined for this study is the interaction between treatment arm and time in 
the longitudinal model.  
 
5.3 Analysis under MCAR assumptions  
Even though there was evidence in the data that the missing data process was not MCAR, we 
present the naïve analysis that could be done under the MCAR paradigm in this section for 
comparison purposes.  MCAR assumptions were described in Section 2.2.1.  We include both the 
available case analysis (Section 5.3.1) and the complete case analysis (Section 5.3.2). 
5.3.1 Available case analysis 
Under the available case analysis we perform a cross-sectional analysis of the data observed or 
“available” at each time point.  This was done by simply analysing data as observed at each time 
point.  For example, if a participant had data at the 6 month visit, but not at the 12 month visit this 
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participant was included at 6 months and excluded at 12 months.  This is a suboptimal analysis that 
does not consider the longitudinal nature of the data.  A model can be fitted that takes the 
longitudinal nature of the data into account; such a model would also be valid under MAR and is 
fitted in Section 5.4.1.  The model of interest is the longitudinal model, the cross-sectional model is 
provided merely to describe the data observed at each visit in detail.  The advantage of 
summarising the data observed at each time point is that it gives a description of the observed data 
without including any modelling assumptions. 
 
In the available case analysis missing data were ignored and data were summarised at 6, 12, 18 and 
24 months using all observed CD4+ counts (Table 5.4 and Figure 5.2).  
 
Table 5.4:  Available case analysis of CD4+ counts (cell/mm3) 















6 months       <0.001* <0.001 
N 173 159 154      
Mean 305.0 255.4 173.5 16.6 15.1 12.0  
SD 196.1 166.9 141.4 5.51 5.28 5.38  
Standard error 14.9 13.2 11.4 0.42 0.42 0.43  
Median 250.0 225 142 15.8 15.0 11.9  
12 months       <0.001
$ <0.001 
N 160 150 128      
Mean 357.7 302.1 268.6 18.2 16.7 15.5  
SD 192.8 169.2 161.1 5.08 4.99 5.22  
Standard error 15.2 13.8 14.2 0.40 0.41 0.46  
Median 322.5 286.0 243 18.0 16.9 15.6  
18 months       0.002
# 0.003 
N 152 143 123      
Mean 394.3 353.1 319.0 19.2 18.2 17.0  
SD 202.1 185.2 206.4 5.07 4.85 5.65  
Standard error 16.4 15.5 18.6 0.41 0.41 0.51  
Median 367.5 328.0 292.0 19.2 18.1 17.1  
24 months       0.06 0.03 
N 145 131 123      
Mean 428.8 392.7 379.1 20.1 19.2 18.6   
SD 212.1 210.1 238.4 5.06 4.97 5.88   
Standard error 17.6 18.4 21.5 0.42 0.43 0.53   
Median 411.0 368.0 327.0 20.3 19.2 18.1   
ANOVA:  Analysis of variance; SD: Standard deviation 
* Bonferroni pairwise comparison:  All arms significantly different from each other 
$ Bonferroni pairwise comparison:  Early integrated treatment arm significantly different from the other two arms.   
# Bonferroni pairwise comparison:  Early integrated treatment arm significantly different from sequential treatment arm 
 
The conclusion drawn was that CD4+ count was significantly different between the arms at all time 
points.  At all visits before 24 months the early integrated treatment arm had significantly higher 
mean CD4+ counts than the other arms with small p-values.  At 24 months the p-value was not as 





Figure 5.2:  Mean CD4+ counts (cells/mm3) over time, available case analysis 
The lines indicate the available case analysis and the dots indicate the observed means under the 
complete case analysis. 
5.3.2 Complete case analysis 
In the complete case analysis only participants with no missing data were included in the analysis 
and data were summarised at 6, 12, 18 and 24 months using all observed CD4+ counts for these 
participants (Table 5.5 and Figure 5.3).  The difference between the complete case analysis and the 
available case analysis was that list wise deletion was applied in the complete case analysis.  In 
other words, if a participant had missing data at any visit, all data for this participant at all visits 
were deleted.  List wise deletion is often the default in statistical software.  
 
We fitted both a cross-sectional model (Table 5.5), comparing the treatment arms at each visit and 
a longitudinal model (Table 5.6) under complete case.  The cross-sectional analysis is not intended 
to be similar to the longitudinal model fitted and should not be directly compared.  The cross-
sectional analysis done under the available case analysis (Section 5.3.1) can be contrasted to the 
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According to the cross-sectional analysis, at baseline there was no difference between the treatment 
groups in mean CD4+ count.  Mean CD4+ count was significantly different between the arms at 6, 
12 and 18 months, but not at 24 months.  At all visits before 24 months the early integrated 
treatment arm had significantly higher mean CD4+ counts than the other arms.  The same 
conclusions were drawn with the complete case and the available case cross-sectional analysis. 
 
Table 5.5:  Cross-sectional complete case analysis of CD4+ counts (cell/mm3)   
 Treatment arm p-value 
 Early integrated 
N = 137 
Late integrated
N = 122 
Sequential 
N = 108 
ANOVA Kruskal-
Wallis 
Baseline    0.69 0.61 
Mean 163.2 147.3 160.4   
Standard deviation 126.5 107.2 106.8   
Standard error 10.8 9.7 10.3   
Median 146 123 142   
6 months    <0.001* <0.001 
Mean 306.7 251.8 177.0   
Standard deviation 199.0 171.2 144.1  
Standard error 17.0 15.5 13.9  
Median 254.0 221.0 143  
12 months    <0.001
$ <0.001 
Mean 351.8 300.5 268.2   
Standard deviation 192.4 160.0 163.5  
Standard error 16.4 14.5 15.7  
Median 327.0 276.5 240.5  
18 months    0.003
# 0.007 
Mean 394.5 337.8 325.9   
Standard deviation 197.4 162.9 211.7  
Standard error 16.9 14.7 20.4  
Median 365.0 321.0 292.5  
24 months    0.15 0.08 
Mean 427.2 390.4 388   
Standard deviation 210.0 198.7 245.2   
Standard error 17.9 18.0 23.6   
Median 409.0 370 327   
ANOVA:  Analysis of variance 
* Bonferroni pairwise comparison:  All arms significantly different from each other  
$ Bonferroni pairwise comparison:  Early integrated treatment arm significantly different from each of the other two arms 
# Bonferroni pairwise comparison:  Early integrated treatment arm significantly different from sequential treatment arm 
 
The residuals for the repeated measures linear model were not normally distributed (Figure 5.4).  
The residuals were normally distributed when the square root transformed CD4+ counts were 
modelled (Figure 5.5).  The model was fitted using the square root transformed CD4+ counts.  The 





Figure 5.3:  Observed mean CD4+ counts (cells/mm3) over time, complete case 
analysis 
 
Figure 5.4:  Studentised residuals for the model fitted using SAS procedure MIXED: 






Figure 5.5:  Studentised residuals for the model fitted with square root transformed 
CD4+ counts using SAS procedure MIXED: complete case analysis (Table 5.6) 
 
The model for the complete cases was fitted by REML using procedure MIXED in SAS and 
assumed an unstructured covariance matrix while using the Kenward-Roger (Kenward & Roger, 
1997) method for the degrees of freedom.  A different covariance matrix was assumed for each 
treatment group.  Because the unstructured covariance structure does not assume any particular 
pattern about the variance and covariance between measurements it was regarded to be a valid 
choice of covariance matrix.  Fitting time either as a continuous or categorical variable would be 
consistent with MAR.  Time was included as a continuous variable, because that leads to a more 
parsimonious model and enables a more concise summary of the effect of treatment arm over time.  
Adding time as a discrete variable will be more comparable to the cross-sectional analysis 
presented, but the cross-sectional analysis is merely given for additional information and was not 
the focus of this analysis.    The mean profiles were not linear over time and a quadratic time effect 
was added to the model.  This improved the fit of the model.  The following code was used: 
 
proc mixed data = completecase method = reml ; 
  class pid pointx treatment; 
  model cd4count = point treatment point*treatment pointsquared/ solution ddfm = kr htype = 2; 
  repeated pointx / subject = pid type = un group = treatment; 
  lsmeans point treatment; 




Table 5.6:  Complete case analysis using procedure MIXED in SAS  
 Square root transformed Raw data 
Effect Estimate Standard 
error 
p-value Estimate Standard 
error 
p-value 
Intercept 7.93 0.51  61.08 12.07  
Time  3.81 0.23 <0.001 94.41 8.20 <0.001 
Time squared -0.34 0.04 <0.001 -7.23 1.32 <0.001 
Early integrated treatment arm (ref: 
sequential treatment arm) 
0.73 0.68 0.28 -0.55 15.71 0.97 
Late integrated treatment arm (ref: 
sequential treatment arm)  
-0.46 0.65 0.48 -15.28 14.47 0.29 
Interaction between treatment arm and 
time (early integrated compared to 
sequential treatment arm) 
0.14 0.15 0.34 11.18 5.88 0.06 
Interaction between treatment arm and 
time (late integrated compared to 
sequential treatment arm) 
0.22 0.15 0.15 9.25 5.73 0.11 
 
In addition to the p-values given in the table, the F-test comparing the interaction between all three 
treatment arms and time adjusting for the main effects was not significant for either the raw data 
(p=0.15) or the square root transformed data (p=0.35).   This means that the change in mean CD4+ 
count over time did not differ between the treatment arms. There is an indication that the 
interaction between the early integrated and sequential treatment arms and time could be 
statistically significant (p=0.06), while the interaction between the late integrated and sequential 
treatment arms was not statistically significant (p=0.11).     
5.3.3  Conclusions of MCAR analysis 
Under MCAR we conclude from the cross-sectional analysis that there is a significant difference 
between the three treatment arms at each of the time points.  From the mixed model we conclude 
that there is no difference between the treatment arms in mean change in CD4+ count over time.   
 
Both the available case analysis and the complete case analyses are only valid under the MCAR 
assumption.  We have shown in Section 5.2 that the CD4+ count data in the SAPiT study were not 
MCAR; therefore these analyses were not valid.  It is worth remembering that the complete case 
method is inefficient because it does not utilise all available information, even when it is valid. 
 
None of the analyses done under the MCAR assumption estimate the estimand of interest, namely 
Estimand 1 defined by the National Research Council (2010).  Rather, the cross-sectional analysis 
estimate the treatment effect at each visit for participants who attended either the respective visit or 
all visits, whether or not they adhered to treatment.  In the longitudinal analysis this estimate is the 
treatment effect for participants who had complete data, whether or not they adhered to treatment.  
These estimates do not correspond to the ITT definition.  Therefore, in addition to not being valid 
or optimal, the MCAR analysis also does not measure the estimand of interest. 
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The models include a second order polynomial of time.  The treatment groups were only interacted 
with time and not with a second order term of time.  This means that the interaction interpreted 
refers to the comparison of the treatment groups with respect to the linear slopes of the curves, 
excluding the curvature.  The curvature is more pronounced later in follow-up than early in follow-
up.  It is thus predominantly the trend up to 6 months that is being compared for the different 
treatment arms. 
5.4 Analysis under MAR assumptions  
We have shown that MCAR assumptions are not valid.  MAR assumptions, discussed in Section 
2.2.2, could however be valid.  Using the observed data we cannot show that MAR assumptions are 
more valid than MNAR assumptions.  Under MAR assumptions we use four valid frameworks to 
analyse the data; these are direct likelihood-based approaches (discussed in Section 3.4), multiple 
imputation (discussed in Section 3.2), Bayesian analysis (discussed in Section 3.6) and inverse 
probability weighting (discussed in Section 3.5). 
5.4.1 Direct likelihood-based approaches 
Direct likelihood-based approaches are valid under the MAR assumption and the separability 
condition.  Direct likelihood analyses can be done in SAS with the MIXED, GLIMMIX and 
NLMIXED procedures.  Valid point estimates are obtained from maximizing the likelihood.  The 
observed information matrix gives less biased results than the expected information matrix.  The 
observed information matrix is easy to calculate and available in statistical packages.  An 
unconditional expected information matrix calculated under the correct specification of the MAR 
missingness mechanism could also be used, but is not standard output of statistical software 
(Kenward & Molenberghs, 1998).  The difference between the two could be small in practice 
(Molenberghs & Kenward, 2007).   
 
Procedure MIXED in SAS uses the Fisher scoring or Newton-Raphson methods.  The MIXED 
procedure uses the REML method to obtain estimates of parameters by minimising the likelihood 
of residuals.  The expected Hessian matrix rather than the observed matrix is used to calculate 
standard errors.  Procedure GLIMMIX has the same shortcomings as procedure MIXED, namely 
that the variability of the variance components is not used when calculating the standard errors of 
the fixed effects.  However, procedure NLMIXED uses the full Hessian matrix for the computation 
of precision estimates and is fully consistent with direct likelihood estimation (SAS Institute Inc., 




In procedure MIXED in SAS the following code was used to fit a model using the direct likelihood 
approach: 
proc mixed data = cd4count method = reml ; 
  class pointx treatment pid ; 
  model cd4count = treatment point point*treatment pointsquared/ solution ddfm = kr; 




Figure 5.6:  Studentised residuals for the model fitted using procedure MIXED in 
SAS for the direct likelihood-based analysis under MAR assumptions 
 
The “ddfm = kr” statement ensures that the Kenward-Roger (Kenward & Roger, 1997) correction 
is applied when calculating degrees of freedom.  An unstructured covariance matrix was assumed, 
while the group = treatment statement requests a different correlation matrix for each treatment 
group.   
 
As shown in Figure 5.6 the residuals for the repeated measures linear model did not follow a 
normal distribution.  The residuals were normally distributed when the square root transformed 





Figure 5.7:  Studentised residuals for the model fitted with square root transformed 
CD4+ count using procedure MIXED in SAS for the direct likelihood-based analysis 
under MAR 
Figure 5.8:  Mean CD4+ counts (cells/mm3) over time, direct likelihood-based 
approach (mixed model) analysis under MAR assumptions 
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Table 5.7:  CD4+ count over time.  Direct likelihood-based parameter estimates and 
standard errors when using procedure MIXED in SAS under MAR assumptions 
 Raw data Square root transformed data 
Effect Estimate Standard 
error 
p-value Estimate Standard 
error 
p-value 
Intercept 77.19 10.11  8.50 0.41  
Early integrated treatment arm (ref: 
sequential treatment arm) 
3.35 12.88 0.80 0.86 0.54 0.11 
Late integrated treatment arm (ref: 
sequential treatment arm) 
3.76 12.00 0.75 0.47 0.51 0.36 
Time 77.72 7.36 <0.001 3.14 0.21 <0.001 
Time squared -5.33 1.25 <0.001 -0.26 0.03 <0.001 
Interaction between treatment arm and 
time (early integrated compared to 
sequential treatment arm) 
14.94 5.31 0.005 0.25 0.14 0.08 
Interaction between treatment arm and 
time (late integrated compared to 
sequential treatment arm) 
14.97 5.18 0.004 0.29 0.14 0.04 
 
The p-value for the interaction between time and the treatment arms, comparing the late integrated 
treatment arm to the sequential treatment arm (p=0.04) and comparing the early integrated 
treatment arm to the sequential treatment arm (p=0.08) was small when using the square root 
transformed data.  This means that we can conclude that the change in mean CD4+ count over time 
was higher in the late integrated treatment arm and early integrated treatment arm than in the 
sequential treatment arm.  In addition to the p-values given in the table, the F-test comparing the 
interaction between all three treatment arms and time adjusted for the main effects in the model had 
p=0.006 for the raw data and p=0.009 for the square root transformed data.   
5.4.2 Multiple imputation 
Multiple imputation can be done in SAS by using two procedures, MI and MIANALYZE.  
Procedure MI does the multiple imputation, corresponding to Step 1 in Section 3.2, after which 
complete data methods are used to analyse each completed data set, using the appropriate SAS 
procedure; corresponding to Step 2 in Section 3.2.  Afterwards the data are combined using the 
SAS procedure MIANALYZE, as described in Step 3 (Horton & Kleinman, 2007).   
 
Procedure MI was used to generate 100 different imputed data sets and procedure MIANALYZE 
was used to combine the results of the 100 analyses on these data sets.  In the imputer’s model 
square root CD4+ count at 6, 12, 18 and 24 months and log viral load at baseline were imputed and 
WHO status, square root CD4+ count at baseline, age, gender, history of tuberculosis, and whether 
the participant had extra-pulmonary tuberculosis or multidrug resistant tuberculosis were included 
as covariates in this model.  These variables were chosen because the clinical staff believed that 
these variables were related to tuberculosis and HIV outcomes.  It is strongly suggested that 
multiple imputation should include all variables that could be related to the missingness process, 
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therefore all possibly relevant baseline variables were included in the imputer’s model.  Separate 
imputations were done for each of the three treatment arms.   
 
The multiple imputation procedure in SAS software assumes that the missing data are MAR.  Since 
the missing data pattern in the CD4+ count data was not monotone, the MCMC imputation method 
was used.  It assumes multivariate normality to create multiple imputations by drawing simulations 
from a Bayesian predictive distribution.  The EM algorithm was used and the means and 
covariances from complete cases were taken as the initial estimates.  A single chain was used for 
all the imputations.  The procedure used a non-informative Jeffreys prior to derive the posterior 
mode from the EM algorithm as the starting values for the MCMC process (SAS Institute Inc., 
2004).   
 
The following code was used in SAS to do the multiple imputation step in procedure MI, using the 
square root of CD4+ count: 
 
proc mi data = withcovariate out = full nimpute = 100 seed = 1 round = 1 1 1 1 0.001 . maximum = 
1000 1000 1000 1000 8 minimum = 1 1 1 1 0; 
  em initial = cc; 
  mcmc impute = full chain = single timeplot (mean(cd4at6 cd4at12 cd4at18 cd4at24)) acfplot 
(mean (cd4at6 cd4at12 cd4at18 cd4at24)); 
  var cd4at6 cd4at12 cd4at18 cd4at24 logvl who baselinecd4count age gender historytb extrapul 
mdr; 
  by treatment; 
run; 
 
Table 5.8:Multiple imputation variance (Results of multiple imputation in Table 5.10) 
Early integrated treatment   Late integrated treatment  Sequential treatment 
Visit Between Within Total df Between Within Total df Between Within Total   df 
6 months 0.018 0.145 0.164 183 0.020 0.138 0.158 180 0.020 0.148 0.168 179 
12 months 0.014 0.128 0.142 187 0.019 0.115 0.134 174 0.042 0.146 0.188 151 
18 months 0.027 0.120 0.148 162 0.023 0.113 0.136 166 0.074 0.176 0.250 130 
24 months 0.031 0.125 0.157 158 0.048 0.130 0.178 139 0.093 0.178 0.273 118 
df = degrees of freedom 
 
Table 5.8 indicates that the major source of variance was the within imputation variance, the 
between imputation variance added more to the overall variance at the later time points, where 
more data were missing than at the earlier time points.  
 
The relative increase in variance showed that the uncertainty caused by the missing data increased 
the variance more over time in the sequential treatment arm.  This ratio reached a high of 0.528 at 
24 months.  The smallest fraction of missing information was 0.097 at 12 months in the early 
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integrated treatment arm, with the highest fraction, 0.347, at 24 months in the sequential treatment 
arm.   
 
Table 5.9: Relative increase in variance and fraction missing information in 
procedure MI (Results of multiple imputation in Table 5.10) 



















6 months 0.127 0.113 0.145 0.127 0.140 0.123 
12 months 0.107 0.097 0.170 0.146 0.288 0.224 
18 months 0.228 0.186 0.211 0.174 0.423 0.299 
24 months 0.250 0.201 0.369 0.271 0.528 0.347 
 
The timeplot and acfplot statements in SAS display time-series and autocorrelation plots to check 
convergence for the single chain.  It uses the MCMC method to create an iteration plot for the 
successive estimates of the mean of the square root CD4+ count at each of the 6-monthly visits.  
Iterations during the burn-in period are indicated with negative iteration numbers. The plots are 
given in Figure 5.9 and Figure 5.10 for the early integrated treatment arm at 6 months.  No 
evidence was found of a trend or a significant positive or negative autocorrelation in any of the 














Figure 5.9:  Time series plot for the mean square root CD4+ count at 6 months, early 


















Figure 5.10:  Autocorrelation plot with 95% confidence interval for the mean square 
root CD4+ count at 6 months, early integrated treatment arm 
 
After multiple imputation of the missing data was done with procedure MI, the data were analysed 
using a SAS procedure with a by imputation statement, thus doing the analysis separately for each 
imputation.  The MIANALYZE procedure then reads the parameter estimates and associated 
standard errors, or the covariance matrix, from a data set produced by this SAS procedure, 
separately for each imputed data set.  The MIANALYZE procedure used the results from each 
imputation to derive valid univariate inference for these parameters.   
 
Not all parameters of interest or all statistical tests can easily be obtained this way, since not all 
parameter estimates and the associated covariance matrices can be calculated directly in a SAS 
procedure.  The analyses can be done, but require special techniques and is not a straight forward 
application of the usual SAS procedures.  For example the sample means and covariance matrices 
for means can be obtained from the CORR procedure, which was written to generate correlations 
and not means (SAS Institute Inc., 2004).   
 
Some regression procedures, such as procedure REG and LOGISTIC create a data set that contains 
both the parameter estimates for the regression coefficients and their covariance matrix.  Other 
regression procedures such as GLM, MIXED and GENMOD do not generate such data sets.  In 
procedures MIXED and GENMOD ODS output statements can be used to save the parameter 
estimates in a data set and the covariance matrix in a separate data set.  These data sets can then be 
read into the MIANALYZE procedure.  The PARMS option is used to read the parameter estimates 
and the COVB option is used to read the covariance matrix.  For procedure GLM the ODS output 
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statement can be used to save parameter estimates and standard errors in a data set and the    (J.J), matrix in another data set.  These data sets are then read in the MIANALYZE procedure 
with the PARMS option and the XPXI option.  Other examples of procedures that do not 
automatically generate the parameter of interest and covariance matric are correlation coefficients 
between two variables and the ratios of variable means (SAS Institute Inc., 2004).   
 
One of the advantages of multiple imputation as a technique to handle missing data, is that multiple 
imputation can be used with the statistical method of your choice.  There is no need to change the 
statistical method you wanted to use in order to adjust for missing data.  To illustrate the flexibility 
and versatility of multiple imputation, we first present a cross-sectional analysis of the imputed 
data and then we fit a longitudinal model with maximum likelihood analysis of repeated measures, 
using mixed models (Table 5.12).  We acknowledge that the cross-sectional analysis is sub-optimal 
and that the two models are not directly comparable.   
 
The following code was used in SAS to analyse the imputed data using procedure GLM as the 
second step of multiple imputation.  The same code was repeated for each of the 6-monthly CD4+ 
count variables, and is not repeated here.  Means were given in the table and could be computed 
using the UNIVARIATE procedure; however procedure MI calculates means for each of the 
variables and doing the extra steps with procedure UNIVARIATE and MIANALYZE gave the 
same means as generated by procedure MI.  Medians could only be obtained by using procedure 
SURVEYMEANS because other procedures do not provide the standard errors for medians.  The 
data were square root transformed before the imputations were done, and the imputed values were 
squared before the data were summarised.  
 
Proc glm data=full; 
   model cd4at6= treatment/inverse; 
   by _Imputation_; 
   ods output ParameterEstimates=glmparms InvXPX=glmxpxi; 
quit; 
 
proc mianalyze parms=glmparms xpxi=glmxpxi ; 
   modeleffects Intercept treatment; 
run; 
 
Comparing the means and standard errors in Table 5.4 and Table 5.10 is interesting.  All the 
standard errors were lower with the multiple imputation than when using the available case 
analysis.  This was because the multiple imputation analysis is more efficient than the available 
case analysis and included auxiliary variables in the imputation.  All the means at Months 6 and 12 
were higher with the multiple imputed data than with the available case analysis.  At Months 18 
and 24, the means for the late integrated treatment arm were lower with the multiple imputation, 
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while the means for the early integrated and sequential treatment arms were higher with the 
multiple imputation than with the available case analysis.  The interpretation of the p-values was 
the same for the available case analysis and the multiple imputation analysis.  Having higher mean 
CD4+ counts at most visits with the multiple imputation analysis than with the available case 
analysis was surprising.   
 
Table 5.10: Cross sectional summaries of CD4+ counts (cell/mm3) after multiple 
imputation of missing values 
 Early integrated 
treatment arm 
N = 214 
Late integrated 
treatment arm 
N = 215 
Sequential  treatment 
arm 
N = 213 
p-
value* 
 Mean  
(standard error) 
Median Mean  
(standard error) 
Median Mean  
(standard error) 
Median  
6 months 308.1 (14.5) 253.4 266.1 (13.1) 230.9 175.5 (11.0) 139.5 <0.001 
12 months 360.9 (14.4) 322.0 309.7 (12.7) 286.7 267.8 (13.9) 236.9 <0.001 
18 months 390.6 (15.2) 361.3 359.1 (14.1) 327.5 314.4 (17.8) 274.9 0.007 
24 months 424.0 (16.3) 399.0 411.8 (17.7) 373.1 371.8 (20.1) 320.2 0.047 
* Calculated using procedures GLM and MIANALYZE in SAS 
 
Most of the medians were similar between the available case analysis and the multiple imputation 
analysis, exceptions were the median in the sequential arm at 18 months and the median at 24 
months in the early integrated treatment arm, both were lower with the multiple imputation 
analysis.   
 
We now move away from the cross-sectional analysis and give the longitudinal analysis.  
Procedure MI was the same as previously given (Step 1 of the multiple imputation process).  The 
following code was used in SAS to analyse the imputed data using procedure MIXED (Step 2 of 
the multiple imputation process).  This differs from the code used under the likelihood-based 
analysis in Section 5.4.1 only in the addition of the by _imputation_ statement and the ods output 
statement.  The by statement ensures that a separate analysis is done for each imputed dataset and 
the ods statement writes the results to datasets that are used in the next step in procedure 
MIANALYZE.  The variance information for this model is given in Table 5.11.   
 
proc mixed data = full method = reml; 
  class pid treatment pointx; 
  model cd4square = point treatment point*treatment  pointsquared / solution covb ddfm = kr ; 
  repeated pointx / subject = pid type = un group = treatment; 
  by _imputation_;  
  ods output solutionf = mixparms covb = mixcovb; 
run; 
 
A data step is needed to rename the effect variable, in order to have unique effect variables for the 
treatment and week combinations, since these are captured in two different variables in the 




proc mianalyze parms=mixparms ; 
      modeleffects Intercept visit trt1 trt2 trt1_week trt2_week; 
   run; 
 
Table 5.11: Variance, relative increase in variance and fraction missing information 















Intercept 0.057 0.165 0.223 1465 0.351 0.261 0.997 
Early integrated treatment 
arm (ref: sequential 
treatment arm) 
0.053 0.296 0.350 4191 0.182 0.154 0.998 
Late integrated treatment 
arm (ref: sequential 
treatment arm)  
0.050 0.283 0.334 4348 0.178 0.151 0.998 
Time  0.025 0.035 0.061 554 0.732 0.425 0.996 
Time squared 0.0005 0.001 0.001 687 0.612 0.381 0.996 
Interaction between 
treatment arm and time 
(early integrated compared 
to sequential treatment arm) 
0.012 0.014 0.026 447 0.889 0.473 0.995 
Interaction between 
treatment arm and time (late 
integrated compared to 
sequential treatment arm) 
0.009 0.014 0.023 586 0.698 0.413 0.996 
df: Degrees of freedom 
 
Multiple imputation and maximum likelihood methods are expected to have similar results when 
the imputation model is congenial, i.e. the imputation model includes the same variables as the 
analytic model.  A major difference between the two models is that the likelihood-based model did 
not include any covariates, while the model fitted under multiple imputation included several 
covariates in the imputer’s model.  This is strongly encouraged, because the biggest problem with 
the imputer’s model is excluding variables that are associated with the outcome.  Rubin (1996) 
recommended that as many variables as possible are included in the imputer’s model.  If the goal of 
this chapter was to compare results obtained using different available methods, the multiple 
imputation analysis should have been done without including these covariates in the imputer’s 
model.  However, the goal is to show how available missing data methods can be used optimally to 
analyse data, therefore the best possible imputer’s model was used.  In addition to the model 
including covariates a secondary model was also fitted where the imputation model did not include 
any covariates.  This was done to investigate whether the inclusion of covariates played an 




Table 5.12:  CD4+ count longitudinal analysis.  Direct likelihood-based parameter 
estimates and standard errors when using procedure MIXED in SAS, with and 
without multiple imputation of square root CD4+ counts (ûüýþþ/) 
 Multiple imputation with 
auxiliary covariates 
Multiple imputation without 
auxiliary covariates 
Effect Estimate Standard 
error 
p-value Estimate Standard 
error 
p-value 
Intercept 8.88 0.47  9.19 0.47  
Early integrated treatment arm (ref: 
sequential treatment arm) 
1.12 0.59 0.06 0.92 0.61 0.13 
Late integrated treatment arm (ref: 
sequential treatment arm) 
0.75 0.58 0.20 0.58 0.59 0.32 
Time  3.01 0.25 <0.001 2.76 0.22 <0.001 
Time squared -0.23 0.04 <0.001 -0.21 0.04 <0.001 
Interaction between treatment arm 
and time (early integrated compared 
to sequential treatment arm) 
0.08 0.16 0.62 0.22 0.15 0.14 
Interaction between treatment arm 
and time (late integrated compared 
to sequential treatment arm) 
0.12 0.15 0.43 0.20 0.14 0.17 
 
Comparing the model fitted using likelihood-based methods with (Table 5.12) and without (Table 
5.7) multiple imputation, we draw a different conclusion for the interaction between the two 
treatment arms and time.  This interaction is estimated to be larger when the data are not imputed 
than when the data are imputed.  The standard errors are similar in both models, for all the 
variables.  The covariates included in the imputer’s model did make a difference in the effect 
estimates, which differed substantially between the model with and without covariates.  However, 
the inclusion of covariates did not explain all the difference between the likelihood-based model 
and the model fitted after multiple imputation of missing data.  The results differed slightly 
between the likelihood-based model and the model fitted after multiple imputation that did not 
include covariates in the imputer’s model.  This is because the multiple imputation is done treating 
time as a categorical variable.  Outcome data of all the time points are included in the multiple 
imputation, but the longitudinal nature of the outcome data is not taken into account.  Fitting 
likelihood-based models, the longitudinal nature of the data is taken into account.   
 
We conclude that there is no significant treatment by time interaction from both the model 
including covariates in the imputer’s model and from the model that did not include covariates in 
the imputer’s model. 
 
Multiple imputation offers advantages if covariates are missing, because likelihood-based analyses 
in these instances might be impracticable.  However, in this instance where covariates were 





Multiple imputation assumed that the data are MAR and used observed data to imputer unobserved 
data.  If future missing measurements could not be predicted from the past observed data combined 
with the covariates, it was unlikely that the multiple imputations are correct.   
  
Figure 5.11:  Square root CD4+ counts over time using multiple imputation, by 
participant.  Early integrated treatment arm. 
The graph includes only participants who died and had missing CD4+ counts from the time 
they died.  Time of death is indicated with a black solid dot.  CD4+ counts from the black 
solid dot onwards are imputed CD4+ counts.   
 
Figure 5.12:  Square root CD4+ counts over time using multiple imputation, by 
participant.  Late integrated treatment arm. 
The graph includes only participants who died and had missing CD4+ counts from the time 
they died.  Time of death is indicated with a black solid dot.  CD4+ counts from the black 








Figure 5.13:  Square root CD4+ counts over time using multiple imputation, by 
participant.  Sequential treatment arm.  
The graph includes only participants who died and had missing CD4+ counts from the time 
they died.  Time of death is indicated with a black solid dot.  CD4+ counts from the black 
solid dot onwards are imputed CD4+ counts.   
 
As can be seen from Figure 5.11, Figure 5.12 and Figure 5.13 the multiple imputation process did 
not impute lower CD4+ counts for participants who died, in fact for most participants CD4+ counts 
were higher after death than before. 
5.4.3 Bayesian MAR analysis 
It is fairly straightforward to accommodate missing data while fitting a Bayesian model.  The 
Bayesian model fitted in this section does not take the missing data mechanism into account, but 
fits all participants, those with and without missing data; it is thus valid under MAR.  Its validity is 
the same as under direct likelihood.  Bayesian analysis provides a natural way of handling the 
missing data, because a probability distribution is estimated for each missing value, allowing for 
uncertainty to be captured.  Missing data are treated as additional unknown quantities, thus no 
distinction is made between missing data and unknown parameters.  OpenBugs will simulate values 
for the missing observations according to the specified likelihood distribution, given the values of 
the relevant parameters.  The Bayesian model, when the missing data mechanism is ignorable, is 
the same model that would be used for a complete case analysis.  If a model was to be fitted under 




The definition of the statistical notation is given in Section 5.1.4.  We fitted a longitudinal model 
with an unstructured covariance matrix.  Consider  |ë =  ~ Mutivariate Normal(ev,
v) 
where ë =  indicates that the observation belongs to treatment k..  For example, if ë = 1 then 
this implies E= 1 and L = 0; if ë = 2 then this implies E= 0 and L = 1 and if ë = 3 then this 
implies E= 0 and L = 0.  The model fitted was as follows:  à =  >? +  >E + >9L + >Q + (>ú +  >í)Q + >Q9   
 
This model fits a different unstructured covariance matrix for each of the treatment arms.  
Uninformative priors were chosen for the unknown parameters of the model of interest.  Different 
sets of prior distributions were assigned.  In Set 1, the β parameters (>?, >, >9, >, >, >, >) are 
assigned Normal(0, 100 000) priors and the inverse of Ω was assigned a Wishart(I, 5) prior, where 
I is the identity matrix.  Prior Set 2 assigned all the β parameters a Normal(0, 1000) prior and the 
inverse of Ω was assigned a Wishart(A, 5) prior, where A is a diagonal matrix with 0.1 on the 
diagonal.  Prior Set 3 assigned all the β parameters a Normal(0, 10) prior and the inverse of Ω a 
Wishart(A, 5) prior, where A is a diagonal matrix with 10 on the diagonal. 
 
All the models were fitted using OpenBugs, which uses MCMC methods and run for 40000 
iterations, including 20000 burn-in iterations.  Two chains with different starting values were used 
and convergence was assumed if a visual inspection of the trace plots was satisfactory.  All the runs 
discussed converged.   
 
The following code was used in OpenBugs:    
model { 
          for(i in 1:N) { 
       cd4square[i,1:5] ~ dmnorm(mu[i,1:5], omega[S[i], ,]) 
  S[i] <- 1+1*equals(dummyearly[i],1) + 2*equals(dummylate[i],1) 
        for(j in 1:W) {                
          mu[i,j] <- beta[1] +beta[2]*(j) + beta[3]*dummyearly[i] + beta[4]*dummylate[i] + 
beta[5]*dummyearly[i]*(j)+beta[6]*dummylate[i]*(j) +beta[7]*(j)*(j)}                       } 
 
 # Priors 
for(k in 1:3){ 
omega[k,1:5,1:5] ~ dwish(R[k, ,],5) 
sigma[k,1:5,1:5] <- inverse(omega[k, ,])  } 
     for(k in 1:7) {  




Table 5.13:  CD4+ count (square root) posterior means, standard deviations and 
credible intervals according to Bayesian analysis under MAR assumptions  
 Prior set 1 
β ~ Normal(0, 100 000) 
Ω~Wishart(I,5) 
I: Identity matrix 
Prior set 2  
β ~ Normal(0, 1000)  
Ω~Wishart(A,5) 
A: diag (0.1, 0.1, 0.1, 0.1, 0.1) 
Prior set 3  
β ~ Normal(0, 10) 
Ω~Wishart(A,5) 
A: diag (10, 10, 10, 10, 10) 
Effect Mean SD 95% 
credible 
interval 
Mean SD 95% 
credible 
interval 
Mean SD 95% 
credible 
interval >?  9.02 0.48  9.02 0.48  8.79 0.47  >  1.09 0.62 -0.12; 2.3 1.09 0.62 -0.12; 2.30 1.23 0.60 0.04; 2.40 >9  0.41 0.59 -0.73; 1.55 0.41 0.58 -0.73; 1.55 0.58 0.57 -0.53; 1.70 > 2.71 0.24 2.23; 3.17 2.71 0.23 2.25; 3.17 2.79 0.24 2.31; 3.26 >  0.28 0.15 0.02; 0.58 0.28 0.15 -0.01; 0.58 0.27 0.15 -0.03; 0.58 >  0.37 0.15 0.08; 0.67 0.38 0.15 0.09; 0.67 0.34 0.15 0.05; 0.64 > -0.21 0.04 -0.29; -0.14 -0.21 0.04 -0.29; -0.14 -0.22 0.04 -0.30; -0.14 
SD: Standard deviation >?: Intercept, > Early integrated treatment arm (ref: sequential treatment arm); >9: Late integrated treatment arm (ref: sequential 
treatment arm),  >: Time; > Interaction between treatment arm and time (early integrated compared to sequential treatment arm) > Interaction between treatment arm and time (late integrated compared to sequential treatment arm); >: Time squared 
Highlighted sections indicate statistical significance 
 
The choice of vague prior did not change the results appreciably in the MAR analysis (Table 5.13), 
and the results were almost identical with prior sets 1 and 2.  The results are slightly different under 
prior set 3.  This set of priors makes an assumption about the prior distribution of Ω that is very 
different from the observed covariance matrices, and the prior distributions of the β’s are much less 
uninformative than the priors used under sets 1 and 2.  Of course, many more choices of priors are 
possible.  Both the interactions between time and treatment arm were significant, under prior set 1, 
indicating that both the early integrated and late integrated treatment arms had higher increase in 
mean CD4+ count than the sequential treatment arm.  Under prior sets 2 and 3 only the interaction 
between time and the late integrated treatment arm compared to the sequential treatment arm was 
significant, although the posterior mean for the interaction between time and the early integrated 
treatment arm compared to the sequential treatment arm was similar to the posterior mean when 
prior set 1 was used.   
 
The results of the Bayesian analysis were similar to the results of the likelihood-based analysis 
(Table 5.7).  In both models we conclude that the interaction between time and the late integrated 
treatment arm compared to the sequential treatment arm is significant.  In the Bayesian model, we 
conclude that the interaction between time and the early integrated treatment arm compared to the 
sequential treatment arm was statistically significant.  This was not significant in the likelihood-
based model, although the p-value was small (0.08).  
 
The addition of a prior distribution to the model means that the validity of the Bayesian answer 
depends both on the validity of the substantive model as well as the validity of the prior model.  By 
choosing non-informative priors, we hope that the results are not sensitive to the choice of the 
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prior.  Differences between the likelihood-based analysis and the Bayesian analysis can be 
attributed to the addition of a prior distribution.  
5.4.4 Inverse probability weighting 
Inverse probability weighting requires that the data set follows a monotone missing pattern.  We 
imputed the few intermittent missing values in order to create a monotone missing data set.  The 
data set with a monotone missing pattern was formatted that the last observation for participants 
with incomplete data was an entry with the missingness indicator equal to 0.  Logistic regression 
was used to model the probability of having a missing observation at each visit.  The model 
included CD4+ counts at all the previous visits.  The following SAS code was used to model the 
probability of missingness at the last time point.  Similar code was used for the earlier time points.   
 
proc logistic data=dataset; 
  class mis treatment; 
  model mis = sqr_cd4at0  sqr_cd4at6  sqr_cd4at12  sqr_cd4at18  treatment; 
  where point = 5; 
output out=predict P=probs; 
run; 
 
More covariates can also be added to the missingness model to improve the prediction.  In the 
second model in Table 5.14 the covariates WHO status, age, gender, history of tuberculosis, and 
whether the participant had extra-pulmonary tuberculosis or multidrug resistant tuberculosis were 
included as covariates in the model used to estimate the probability of being observed.  Viral load 
was not included as a covariate, since some of the viral load values were missing.   
 
Since the baseline visit was observed for all participants, the probability of being observed assigned 
to the baseline visit was 1.  The estimated cumulative probability of being observed was the 
product of the probability of being observed at all the time points.  The inverse probability weight 
is calculated as the inverse of the cumulative probability.  The following code was used in SAS: 
 
data wgt (keep=pid visit cumprobs probs); 
  merge dataset predict; 
  by pid visit; 
  retain cumprobs; 
  if first.pid then cumprobs=probs; 
  else cumprobs=cumprobs*probs; 
  if (visit=1) then ipw=1; 
  else ipw=1/cumprobs; 
run; 
 
GEE are then applied with a working independence covariance structure using the weight statement 




proc genmod data=wgt; 
weight ipw; 
class pid treatment; 
model cd4square = treatment visit visit*treatment pointsquare /dist=n link = identity; 
where mis=1; 
repeated subject=pid /type=ind; 
run; 
 
Two models were fitted.  In one model weights were calculated using a logistic regression model 
including auxiliary covariates and in the other model weights were calculated using a logistic 
regression model not including auxiliary covariates.  The estimates calculated using these two sets 
of weights were similar.  The conclusion is that the additional covariates do not improve the 
accuracy of the weights calculated.   
 
The standard errors calculated using procedure GENMOD are in principle not correct because they 
do not take the estimation of weights into account.  Correct standard errors were calculated by 
drawing bootstrap samples.  One hundred bootstrap samples of the same size as the original data 
set were drawn with replacement.  The results using the bootstrap samples, both with and without 
additional covariates in the calculation of the weights, are also included in Table 5.14.  The 
incorrect standard errors calculated using procedure GENMOD and the standard errors calculated 
using bootstrap are similar and the conclusions drawn are similar.  This underscores that the effect 
of neglecting uncertainty in the weights may have limited consequences only. 
 
Using weighted GEE, the estimates for the comparison of the effect of the early integrated 
treatment arm compared to the sequential treatment arm over time as well the effect of the late 
integrated treatment arm compared to the sequential treatment arm over time are both negative.  
This means that this model estimates that CD4+ count increases less in the two integrated treatment 
arms compared to the sequential treatment arm.  This is different from any of the other models 
fitted under MAR.  Neither of these effects was statistically significant.  In addition to employing 
inverse probability weighting, this model differs from the other models fitted because it was fitted 
using GEE as estimation method, while the other methods were fitted using maximum likelihood 
(Table 5.14).   
 
These models are inefficient, with inconsistent parameter estimates.  If some weights are large, 
some observations could be given undue importance in the estimation of parameters.  The 




The last model included in Table 5.14 was fitted with doubly robust methods, using bootstrap 
samples to calculate correct confidence intervals, by following three steps.  In step 1 a logistic 
regression was fitted to estimate the probability of being observed as a function of previous 
observations of the outcome variable and covariates.  In step 2 a mixed model was fitted to the 
response for the completely observed observations, weighted using the weights of the inverse 
probability of being observed at each visit as calculated in the previous step.  As output from this 
model, =∗, the fitted values of the response for all participants, those who were observed and those 
who had missing values, were saved to a data set.  In step 3, the values of the response - were 
replaced with the fitted values, =∗ and another mixed model was fitted for all observations (both 
observed and those with missing values) to the new response, =∗ including only the covariates of 
interest (treatment arm) and not the covariates predictive of missingness.  
 
The Vansteelandt macro, available from http://missingdata.lshtm.ac.uk/index.php?option 
=com_content&view=article&id=225:vansteelandts-doubly-robust-estimation-method&catid=60 
:inclusive-modeling-approaches&Itemid=137, was used to draw the bootstrap samples and prepare 
the data sets, but the models were fitted using the following code in SAS. 
 
Step 2: 
proc mixed data= indata ; 
class pointx pid ; 
model cd4square= point dummyearly dummylate  point*dummyearly  point*dummylate  
pointsquare                 /solution outp=first_glm_out; 





In the SAS code prob is the inverse of the probability of being observed that was calculated in step 
1 using the Vansteelandt macro.  This was done both including and excluding additional covariates 
predictive of missingness.  Replicate refers to the replicate number of the bootstrap sample.  In 
other models fitted throughout this chapter the unstructured covariance matrix was used.  These 
models did not converge if the unstructured covariance structure was used.  It did converge with 
the autoregressive covariance matrix assumed.  This covariance matrix is applicable because the 




Table 5.14:  CD4+ count (square root) analysed with inverse probability weighting 
methods  
 Weighted GEE without 
covariates 
Weighted GEE with 
covariates 
Effect Estimate Standard 
error 
p-value Estimate Standard 
error 
p-value 
Intercept 7.18 0.47  7.13 0.47  
Early integrated treatment arm (ref: 
sequential treatment arm) 
2.41 0.57 <0.001 2.39 0.58 <0.001 
Late integrated treatment arm (ref: 
sequential treatment arm) 
1.88 0.57 0.001 1.89 0.57 0.001 
Time  3.73 0.27 <0.001 3.77 0.28 <0.001 
Time square -0.29 0.04 <0.001 -0.30 0.04 <0.001 
Interaction between treatment arm and 
time (early integrated compared to 
sequential treatment arm) 
-0.09 0.17 0.61 -0.06 0.17 0.71 
Interaction between treatment arm and 
time (late integrated compared to 
sequential treatment arm) 
-0.22 0.18 0.20 -0.19 0.18 0.28 
 Weighted GEE without 
covariates using bootstrap 
Weighted GEE with 
covariates using bootstrap 
 Estimate Standard 
error 
p-value Estimate Standard 
error 
p-value 
Intercept 7.15 0.43  7.12 0.45  
Early integrated treatment arm (ref: 
sequential treatment arm) 
2.44 0.59 <0.001 2.43 0.59 <0.001 
Late integrated treatment arm (ref: 
sequential treatment arm) 
1.93 0.58 <0.001 1.91 0.60 0.002 
Time  3.72 0.26 <0.001 3.74 0.28 <0.001 
Time square -0.29 0.04 <0.001 -0.30 0.04 <0.001 
Interaction between treatment arm and 
time (early integrated compared to 
sequential treatment arm) 
-0.07 0.18 0.69 -0.03 0.19 0.89 
Interaction between treatment arm and 
time (late integrated compared to 
sequential treatment arm) 
-0.23 0.18 0.19 -0.16 0.18 0.38 
 Doubly robust weighting 
method without covariates  
Doubly robust weighting 
method with covariates 
 Estimate Standard 
error 
p-value Estimate Standard 
error 
p-value 
Intercept 9.52 0.64  10.52 0.56  
Early integrated treatment arm (ref: 
sequential treatment arm) 
5.15 1.03 <0.001 4.41 0.81 <0.001 
Late integrated treatment arm (ref: 
sequential treatment arm) 
3.23 0.85 <0.001 2.96 0.78 <0.001 
Time  3.05 0.28 <0.001 3.37 0.43 <0.001 
Time square -0.20 0.05 <0.001 -0.27 0.06 <0.001 
Interaction between treatment arm and 
time (early integrated compared to 
sequential treatment arm) 
-0.95 0.31 0.003 -0.94 0.30 0.002 
Interaction between treatment arm and 
time (late integrated compared to 
sequential treatment arm) 





proc mixed data= dataset ; 
class pointx pid ; 
model pred= point  dummyearly  dummylate  point*dummyearly  point*dummylate  pointsquare 
                /solution outp=abc3; 
        repeated pointx/ subject = pid type = ar(1);   
        by replicate; 
ds output ConvergenceStatus=MixedStatus  solutionf = abmixparms ; 
run; 
 
The parameter estimates are saved to abmixparms for all the bootstrap samples and these are then 
averaged to calculate the bootstrap average and standard error.  The number of participants who 
had missing data was higher in the sequential treatment arm than in the two integrated treatment 
arms.  This implies that the observed participants in the sequential arm will have higher weights.  
The mean of the weights in the early integrated treatment arm was 1.33, in the later integrated 
treatment arm was 1.45 and in the sequential treatment arm was 1.54.  If the participants who had 
better outcomes were more likely to be observed, these participants with better outcomes will be 
weighted more heavily in the sequential treatment arm than in the other two treatment arms.  Table 
5.15 shows that the sequential treatment arm had a larger proportion of participants with large 
weights than the other treatment arms.  In addition, although the mean CD4+ count was lower in 
the sequential treatment arm, the mean CD4+ count was higher for participants with high weights 
than for participants with low weights.  This was true in all three treatment arms.  This means that 
the inverse probability weighted analysis, where participants with higher weights are more 
influential, increased the mean CD4+ counts more in the sequential treatment arm than in the other 
two treatment arms.   
 
Table 5.15:  Mean square root of CD4+ count by treatment arm and probability of 
being observed  


















Weight > 1.4 18.98  20.2% 18.09  42.6% 16.77  49.7% 
Weight < 1.4 18.10  79.8% 15.61  57.4% 12.32  50.4% 
 
The doubly robust analysis provides some protection against some of the disadvantages of the 
inverse probability weighting, such as extreme weights and misspecification of the weighting 
model.  However, it still requires either the missingness model or the imputation model to be 
correctly specified, as well as the substantive model.  If neither of these models is correctly 
specified, this method does not provide valid results. 
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5.4.5 Conclusions of MAR analysis 
Under the MAR framework, longitudinal models were fitted using likelihood-based methods, 
multiple imputation, Bayesian methods and inverse probability weighting.  Although pattern-
mixture models are generally regarded as MNAR methods, MAR assumptions can be expressed in 
the pattern-mixture framework through identifying restrictions related to the available case missing 
value (ACMV) as discussed in Section 3.3.2 (Molenberghs et al., 1998).  This is given in Section 
5.5.1.3 where pattern-mixture models are discussed. 
 
Table 5.16:  Summary of MAR sensitivity analyses 
 Interaction between treatment arm and time  
 Early integrated treatment 
arm compared to sequential 
treatment arm 
Late integrated treatment 
arm compared to 
sequential treatment arm 
 Estimate p-value Estimate p-value 
Likelihood-based methods 0.25 0.08 0.29 0.04 
Multiple imputation (excluding additional 
covariates in imputer’s model) 
0.22 0.14 0.20 0.17 
Bayesian analysis (Prior set 1) 0.28 Significant 0.37 Significant 
Inverse probability weighting:  weighted 
GEE without covariates and using 
bootstrap for standard errors 
-0.07 0.69 -0.23 0.19 
 
Most of the estimated coefficients for the interaction between time and the early integrated 
treatment arm compared to the sequential treatment arm were between 0.22 and 0.28.  The 
exception was the results of the inverse probability weighting.  The interaction between time and 
the early integrated treatment arm compared to the sequential treatment arm was only significant in 
the Bayesian model (Table 5.16).  Excluding the inverse probability weighting, the interaction 
between time and the late integrated treatment arm compared to the sequential treatment arm was 
between 0.20 and 0.37.  The estimate was only significant in the likelihood-based model and in the 
Bayesian model.  We therefore conclude that there was some evidence of a higher mean increase 
over time in CD4+ count in the early and late integrated treatment arms compared to the sequential 
treatment arm.   
 
If the MAR assumption holds, the missingness mechanism is ignorable and future statistical 
behaviour of observations from a participant, conditional on the history, is the same for participants 
who have missing data and participants who are observed, and participants who have missing data 
continued to adhere to treatment, then these analyses give Estimand 1.  Under those conditions 
these results are the ITT estimand, including all data at the planned end of the study on all 
participants analysed as randomised.  If we want to interpret this estimand as the ITT estimate of 
the effectiveness of a treatment policy, we need to make the assumption that participants had the 
same adherence to study treatment after dropout from the study as during follow-up.  However, the 
128 
  
effects of the drugs wane after discontinuation and the assumption that participants continued to 
adhere after drop out is not very plausible; except for a few participants who relocated and 
continued to take treatment at a different clinic.  Some participants had not adhered to treatment 
during follow-up and for those participants it is reasonable to expect that their adherence after 
dropout was the same as during follow-up.   
 
Estimand 1 is estimated by all of the MAR analyses reported.  Data at the end of the planned study 
period were available for all randomised participants through a different mechanism in each of 
these methods.  In the likelihood-based analysis, missing data are filled in following the slope 
estimated for each participant using the observed data.  The analysis using multiple imputation 
created a complete data set by imputing the missing data, and could therefore be valid under the 
requirement for an ITT analysis, provided that future statistical behaviour can be accurately 
imputed given past observations, and the imputer’s model is correct.  In the Bayesian analysis, the 
missing data are filled in through sampling from the conditional posterior distribution via the Gibbs 
sampler.  The model fitted using inverse probability weighting weights the observed observations 
and gives observations with a low probability of being observed at the end of the study more 
weight in order to adjust the final estimate for the unobserved observations.  In this way the 
estimate represents all participants at the end of the study.  
 
Mortality was high in the SAPiT study.  Death as an endpoint has been analysed separately using 
standard survival analysis techniques (Abdool Karim et al., 2010; Abdool Karim et al., 2011) and it 
has been shown that the sequential treatment arm had higher mortality than the two integrated 
treatment arms.  There is therefore an imbalance in death between the treatment arms. 
 
It is thus important to consider death as a cause of missing data.  One could argue that values post 
death are not missing in the strictest sense.  In our analysis of CD4+ count death has just been 
treated as another cause of missing data.  The methods that are valid under MAR with ignorable 
missing data, such as likelihood-based models, impute CD4+ count after dropout implicitly, 
because of the structure imposed by correlation between each participant’s longitudinal 
observations.  This implies that we are drawing inferences on CD4+ count in an immortal cohort.  
We are not modelling the association between CD4+ count and treatment in the living only, but 
also include imputed data after death.   
 
Dufouil et al. (2004) suggested an adjustment to inverse probability weighting that allows one to 
treat missing data due to dropout and death differently.  This has not been applied in our analysis, 
but could certainly be done.   
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5.5 Analysis under MNAR assumptions  
A sensitivity analysis is performed by doing several analyses that are valid under MNAR 
assumptions.  MNAR assumptions are described in Section 2.2.3.  The data are analysed using 
pattern-mixture models (discussed in Section 3.3.2), selection models (discussed in Section 3.3.1) 
using Bayesian models (discussed in Section 3.6) and shared-parameter models (discussed in 
Sections 3.3.3 and 3.3.4).   
5.5.1 Pattern-mixture models  
Various applications of pattern-mixture models have been discussed in the literature.  We analyse 
the SAPiT data using four of these applications.  The first uses mixed models as discussed by 
Hedeker and Gibbons (1997).  The second uses multiple imputation (Carpenter & Kenward, 2007).  
The third uses Bayesian methodology as discussed by White et al. (2007).  The fourth uses 
identifying restrictions and multiple imputation (Curran et al., 2004; Thijs et al., 2002).  This is by 
no means an exhaustive list of all available pattern-mixture applications. 
 
Patterns of missing data are identified as in Table 5.2.  The first challenge using pattern-mixture 
models is to determine how the various dropout patterns are grouped.  Three different dropout 
variables were defined; each indicating more detailed dropout groups.  In the first model dropout 
was a binary variable created to indicate whether a participant completed the study or not.  Dropout 
was assigned a value of zero if the study was completed and a value of one if the study was not 
completed (Model 1 in Table 5.21).  In addition, a second dropout variable was created with three 
categories, an indicator whether the study was completed, whether the study was not completed or 
whether the participant died (Model 2).  The third dropout variable has, in addition to the categories 
in Model 2, a category for people who had information at baseline only and dropped out after that 
(Model 3).  The pattern where participants had baseline data only was chosen because this was the 
dropout pattern with the most participants.  Table 5.17 gives the number of participants in each of 
these categories.  More dropout patterns can be identified from the data, but some of these patterns 
include a small number of participants.   
 
In the early integrated treatment arm 69 (32.2%) participants dropped out, in the late integrated 
treatment arm 84 (39.1%) participants dropped out and in the sequential treatment arm 90 (42.3%) 
participants dropped out.  In Model 2 we have a category for participants who dropped out due to 
death, but other than that we treat all dropouts the same and do not incorporate the reason for 
dropout in the analysis.  This is not necessarily the optimal strategy, since participants have 
different reasons for dropping out and these reasons for dropping out, rather than the timing of 
dropout, may be related to outcomes in different ways.   
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Table 5.17: Number of participants in each of the categories of missing data 
 Early integrated 
treatment arm 
N = 214 
Late integrated 
treatment arm 
N = 215 
Sequential  
treatment arm 
N = 213 
Model 1: Binary dropout variable    
Completed 145 (67.8%) 131 (60.9%) 123 (57.8%) 
Dropped out 69 (32.2%) 84 (39.1%) 90 (42.3%) 
Model 2:  Dropout and death included    
Completed 145 (67.8%) 131 (60.9%) 123 (57.8%) 
Dropped out 52 (24.3%) 67 (31.2%) 55 (25.8%) 
Died 17 (7.9%) 17 (7.9%) 35 (16.4%) 
Model 3:  Dropout, death and baseline data   
Completed 145 (67.8%) 131 (60.9%) 123 (57.8%) 
Dropped out 29 (13.6%) 29 (13.6%) 26 (12.2%) 
Baseline data only 23 (10.8%) 38 (17.7%) 29 (13.6%) 
Died 17 (7.9%) 17 (7.9%) 35 (16.4%) 
 
Table 5.18: Estimates and standard errors of coefficients from the different patterns 
of missing data 
 Dropout Dead  Completed 






Intercept 8.89 1.10 7.00 1.76 8.32 0.47 
Early integrated treatment arm (ref: 
sequential treatment arm) 
3.05 1.07 -0.66 2.11 0.56 0.65 
Late integrated treatment arm (ref: 
sequential treatment arm) 
3.51 0.84 -1.61 2.02 -0.41 0.62 
Time  2.08 1.03 2.54 1.90 3.52 0.23 
Time squared -0.05 0.23 -1.02 0.52 -0.31 0.03 
Interaction between treatment arm and 
time (early integrated compared to 
sequential treatment arm) 
-0.06 0.66 1.55 1.34 0.21 0.14 
Interaction between treatment arm and 
time (late integrated compared to 
sequential treatment arm) 
0.15 0.58 1.71 1.15 0.26 0.14 
 
Table 5.18 gives the estimates for each of the patterns of missing data.  MAR models assume the 
slope of the CD4+ count over time is the same across patterns; however the coefficient for the 
interaction between treatment arm and time differs substantially between the three patterns of 
missing data, meaning that the MAR assumption might not be supported by the data.    
 
5.5.1.1 Pattern-mixture models using random-effects mixed models 
Procedure MIXED in SAS was used to fit the model.  Square root CD4+ count was the dependent 
variable.  Independent variables included the fixed, categorical effects of treatment, dropout, and 
the dropout by treatment interaction, as well as the continuous effect of time and time squared.  The 
time by treatment, dropout by time and dropout by treatment interaction and the three level 
interaction of dropout, treatment and time were included.  Adding a term for time squared 
improved the fit of the model since it was not a linear pattern.  An unstructured covariance matrix 
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was used to model the within participant errors, which was modelled separately for each treatment 
arm.  Parameters were estimated using REML with the Newton–Raphson algorithm.  Denominator 
degrees of freedom was estimated using the Kenward-Roger correction (Kenward & Roger, 1997).   
 
The following SAS code was used: 
proc mixed method = reml ; 
  class pointx treatment pid dropout; 
  model cd4square = treatment  point  pointsquared  point*treatment  dropout  dropout*point  
dropout*treatment  dropout*treatment*point / solution residual ddfm = kr outp = cd4mixedpred; 
  repeated pointx / subject = pid type = un group = treatment; 
run; 
 
The regression equation for the pattern-mixture model with binary dropout (Model 1)    - =  β? + βE + β9L +  βt + (βE +  β9L)t  + βD + βtD + βt19 + βDE + β9D L + (βE + β9L)Dt + ε1  
 
Regression equation for pattern-mixture model with three dropout categories (dropout, dead, 
completed, Model 2) - =  β? + βE + β9L +  βt + (βE +  β9L)t  + βC + β9F + (βC + β9F)t +
βt19 +  βEC + β9 EF + β9LC + β99 LF + (βEC + β9 EF + β9LC +
β99 LF) t +  ε1 
Where ï = 1 when completed, 0 otherwise and  = 1 when died, 0 otherwise 
 
Regression equation for pattern-mixture model with four dropout categories (dropout, dead, 
completed, baseline data only, Model 3) - =  β? + βE + β9L +  βt + (βE +  β9L)t  + βC + β9F + βB + (βC +
β9F+ βB)t + βt19 +  βEC + β9 EF + β EB + β9LC + β99 LF +
β9 LB + (βEC + β9 EF + β9 EB + β9LC + β99 LF + β9 LB) t  +  ε1 
Where ï = 1 when completed, 0 otherwise;  = 1 when died, 0 otherwise and 4 = 1 when there 




Table 5.19:  F-test of fixed effects for models including all two way interactions and a 
three way interaction between treatment arm, dropout and time adjusted for all other 
variables and interactions in the model 
 Degrees of freedom F-value p-value 
Effect Numerator Denominator   
Model 1: Binary dropout variable     
Treatment 2 534 0.93 0.40 
Time 1 537 237.20 <0.001 
Time squared 1 432 73.95 <0.001 
Dropout 1 739 7.69 0.006 
Interaction time and treatment 2 470 3.32 0.04 
Interaction between time and dropout 1 629 14.93 <0.001 
Interaction between treatment and dropout 2 534 0.80 0.45 
Interaction between time, treatment and dropout 2 466 1.26 0.28 
     
Model 2:  Dropout and death included    
Treatment 2 595 0.69 0.50 
Time  1 721 98.12 <0.001 
Time squared 1 437 74.97 <0.001 
Dropout 2 798 9.22 <0.001 
Interaction time and treatment 2 435 2.17 0.12 
Interaction between time and dropout 2 639 22.22 <0.001 
Interaction between treatment and dropout 4 638 0.28 0.89 
Interaction between time, treatment and dropout 4 512 0.56 0.69 
    
Model 3:  Dropout and death included, with baseline data only   
Treatment 2 568 0.76 0.47 
Time  1 720 99.05 <0.001 
Time square 1 437 75.30 <0.001 
Dropout 2 766 3.92 0.02 
Interaction time and treatment 2 453 1.66 0.19 
Interaction between time and dropout 2 638 21.97 <0.001 
Interaction between treatment and dropout 4 599 0.26 0.91 
Interaction between time, treatment and dropout 4 509 0.55 0.70 
 
The dummy coded variables for dropout were entered into a longitudinal mixed model as a main 
effect and as interactions with the variables treatment and time (Table 5.19).  In all the models the 
three way interaction and the interaction between treatment and dropout was not significant.  The 
non-significant three way interaction indicated that the treatment arm by time interaction (which 
indicates a more dramatic improvement over time for participants in the integrated treatment arms 
compared to the sequential treatment arm) was not more pronounced for any one dropout category 
(completers, dropouts or participants who died).  Although the interaction between time and 
treatment was not significant in Models 2 and 3, it was kept in the final model fitted, because that 
was the comparison that was of interest.  The final model fitted excluded the non-significant three-
way interaction and excluded the non-significant interaction between treatment and dropout (Table 




Table 5.20:  CD4+ count over time (square root transformed).  Final model fitted, 
with non-significant interactions removed 




Dropout and death 
Model 3 
Dropout, death and 
baseline only 
Effect Estimate SE p-value Estimate    SE p-value Estimate    SE p-value 
Intercept 8.56 0.51  10.08 0.70  9.34 0.97  > Early integrated treatment  
(ref: sequential treatment) 
0.46 0.67 0.50 0.64 0.95 0.50 1.12 1.28 0.38 
>9 Late integrated treatment 
(ref: sequential treatment)  
-0.58 0.65 0.37 1.18 0.84 0.16 1.69 1.21 0.17 
> Time 3.39 0.22 <0.001 3.02 0.27 <0.001 3.06 0.27 <0.001 > Time squared -0.30 0.03 <0.001 -0.30 0.03 <0.001 -0.30 0.03 <0.001 > Interaction  treatment 
arm, time (early integrated 
compared to sequential 
treatment arm) 
0.27 0.14 0.05 0.25 0.14 0.07 0.25 0.14 0.07 
>9 Interaction treatment arm, 
time (late integrated 
compared to sequential 
treatment arm) 
0.35 0.14 0.01 0.34 0.14 0.01 0.34 0.14 0.01 
> Dropout 0.19 0.73 0.79 - - - - - - > Completed compared to 
dropout  
- - - -1.61 0.81 0.05 -0.90 1.05 0.39 
>9 Dead compared to 
dropout 
- - - -1.57 1.18 0.18 -0.83 1.36 0.54 
> Baseline data only 
compared to dropout 
- - - - - - 1.34 1.27 0.29 
> Interaction time and 
dropout 
-0.75 0.21 <0.001 - - - - - - 
> Interaction time, dropout 
(Completed compared to 
dropout) 
- - - 0.37 0.22 0.09 0.34 0.23 0.13 
>9 Interaction time, dropout 
(Dead compared to dropout) 
- - - -2.70 0.52 <0.001 -2.74 0.52 <0.001 
Interaction treatment arm and dropout       > Interaction early 
integrated treatment arm and 
dropout (Completed 
compared to drop out; early 
compared to sequential)  
0.84 1.00 0.40 -0.10 1.10 0.92 -0.54 1.39 0.70 
>9 Interaction early 
integrated treatment arm and 
dropout (Dead compared to 
drop out; early compared to 
sequential) 
- - - -0.22 1.72 0.90 -0.69 1.92 0.72 
> Interaction early 
integrated treatment arm and 
dropout (Baseline data only 
compared to dropout; early 
compared to sequential) 
- - - - - - -0.80 1.87 0.67 
>9 Interaction late 
integrated treatment arm and 
dropout (Completed 
compared to drop out; late 
compared to sequential) 
2.37 0.93 0.01 -1.67 1.00 0.09 -2.14 1.32 0.11 
>99 Interaction late 
integrated treatment arm and 
dropout (Dead compared to 
drop out; late compared to 
- - - -1.14 1.54 0.46 -1.64 1.77 0.35 
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Table 5.20:  CD4+ count over time (square root transformed).  Final model fitted, 
with non-significant interactions removed 




Dropout and death 
Model 3 
Dropout, death and 
baseline only 
Effect Estimate SE p-value Estimate    SE p-value Estimate    SE p-value 
sequential) >9 Interaction late 
integrated treatment arm and 
dropout (Baseline compared 
to drop out; late compared to 
sequential)  
- - - - - - -0.99 1.64 0.55 
SE: Standard error 
 
The degree to which the missing data patterns moderated the influence of other model terms was 
investigated through interactions with the missing data patterns.  In all three models the interaction 
between dropout and time was statistically significant and the interaction between time and 
treatment had a p-value of 0.06, which is close to statistical significance.  The extra category of 
baseline data only in Model 3 did not seem to add much value.  Therefore Model 2 was chosen as 
the most parsimonious model to represent the data (Table 5.21).   
 
Table 5.21:  F-test of fixed effects for final models with non-significant interactions 
removed, adjusted for all other variables and interactions in the model 
 Degrees of freedom F-value p-value 
Effect Numerator Denominator   
Model 1: Binary dropout variable    
Treatment 2 419 1.51 0.22 
Time 1 441 286.01 <0.001 
Time squared 1 433 74.09 <0.001 
Dropout 1 739 7.81 0.01 
Interaction between time and dropout 1 587 12.62 <0.001 
Interaction between time and treatment 2 295 2.80 0.06 
    
Model 2:  Dropout and death included    
Treatment 2 423 0.69 0.50 
Time 1 719 102.78 <0.001 
Time squared 1 439 75.48 <0.001 
Dropout 2 797 10.15 <0.001 
Interaction between time and dropout 2 638 21.13 <0.001 
Interaction between time and treatment 2 303 2.82 0.06 
    
Model 3:  Dropout, death and baseline data only    
Treatment 2 423 0.77 0.46 
Time  1 718 103.97 <0.001 
Time squared 1 439 75.83 <0.001 
Dropout 2 763 4.03 0.02 
Interaction between time and dropout 2 634 20.86 <0.001 
Interaction between time and treatment 2 303 2.84 0.06 
 
The following assumptions were made: 
• It was assumed that data are distributed normally within a pattern of missingness 
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• The conditional distribution of CD4+ count was assumed to depend on dropout time 
through the assigned category only (completed, dropped out or died) and CD4+ count was 
assumed to be independent of dropout time within the pattern of missingness  
• Intermittent missingness was assumed to be MAR   
• It was assumed that covariate effects were the same for missing and observed data within a 
dropout pattern 
 
Figure 5.14 shows that the trajectory for CD4+ count over time was different for the different 
patterns of dropout, especially for the participants who died.  The predicted mean curve fitted the 
observed means well.  The improvement in CD4+ count over time depended on treatment and 
dropout status.   
 
On the basis of the model estimates we derived the predicted mean curve for the groups in Figure 
5.14.   
Completers in the early integrated treatment arm:  D = 7.35 + 3.64 t − 0.30 t9   
Completers in the late integrated treatment arm:  D = 7.88 + 3.74 t − 0.30 t9   
Completers in the sequential treatment arm: D = 8.48 + 3.40 t − 0.30 t9  
Dropouts (not dead) in the early integrated treatment arm: D = 11.03 + 3.27 t − 0.30 t9  
Dropouts (not dead) in the late integrated treatment arm: D = 11.26 + 3.36 t − 0.30 t9  
Dropouts (not dead) in the sequential treatment arm:  D = 10.08 + 3.02 t − 0.30 t9   
Participants who died in the early integrated treatment arm:  D = 8.94 + 0.57 t − 0.30 t9  
Participants who died in the late integrated treatment arm: D = 8.33 + 0.66 t − 0.30 t9  
Participants who died in the sequential treatment arm: D = 8.51 + 0.32 t − 0.30 t9  
 
The predicted mean curve for completers was:   D = 8.48 + 0.79 E − 0.15 L  + 3.40 t  − 0.30 t9  
The predicted mean curve for dropouts who did not die was:  D = 10.08 + 0.89 E + 1.52 L + 3.02  t − 0.30 t9  








Figure 5.14:  CD4+ counts (square root) over time and treatment group for (a) 
completers, (b) dropouts (not dead) and (c) participants who died.  





Overall population estimates, averaging over the missing data patterns, are calculated for the fixed 
effects using the following formula: >"B =  ∑ 6̧rD   The sample proportion, rD, for completers was 
0.6215, for dropouts was 0.2710 and for participants who died was 0.1075.  This gave the average 
estimates for >"B  as given in Table 5.23.  The corresponding standard errors were calculated using 
the methodology from Section 3.3.2.1 and are given in Table 5.22.  
 
Table 5.22: Population averaged estimates and standard errors of pattern mixture 
model using random-effects mixed model (Model 3: Dropout categories were dropout, 
died and completed study) 
Effect 3̀0 Standard 
error 
Z-statistic Degrees of freedom p-value 
Intercept 9.039 0.468 19.22 419 <0.001 
Early integrated treatment arm (ref: 
sequential treatment arm) 
0.710 0.653 1.09 835 0.28 
Late integrated treatment arm (ref: 
sequential treatment arm) 
-0.160 0.526 -0.30 514 0.76 
Time  2.829 0.370 7.64 748 <0.001 
Time squared -0.283 0.084 -3.37 700 <0.001 
Interaction between treatment arm 
and time (early integrated compared 
to sequential treatment arm) 
0.237 0.213 0.97 608 0.33 
Interaction between treatment arm 
and time (late integrated compared 
to sequential treatment arm) 
0.506 0.244 2.37 514 0.02 
 
The assumptions and fit of the pattern-mixture model was checked by assessing how well the 
predicted means of CD4+ count matched the observed means for each treatment arm and dropout 
category and looking at residual plots to identify outliers and departures from the model as 
described by Hogan et al. (2004) in Figure 5.14.   
 
This specific pattern-mixture model can be interpreted as that the increase over time in mean CD4+ 
count is not significantly different between the early integrated treatment arm and the sequential 
treatment arm.  The increase over time is significantly different between the late integrated and the 
sequential treatment arms.  Participants in the late integrated treatment arm had larger increases in 
CD4+ count than participants in the sequential treatment arm.   
 
In this analysis, CD4+ counts after dropout were extrapolated.  These extrapolations are done 
separately for each pattern of missing data, assuming the future behaviour of participants who 
dropped out and died could be predicted by their past behaviour.  Although a similar likelihood-
based mixed model was fitted, this differed from the MAR likelihood-based analysis by allowing 
different profiles to be fitted for participants who completed the study, participants who died and 
participants who dropped out.  We thus made different assumptions about the future behaviour of 
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participants in each of these patterns.  These participants had quite different profiles over time 
(Figure 5.14), and one would expect this model to have different results from the model under 
MAR.   
 
Demirtas and Schafer (2003) criticised random coefficient pattern-mixture models for their implicit 
polynomial extrapolation.  Their criticism was that in these models the levels of time over which 
extrapolations have to be made are more than the number of patterns of dropout actually seen.  All 
responses are missing where the time variable is larger than the dropout indicator.  One needs to 
generate predictions for cells where data are not observed.  Strong assumptions then need to be 
made about the shape of the response surface; especially predicting to the far corner is dangerous.  
Even if the model is correct, the predictions may be highly variable.  If the model is misspecified 
these predictions have large bias.  Conclusions from these analyses are heavily model-dependent; 
while the data do not provide reassurance that the model chosen is appropriate.  However, 
collapsing dropouts into fewer categories, as we did in this example, tends to stabilise the 
extrapolation for those who leave early.  This greater stability should be weighed against loss of 
information and introduction of bias if the true pattern is gradual, rather than only pattern specific.  
Molenberghs and Kenward (2007) also highlighted the same concerns about these methods, namely 
that using the fitted profiles to predict CD4+ trajectory after dropout implies extrapolation.  The 
results are sensitive to the extrapolations made, which may be inappropriate, especially if based on 
lower order polynomials.  The assumptions about the dropout mechanism that these extrapolations 
imply are not transparent.  
 
Demirtas and Schafer (2003) simulated several data sets and applied random coefficient pattern-
mixture models to these data sets.  They expressed serious concerns over these methods and found 
that none of the models tested performed well.  They observed that the polynomial coefficient 
restriction models (similar in spirit to the identifying restrictions) performed better than 
conventional polynomial surfaces.  The complete case polynomial coefficient method that gave the 
best coverage in their simulated studies gave a treatment effect which lay outside of the 95% 
interval calculated by Hedeker and Gibbons (1997) using these methods.  They have shown that 
random coefficient pattern-mixture models can be unstable and non-robust.  These methods should 
therefore be used with care.  This strategy is computationally simpler than the identifying 
restriction strategy discussed later, but the identifying restrictions alleviate many of the concerns 




5.5.1.2 Pattern-mixture models using multiple imputation 
White et al. (2007) and Carpenter and Kenward (2007) described how pattern-mixture models can 
be implemented using multiple imputation.  Using the approach 50 multiple imputations were 
created under MAR, as discussed in Section 3.2 and implemented in Section 5.4.2.  With three 
treatment groups, for each imputation, k, we sampled  
xuvu9vuv{ ~c #x
___{ ,$
C9 0 00 C9 00 0 C9%& 
for each participant, in each of the treatment arms (l = 1, 2, 3).  For each participant we then 
decreased the first imputed observation by usv, the second by 2usv and so on.  The resulting data 
sets were analysed and combined as described in Section 3.2 and implemented in Section 5.4.2.  
Correlations between treatment arms are set to 0, thus C9, C and C9 are set to 0 and in the 
absence of prior information let C 9 = C9 = C99 = C9 = 1. 
Sensitivity analyses are done using different values of δ, while δ is assumed to differ for 
participants who dropped out and those who died.  δ indicates the association between low 
unobserved CD4+ count and dropout.  
 
The variance increased with increasing missing data because this methodology incorporated the 
uncertainty introduced by missing values.  The fairly large increase in variance meant that p-values 
at later time points were not significant.  This should not be taken to mean that the effect of 
treatment has been removed using this methodology, but rather that uncertainty has been increased 
so much that conclusions are harder to draw. 
 
In Table 5.23 C9 was set equal to one.  If a larger variance was chosen, the values increased more 
and if a smaller variance was chosen, the values increased less.  Different values of σ and δ lead to 
different answers, but the following trends were seen:  In almost all scenarios included in Table 
5.23 the mean CD4+ counts were the highest in the early integrated treatment arm, followed by the 
late integrated treatment arm, which was higher than the sequential treatment arm.  The only 
exceptions was Model 5 at 24 months where the late integrated arm had the highest mean.  The first 
four models assumed that participants who died had lower mean CD4+ counts than other 
participants and that participants who did not complete the study had lower mean CD4+ counts 
than participants who completed the study.  The SAS code is given in Appendix 3. 
 
The same imputations were done in Table 5.23, Table 5.24 and Figure 5.15.  Table 5.23 gives 
cross-sectional results; means and standard errors at each of the time points are given.  The 
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intention is not to imply that the cross-sectional model is the same as the longitudinal model fitted 
in Table 5.24.  Rather, the goal is to show the versatility of the method.  It can be used to impute 
data that can then be modelled in many different modelling frameworks.  The cross-sectional 
analysis is also useful when communicating with clinicians and other non-statisticians, who find it 
harder to interpret regression coefficients than means and standard errors.  The implications of the 
different assumptions can be communicated more clearly when clinicians can see how varying σ 
and δ lead to either higher or lower means or standard errors.  In that regard, graphical 
representations, as in Figure 5.15 are also useful.   
 
Table 5.23: Multiple imputation of CD4+ counts (cell/mm3) using a pattern-mixture 
approach, mean (standard error) 
 Early integrated 
treatment arm 
 N = 214 
Late integrated 
treatment arm 
 N = 215 
Sequential  treatment 
arm 
 N = 213 
p-value* 
Assuming decrease in CD4+ count for participants who dropped out and died  
Model 1: δ for dropout = 0.5 and δ for participants who died = 1   
6 months 303.8 (15.0) 259.8 (13.8) 172.1 (11.4) <0.001 
12 months 347.5 (27.8) 290.9 (31.1) 252.5 (28.7) 0.04 
18 months 368.9 (60.5) 326.2 (65.4) 288.4 (63.1) 0.42 
24 months 416.3 (118.1) 382.6 (136.0) 365.4 (126.5) 0.79 
Model 2: δ for dropout = 1 and δ for participants who died = 2   
6 months 300.1 (14.8) 255.8 (13.6) 168.8 (11.2) <0.001 
12 months 332.2 (25.4) 274.4 (27.9) 233.7 (25.4) 0.02 
18 months 343.0 (47.0) 296.8 (49.5) 258.3 (47.1) 0.25 
24 months 397.2 (87.0) 355.7 (105.0) 349.2 (99.4) 0.72 
Model 3: δ for dropout = 0.2 and δ for participants who died = 0.5   
6 months 306.0 (15.1) 262.1 (13.9) 174.1 (11.5) <0.001 
12 months 357.3 (29.4) 301.7 (33.0) 264.8 (30.7) 0.06 
18 months 390.6 (69.2) 350.8 (75.5) 316.3 (74.0) 0.52 
24 months 451.6 (144.4) 424.3 (163.9) 413.1 (158.6) 0.87 
Model 4: δ for dropout = 0.3 and δ for participants who died = 1   
6 months 304.6 (15.0) 261.0 (13.9) 172.9 (11.5) <0.001 
12 months 351.5 (28.6) 296.3 (32.30 256.9 (29.7) 0.05 
18 months 378.6 (65.1) 338.6 (71.4) 299.3 (68.5) 0.46 
24 months 434.5 (133.1) 404.4 (151.6) 386.0 (143.6) 0.82 
Assuming increase in CD4+ count for participants who dropped out and decrease for those who died 
Model 5: δ for dropout = -1 and δ for participants who died = 2  
6 months 307.9 (15.4) 268.1 (14.6) 176.4 (11.9) <0.001 
12 months 375.8 (33.8) 333.8 (40.6) 282.1 (36.0) 0.09 
18 months 458.7 (95.5) 446.8 (112.7) 390.0 (104.0) 0.66 
24 months 641.8 (239.5) 662.6 (278.2) 630.6 (270.6) 0.98 
Model 6: δ for dropout = -0.5 and δ for participants who died = 0.5   
6 months 308.7 (15.3) 266.5 (14.3) 176.8 (11.8) <0.001 
12 months 373.0 (32.3) 323.2 (37.5) 282.2 (34.4) 0.10 
18 months 433.5 (85.9) 406.7 (97.9) 365.3 (93.2) 0.64 
24 months 545.5 (200.7) 543.4 (231.1) 521.6 (222.9) 0.94 





   
Figure 5.15:  Mean CD4+ count (cell/mm3): Multiple imputation of CD4+ counts 
using a pattern-mixture approach, Models as in Table 5.23 
Early integrated treatment arm 
Late integrated treatment arm 




















































It is unrealistic to assume that CD4+ counts would be increasing over time for participants who 
died, therefore this assumption was not made for any of the sensitivity analyses.  However, it is 
possible, but unlikely, that CD4+ counts could increase over time for participants who dropped out 
of the study (Models 5 and 6).  If this assumption was made, the CD4+ counts were much higher at 
later time points.  In addition, the difference between the early and late integrated treatment arms 
became smaller, whereas the sequential treatment arm had lower mean CD4+ counts than the other 
two arms.  
 
In Models 1, 3, 4 and 6 the two interaction terms between treatment arm and time were not 
statistically significant.  However, in Model 2, where a larger decrease in CD4+ count was assumed 
for participants who died and dropped out, the interaction between time and the early integrated 
arm compared to the sequential arm was significant.  This is interpreted as that mean CD4+ count 
increased more in the early integrated treatment arm than in the sequential treatment arm.  It has 
been shown previously that survival was different between the integrated treatment arms and the 
sequential treatment arm.  It is possible that the larger increase in CD4+ counts observed with these 
models reflect the higher number of deaths in the sequential treatment arm.  Model 6 that assumed 
an increase in CD4+ count for participants who dropped out did not have a significant treatment by 
time interaction, whereas Model 5 did.  In Model 5 a large increase in CD4+ count was assumed 
for participants who dropped out, while a large decrease in CD4+ count was assumed for 
participants who died.  The interaction between both treatment arms and time was statistically 
significant in Model 5, indicating that the mean increase in CD4+ count was different in the early 
and late integrated treatment arms compared to the sequential treatment arm. 
 
The sensitivity analysis showed that although the actual CD4+ counts depended on the size of the 
mean difference assumed, the only models where the interaction between time and treatment arm 
was significant, were Model 2, where a large decrease in CD4+ count was assumed for participants 
who died and dropped out, and Model 6, which made the rather unlikely assumption that CD4+ 
count increased after dropout.  
 
This method fitted the same substantive model as under the MAR multiple imputation in Section 
5.4.2.  The difference is that the data were changed after imputation according to the pattern 
assumed in the different drop out groups.  If the assumed patterns were correct, these results should 
provide more accurate estimates of the parameters of interests.  However, if these assumptions 




These models lead to curves that follow a different pattern from the curves fitted previously.  The 
reason is that for participants with monotone missing data, the assumption is that each subsequent 
missing value is further and further away from the imputed value.  This means that when a 
participant dropped out the assumptions compound for the later time points, giving results that are 
increasingly away from the MAR model fitted.   
 
Table 5.24: Multiple imputation of CD4+ counts using a pattern-mixture approach, 
results of mixed model  
 Model 1 
δ for dropout = 0.5,  
δ for participants who 
died = 1 
Model 2 
δ for dropout = 1,  
δ for participants who 
died = 2 
Model 3 
δ for dropout = 0.2;  
δ for participants who 
died = 0.5 
Effect Estimate SE p-value Estimate SE p-value  Estimate SE p-value 
Intercept 11.33 0.42 <0.001 11.34 0.41  11.36 0.43 <0.001 
Early integrated treatment 
arm (ref: sequential treatment 
arm) 
1.00 0.61 0.11 0.92 0.60 0.13 1.02 063 0.10 
Late integrated treatment arm 
(ref: sequential treatment 
arm) 
0.70 0.58 0.22 0.72 0.57 0.21 0.67 0.59 0.26 
Time  2.41 0.53 <0.001 2.31 0.48 <0.001 2.43 0.50 <0.001 
Time squared -0.45 0.16 0.01 -0.66 0.18 0.0004 -0.24 0.16 0.03 
Interaction between 
treatment arm and time 
(early integrated compared 
to sequential treatment arm) 
1.11 0.91 0.23 1.56 0.75 0.04 0.88 0.94 0.35 
Interaction between 
treatment arm and time (late 
integrated compared to 
sequential treatment arm) 
0.61 0.70 0.39 0.84 0.64 0.19 0.52 0.68 0.45 
 Model 4 
δ for dropout = 0.3;  
δ for participants who 
died = 1 
Model 5 
δ for dropout = -1;  
δ for participants who 
died = 2 
Model 6 
δ for dropout = -0.5;  
δ for participants who 
died = 0.5 
 Estimate SE p-value Estimate SE p-value  Estimate SE p-value 
Intercept 11.31 0.41  11.28 0.41  11.29 0.41  
Early integrated treatment 
arm (ref: sequential treatment 
arm) 
1.04 0.62 0.09 1.09 0.67 0.10 1.15 0.64 0.07 
Late integrated treatment arm 
(ref: sequential treatment 
arm) 
0.72 0.58 0.22 0.66 0.61 0.28 0.70 0.60 0.24 
Time  2.38 0.51 <0.001 1.96 0.36 <0.001 2.29 0.45 <0.001 
Time squared -0.41 0.16 0.01 -0.24 0.16 0.14 -0.20 0.15 0.18 
Interaction between 
treatment arm and time 
(early integrated compared 
to sequential treatment arm) 
1.07 0.91 0.25 1.46 0.66 0.03 0.84 0.94 0.37 
Interaction between 
treatment arm and time (late 
integrated compared to 
sequential treatment arm) 
0.62 0.69 0.37 1.00 0.49 0.04 0.60 0.63 0.35 
SE = standard error 
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5.5.1.3 Pattern-mixture models using identifying restrictions 
Multiple imputation was done in order to create monotone missing data, because this model 
required monotone missing data.  A model was then fitted for each pattern.  An estimate was 
calculated over all patterns where the required components were observed, and the conditional 
distributions of the unobserved outcomes given the observed outcomes were calculated.  Separate 
likelihood-based models were fitted for each pattern of missing data using procedure MIXED in 
SAS.   
 
We imputed 70 data sets using each of the identifying restrictions.  Imputed data were truncated at 
35 and 3 respectively to ensure that only biologically plausible values were generated.  Only a 
small fraction of the imputed values were affected by the truncation.  After the imputations under 
each of the restrictions, the data were analysed using the same substantive model as previously 
under multiple imputation and in Section 5.4.1.  This mixed model was fitted for each imputation 
with continuous time, treatment and treatment by time interaction as fixed effects, using an 
unstructured covariance matrix.  The separate imputations were then combined using procedure 
MIANALYZE.  The SAS code for fitting pattern-mixture models using identifying restriction is 
included in Appendix 3. 
 
The goal of fitting the pattern-mixture models was to represent a MNAR mechanism.  The MAR 
condition can be imposed using pattern-mixture models by fitting models using the ACMV 
identifying restriction.  This model is given here in order to contrast the MAR case with the MNAR 
case.   
 
The covariates in the imputer’s model differed from the covariates included in the model fitted in 
the multiple imputation section.  In the previous model using multiple imputation, several baseline 
covariates were included in the imputers’ model.  In the pattern-mixture model using identifying 
restrictions only the observed outcomes are included in the imputers’ model.  Because both the 
analysis and the imputation are done by pattern of missing data, it is more elaborate than the model 




Table 5.25:  CD4+ count over time, pattern-mixture model with identifying restrictions 
 ACMV CCMV NCMV 
Effect Estimate SE p-value Estimate SE p-value  Estimate SE p-value 
Intercept 8.54 0.45  8.39 0.44  9.22 0.71  
Early integrated treatment arm 
(ref: sequential treatment arm) 
1.02 0.53 0.06 1.25 0.53 0.02 1.00 0.62 0.10 
Late integrated treatment arm 
(ref: sequential treatment arm) 
0.66 0.53 0.21 0.80 0.52 0.13 0.40 0.60 0.50 
Time  2.99 0.29 <0.001 3.04 0.26 <0.001 2.34 0.62 <0.001 
Time squared -0.27 0.05 <0.001 -0.27 0.04 <0.001 -0.17 0.10 0.09 
Interaction between treatment 
arm and time (early integrated 
compared to sequential 
treatment arm) 
0.23 0.13 0.09 0.16 0.12 0.19 -0.11 0.24 0.65 
Interaction between treatment 
arm and time (late integrated 
compared to sequential 
treatment arm) 
0.15 0.13 0.22 0.11 0.11 0.35 0.15 0.25 0.55 
SE = standard error; ACMV: available case missing values; CCMV:  complete case missing values; NCMV:  
neighbouring case missing values 
 
Both the likelihood-based method and the pattern-mixture model using ACMV identifying 
restrictions are valid under MAR assumptions, and the sizes of the regression coefficients are 
relatively similar with the two models.  In the pattern-mixture model with ACMV identifying 
restriction the interaction between time and the late integrated treatment arm compared to the 
sequential treatment arm was not statistically significant, while it was statistically significant under 
the likelihood-based method.  The interaction between time and the early integrated treatment arm 
compared to the sequential treatment arm was similar in the two models.   
 
The results for the CCMV identifying restriction were fairly similar to the results for the ACMV 
identifying restrictions (the MAR case).  The same conclusions are drawn.  However, the results 
with the NCMV identifying restrictions were different.  The NCMV model was also the only model 
fitted where the estimate for the interaction between time and the early integrated treatment arm 
compared to the sequential treatment arm was negative.  This was not statistically significant.   
 
In these models the non-identified distributions are calculated using linear combinations of the 
identified distributions.  Comparing the CCMV and NCMV identifying restrictions models to the 
ACMV model indicates how these pattern-mixture models differ from the MAR model.  In the 
ACMV case identifying restriction uses all available patterns where +(|, … , ,) is identified 
by the data.  With CCMV constraints the distributions for those with missing data are equated to 
those with complete data.  Therefore participants who stayed in the study longer, who probably had 
better outcomes because they did not die during the course of the study, had a larger influence on 
results.  CCMV are therefore more influenced by completers and thus more similar to the ACMV 
(MAR) case.  NCMV borrowed information from participants with the closest dropout time.  
Usually there are many completers, but some of the closest neighbours the NCMV identifying 
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restrictions borrow information from could be sparse.  These models fit the same substantive model 
as in previous analyses, but use information borrowed according to the specific identifying 
restriction under the MNAR assumption.   
 
For all three treatment arms the ACMV and CCMV models were similar. However for the early 
and late integrated treatment arms, the NCMV model (the thick black line with squares as symbols 
for the early integrated treatment arm and the thick dotted black line with circles as symbols for the 
late integrated arm in Figure 5.16) was different from the other two models.  It imputed a lower 
mean CD4+ count at each time point than the other two models.  For the sequential treatment arm, 
the NCMV model also had lower mean CD4+ counts at all time points, but these were much closer 
to the other models (the black dotted line with triangles as symbols).  Because there were more 
dropouts in the sequential arm, the nearest neighbours were more similar to the complete case or 
available case than in the other treatment arms.   
 
Under the pattern-mixture model using ACMV identifying restrictions, the missing data are 
imputed.  This model makes the additional assumption that data that follow the same missingness 
pattern has the same future statistical behaviour conditional on observed past data.   
 
Figure 5.16:  Models fitted using identifying restrictions  
The lines indicate fitted model and the unconnected symbols indicate the observed means  
Legend: 
Red: ACMV restriction 
Blue:  CCMV restriction 
Black:  NCMV restriction 
□: Early integrated treatment arm 
o: Late integrated treatment arm 
∆: Sequential treatment arm 
For example:  Red line with triangle is 






5.5.2 Selection model approaches 
Under an MNAR assumption, and using selection model factorisation, we fitted several Bayesian 
models under several different assumptions about the missing data mechanism.  The Bayesian 
paradigm was chosen because it lends itself to building complex models by linking smaller sub-
models into a coherent model of the joint distribution for the full data.  In a non-Bayesian 
paradigm, integrating the joint model created through a selection model is not always possible 
analytically, and the integration would need to be performed numerically.  Often this is non-trivial.  
An alternative is to do it through some form of an EM algorithm.  In the Bayesian framework, if we 
use uninformative priors, the results will approximately agree with maximum likelihood estimates 
and the calculations are easier.  The Gibbs sampler can be used to draw samples from the posterior 
distribution of the full joint distribution.  This can be done in a routine way using software such as 
OpenBUGS.   
 
The same model for the observed data was fitted in the Bayesian analysis under MNAR as was 
fitted under MAR using an unstructured covariance matrix, namely |ë =  ~ Mutivariate Normal(ev,
v) 
where ë =  indicates that the observation belongs to treatment k à =  >? +  >E + >9L + >Q + (>ú +  >í)Q + >Q9   
The priors for the parameters included in the substantive model was the same as the priors defined 
in Section 5.4.3 and are given in Table 5.26.   
 
In addition, a model of missingness was added.  We fitted four different models of missingness.  
The first model of missingness had the form 
m1 ~ Bernoulli(p1), logit$p1& =  θ? + ∆y1 
where = was a binary missing value indicator for -.  A flat prior was specified on the scale of G by specifying a logistic(0, 1) prior for H? in all sets.  For Prior Set 1 ∆ was assigned a non-
informative Normal(0, 10 000) distribution.  For Prior Set 2 the prior for ∆ was Normal(1, 1000) 
and for Prior Set 3 the prior for ∆ was Normal(1, 10).   
 







Since there is not just one MNAR model that is consistent with the observed data, a second MNAR 
model was also fitted.  In the second MNAR model the model of missingness had the following 
form:  
m1 ~ Bernoulli(p1), ]STUQ G =  H + H9,, +  H( − ,,). 
 
This model allowed the missingness to depend on the previous CD4+ count and the change in 
CD4+ count from the previous visit to the visit where the missing data occurred.  The prior sets 
were: 
Prior set 1: H, H9 and H ~ logistic(0,1) 
Prior set 2:  H, H9, H ~ Normal(0, 10000) 
Prior set 3: H, H9, H ~ Normal(0, 100) 
 
The OpenBUGS code for this missingness model was: 
mis[i,w]~dbern(p.bound[i,w]) 
logit(p[i,w])<-theta[1] + theta[2]*cd4square[i,w-1] + theta[3]*(cd4square[i,w] –  cd4square[i,w-1]) 
p.bound[i,w]<-max(0, min(1,p[i,w]))     
 
The third MNAR model fitted allowed missingness to depend on all previous CD4+ counts, not 
only the CD4+ count immediately prior to drop out.  The model for missingness was: 
m1 ~ Bernoulli(p1), 
If visit = 2 then:  ]STUQ G =  H +  H9 
If visit = 3 then:  ]STUQ G =  H + H9,, + H 
If visit = 4 then:  ]STUQ G =  H + H9,,9 + H,, +  H 
If visit = 5 then:  ]STUQ G =  H + H9,, + H,,9 + H,, + H 
 
The prior sets for the missingness model were:  
Prior set 1:  H, H9, H, H  and H~ logistic(0,1) 
Prior set 2:  H, H9,H, H  and H~  ~ Normal(0,10000) 
Prior set 3: H, H9,H, H  and H~  ~ Normal(0, 100)  
 
The OpenBUGS code for this missingness model, using the first set of prior distributions, was: 
for (w in 2:2)   {  # W weeks with drop-out 
for (i in 1:509) {  # exclude individuals who have already dropped out 
mis[i,w]~dbern(p.bound[i,w]) 
logit(p[i,w])<- theta[1]+theta[2]*cd4square[i,w] 
p.bound[i,w]<-max(0, min(1,p[i,w]))     } 
  } 
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for (w in 3:3)   {  # W weeks with drop-out 
for (i in 1:449) {  # exclude individuals who have already dropped out 
mis[i,w]~dbern(p.bound[i,w]) 
logit(p[i,w])<-theta[1] + theta[2]*cd4square[i,w-1] + theta[3]*cd4square[i,w] 
p.bound[i,w]<-max(0, min(1,p[i,w]))     } 
  } 
for (w in 4:4)   {  # W weeks with drop-out 
for (i in 1:428) {  # exclude individuals who have already dropped out 
mis[i,w]~dbern(p.bound[i,w]) 
logit(p[i,w])<-theta[1] + theta[2]*cd4square[i,w-2] + theta[3]*cd4square[i,w-1]  + 
theta[4]*cd4square[i,w] 
p.bound[i,w]<-max(0, min(1,p[i,w]))     } 
  } 
for (w in 5:5)   {  # W weeks with drop-out 
for (i in 1:399) {  # exclude individuals who have already dropped out 
mis[i,w]~dbern(p.bound[i,w]) 
logit(p[i,w])<-theta[1] + theta[2]*cd4square[i,w-3] + theta[3]*cd4square[i,w-2] + 
theta[4]*cd4square[i,w-1] + theta[5]*cd4square[i,w] 
p.bound[i,w]<-max(0, min(1,p[i,w]))     }  } 
 
# Priors 
for(k in 1:3){ 
omega[k,1:5,1:5] ~ dwish(R[k, ,],5) 
sigma[k,1:5,1:5] <- inverse(omega[k, ,])  } 
for(m in 1:5) {   
    theta[m] ~ dlogis(0,1)         }  } 
 
The fourth MNAR model fitted allowed missingness to depend on the interaction between 
treatment group and the unobserved CD4+ count.  The model for missingness was: 
m1 ~ Bernoulli(p1), ]STUQ G =  H + H9ú +  Hí + H +  Hú +  Hí   
 
The prior sets for the missingness model were:  
Prior set 1:  H to  H, ~ logistic(0,1) 
Prior set 2:  H to  H, ~  ~ Normal(0,10000) 
Prior set 3:  H to  H, ~  ~ Normal(0, 100)  
 
The OpenBUGS code for the missingness model was: 
hamdmis[i,w]~dbern(p.bound[i,w]) 
logit(p[i,w])<-theta[1] + theta[2]*cd4square[i,w]*dummyearly[i] + 
theta[3]*cd4square[i,w]*dummylate[i] + theta[4]*cd4square[i,w] + theta[5]*dummyearly[i] 
+theta[6]*dummylate[i] 
p.bound[i,w]<-max(0, min(1,p[i,w]))    
 
Many other models for non-random missingness could be fitted, depending on the assumptions 
made regarding the missing data mechanism.  These are not the only plausible models.   
150 
  
Table 5.26: CD4+ count (square root) posterior means, standard deviations and 
credible intervals according to MNAR Bayesian analysis (selection models) 
MNAR model 1 m1 ~ Bernoulli(p1); logit$p1& =  θ? + ∆y1  
 MNAR model 1: Prior Set 1 
β~Normal(0, 100 000),  
Ω~Wishart(I,5) 
I: Identity matrix, H?~logistic(0,1), 
∆~Normal(0,10 000) 
MNAR model 1: Prior Set 2 
β~Normal(0, 1000),  
Ω~Wishart(A,5) 
A: diag (0.1, 0.1, 0.1, 0.1, 0.1 H?~logistic(0,1), ∆~Normal(0,100) 
MNAR model 1: Prior Set 3 
β~Normal(0, 10),  
Ω~Wishart(A,5) 
A: diag (10, 10, 10, 10, 10) H?~logistic(0,1), 
∆~Normal(0,10) 
Effect Mean SD 95% credible 
interval 
Mean SD 95% credible 
interval 
Mean SD 95% credible 
interval >?  8.78 0.51 7.77;9.79 8.78 0.51 7.78;9.78 8.61 0.49 7.63; 9.57 > 1.12 0.65 -0.17; 2.38 1.11 0.65 -0.16; 2.37 1.25 0.62 0.03; 2.47 >9  0.38 0.62 -0.83; 1.59 0.36 0.61 -0.84; 1.55 0.53 0.58 0.62; 1.67 >  2.97 0.24 2.48; 3.44 2.97 0.24 2.49; 3.45 2.99 0.25 2.50; 3.46 >  0.25 0.16 -0.06; 0.56 0.25 0.16 -0.06; 0.58 0.24 0.16 -0.06; 0.56 >  0.32 0.16 0.01; 0.62 0.32 0.16 0.02; 0.63 0.31 0.16 0.003; 0.61 > -0.25 0.04 -0.32; -0.17 -0.25 0.04 -0.32; -0.17 -0.25 0.04 -0.32; -0.17 
∆ -0.06 0.04 -0.13; 0.01 -0.06 0.04 -0.14; 0.01 -0.06 0.04 -0.32; -0.17 H?  -2.76 0.55 -3.84; -1,71 -2.69 0.60 -3.92; -1,58 -2.67 0.61 -3.90; -1.51 
MNAR model 2  m1 ~ Bernoulli(p1);  ]STUQ G,* =  H + H9,*, + H(,* − ,*,). 
 MNAR model 2: Prior Set1 
β~Normal(0, 100 000),  
Ω~Wishart(I,5) 
I: Identity matrix, H, H9,, H ~logistic(0,1) 
MNAR model 2: Prior Set 2 
β~Normal(0, 1000),  
Ω~Wishart(A,5) 
A: diag (0.1, 0.1, 0.1, 0.1, 0.1 H, H9,, H ~Normal(0, 10000) 
MNAR model 2: Prior Set 3 
β~Normal(0, 10),  
Ω~Wishart(A,5) 
A: diag (10, 10, 10, 10, 10) H, H9,, H ~Normal(0, 100) 
 Mean SD 95% credible 
interval 
Mean SD 95% credible 
interval 
Mean SD 95% credible 
interval >?  8.80 0.51 7.77; 9.78 8.83 0.50 7.84; 9.81 8.61 0.49 7.64; 9.56 > 1.11 0.64 -0.14; 2.38 1.09 0.65 -0.18; 2.36 1.25 0.62 0.02; 2.47 >9  0.37 0.61 -0.82;1.59 0.33 0.60 -0.84; 1.52 0.52 0.59 -0.63; 1.67 >  2.95 0.24 2.45; 3.43 2.94 0.24 2.47; 3.42 2.99 0.25 2.50; 3.48 >  0.26 0.16 -0.05; 0.58 0.26 0.16 -0.05; 0.57 0.24 0.16 -0.06; 0.56 >  0.33 0.16 0.02; 0.64 0.32 0.15 0.02; 0.63 0.31 0.16 <-0.001; 0.61 > -0.24 0.04 -0.32; -0.17 -0.24 0.04 -0.32; -0.17 -0.25 0.04 -0.33; -0.17 H  -2.75 0.59 -3.97; -1.66 -2.64 0.99 -4.15; -0.47 -2.94 0.60 -4.17; -1.81 H9  -0.06 0.04 -0.13; 0.02 -0.07 0.06 -0.21; 0.02 -0.05 0.04 -0.12; 0.02 H  -0.08 0.07 -0.22; 0.05 -0.09 0.08 -0.24; 0.05 -0.07 0.07 -0.21; 0.06 
MNAR model 3  m1 ~ Bernoulli(p1); ]STUQ G,* =  H + H9,*, + H,*,9 + H,*, + H,* 
 MNAR model 3: Prior Set1 
β~Normal(0, 100 000),  
Ω~Wishart(I,5) 
I: Identity matrix, H QS H,~logistic(0,1)  
MNAR model 3: Prior Set 2 
β~Normal(0, 1000),  
Ω~Wishart(A,5) 
A: diag (0.1, 0.1, 0.1, 0.1, 0.1 H to H ~ Normal(0, 10000) 
MNAR model 3: Prior Set 3 
β~Normal(0, 10),  
Ω~Wishart(A,5) 
A: diag (10, 10, 10, 10, 10) H to H ~Normal(0, 100) 
 Mean SD 95% credible 
interval 
Mean SD 95% credible 
interval 
Mean SD 95% credible 




Table 5.26: CD4+ count (square root) posterior means, standard deviations and 
credible intervals according to MNAR Bayesian analysis (selection models) 
MNAR model 4  m1 ~ Bernoulli(p1), ]STUQ G =  H +  H9ú +  Hí + H + Hú +  Hí    
 MNAR model 4: Prior Set1 
β~Normal(0, 100 000), 
Ω~Wishart(I,5) 
I: Identity matrix, H QS H,~logistic(0,1) 
MNAR model 4: Prior Set 2 
β~Normal(0, 1000), 
Ω~Wishart(A,5) 
A: diag (0.1, 0.1, 0.1, 0.1, 0.1 H to H ~ Normal(0, 10000) 
MNAR model 4: Prior Set 3 
β~Normal(0, 100), 
Ω~Wishart(A,5) 
A: diag (10, 10, 10, 10, 10) H to H ~Normal(0, 100) 
 Mean SD 95% credible 
interval 
Mean SD 95% credible 
interval 
Mean SD 95% credible 
interval >?  8.79 0.50 7.81; 9.77 8.81 0.50 7.81; 9.79 8.63 0.50 7.63; 9.59 > 1.14 0.65 -0.14; 2.40 1.11 0.64 -0.15; 2.38 1.23 0.63 0.03; 2.48 >9  0.38 0.61 -0.82; 1.56 0.34 0.61 -0.86; 1.54 0.49 0.60 -0.69; 1.67 >  2.94 0.25 2,45; 3.42 2.95 0.24 2.49; 3.45 3.00 0.25 2.52; 3.48 >  0.25 0.16 -0.07; 0.57 0.26 0.16 -0.06; 0.57 0.24 0.16 -0.07; 0.56 >  0.32 0.16 0.01; 0.63 0.32 0.16 0.01; 0.64 0.31 0.16 0.004; 0.62 > -0.24 0.04 -0.32; -0.16 -0.24 0.04 -0.32; -0.17 -0.25 0.04 -0.33; -0.17 H  -2.65 0.71 -4.10; -1.32 -0.70 0.65 -2.08; 0.22 -2.83 0.81 -4.49; -1.34 H9  -0.04 0.08 -0.19; 0.11 0.04 0.09 -0.09; 0.22 -0.03 0.09 -0.20; 0.14 H  -0.04 0.07 -0.18; 0.11 -0.06 0.09 -0.24; 0.10 -0.05 0.09 -0.23; 0.11 H  -0.04 0.05 -0.13; 0.06 -0.16 0.05 -0.24; -0.06 -0.02 0.05 -0.13; 0.08 H  -0.36 1.22 -2.77; 2.04 -1.44 1.65 -4.77; 0.19 -0.42 1.50 -3.45; 2.30 H  -0.27 1.11 -2.54; 1.82 0.07 1.30 -2.47; 2.29 -0.10 1.35 -2.72; 2.65 
MNAR: Missing not at random, SD: Standard deviation   >? Intercept;  > Early integrated treatment arm (ref: sequential treatment arm); >9 Late integrated treatment arm (ref: 
sequential treatment arm),  > Time; > Interaction between treatment arm and time (early integrated compared to 
sequential treatment arm);  > Interaction between treatment arm and time (late integrated compared to sequential 
treatment arm); >: Time squared 
Highlighted sections indicate statistical significance 
 
All the models were fitted using OpenBugs, which uses MCMC methods and run for 40 000 
iteration, including 20 000 burn-in iterations.  Two chains with different starting values were used 
and convergence was assumed if a visual inspection of the trace plots was satisfactory.  All the runs 
discussed converged.   
 
The choice of prior distribution did not appreciably change the results.  In addition, similar 
conclusions were drawn from all four of the MNAR models.  In all four of the MNAR Bayesian 
models fitted the interaction between time and the early integrated treatment arm compared to the 
sequential treatment arm was not significant, under any of the prior sets used.  In all four of the 
MNAR models fitted, the interaction between time and the late integrated treatment arm compared 
to the sequential treatment arm was significant.  One of the 95% credible intervals included 0 
(Model 2, prior set 3), but only barely so.  We therefore conclude that the change in mean CD4+ 
count increase is larger in the late integrated treatment arm than in the sequential treatment arm, 
while the change over time in mean CD4+ count is similar in the early integrated treatment arm and 
the sequential treatment arm.   
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5.5.3 Shared parameter models 
In this setting, the occurrence of an event, dropout, also corresponds to the discontinuation of the 
longitudinal process.  Joint models were fitted for the longitudinal CD4+ counts and the time to 
dropout where both the measurement and dropout processes share random effects, conditional upon 
which they are assumed to be independent.  It is assumed that some underlying individual 
characteristic, such as disease process, influences both whether a participant drops out of the study 
or whether CD4+ counts improve.  The linear mixed model for CD4+ count included as fixed 
effects an intercept, the treatment and time variables and the interaction between the treatment 
variables and time.  The measurement error terms are assumed to be independent and to follow a 
normal distribution with mean 0 and variance C9.  Dropout is modelled through a linear effect of 
the treatment variables, intercept and a random disturbance term in a time to event model.  The 
baseline hazard function follows a Weibull distribution.  The connection between CD4+ count and 
time to dropout is accomplished via the random effects U and V.  The random effects have mean 0 
and the parameters L and L rescale their variances to account for the different scales of CD4+ 
count and the time variable.  A Cholesky parameterisation of the random effects covariance matrix 
was used to ensure positive definiteness.  Conditional on random effects we have independent 
Gaussian contributions.  The initial values of the parameters were estimated by fitting the 
longitudinal model and survival model separately.  
 
The following model was fitted where the random effect for the intercept, U, and the random 
effect for the slope, V, were shared between the survival and the longitudinal sub-models.   
Survival sub-model:  ℎ(Q) =  ℎ?(t)exp [L? + LE1 + L9L1 + LU  + LV   
where ℎ?(t) is the baseline hazard function and follows a Weibull distribution. 
Longitudinal sub-model:  - = > + U + >9Q + VQ + >E1 + >L1 + >E1Q + >L1Q +  >Q9 +  A 
 
The following SAS code was used for the model with random intercept and slope linkage: 
proc nlmixed data = dataset; 
if (last) then do; 
   linpsurv = a0 + adumearly*dummyearly + adumlate*dummylate + aInt*U0 + r2*u1; 
   alpha = exp(-linpsurv*gamma); 
   G_t = exp(-alpha*last_t**gamma); 
   g = gamma*alpha*last_t**(gamma-1)*G_t; 
   llsurv = (death=1)*log(g) + (death=0)*log(G_t); 
  end; 
else llsurv = 0; 
 
v11 = a11*a11; 
v12 = a11*a12; 




linplong = (bl0 + u0) + (point*bt + u1*point)  + dummyearly*bdumearly +dummylate*bdumlate + 
dummyearly*point*btdumearly +dummylate*point*btdumlate+ pointsquared*btsquare; 
resid = (cdsquare-linplong); 
 
    if (abs(resid) > 1E100) or (s2 < 1e-12) then do; 
       Llong = -1e20; 
    end; else do; 
       Llong = -0.5*(1.837876 + resid**2 / s2  + log(s2)); 
    end; 
model last ~ general (llong + llsurv); 
random u0 u1 ~ normal ([0,0],[v11,v12,v22]) subject = pid; 
estimate 'Var[u0]' v11; 
estimate 'cov[u0,u1]' v12; 
estimate 'var[u1]' v22; 
run; 
 
The following model was fitted where the random effect for intercept, U, only was shared between 
the survival and the longitudinal sub-models.  In the longitudinal sub-model the U serve as 
participant specific random effects and in the survival sub-model the U serve as participant 
specific covariates. 
Survival sub-model:  ℎ(Q) =  ℎ?(t)exp [L? + LE1 + L9L1 + LU  
where ℎ?(t) is the baseline hazard function and follows a Weibull distribution 
Longitudinal sub-model:  - = > + U + >9Q + >E1 + >L1 + >E1Q + >L1Q +  >Q9 +  A 
 
The following SAS code was used for the model with intercept linkage: 
proc nlmixed data = dataset; 
PARMS a0 = 10 adumearly = 0.38 adumlate = -0.13 bdumearly = 1.74 bdumlate = 1.34 btdumlate 
= 0.05 btsquare = -0.28 bt = 3.445 btdumearly = 0.156 aint = 0; 
if (last) then do; 
   linpsurv = a0 + adumearly*dummyearly + adumlate*dummylate + aInt*U0 ; 
   alpha = exp(-linpsurv*gamma); 
   G_t = exp(-alpha*last_t**gamma); 
   g = gamma*alpha*last_t**(gamma-1)*G_t; 
   llsurv = (death=1)*log(g) + (death=0)*log(G_t); 
  end; 
else llsurv = 0; 
 
var = s11*s11; 
 
linplong = (bl0 + u0) + t*bt  + dummyearly*bdumearly +dummylate*bdumlate + 
dummyearly*t*btdumearly +dummylate*t*btdumlate+ pointsquared*btsquare; 
     resid = (cd4square-linplong); 
 
    if (abs(resid) > 1E100) or (s2 < 1e-12) then do; 
       Llong = -1e20; 
    end; else do; 
       Llong = -0.5*(1.837876 + resid**2 / s2  + log(s2)); 
    end; 
 model last ~ general (llong + llsurv); 
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 random u0 ~ normal(0,var) subject= pid;  
        estimate 'Var[u0]' var; 
 run; 
 
Table 5.27:  Joint model for CD4+ count over time and time to dropout 
 Intercept linkage Intercept and linear slope 
linkage 
Effect Parameter Estimate Standard 
error 
p-value Estimate Standard 
error 
p-value 
Longitudinal sub-model        
Intercept > 7.68 0.44 <0.001 7.70 0.43 <0.001 
Time  >9 3.45 0.23 <0.001 3.45 0.22 <0.001 
Early integrated treatment 
arm (ref: sequential treatment 
arm) 
> 1.76 0.53 0.001 1.70 0.53 0.002 
Late integrated treatment arm 
(ref: sequential treatment arm) 
> 1.32 0.53 0.013 1.32 0.54 0.014 
Interaction between treatment 
arm and time (early integrated 
compared to sequential 
treatment arm) 
> 0.15 0.11 0.152 0.18 0.13 0.168 
Interaction between treatment 
arm and time (late integrated 
compared to sequential 
treatment arm) 
> 0.05 0.11 0.624 0.08 0.14 0.575 
Time squared > -0.28 0.04 <0.001 -0.29 0.03 <0.001 
Time to dropout sub-model        
Intercept survival model only L? 10.03 22.89 0.661 10.18 31.97 0.750 
Early treatment arm compared 
to sequential 
L 0.39 21.53 0.986 0.43 22.08 0.984 
Late integrated treatment arm 
(ref: sequential treatment arm) 
L9 0.14 20.29 0.995 0.22 21.84 0.992 
Intercept shared L 0.01 2.03 0.995 -0.21 2.67 0.939 
Slope shared L    1.06 16.13 0.948 
 
The results were similar for the joint model where a random slope and intercept were shared 
between the sub-models and where a random intercept only was shared.  Both models lead to the 
conclusion that neither the early nor the late integrated treatment arm was associated with a 
reduction in mean CD4+ count compared to the sequential treatment arm.  The shared intercept 
(L) estimate was close to 0 in the random intercept joint model and not significant in both models, 
indicating that baseline CD4+ count did not influence dropout time.  The shared slope was positive 
and not significant.  The positive slope indicated that participants with larger linear increase in 
CD4+ count also had an increase in dropout time, but this was not statistically significant (Table 
5.27).   
 
These joint models differ from the MAR models by allowing the longitudinal CD4+ count profiles 
and the missingness process to share random effects.  The models need to be interpreted 
conditional on these random effects.  Shared-parameter and selection models differ in how they 
relate the probability of a missing observation and the longitudinal CD4+ counts.  Shared-random 
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effects models link the two by relating a participant’s propensity to respond with his or her 
propensity to miss a visit, while selection models directly model the probability of a missed visit as 
a function of the response.  Shared-parameter models are more appropriate when the missingness is 
related to an individual’s disease process.   
 
The substantive model in these joint models differs from the substantive model fitted previously.  
SAS is not able to fit a joint model with the same substantive model as previously fitted.  In order 
to compare the joint model fitted with a model under the MAR case, the MAR model was fitted as 
a random intercept model.  The within-participant effect was taken into account by adding a 
random participant specific effect to the model.  This model was fitted with a compound symmetry 
covariance matrix.  A model with a subject specific random effect and random slope was also 
fitted.  These models are given in Table 5.28.    
 
Table 5.28:  MAR longitudinal model with random subject specific effects: 
comparable to the longitudinal sub-model in Table 6.27 
 Intercept linkage Intercept and linear slope 
linkage 
Effect Parameter Estimate Standard 
error 
p-value Estimate Standard 
error 
p-value 
Longitudinal sub-model        
Intercept > 7.68 0.44 <0.001 7.78 0.37 <0.001 
Time  >9 3.45 0.23 <0.001 3.37 0.27 <0.001 
Early integrated treatment 
arm (ref: sequential treatment 
arm) 
> 1.74 0.53 0.001 1.71 0.38 <0.001 
Late integrated treatment arm 
(ref: sequential treatment arm) 
> 1.34 0.53 0.011 1.20 0.38 0.002 
Interaction between treatment 
arm and time (early integrated 
compared to sequential 
treatment arm) 
> 0.16 0.11 0.145 0.20 0.18 0.269 
Interaction between treatment 
arm and time (late integrated 
compared to sequential 
treatment arm) 
> 0.05 0.11 0.639 0.14 0.18 0.452 
Time squared > -0.28 0.04 <0.001 -0.28 0.04 <0.001 
 
Comparing the β-estimates between Table 5.27 and Table 5.28 there is almost no difference in the 
random intercept model.  The random intercept and slope model had small differences between the 
MAR and MNAR models, but the same conclusions are drawn from both models.  It seems that the 
deviations from MAR assumed by the joint model do not change the conclusions.   
 
Death as a cause of missing data deserves special attention.  In order to investigate the relationship 
between CD4+ count and death, the same joint models were fitted, with the only change that the 
survival model modelled the time to death instead of the time to dropout.  Participants who dropped 
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out were censored.  This model creates a joint model of the probability of being alive and healthy.  
The results are given in Table 5.29 and were similar to the results of the joint model for time to 
dropout and longitudinal CD4+ count.  The similarity in results can partly be explained by the fact 
that a large proportion of the dropouts were caused by death.  For the participants who died time to 
death and time to dropout was the same.  
 
Table 5.29:  Joint model of longitudinal CD4+ count and time to death 
 Intercept linkage Intercept and linear slope 
linkage 
Effect Parameter Estimate Standard 
error 
p-value Estimate Standard 
error 
p-value 
Longitudinal sub-model        
Intercept > 7.68 0.44 <0.001 7.70 0.43 <0.001 
Time  >9 3.45 0.23 <0.001 3.45 0.22 <0.001 
Early integrated treatment 
arm (ref: sequential treatment 
arm) 
> 1.77 0.53 0.001 1.71 0.53 0.002 
Late integrated treatment arm 
(ref: sequential treatment arm) 
> 1.32 0.53 0.013 1.30 0.54 0.016 
Interaction between treatment 
arm and time (early integrated 
compared to sequential 
treatment arm) 
> 0.15 0.11 0.153 0.18 0.13 0.173 
Interaction between treatment 
arm and time (late integrated 
compared to sequential 
treatment arm) 
> 0.05 0.11 0.623 0.08 0.14 0.564 
Time squared > -0.28 0.04 <0.001 -0.29 0.03 <0.001 
Survival sub-model        
Intercept survival model only L? 10.59 12.85 0.410 11.29 14.80 0.446 
Early treatment arm compared 
to sequential 
L -0.08 10.65 0.994 0.18 10.42 0.986 
Late integrated treatment arm 
(ref: sequential treatment arm) 
L9 0.08 12.10 0.995 0.32 11.24 0.977 
Intercept shared L 0.01 1.05 0.992 0.05 1.15 0.963 
Slope shared L    1.00 7.45 0.894 
 
5.5.4 Conclusions of MNAR models 
Several MNAR models were fitted using both pattern-mixture models and selection models.  These 
methods form part of a sensitivity analysis and is by no means an exhaustive list of plausible 
models that could be fitted.  In fact, this is not even an exhaustive list of the different methods that 
could be used to fit these models.  Nor do the models fitted give any indication as to which of the 




Table 5.30:  Summary of findings in MNAR sensitivity analyses 
 Interaction between treatment arm and time  
 Early integrated compared to 
sequential treatment arm 
Late integrated compared to 
sequential treatment arm 
 Estimate p-value Estimate p-value 
Pattern-mixture model     
Pattern-mixture model using random-
effects mixed models for each of the 
patterns of missing data (Table 
5.22FTa) 
0.24 0.33 0.51 0.02 
Pattern-mixture models using multiple 
imputation 
    
Model 1: δ for dropout = 0.5 and δ for 
participants who died = 1 
1.11 0.23 0.61 0.39 
Model 2; δ for dropout = 1, δ for 
participants who died = 2 
1.56 0.04 0.84 0.19 
Model 3; δ for dropout = 0.2; δ for 
participants who died = 0.5 
0.88 0.35 0.52 0.45 
Model 4; δ for dropout = 0.3; δ for 
participants who died = 1 
1.07 0.25 0.62 0.37 
Model 5; δ for dropout = -1; δ for 
participants who died = 2 
1.46 0.03 1.00 0.04 
Model 6; δ for dropout = -0.5; δ for 
participants who died = 0.5 
0.84 0.37 0.60 0.35 
Pattern-mixture models using 
identifying restrictions 
    
CCMV 0.16 0.19 0.11 0.35 
NCMV -0.11 0.65 0.15 0.55 
Selection model approaches (Prior set 1)    
Bayesian MNAR model 1 0.25 NS 0.32 Sign 
Bayesian MNAR model 2 0.26 NS 0.33 Sign 
Bayesian MNAR model 3 0.38 NS 0.31 Sign 
Bayesian MNAR model 4 0.25 NS 0.32 Sign 
Shared-parameter model     
Joint model with intercept shared 0.15 0.15 0.05 0.62 
Joint model with intercept and slope 
shared 
0.18 0.17 0.08 0.58 
Sign = significant, NS = Not significant 
 
The answer to the question of whether mean CD4+ count increases over time differed between the 
treatment arms was complicated.  If we look at the interaction between time and the early 
integrated treatment arm compared to the sequential treatment arm, we conclude that this 
interaction was not statistically significant.  It was statistically significant only in Models 2 and 5 
with multiple imputation which makes quite strong assumptions, namely that participants who died 
had much lower mean CD4+ counts than participants who remained in the study.  We therefore 
conclude that unless very strong assumptions are made about CD4+ counts that are not observed, 
there is no difference between the early integrated and sequential treatment arms over time in the 
change in CD4+ count (Table 5.30).   
 
Regarding the interaction between time and the late integrated treatment arm compared to the 
sequential treatment arm, half the models found a significant interaction and the other half did not.  
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The models that found significant interactions were the pattern-mixture model using random-
effects mixed models for each of the patterns of missing data, Model 5 with multiple imputation 
and all the selection models.  In the former, participants who died had lower mean CD4+ counts 
than other participants.  There were more participants who died in the sequential treatment arm and 
we speculate that this pattern reduced the mean CD4+ count in the sequential treatment arm.  As 
mentioned previously, Model 5 with multiple imputation makes quite strong assumptions, namely 
that the imputed CD4+ count for participants who died was lower and the imputed CD4+ count for 
participants who dropped out was higher than if they had remained in the study.  The coefficients 
estimated under the selection model were similar to the coefficients estimated under the MAR case 
with the MAR Bayesian model.  Therefore these models did not show major sensitivity for the 
deviations from MAR assumed under these models.  
 
The estimand considered under MNAR assumptions is the same as the one under the MAR 
assumptions.  We would like to have an estimator for Estimand 1 as described by the National 
Research Council (2010).  This is the de facto or ITT estimand, including all data on all 
participants analysed as randomised.  The different MNAR models fitted merely made different 
assumptions about the data not observed, but did not change the estimand of interest.   
 
Under the pattern-mixture model using random-effects models for each of the patterns of missing 
data, if the future behaviour of observations from a participant in a specific pattern of missing data, 
conditional on the history, was correctly modelled then this analysis leads to an estimate for 
Estimand 1.  We assumed that participants who dropped out continued to adhere to treatment post 
dropout and we also assumed that participants who died continued with the same drug taking 
behaviour as prior to death.   
 
The analysis using multiple imputation includes data on participants after withdrawal or loss to 
follow-up, because the missing data are imputed according to previously observed data and the 
assumptions made about the missing data.  This analysis could therefore give a valid analysis under 
the requirement for an ITT analysis when data are incomplete, provided the imputer’s model used 
is correct and the assumptions made about missing data after dropout is correct.   
 
The analyses using identifying restrictions include data after withdrawal or loss to follow-up, 
because the identifying restrictions borrow information from the appropriate pattern of data to 
complete the profiles.  This analysis could therefore give a valid analysis under the requirement for 
an ITT analysis provided assumptions made about missing data after dropout is correct.  The 




Pattern-mixture models, fitted under the MNAR assumption, allow one to treat missing data due to 
drop out and death differently.  The models fitted in Sections 5.5.1.1 and 5.5.1.2 explicitly fitted 
different models for participants who died and those who dropped out.  Although these models did 
not make the assumption that trajectories were the same for participants who died and those who 
dropped out, these models still imputed CD4+ counts for participants post death; thus creating an 
immortal cohort.  These models could be adjusted to only impute data for participants who dropped 
out and to censor participants who died.  In Table 5.29 a joint model for longitudinal CD4+ count 
and time to death was fitted.  This model modelled the effect of treatment arm on changes in CD4+ 
count jointly with the probability of surviving.  None of the other models fitted under the MNAR 
assumption treated missingness due to death differently from missingness due to drop out.   
 
We cannot interpret the CD4+ count trajectories over time as the CD4+ counts of participants who 
were still alive.  Where declining CD4+ count preceded death and where lower CD4+ counts were 
imputed for participants who died, one would assume that treatment arms with higher death rates 
would have lower CD4+ counts modelled at later time points.  If CD4+ count is modelled because 
it is a surrogate marker for disease status, with very low CD4+ count as predictive of pending 
death, this might not be as incorrect as it sounds. 
5.6 Conclusion 
The conclusion reached when the survival data were analysed was that integrated treatment saved 
lives and the recommendation was made that tuberculosis and HIV treatment should be integrated 
(Abdool Karim et al., 2010; Abdool Karim et al., 2011).  A secondary question is whether 
integrated treatment changed the HIV treatment outcomes, measured by CD4+ counts.  In this 
study about a third of the CD4+ counts are missing, either due to loss to follow-up or death.  The 
CD4+ count over time can therefore not be evaluated without taking missing data into account. 
 
There is evidence that the missing data process is not MCAR.  The missing data process could be 
MAR, and MNAR cannot be ruled out.  Under the MAR assumption, the likelihood-based method 
and the Bayesian method showed a significant difference between treatment arms in mean CD4+ 
count over time.  The early and late integrated treatment arms both had a higher mean increase in 
CD4+ count over time than the sequential treatment arm.  The other methods did not show a 
significant effect of treatment arm over time, although the pattern-mixture model under the ACMV 
identifying restriction had a small p-value for the interaction between time and the early integrated 
treatment arm.  Under MNAR the majority of methods did not find a significant interaction 
between time and the early integrated treatment arm compared to the sequential treatment arm.  
The interaction between time and the late integrated treatment arm compared to the sequential 
treatment arm was not significant under most assumptions, the selection model approach is an 
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exception.  With the selection models, which gave results similar to the MAR case, this interaction 
was significant.  The conclusion therefore needs to be tempered slightly by stating that treatment 
arm could have an effect on mean CD4+ count over time, under certain assumptions made about 
the unobserved data. 
 
This secondary analysis was done to determine whether integrated HIV and tuberculosis treatment 
would compromise CD4+ counts.  Although the results were not consistent under all the 
assumptions made and with all the different methods used, none of these analyses found any 
evidence that CD4+ count increased more in the sequential treatment arm than in the other 
treatment arms.  We can therefore safely recommend integrated treatment, knowing that as a 
treatment policy this will save lives and not compromise CD4+ counts.  CD4+ count measures 
immune system health and is not specific to HIV.  Tuberculosis treatment on its own is known to 
increase in CD4+ count (Martin et al., 1995), which probably explains some of the similarity in all 
the treatment arms, since all participants started tuberculosis treatment shortly prior to being 






St John’s Wort trial 
In the previous chapter we applied the theory around analysis of incomplete longitudinal data to a 
clinical trial with three treatment arms in HIV-infected patients.  We continue our investigation of a 
proper analysis of a clinical trial with missing data with a second example.  We follow the same 
organisation as in the previous chapter.  In Section 1 we describe the design and published results 
of the trial.  Section 2 follows with a description of the missing data in the trial.  We then analyse 
the data using MCAR methods in Section 3, MAR methods in Section 4 and MNAR methods in 
Section 5.  We conclude the chapter by contrasting these analyses and drawing a conclusion 
regarding the findings. 
6.1 The St John’s Wort (hypericum perforatum) trial 
This trial was chosen to illustrate missing data analysis because of large amounts of missing data.  
In addition to participants discontinuing from the trial for various reasons and lost to follow up as 
in the previous SAPiT example, the trial also introduced missing data from Week 8 onwards by 
design.  The design of the trial is discussed in Section 6.1.2.  The next section describes the design 
and available results of the hypericum trial. 
         Chapter 6 
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6.1.1 Background to the St John’s Wort trial 
Hypericum perforatum, also known as St John’s Wort, is a herbal remedy believed to treat, among 
other things, depression.  Especially in European countries, such as Germany, hypericum 
perforatum is often prescribed for treatment of mild depression, also in children and adolescents 
(Fegert et al., 2006).  It was shown to be more effective than placebo (Kalb, Trautmann-Sponsel, & 
Kieser, 2001) in treating depression and is believed to have fewer side effects than standard 
antidepressive therapies, thus making it an attractive option for many patients (Linde et al., 1996).  
Some studies and meta-analyses have found hypericum to be as effective as standard antidepressive 
therapies (Linde, Berner, & Kriston, 2008; Rahimi, Nikfar, & Abdollahi, 2009), while other studies 
found no difference between hypericum and placebo (Shelton et al., 2001) 
 
Because different studies had contradictory results about the relative effectiveness of hypericum 
when compared to placebo and standard antidepressive drugs, a trial was designed to compare both 
a standard antidepressive therapy (sertraline) and hypericum to placebo (Hypericum Depression 
Trial Study Group, 2002).  Sertraline is an antidepressant of the selective serotonin reuptake 
inhibitor (SSRI) class.  It was brought to market by Pfizer in 1991 under the trademark name 
Zoloft.   
6.1.2 Methods 
The trial was a randomised, double blind, parallel-arm, 8-week, outpatient trial of hypericum, 
sertraline, or placebo treatment for major depressive disorder, followed by 18 weeks of double 
blind continuation treatment in participants meeting response criteria at Week 8 (Hypericum 
Depression Trial Study Group, 2002).  Participants with major depression were recruited from 
December 1998 to June 2000 at 12 centres.   
 
The trial included outpatients with major depression of moderate severity.  Specifically, the 
inclusion criteria included: aged 18 years or more; diagnosis of major depression; a score of 20 or 
more on the Hamilton Depression scale (HAM-D) (Hamilton, 1960), and a score of 60 or less on 
the Global Assessment of Functioning (GAF) scale at screening and baseline, capable of giving 
informed consent and identification of a personal contact.  Exclusion criteria included: suicide or 
homicide risk, current or planned pregnancy, breastfeeding or not using birth control; and some 
relevant medical conditions, such as liver disease, use of either hypericum or sertraline in the 
previous 6 months or current use of other psychotropic drugs or current psychotherapy.  Complete 
inclusion and exclusion criteria are available in the trial protocol and in the trial paper (Hypericum 




The eligibility of participants was assessed, after which they gave written informed consent and 
participated in a one-week placebo run-in.  Participants meeting eligibility criteria after this one-
week run-in were randomised to one of the three treatment arms in a 1:1:1 ratio.  Participants were 
assessed weekly from Week 1 to Week 8 (with the exception of Week 5).  Participants who were 
regarded as responders at Week 8 (the end of the acute phase) could enter the continuation phase, 
with visits at Weeks 10, 14, 18, 22 and 26.  The HAM-D, Global Assessment of Functioning 
(GAF) scale, Clinical Global impressions scales for severity (CGI-S) and improvement (CGI-I) and 
the Beck Depression Inventory (BDI) were assessed at all visits.  Other safety related information 
was also collected; such as vital signs, adverse events and blood chemistry and haematology 
(Hypericum Depression Trial Study Group, 2002).  For the purpose of this study we analyse the 
response over time on the HAM-D.  The HAM-D scale is a measure of depression, with a higher 
score indicative of more severe depression. 
 
Hypericum and matching placebo were provided by Lichtwer Pharma and sertraline and matching 
placebo were provided by Pfizer.  Dosing was three times daily.  Participants were started on a 
standard dose, which could be increased according to a predetermined algorithm if required.  
Medication was provided in double-dummy fashion (Hypericum Depression Trial Study Group, 
2002).   
 
Response at Week 8 was defined as either full or partial response.  Full response was defined as a 
CGI-I score of 1 or 2 and a HAM-D total score of 8 or less.  Partial response was defined as a CGI-
I score of 1 or 2, a decrease in the HAM-D score from baseline of at least 50% and a HAM-D score 
between 9 and 12 (Hypericum Depression Trial Study Group, 2002).   
6.1.3 Primary and secondary endpoints 
The main hypothesis was whether hypericum was superior to placebo after 8 weeks.  The endpoints 
were defined as the change in the HAM-D score from baseline to Week 8 and the proportion of 
participants who had a full response at Week 8.  The principal comparison was between the 
hypericum and placebo arms.  The sertraline arm was included as an active control arm to validate 
the study, but no comparison between hypericum and sertraline was intended and the trial was not 
powered for such a comparison or for multiple comparisons with placebo (Hypericum Depression 
Trial Study Group, 2002).   
 
In the original analysis treatment differences in the change in HAM-D score from baseline to 
Week 8 were evaluated through a random-coefficient linear regression model.  Fixed effects were 
treatment, site, sex, week and treatment by week interaction.  A random intercept and slope over 
time were included for each participant.  Tests of treatment differences for the change in HAM-D 
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scores from baseline to Week 8 were equivalent to tests of treatment differences in the slopes over 
time.  The original paper also included a completers’ analysis and a LOCF analysis of the acute 
phase.  No endpoint data were presented from the continuation phase (Hypericum Depression Trial 
Study Group, 2002).   
 
The trial enrolled 428 participants in the run-in phase and 340 were randomised to the three 
treatment arms (Figure 6.1).  The demographic data of the sample is described elsewhere 
(Hypericum Depression Trial Study Group, 2002).  They found that the HAM-D scores declined 
with time and differed by site and sex.  The scores were lower for men.  They did not find that 
trend with time differed significantly by treatment; either for the comparison between hypericum 
and placebo or for the comparison between sertraline and placebo.  The full response rate at Week 
8 did not differ between hypericum and placebo or between sertraline and placebo.  The conclusion 
was that neither hypericum nor sertraline were superior to placebo on the primary efficacy 
measures.  The authors highlighted the high level of improvement in placebo arms often seen in 
depression trials.   
 
 
Figure 6.1:  Disposition of the trial participants during the acute phase taken from 
Hypericum depression trial study group (2002).  
 
A separate publication described the results during the continuation phase using a completers’ 
analysis and LOCF.  This analysis confirmed the findings during the acute phase, namely that 
participants in all three treatment arms showed a large improvement over time, but there was no 
difference between the treatment arms (Sarris et al., 2012).   
 
Our re-analysis of the original data included an analysis of the HAM-D score only.  The 
longitudinal pattern of this variable was evaluated, taking account of missing data, rather than just 
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looking at the change from baseline to Week 8 as in the original analysis.  In addition, the data 
from Week 8 to Week 26 were analysed.  This analysis was not done in the original paper.   
 
The decision to continue a participant to the continuation phase was based on the response of the 
participant up to Week 8.  Since only responders continued with the continuation phase, the data up 
to Week 8 can be used to predict whether a participant continued beyond Week 8.  Missingness 
after Week 8 was, by design, based on observed data (HAM-D score), therefore the missing data 
were likely MAR.  However, data could also be missing for reasons not related to treatment 
response, therefore the data were not guaranteed to be MAR.  MCAR could, however be ruled out. 
 
This study created missing data by design, because participants were discontinued from the study at 
Week 8 if they did not respond.  It is therefore questionable whether the missing data from Week 8 
onwards should really be regarded as missing data.   
 
Since there was a large amount of missing data after Week 8, some estimates were unstable and the 
analysis could be questionable, since it relied on the assumptions about the missing data pattern 
more than on the actual observed data.  To mitigate this, the data were analysed from Week 0 to 
Week 8, accounting for missing data, and the data were also separately analysed from Week 0 to 
Week 26, while accounting for missing data.  This also answered the research question of treatment 
effect during the acute phase (First 8 weeks) only.   
 
As was the case with the SAPiT study in Chapter 5, the hypericum trial had three treatment arms.  
The relevant issues when more than two arms are to be compared were discussed in Section 5.3.  
This study was designed to primarily compare the hypericum and placebo arms; therefore the 
primary focus of the analysis is on that pairwise comparison.  The pairwise comparison between 
the sertraline and placebo arms was also done.  In this study the interest lay in the pairwise 
comparisons between each of the active arms and placebo, in contrast to the study in Chapter 5 
where it was not clear what the control arm was.  All three treatment arms were included in the 
covariance matrix to increase the precision of models.   
6.1.4 Statistical notation 
The statistical notation was introduced in Section 2.1 and is adapted to this data set as follows.  We 
assume N independent participants, indicated by i = 1, …,N.  The HAM-D score for the ith 
participant at the jth occasion is given by -.  Treatment is indicated by the two variables Â and Ô.  
If the ith participant is in the hypericum arm, then Â = 1, else Â = 0.  If the ith participant is in the 
sertraline arm, then Ô = 1, else Ô = 0.  tij is the week for the ith participant at the jth occasion.  
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When dropout is defined as a binary variable, dropout is indicated by .  If participant i dropped 
out, then  = 1, if participant i did not drop out then  = 0.   
 
6.2 Patterns of missing data 
The number of missing data points over time and the reasons for having missing data are provided 
in Table 6.1.  Trial discontinuation prior to Week 8 was high; 31 (27.4%) participants in the 
hypericum arm, 32 (28.8%) participants in the sertraline arm and 32 (27.6%) participants in the 
placebo arm discontinued prior to Week 8.  A large number of these discontinued because of 
insufficient response (24), although some were lost to follow-up (25) and some withdrew consent 
(23), often because they wanted to pursue other therapies since they perceived the therapy not to be 
of benefit.  There is no relationship between treatment arm and the number of participants not 
completing the acute phase of the study (Chi-square test, 2 degrees of freedom, p = 0.99).   
 
A large number of participants did not meet the protocol definition of a responder in order to be 
allowed to continue with the continuation phase.  Only a small number of participants entered the 
continuation phase; 49 (44.1%) in the sertraline arm, 38 (33.6%) in the hypericum arm and 42 
(36.2%) in the placebo arm.  Of those who entered the continuation phase, only a small number 
completed the entire study to Week 26; 28 (57.1%) in the sertraline arm, 24 (63.2%) in the 
hypericum arm and 27 (64.3%) in the placebo arm.  Table 6.2 gives the pattern of missing data.  It 
is clear that there is a large amount of missing data in this data set.   
 
A central question is whether the missing data are MCAR, MAR or MNAR.  Since only 
participants who showed a response on treatment entered the continuation phase, missing data are 
probably MAR by design from Week 8 onwards.  There was also missing data caused by reasons 
other than discontinuation due to non-response, therefore MNAR cannot be ruled out.  The large 
amount of missing data prior to Week 8 could be MAR or MNAR.  As mentioned in Section 2.2.3, 
although the data cannot exclude MNAR, it can hold some evidence of informative missingness.   
 
Figure 6.2 compares the mean HAM-D score of participants who dropped out at the next visit to 
those of participants who did not drop out at the next visit.  It seems that participants who dropped 
out are different from those who did not drop out.  Prior to Week 4 those who dropped out had 
lower HAM-D scores than those who did not drop out.  From Week 4 onwards participants who 
dropped out had higher HAM-D scores (indicative of more severe depression) than participants 
who did not drop out.  This is also true during the continuation phase.  This suggests that dropout 
depends at least on observed HAM-D score, and implies that model-based means could be different 
from observed means.  It also suggests that the observed HAM-D scores were associated with 
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dropout.  Figure 6.3 gives the same summary by treatment arm.  The pattern over time was similar 
in all three treatment arms for participants who did not drop out.     
 
Table 6.1:  Number of participants attending each visit in the hypericum trial 
 Sertraline 
N = 111 
Hypericum  
 N = 113 
Placebo 
N = 116 
Number with Hamilton 
depression scale score at 
N Number missing 
(%) 
N Number missing 
(%) 
N Number missing 
(%) 
Baseline 111 - 113 - 116 - 
Week 1 101 10 (9.0) 101 12 (10.6) 111 5 (4.3) 
Week 2 90 21 (18.9) 102 11 (9.7) 107 9 (7.8) 
Week 3 90 21 (18.9) 100 13 (11.5) 94 22 (19.0) 
Week 4 89 22 (19.8) 97 16 (14.2) 99 17 (14.7) 
Week 6 82 29 (25.1) 91 22 (19.5) 93 23 (19.8) 
Week 7 79 32 (28.8) 82 31 (27.4) 84 32 (27.6) 
Week 8 79 32 (28.8) 82 31 (27.4) 84 32 (27.6) 
Enter continuation phase 49 62 (55.9) 38 75 (66.4) 42 74 (63.8) 
Week 10 48 63 (56.8) 35 78 (69.0) 39 77 (66.4) 
Week 14 43 68 (61.3) 33 80 (70.8) 37 79 (68.1) 
Week 18 39 72 (64.9) 27 86 (76.1) 32 84 (72.4) 
Week 22 32 79 (71.2) 25 88 (77.8) 27 89 (76.7) 
Week 26 31 80 (72.1) 24 89 (78.8) 27 89 (76.7) 
Reasons not completing acute phase (Week 8)     
Loss to follow-up 10  8  7  
Insufficient response 7  6  11  
Withdrew consent 8  7  8  
Adverse event 5  2  3  
Protocol violation 2  8  3  
Reasons not enrolled into continuation phase     
Did not complete acute phase 32  31  32  
Non-responder 27  40  38  
Responder, but did not want 
to continue to continuation 
phase 
3  4  4  
Reasons not completing continuation phase (Week 26)    
Completed 28  24  27  
Insufficient response 3  2  4  
Loss to follow up 1  2  1  
Adverse event 3    2  
Withdrew consent 12  8  5  






Figure 6.2:  Sample mean of Hamilton depression scale at each week for all treatment 
arms combined.   
The triangles in red are the means for participants who did not drop out before the subsequent 
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Figure 6.3:  Sample mean of Hamilton depression scale at each week by treatment 
group.   
The solid lines are the means for participants who did not drop out before the subsequent 
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Table 6.2:  Pattern of missing data in each of the treatment arms in the hypericum 
trial 
 Week     
 Acute phase Continuation phase  Sertraline Hypericum Placebo 
Pattern 1 2 3 4 6 7 8 10 14 18 22 26 Description N = 111 N = 113 N =116 
1 X X X X X X X X X X X X Complete* 31 24 27 
2 X X X X X X X X X X X   2 1 1 
3 X X X X X X X X X X   * 6 2 4 
4 X X X X X X X X X    * 5 6 5 
5 X X X X X X X X     * 5 2 3 
6 X X X X X X X      Non-response* 27 39 37 
7 X X X X X X X      Response but 
refused 
continuation* 
3 4 4 
8 X X X X X X X      Continued to 
continuation 
phase, did not 
have data 
0 3 2 
9 X X X X X X       * 2 2 2 
10 X X X X X        * 2 7 5 
11 X X X X         * 6 5 6 
12 X X X          * 2 3 5 
13 X X           * 2 2 6 
14 X             10 2 1 
15             Baseline only 7 9 4 
16 With more than 
one interim 
missing data point 
X       1 2 4 
* A minority of participants in this pattern missed a visit, but attended all visits thereafter. 
 
As suggested by Carpenter and Kenward (2007) we used logistic regression to determine key 
independent variables associated with withdrawal in either the acute or continuation phases (Table 
6.3).  In the acute phase age (OR = 0.97) and duration of current depression (OR = 1.04) were 
associated with dropping out prior to Week 8.  Older people were less likely to drop out than 
younger people and participants with longer duration of depression were more likely to drop out.  
None of the baseline demographic variables were indicative of drop out during the continuation 
phase.  The only variable associated with dropout during the continuation phase was the HAM-D 
score at Week 8 (OR = 1.24) (Table 6.3). 
 
Since withdrawal in the acute phase was associated with baseline variables the data could not be 
assumed to be MCAR and any data analysis that made the assumption of MCAR data could be 
biased and give incorrect results.  It was not possible to rule out that the data were MNAR using the 
observed data only, since the definition of MNAR depended on unobserved observations.  We 
therefore made the assumption that the HAM-D data were either MAR or MNAR and proceeded to 
do a sensitivity analyses under these assumptions. 
 
The high withdrawal rate (about a quarter of participants did not complete the acute phase of the 
study) combined with the fact that many withdrawals were due to insufficient response suggested 
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that HAM-D score could not be analysed without taking missing data into account.  The goal of 
this analysis was to analyse the HAM-D score in a valid way, while taking missing data into 
account.   
 
Table 6.3: Variables associated with dropping out, modelling the probability of 





 Odds Ratio 
 (95% CI) 
p-value Odds Ratio  
(95% CI) 
p-value 
Variables associated with not completing the acute phase   
Treatment arm (ref placebo) 32/116 (27.6)     
- Sertraline 32/111 (28.8) 1.06 (0.60; 1.90) 0.84 1.23 (0.67; 2.25) 0.51 
- Hypericum 31/113 (27.4) 0.99 (0.56; 1.77) 0.98 1.04 (0.57; 1.90) 0.91 
Baseline HAM-D - 1.00 (0.91; 1.09) 0.94 1.02 (0.93; 1.12) 0.74 
Duration of current 
depression (years) 
- 1.04 (1.00; 1.08) 0.04 1.05 (1.01; 1.10) 0.02 
Age - 0.97 (0.95; 0.99) 0.002 0.97 (0.95; 0.99) 0.001 
Gender (ref female) 66/224 (29.5)     
- Male 29/116 (25.0) 0.80 (0.48; 1.33) 0.38 1.27 (0.75; 2.16) 0.37 
Race (ref = white) 71/257 (27.6)     
- Hispanic 12/27 (44.4) 2.10 (0.94; 4.70) 0.07 1.79 (0.76; 4.20) 0.18 
- Black 9/35 (25.7) 0.91 (0.41; 2.03) 0.81 0.87 (0.38; 2.00) 0.75 
- Other 3/21 (14.3) 0.44 (0.13; 1.53) 0.19 0.36 (0.10; 1.29) 0.12 
      
Variables associated with not completing the continuation phase given the acute phase was completed 
Treatment arm (ref placebo) 57/84 (67.9)     
- Sertraline 48/79 (60.8) 0.73 (0.39; 1.40) 0.34 0.74 (0.34; 1.61) 0.47 
- Hypericum 58/82 (70.7) 1.15 (0.59; 2.22) 0.69 0.97 (0.44; 2.16) 0.66 
Baseline HAM-D - 1.05 (0.95; 1.17) 0.36 0.90 (0.78; 1.04) 0.34 
Duration of current 
depression (years) 
-   1.02 (0.94; 1.11) 0.33 
Age - 0.99 (0.97; 1.01) 0.46 0.99 (0.96; 1.01) 0.44 
Gender (ref female) 104/158 (65.8)     
- Male 59/87 (67.8) 1.09 (0.63; 1.91) 0.75 1.29 (0.65; 2.55) 0.83 
Race (ref = white) 127/186 (68.3)     
- Hispanic 11/15 (73.3) 1.28 (0.39; 4.18) 0.69 3.15 (0.79; 12.5) 0.73 
- Black 15/26 (57.7) 0.63 (0.27; 1.46) 0.29 0.75 (0.28; 2.04) 0.27 
- Other 10/18 (55.6) 0.58 (0.22; 1.55) 0.28 0.52 (0.19; 1.43) 0.21 
Week 8 HAM-D - 1.24 (1.16; 1.32) <0.001 1.27 (1.19; 1.36) <0.001 
HAM-D: Hamilton depression scale 
 
The primary analysis during the drug development process is usually the traditional ITT analysis, 
and is the estimand we were interested in.  This corresponds to what the National Research Council 
(2010) called Estimand 1.  This estimand gives the difference in outcome at the planned endpoint 
of the trial for all participants.  This is not the most relevant estimand when one wants to determine 
the efficacy of a new drug.  The de jure estimand is more relevant if one is interested in the efficacy 
of the drug, versus the effectiveness of the treatment policy.  In ideal conditions one would like to 
determine Estimand 3, however in a trial like this with high drop out and possible non-adherence to 
the protocol this may not be possible.  Estimand 6, defined by Mallinckrodt et al. (2012), which 
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gives the difference in outcome in all randomised participants attributable to the randomised 
medication, is also a viable secondary objective of the trial. 
 
SAS code was given in the corresponding sections of Chapter 5 and was not repeated in this 
chapter. 
6.3 Analysis of HAM-D score in the hypericum study under 
MCAR assumptions  
Although MCAR assumptions were not valid, we analysed the data using an available case analysis 
and complete case analysis (discussed in Section 3.1) under MCAR assumptions.  This is done 
solely to contrast the naïve and incorrect analysis to the more appropriate analyses done under the 
MAR and MNAR assumptions. 
6.3.1 Available case analysis 
In the available case analysis missing data were ignored and observed data were summarised at 
each of the visits using all observed HAM-D scale total scores (Table 6.4 and Figure 6.4).  We 
performed a cross-sectional analysis of the data observed or “available” at each time point.  A 
model that takes the longitudinal nature of the data into account was also fitted and is given in 
Section 6.4.1.  The cross-sectional analysis is provided to give additional information, but we do 
not imply that the cross-sectional analysis is equivalent to the longitudinal analysis done later.  The 
summaries at all time points of the available data also provide a description of the observed data, 
without including any modelling assumptions.   
 
Mean HAM-D scores decreased over time.  The mean HAM-D scores did not differ between the 
treatment arms for most of the weeks.  The exceptions were Weeks 2 and 7 where a statistically 
significant difference between the treatment arms existed.  Bonferroni pairwise comparisons 
showed that the sertraline arm had lower mean scores than the other two arms at these visits.   
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Table 6.4: Available case analysis of Hamilton depression scale 
 Sertraline Hypericum Placebo ANOVA p-value 
Baseline    0.25 
N 111 113 116  
Mean 22.5 23.1 22.7 
SD 2.5 2.7 2.7 
Standard error 0.24 0.26 0.25 
Median 22 23 22 
Week 1    0.33 
N 101 101 111  
Mean 19.5 20.1 18.9 
SD 5.1 5.2 4.9 
Standard error 0.51 0.51 0.46 
Median 20 20 19 
Week 2    0.05
a 
N 90 102 107  
Mean 16.5 18.6 17.7 
SD 5.5 5.7 5.7 
Standard error 0.58 0.57 0.55 
Median 17 18.5 18.0 
Week 3    0.08 
N 90 100 94  
Mean 15.5 17.9 17.1 
SD 6.3 6.4 6.5 
Standard error 0.67 0.64 0.67 
Median 16.5 19 18 
Week 4    0.16 
N 89 97 99  
Mean 14.3 16.9 15.9 
SD 6.1 7.1 6.5 
Standard error 0.65 0.72 0.65 
Median 14 18 16 
Week 6    0.07 
N 82 91 93  
Mean 12.8 15.6 14.9 
SD 6.6 7.1 7.0 
Standard error 0.72 0.75 0.73 
Median 13 17 15 
Week 7    0.01
a 
N 79 82 84  
Mean 11.4 14.3 12.3 
SD 6.5 6.5 7.1 
Standard error 0.73 0.72 0.77 
Median 11 14 11  
Week 8    0.22 
N 79 82 84  
Mean 10.6 12.9 12.0  
SD 5.9 7.1 7.5  
Standard error 0.66 0.79 0.82  
Median 10 12 10  
Week 10    0.21 
N 48 35 39  
Mean 8.1 9.5 7.3  
SD 4.6 5.0 4.8  
Standard error 0.66 0.85 0.77  
Median 7 9 7  
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Table 6.4: Available case analysis of Hamilton depression scale 
 Sertraline Hypericum Placebo ANOVA p-value 
Week 14    0.09 
N 43 33 37  
Mean 7.6 9.8 7.8  
SD 5.0 5.0 5.0  
Standard error 0.77 0.86 0.82  
Median 6 8 7  
Week 18    0.21 
N 39 27 32  
Mean 6.7 8.7 5.7  
SD 4.7 6.5 4.0  
Standard error 0.76 1.24 0.71  
Median 6 7 6.5  
Week 22    0.34 
N 32 25 27  
Mean 7.1 8.2 7.0  
SD 6.1 4.6 6.0  
Standard error 1.07 0.91 1.15  
Median 5 7 5  
Week 26    0.36 
N 31 24 27  
Mean 7.1 6.6 5.7  
SD 5.4 4.5 5.4  
Standard error 0.97 0.93 1.04  
Median 6 5.5 4  
a:  Bonferroni pairwise comparison:  Sertraline arm significantly different from hypericum arm 
ANOVA:  Analysis of variance 
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6.3.2 Complete case analysis 
In the complete case analysis only participants with no missing data are included and observed 
HAM-D scores are summarised at all the visits for these participants. In other words, list wise 
deletion is done.  Two separate analyses are done, one including participants who have complete 
data up to Week 8 and one including participants who have complete data up to Week 26 (Table 
6.5, Figure 6.5 and Figure 6.6).  The latter analysis includes only a fraction (19.1%) of the enrolled 
participants and is biased, since it includes only participants deemed responders at Week 8. 
 
The graphical representation of the complete case analysis differs from the available case analysis.  
As with the available case analysis, we perform a cross-sectional analysis to provide additional 
information.  This cross-sectional analysis can be compared to the cross-sectional analysis done in 
an available case manner.  The intention is not to imply that the cross-sectional analysis fits the 
same model as the longitudinal analysis also provided.  In the cross-sectional analysis of complete 
data up to Week 8, the treatment arms are only significantly different at baseline.  This is in part 
due to the small number of participants included in this analysis and highlights the effect of 
analysing only a small, biased subset of the data.  Only one, at 8 weeks, of the p-values comparing 
the means at each time point for the participants with complete data up to Week 26 is significant.  
In addition to being biased, the complete case analysis is inefficient because it does not utilise all 
available information. 
 
Table 6.5:  Complete case analysis of Hamilton depression scale  
 Complete data up to Week 26 Complete data up to Week 8 
 Sertraline 
N = 23 
Hypericum 
N = 22 
Placebo 
N = 20  
p-value$ Sertraline 
N = 67 
Hypericum 
N = 79 
Placebo 
N = 68 
p-value$ 
Baseline    0.54    0.05* 
Mean 22.2 22.9 22.9  22.1 23.2 22.9  
SD 2.4 2.0 2.5 2.1 2.8 2.8 
Standard error 0.50 0.42 0.56 0.26 0.31 0.34 
Median 22 23 22.5 21 23 22 
Week 1    0.20    0.83 
Mean 20.0 18.3 17.9  19.7 19.9 19.4  
SD 4.2 4.6 3.4 4.8 5.3 4.4  
Standard error 0.87 0.97 0.76 0.58 0.59 0.53  
Median 20 18 17 20 20 20  
Week 2    0.84    0.06 
Mean 16.6 16.2 15.7  16.4 18.5 18.0  
SD 4.9 5.2 5.1 5.0 5.9 5.0  
Standard error 1.00 1.11 1.14 0.61 0.67 0.61  
Median 17 16 16 17 18 18.5  
Week 3    0.91    0.12 
Mean 15.0 14.7 14.2  15.4 17.4 17.2  
SD 5.5 6.4 6.7 5.6 6.4 6.5 
Standard error 1.16 1.37 1.50 0.69 0.72 0.78 
Median 15 15 15 17 18 18 
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Table 6.5:  Complete case analysis of Hamilton depression scale  
 Complete data up to Week 26 Complete data up to Week 8 
 Sertraline 
N = 23 
Hypericum 
N = 22 
Placebo 
N = 20  
p-value$ Sertraline 
N = 67 
Hypericum 
N = 79 
Placebo 
N = 68 
p-value$ 
Week 4    0.22    0.09 
Mean 14.6 12.3 12.2  14.1 16.5 15.1  
SD 4.7 5.9 5.0 5.9 7.0 6.4  
Standard error 0.98 1.26 1.11 0.72 0.79 0.78  
Median 14 11.5 11 14 18 15  
Week 6    0.45    0.12 
Mean 12.4 11.5 10.2  13.2 15.4 14.8  
SD 5.6 6.4 5.3 5.6 7.0 6.6  
Standard error 1.17 1.35 1.19 0.69 0.79 0.80  
Median 12 12 9.5 13 17 15  
Week 7    0.19    0.13 
Mean 10.7 10.0 8.2  11.9 14.1 12.8  
SD 5.6 4.0 3.6 6.0 6.5 7.1  
Standard error 1.17 0.85 0.82 0.73 0.73 0.86  
Median 10 10 8  11 14 11  
Week 8    0.04    0.27 
Mean 8.6 7.0 6.2  11.1 12.7 12.7  
SD 2.5 3.6 3.2  5.2 7.2 7.6  
Standard error 0.52 0.77 0.72  0.64 0.81 0.92  
Median 9 7.5 6.5  10 12 11.5  
Week 10    0.35    0.35 
N     42 35 30  
Mean 8.4 9.9 7.9  8.2 9.5 7.9  
SD 4.0 4.6 5.1  4.6 5.0 4.8  
Standard error 0.83 0.98 1.14  0.71 0.85 0.87  
Median 8 9.5 7.5  7 9 8  
Week 14    0.77    0.07 
N     38 33 30  
Mean 7.4 8.1 8.2  7.2 9.8 8.1  
SD 4.4 3.6 3.8  4.4 5.0 4.8  
Standard error 0.92 0.77 0.85  0.71 0.86 0.88  
Median 7 8 9  7 8 7.5  
Week 18    0.53    0.12 
N     35 27 26  
Mean 7.9 8.2 6.5  7.0 8.7 5.7  
SD 5.1 6.5 3.6  4.9 6.5 4.0  
Standard error 1.07 1.39 0.81  0.82 1.24 0.79  
Median 7 5 7  6 7 6.5  
Week 22    0.95    0.87 
N     28 25 25  
Mean 8.7 8.2 8.6  7.9 8.2 7.4  
SD 5.7 4.3 6.1  6.0 4.6 6.0  
Standard error 1.20 0.91 1.36  1.13 0.91 1.20  
Median 8 7 7.5  7 7 6  
Week 26    0.37    0.43 
N     27 24 24  
Mean 8.7 6.9 6.7  7.8 6.6 5.9  
SD 5.2 4.5 5.6  5.5 4.5 5.5  
Standard error 1.08 0.96 1.26  1.05 0.93 1.12  
Median 8 5.5 5  7 5.5 4  
*  Bonferroni pairwise comparison:  Sertraline arm significantly different from hypericum arm 





Figure 6.5:  Sample mean of Hamilton depression scale, complete case analysis for 
participants who have complete data up to Week 8 
 
Figure 6.6:  Sample mean of Hamilton depression scale, complete case analysis for 








































































Figure 6.7:  Studentised residuals for the model fitted using SAS procedure MIXED 
for the complete case analysis for participant with complete data up to Week 8 
 
The studentised residuals follows a normal distribution in the complete case analysis for 
participants who had complete data up to Week 8 (Figure 6.7) and up to Week 26 (Figure 6.8).    
 
Table 6.6:  Complete case analysis using SAS procedure MIXED 
 Complete data up to Week 8 Complete data up to Week 26 
Effect Estimate Standard 
error 
p-value Estimate Standard 
error 
p-value 
Intercept 22.90 0.33  22.98 0.60  
Week -1.07 0.11 <0.001 -1.99 0.08 <0.001 
Week squared    0.05 0.01 <0.001 
Sertraline (ref: placebo) -0.32 0.42 0.45 -2.10 0.75 <0.001 
Hypericum (ref: placebo) 0.33 0.47 0.48 -0.20 0.75 0.79 
Interaction week and treatment 
(sertraline compared to placebo)  
-0.26 0.13 0.05 0.11 0.06 0.07 
Interaction week and treatment 
(hypericum compared to placebo) 
-0.11 0.15 0.44 0.08 0.06 0.24 
 
The model for the complete cases was fitted by REML using procedure MIXED in SAS and 
assuming an unstructured covariance matrix while using the Kenward-Roger method for the 
degrees of freedom  (Kenward & Roger, 1997).  A different covariance matrix was estimated for 





Figure 6.8:  Studentised residuals for the model fitted using SAS procedure MIXED 
for the complete case analysis Hamilton depression scale for participants with 
complete data up to Week 26 
 
We conclude that the decrease in mean HAM-D score over time was significantly different in the 
sertraline arm compared to the placebo arm for both the analysis up to Week 8 and Week 26 (where 
the p-value was small, but not <0.05).  The interaction between week and the hypericum arm 
compared to the placebo arm was not significant for either data set (Table 6.6).   
6.3.3 Conclusions under MCAR assumptions 
The MCAR analysis was done for completeness, but since we have evidence that data were not 
MCAR, the MCAR analysis was not valid.  Fitting a mixed model for repeated measures in the 
complete case analysis we conclude that there is a significant interaction between week and 
sertraline arm compared to the placebo arm. 
 
These analyses do not lead to the estimand of interest, namely the effect of treatment assignment at 
the end of the study period according to the ITT principle (Estimand 1).  Using these methods, it 
would also not be possible to estimate Estimands 3 or 6, because analysing all available data or 




6.4 Analysis under MAR assumptions 
MAR assumptions were discussed in Section 2.2.2.  Under MAR assumption, we analysed the data 
using direct likelihood-based approaches (discussed in Section 3.5), multiple imputation (discussed 
in Section 3.3), direct Bayesian approaches (discussed in Section 3.7) and inverse probability 
weighting (discussed in Section 3.5). 
  
A model with a linear term for week fitted the data well up to Week 8 and all models up to Week 8 
were fitted using the following linear model: 
Model up to Week 8: - = >? + >S + >9H + > t + (βS + βH) t +  ε1 
The statistical notation is given in Section 6.1.4.  The profiles from Week 1 to Week 26 did not 
follow a linear trend over time and for this data we fitted a model including a quadratic term for 
week.   
Model up to Week 26: - = >? + >S + >9H + > t + (βS + βH) t + >Q9 + ε1 
In Figure 6.4, one can see that the first part of the observed profiles follow a linear trend in time, 
but from Week 8 onwards, the profiles follow a quadratic trend in time. 
6.4.1 Direct likelihood-based approaches 
As mentioned in Section 5.4.1 direct likelihood-based approaches are valid under the MAR 
assumption and the separability condition.  In this analysis there is no interest in the missing data 
mechanism.  Procedure MIXED in SAS was used.  The Kenward-Roger correction was applied 
when calculating degrees of freedom (Kenward & Roger, 1997).   
 
The choice of covariance structure is very important.  An unstructured covariance matrix is the 
most flexible choice, since each variance-covariance component is estimated from the data, 
therefore making no assumptions that are not supported by the observed data.  This covariance 
matrix has more parameters that need to be estimated than other structures, and is therefore less 
efficient.  We have used the unstructured covariance matrix in this analysis, assuming a different 





Figure 6.9:  Studentised residuals for the model fitted using procedure MIXED in 
SAS for the direct likelihood-based analysis using the HAM-D scores up to Week 8 
 
 
Figure 6.10:  Mean Hamilton depression scale total scores, direct likelihood-based 























Figure 6.11:  Mean Hamilton depression scale total scores, direct likelihood-based 
approach (mixed model) analysis up to 8 weeks 
 
The studentised residuals when the direct likelihood model is fitted followed a normal distribution, 
(Figure 6.9).  The model fitted up to Week 26 is displayed in Figure 6.10 and the model up to 
Week 8 in Figure 6.11. 
 
Table 6.7:  Hamilton depression scale.  Direct likelihood-based parameter estimates 
and standard errors when using procedure MIXED in SAS 
 Data up to Week 26 Data up to Week 8 
Effect Estimate Standard error p-value Estimate Standard error p-value 
Intercept 22.68 0.25  22.64 0.25  
Sertraline (ref: placebo) 0.002 0.34 0.99 0.08 0.34 0.82 
Hypericum (ref: placebo) 0.41 0.38 0.28 0.50 0.36 0.17 
Week -1.46 0.06 <0.001 -1.17 0.10 <0.001 
Week squared 0.04 0.002 <0.001    
Interaction week and treatment 
(sertraline compared to placebo)  
-0.10 0.05 0.07 -0.24 0.12 0.05 
Interaction week and treatment 
(hypericum compared to placebo) 
-0.04 0.06 0.48 0.03 0.13 0.79 
 
For both the analysis using data up to week 8 and using data up to Week 26, the mean decrease 
over time was larger in the sertraline arm than in the placebo arm.  However, for the hypericum 




6.4.2 Multiple imputation 
The SAS procedure MI was used to generate 100 different imputed data sets and procedure 
MIANALYZE was used to combine the results of the 100 analyses on these data sets.  In the 
imputer’s model the HAM-D score at each of the weekly visits was imputed and baseline HAM-D 
score, age, gender, race, BDI, duration of depression, GAF, CGI-S and CGI-I scales were included 
as covariates in this model.  These variables were included because it was thought that they could 
be related to severity of depression over time or to the probability of missingness.  Separate 
imputations were done for each of the three treatment arms.  All variables that were to be included 
in the analyst’s model were included in the imputer’s model, therefore the imputer’s model and the 
analyst’s model were congenial. Since the missing data pattern in the HAM-D scores was not 
monotone, the MCMC imputation method was used on the full data set.  The implementation of 























































0 2000 4000 6000 8000 10000 12000
Wee  
   
   
Week 1 Week 2 













































































































0 2000 4000 6000 8000 10000 12000
   
   
   
   
      
      
Week 6 Week 7 
Week 8 Week 10 
Week 14 Week 18 





















0 2 4 6 8 10 12 14 16 18 20










0 2 4 6 8 10 12 14 16 18 20










0 2 4 6 8 10 12 14 16 18 20










0 2 4 6 8 10 12 14 16 18 20










0 2 4 6 8 10 12 14 16 18 20










0 2 4 6 8 10 12 14 16 18 20










0 2 4 6 8 10 12 14 16 18 20










0 2 4 6 8 10 12 14 16 18 20
      
      
      













Figure 6.13:  Autocorrelation plot with 95% confidence interval for the mean 
Hamilton depression scale, sertraline arm 
 
The trace plots and autocorrelation plots are used to check convergence for the single chain.  The 
trace plots and autocorrelation plots were similar in all three treatment arms, and only the plots for 
the sertraline arm are given in Figure 6.12 and Figure 6.13.  Iterations during the burn-in period are 
indicated with negative iteration numbers.  There is no pattern in the trace plots from Weeks 1 to 8.  
However from Week 10 onwards a pattern is present.  The autocorrelation plots show large positive 
autocorrelations from Week 10 onwards.  The models do not seem to reach a stationary distribution 
and autocorrelation exist between the imputations.  This means that the results from Week 10 
onwards should be regarded with some suspicion.  This is likely due to the fact that more data are 
imputed than present.  This example illustrates the inadequacy of multiple imputation when a 
substantial amount of data are incomplete.   
 
Table 6.8 indicates that the major source of variance from Week 1 to Week 8 was the within 
imputation variance.  The between imputation variance added more to the overall variance at the 
later weeks, where more data were missing than at the earlier weeks.   From Week 10 onwards the 
contribution of the between imputation variation to the total variance is as large or larger as that of 
the within imputation variance.  In the case of the hypericum arm and to a lesser extent the placebo 
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arm, the contribution of the between imputation variance is much higher than the contribution of 
the within imputation variance at the later weeks.  
 
Table 6.8: Multiple imputation variance information  
 Sertraline Hypericum Placebo 
Week Between Within Total df Between Within Total df BetweenWithin Total df 
1 0.036 0.252 0.288 93.1 0.020 0.233 0.252 100.9 0.008 0.204 0.2119 108.7 
2 0.060 0.293 0.353 87.2 0.023 0.289 0.312 101.3 0.011 0.275 0.286 108.6 
3 0.070 0.375 0.446 88.7 0.038 0.379 0.418 99.1 0.045 0.377 0.422 99.7 
4 0.084 0.377 0.462 85.7 0.042 0.446 0.488 99.8 0.029 0.376 0.406 104.4 
6 0.119 0.420 0.540 80.7 0.077 0.469 0.547 92.6 0.080 0.446 0.526 93.6 
7 0.133 0.468 0.602 80.6 0.077 0.412 0.490 90.5 0.094 0.446 0.542 90.5 
8 0.132 0.444 0.577 79.6 0.114 0.487 0.603 86.2 0.134 0.511 0.647 85.9 
10 0.369 0.274 0.647 39.7 1.460 0.519 1.993 24.7 1.873 0.576 2.468 22.8 
14 0.860 0.425 1.294 30.6 2.711 0.442 3.181 13.7 2.032 0.624 2.677 22.8 
18 0.646 0.391 1.044 34.9 8.100 1.400 9.582 14.4 3.118 0.291 3.440 8.8 
22 1.088 1.126 2.226 48.2 11.395 3.130 14.639 20.5 8.973 0.667 9.730 7.3 
26 1.282 0.541 1.835 27.4 10.308 3.277 13.688 22.8 5.056 0.862 5.969 14.6 
df = degrees of freedom 
 
Table 6.9: Relative increase in variance and fraction missing information in 
procedure MI 



















1 0.143240 0.125570 0.084527 0.078052 0.038938 0.037506 
2 0.206724 0.171801 0.080002 0.074178 0.039641 0.038158 
3 0.189869 0.160004 0.101472 0.092280 0.120578 0.107812 
4 0.224152 0.183661 0.094138 0.086176 0.077247 0.071804 
6 0.285394 0.222802 0.166407 0.143019 0.181048 0.153696 
7 0.286370 0.223396 0.188143 0.158776 0.213627 0.176539 
8 0.299118 0.231070 0.236749 0.192026 0.265517 0.210511 
10 1.360650 0.579203 2.843796 0.742670 3.283540 0.769271 
14 2.044079 0.674446 6.190996 0.862974 3.287605 0.769491 
18 1.669447 0.628316 5.842185 0.855954 10.836795 0.916913 
22 0.975947 0.496389 3.676539 0.788787 13.591876 0.932639 
26 2.393768 0.708260 3.177220 0.763356 5.925076 0.857686 
 
The relative increase in variance showed that the uncertainty caused by the missing data increased 
the variance more at later visits (Table 6.9).  Week 26 was an exception, and the relative increase in 
variance was smaller than at preceding visits.  In the sertraline arm the relative increase in variance 
reached a high of 2.4 at Week 26, in the hypericum arm it reached a high of 6.2 at Week 14 and in 
the placebo arm the ratio reached a high of 13.6 at Week 22.  The fraction of missing information 
was above 0.5 at all but one visit post Week 10.  The fraction of missing information in the placebo 




Even though our interest lies in fitting a longitudinal model, we also provide the cross-sectional 
summaries of mean HAM-D scores at each visit (Table 6.10).   
 
Table 6.10: Cross sectional summaries of multiple imputation of Hamilton depression 
scale; mean (standard error) 
 Sertraline Hypericum Placebo p-value 
Week 1 19.6 (0.53) 20.1 (0.50) 18.9 (0.46) 0.31 
Week 2 16.6 (0.59) 18.4 (0.56) 17.7 (0.53) 0.18 
Week 3 15.3 (0.65) 17.5 (0.64) 17.3 (0.65) 0.03 
Week 4 14.3 (0.67) 16.7 (0.70) 15.8 (0.63) 0.14 
Week 6 13.3 (0.72) 15.8 (0.73) 14.9 (0.72) 0.13  
Week 7 11.9 (0.71) 14.5 (0.69) 12.8 (0.73) 0.37 
Week 8 11.0 (0.68) 13.1 (0.75) 12.7 (0.79) 0.12 
Week 10 9.5 (0.78) 13.7 (1.35) 13.0 (1.54) 0.05 
Week 14 7.9 (0.98) 11.1 (1.61) 12.9 (1.57) 0.01 
Week 18 8.1 (0.98) 14.1 (2.29) 7.2 (1.72) 0.65 
Week 22 11.0 (1.27) 10.4 (2.31) 9.8 (2.73) 0.69 
Week 26 9.5 (1.21) 15.9 (2.20) 12.0 (2.28) 0.35 
 
Comparing the means and standard errors of the imputed HAM-D scores (Table 6.10) and the 
results from the available case analysis (Table 6.4) shows that the standard errors and means were 
higher with multiple imputation, especially after Week 10.  The means in the sertraline arm were 
lower than the means in the other two treatment arms at all time points from Week 2 to Week 14.  
P-values at Weeks 3, 10 and 14 were significant.  The multiple imputation chain did not seem to 
converge from Week 10 onwards and the results from Week 10 onwards should be interpreted with 
care.  If future missing measurements could not be predicted from the past observed data combined 
with the covariates, it was unlikely that the multiple imputations are correct.   
 
According to the study design participants who did not respond to treatment by Week 8 were 
discontinued from the study.  Therefore all data in Figure 6.14 to Figure 6.16 from Week 10 
onwards are imputed.  In the placebo arm data after Week 8 seem to have much less variation than 
data before Week 8.  Values seem to decline from Week 8 to Week 22, but increase again at Week 
26.  At Week 22, all values are relatively similar (Figure 6.14).  In the sertraline arm HAM-D 
scores seem to decrease from Week 8 to Week 14 and increase again to Weeks 22 and 26.  HAM-D 
scores at Week 26 were similar to HAM-D scores at Week 8 (Figure 6.15).  In the hypericum arm 
there was no specific pattern in the imputed data (Figure 6.16).  The pattern of imputed values was 





Figure 6.14:  Imputed Hamilton depression scale total scores in the placebo arm for 
participants who completed the acute phase of treatment (up to Week 8) and did not 
continue to the continuation phase due to protocol defined non-response at Week 8.   
The vertical black line at 8 weeks indicates the cut-off between observed and imputed data.  Each 







Figure 6.15:  Imputed Hamilton depression scale total score in the sertraline arm for 
participants who completed the acute phase of treatment (up to Week 8) and did not 
continue to the continuation phase due to protocol defined non-response at Week 8.   
The vertical black line at 8 weeks indicates the cut-off between observed and imputed data.  Each 







Figure 6.16:  Imputed Hamilton depression scale total score in the hypericum arm for 
participants who completed the acute phase of treatment (up to Week 8) and did not 
continue to the continuation phase due to protocol defined non-response at Week 8.   
The vertical black line at 8 weeks indicates the cut-off between observed and imputed data. Each 






All the participants included in Figure 6.14 to Figure 6.16 were terminated from the study at 
Week 8 because of lack of response.  One therefore expects that the HAM-D scores would worsen 
or stay the same from Week 10 onwards, and not that it would improve.  However, in the placebo 
and sertraline arms an improvement is seen in these imputed values. 
 
 
Figure 6.17:  Imputed Hamilton depression scale total score in all arms for 
participants who completed the acute phase of treatment (up to Week 8) and did not 
continue to the continuation phase.  The participants were responding at Week 8, but 
chose not to continue with the study.   
The vertical black line at 8 weeks indicates the cut-off between observed and imputed data. 
 
In contrast Figure 6.17 includes participants who responded at Week 8, but did not for some other 
reason continue into the continuation phase.  One would expect these participants to have 
continued good responses in the imputed data.  However, some of the imputed data showed a slight 
worsening of the depression scores or maintenance of the current score rather than continued 
improvement.   
 
In Table 6.10 multiple imputation was used to calculate the mean and standard deviation at each of 
the visits.  Multiple imputation can also be used to fit a longitudinal model to the data instead of 
summarising the data at each of the visits.  Table 6.11 gives the results when a mixed model is 
fitted using the data sets created using multiple imputation.  This can be contrasted to the mixed 
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model fitted in Table 6.7 without using multiple imputation.  Both methods are valid under MAR 
assumptions and give similar results.   
 
Table 6.11:  Hamilton depression scale.  Likelihood-based parameter estimates and 
standard errors when using procedure MIXED in SAS after multiple imputation  
 Data up to Week 8 Data up to Week 26 
Effect Estimate Standard 
error 
p-value Estimate Standard 
error 
p-value 
Intercept 22.70 0.25  22.55 0.31  
Sertraline (ref: placebo) 0.09 0.35 0.79 -0.26 0.42 0.54 
Hypericum (ref: placebo) 0.42 0.35 0.23 0.42 0.42 0.33 
Week -1.15 0.09 <0.001 -1.50 0.08 <0.001 
Week squared    0.05 0.003 <0.001 
Interaction week and treatment 
(sertraline compared to placebo)  
-0.23 0.13 0.08 -0.04 0.08 0.59 
Interaction week and treatment 
(hypericum compared to placebo) 
0.01 0.13 0.95 0.10 0.09 0.24 
 
One expects the estimates obtained from likelihood-based methods and multiple imputation to be 
similar; especially if the imputer’s model was the same as the analyst’s model.  In this case the 
imputer’s model included several covariates, deemed to possibly be associated with HAM-D score, 
which were not included in the analyst’s model or in the likelihood-based model.  Differences 
between these results and the results from the likelihood-based method (Table 6.7) were in part due 
to the inclusion of covariates in the multiple imputation.  Considering the data up to Week 8, we 
draw similar conclusions; namely that the interaction between week and sertraline compared to 
placebo had a small p-value (0.05 and 0.08, respectively) and that the interaction between week and 
hypericum compared to placebo was not significant.  The estimated effects were also similar 
between the two models.  We concluded that over the first 8 weeks, the improvement in the 
sertraline arm is significantly better than the improvement in the placebo arm.  The same cannot be 
said of hypericum.   
Figure 6.18 gives the models fitted for all three treatment arms.   
 
If we consider the data up to Week 26, there was no significant week by treatment interaction when 
multiple imputation was employed (Table 6.11).  When the likelihood-based analysis was done, the 
estimates were different, and the p-value for the week by sertraline treatment arm compared to 
placebo arm was small (0.07).  The multiple imputation results might not be reliable beyond Week 
10, where more data were imputed than observed and autocorrelation was present.  The results over 







Figure 6.18:  Hamilton depression scale.  Mixed model fitted after multiple 
imputations (Table 6.11) 
6.4.3 Bayesian analysis under MAR 
A Bayesian model was fitted to the data of all participants, those with and without missing data; 
Probability distributions were estimated for the missing values and then simulations were drawn 
from the posterior distribution.  One advantage of using Bayesian methods with missing data is that 
no change is needed to the model specified, i.e. the same model that would be appropriate if there 
weres no missing data can be specified.   
 
We fitted a longitudinal model with a different unstructured covariance matrix in each of the 
treatment arms as follows:  |ë =  ~ Multivariate Normal(ev ,
v) 
where ë =  indicates that the observation belongs to treatment arm k à =  >? +  >S + >9Â + >Q + (>Ô +  >Â)Q 
for the model fitted up to Week 8.   The variables are as defined in Section 6.4.  The model fitted to 















Uninformative priors were chosen for the unknown parameters of the model of interest.  Different 
sets of prior distributions were assigned.  In Set 1, the β parameters (>?, >, >9, >, >, >) and (>?, >, >9, >, >, >, >), respectively are assigned Normal(0; 10,000) priors and the inverse of Ω 
was assigned a Wishart(I,5) prior, where I is the identity matrix.  Prior Set 2 assigned all the β 
parameters a Normal(0, 1000) prior and the inverse of Ω was assigned a Wishart(A,5) prior, where 
A is a diagonal matrix with 0.1 on the diagonal.  Prior Set 3 assigned all the β parameters a 
Normal(0, 10) prior and the inverse of Ω a Wishart(A,5) prior, where A is a diagonal matrix with 
10 on the diagonal. 
 
All models were fitted using OpenBugs, which uses MCMC methods and run for 40000 iterations, 
including 20000 burn-in iterations.  Two chains with different starting values were used and 
convergence was checked by a visual inspection of the trace plots.  All the runs discussed 
converged.  
 
The choice of vague prior did not change the results appreciably in the MAR analysis (Table 6.12).  
The results were almost identical with prior sets 1 and 2.  Of course, many more choices of priors 
are possible.  Using the data up to Week 8, the interaction between week and sertraline arm 
compared to placebo arm was significant.  The interaction between week and the hypericum arm 
compared to the placebo arm was not significant.  The conclusions drawn were the same as with 
the likelihood-based analysis; although the absolute value of the estimate for the interaction 
between week and sertraline arm compared to the placebo arm was larger under the Bayesian 
model.   
 
Using all the data up to Week 26, also leads to the conclusion that the decrease in HAM-D score in 
the sertraline arm compared to the placebo arm was significant, but the decrease over time in the 
hypericum arm compared to the placebo arm was not significant.  This was the same conclusion as 
under the likelihood-based analysis.   
 
Differences between the likelihood-based analysis and the Bayesian analysis can be attributed to 
the addition of prior distributions.  Adding prior distributions added additional assumptions to this 
model, over and above the assumptions made by the substantive model.  By choosing non-
informative priors, we hope that the results are not sensitive to the choice of the prior.  This was 




Table 6.12: Hamilton depression score posterior means, standard deviations and 
credible intervals according to Bayesian analysis under MAR assumptions  
 Prior set 1 
β ~ Normal(0, 10 000) 
Ω~Wishart(I,5) 
I: Identity matrix 
Prior set 2  
β ~ Normal(0, 1000) 
Ω~Wishart(A,5) 
A: diag (0.1, 0.1, 0.1, 0.1, 0.1) 
Prior set 3  
β s ~ Normal(0, 10) 
Ω~Wishart(A,5) 
A: diag (10, 10, 10, 10, 10) 
Effect Mean SD 95% 
credible 
interval 
Mean SD 95% 
credible 
interval 
Mean SD 95% 
credible 
interval 
Data up to Week 8        
Intercept 22.53 0.27  22.53 0.27  22.36 0.27  
Sertraline (ref: 
placebo) 
0.04 0.37 -0.69; 0.77 0.04 0.37 -0.69; 0.77 0.20 0.37 -0.53; 0.93 
Hypericum (ref: 
placebo) 
0.62 0.38 -0.14; 1.37 0.62 0.38 -0.14; 1.37 0.77 0.38 0.03; 1.52 
Week -1.59 0.16 -1.92; -1.28 -1.59 0.16 -1.92; -1.28 -1.59 0.16 -1.91; -1.27 
Interaction week and 
treatment (sertraline 
compared to placebo)  
-0.54 0.22 -0.96; -0.11 -0.54 0.22 -0.96; -0.11 -0.54 0.22 -0.97; -0.11 
Interaction week and 
treatment (hypericum 
compared to placebo) 
-0.02 0.24 -0.49; 0.44 -0.02 0.24 -0.49; 0.44 -0.03 0.24 -0.49; 0.43 
Data up to Week 26        
Intercept 22.45 0.26  22.45 0.26  22.32 0.26  
Sertraline (ref: 
placebo) 
0.16 0.34 -0.53; 0.83 0.16 0.34 -0.53; 0.83 0.29 0.34 -0.39; 0.97 
Hypericum (ref: 
placebo) 
0.67 0.36 -0.03; 1.38 0.67 0.36 -0.03; 1.38 0.80 0.36 0.10; 1.51 
Week -3.15 0.26 -3.66; -2.63 -3.15 0.26 -3.66; -2.63 -3.13 0.27 -3.65; -2.62
Week squared 0.39 0.05 0.28; 0.49 0.39 0.05 0.28; 0.49 0.39 0.05 0.28; 0.49 
Interaction week and 
treatment (sertraline 
compared to placebo)  
-0.50 0.20 -0.90;-0.11 -0.50 0.20 -0.90;-0.11 -0.51 0.20 -0.90; -0.11
Interaction week and 
treatment (hypericum 
compared to placebo) 
0.06 0.22 -0.37; 0.49 0.06 0.22 -0.37; 0.49 0.06 0.22 -0.37; 0.49 
SD: Standard deviation 
Highlighted sections indicate statistical significance 
 
6.4.4 Inverse probability weighting 
Inverse probability weighting assumes monotone missingness and we imputed the few non-
monotone missing values in order to create a monotone dataset.  Inverse probability weighting was 
done through a two-stage process.  A logistic regression model was fitted at each visit to determine 
the probability of observing the outcome measurement.  Baseline covariates and response variables 
for visits 0 to t-1 were included.   For each visit the probability of being observed was conditional 
on being observed at the previous visit.  Any participant who was missing at a visit was not 
included in the estimation of the probability of being observed at a subsequent visit.  The 
conditional probability of being observed at visit t was ä+ = W(+ = 1|,+, = 1, J , -, … , -,+,) 
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The occasion specific unconditional probability of being observed for each visit, r+ = W(+ = 1), 
was then estimated as rD+ = äB × äB9 × …× äB+.  The inverse of this product of conditional 
probabilities was used as the occasion specific weight.  A linear model of interest was then fitted to 




GEE is not generally valid unless the missingness process is MCAR, but weighted GEE is valid 
when the missingness process is MAR.  The results of the weighted GEE method is given in Table 
6.13, both with a logistic regression model including additional covariates (baseline HAM-D score, 
age, gender, BDI, duration of depression, GAF, CGI-S and CGI-I scales) and with a logistic 
regression only including outcome measurements.  Including covariates in the calculation of the 
weights helps improve the accuracy of the weights and therefore improves the results obtained with 
this method.  The weighted GEE analysis used a different estimation method and is not directly 
comparable with the models given earlier.  Standard errors should be calculated using bootstrap 
methods, because the standard errors calculated using standard methods are not accurate.  We give 
here the incorrectly calculated standard errors calculated through procedure GENMOD applying 
GEE, because of problems experienced with bootstrap that will be discussed later.  We argue that 
the loss of precision in the calculation of the standard errors is less serious than the possibility of 
bias introduced when some of the bootstrap samples do not converge.  In Chapter 5 standard errors 
were calculated using bootstrap and the standard errors were similar to the standard errors 
calculated using standard methods in procedure GENMOD.  We therefore believe that the error in 
the calculation of the standard errors is fairly small.   
 
Up to Week 8 the weighted GEE showed an improvement in mean HAM-D score over time in the 
sertraline arm compared to the placebo arm.  This improvement was small and not statistically 
significant.  The interaction between week and the hypericum arm compared to the placebo arm 
was almost 0 and not statistically significant.  The models with and without covariates in the 
logistic regression model to calculate the weights gave similar results.   
 
To improve on the inverse probability weighted GEE fitted, a doubly robust method was also used.  
The application of this method was discussed in more detail in Section 5.4.4.  The standard SAS 
output for the variance of the estimators underestimate the true variance since the response values 
for the final model are the predicted values from a previous weighted model.  Multiple bootstrap 
samples were taken in an attempt to correctly estimate the variance.  Each data set consisted of a 
sample with replacement.  The mean and standard error of the parameter estimates were calculated 




Table 6.13:  Hamilton depression score, inverse probability weighting methods, data 
up to Week 8   
 Weighted GEE without covariates Weighted GEE with covariates 
Effect Estimate Standard 
error 
p-value Estimate Standard error p-value 
Intercept 19.69 0.53  19.78 0.54  
Sertraline (ref: placebo) -0.62 0.81 0.45 -0.73 0.84 0.38 
Hypericum (ref: placebo) 1.01 0.77 0.19 0.98 0.78 0.21 
Week -0.90 0.11 <0.001 -0.90 0.11 <0.001 
Interaction week and treatment 
(sertraline compared to placebo)  
-0.12 0.15 0.41 -0.13 0.16 0.41 
Interaction week and treatment 
(hypericum compared to placebo) 
-0.01 0.15 0.98 -0.04 0.15 0.80 
 Doubly robust estimator without 
covariates 
Doubly robust estimator with 
covariates 
 Estimate Standard 
error 
p-value Estimate Standard error p-value 
Intercept 19.17 0.63  19.12 0.67  
Sertraline (ref: placebo) -0.13 0.72 0.86 -0.24 0.77 0.76 
Hypericum (ref: placebo) 0.98 0.84 0.25 0.74 0.79 0.36 
Week -0.74 0.19 <0.001 -0.68 0.25 0.01 
Interaction week and treatment 
(sertraline compared to placebo)  
-0.30 0.14 0.04 -0.30 0.15 0.05 
Interaction week and treatment 
(hypericum compared to placebo) 
-0.06 0.15 0.68 -0.12 0.18 0.51 
With covariates and without covariates refers to whether auxiliary covariates were included in the logistic regression 
model used to calculate the probability of being observed.  Treatment arm was included as a covariate in both models. 
 
The logistic regression in step 1 used to calculate the probability of being observed had many 
convergence problems, because the bootstrapped samples included duplicate records compared to 
the original data set.  The convergence problems were more extreme when more covariates were 
included in the models.  If the proportion of non-converging samples is high, the estimates may be 
biased.  If auxiliary covariates were included only 34 of 200 bootstrap samples converged.  If 
auxiliary covariates were not included only 61 of 200 bootstrap samples converged.  The resulting 
estimates could therefore be biased.  Despite the possibility of bias introduced, the results of the 
doubly robust estimator (without covariates) are similar to the results found with the likelihood 
based, multiple imputation and Bayesian methods.  From the doubly robust analysis we conclude 
that mean HAM-D score in the sertraline arm improved more over time than mean HAM-D score 
in the placebo arm, and this difference was statistically significant.  The same could not be said 




Table 6.14:  Hamilton depression score, inverse probability weighting methods, data 
up to Week 26   
 Weighted GEE without covariates Weighted GEE with covariates 
Effect Estimate Standard 
error 
p-value Estimate Standard error p-value 
Intercept 19.20 0.73  19.16 0.78  
Sertraline (ref: placebo) 0.18 0.95 0.85 0.04 0.90 0.97 
Hypericum (ref: placebo) 1.72 0.94 0.07 0.96 0.92 0.30 
Week -0.96 0.13 <0.001 -0.91 0.16 <0.001 
Interaction week and treatment 
(sertraline compared to placebo)  
-0.20 0.12 0.08 -0.16 0.07 0.02 
Interaction week and treatment 
(hypericum compared to placebo) 
-0.12 0.11 0.26 0.01 0.08 0.94 
Week squared 0.02 0.004 <0.001 0.02 0.01 0.01 
 Doubly robust estimator without 
covariates 
Doubly robust estimator with 
covariates 
 Estimate Standard 
error 
p-value Estimate Standard error p-value 
Intercept 19.85 2.00     
Sertraline (ref: placebo) -1.61 3.08 0.61    
Hypericum (ref: placebo) 0.95 1.68 0.58    
Week -1.16 0.21 <0.001    
Interaction week and treatment 
(sertraline compared to placebo)  
-0.05 0.13 0.70    
Interaction week and treatment 
(hypericum compared to placebo) 
-0.04 0.14 0.79    
Week squared 0.03 0.01 <0.001    
With covariates and without covariates refers to whether auxiliary covariates were included in the logistic regression 
model used to calculate the probability of being observed.  Treatment arm was included as a covariate in both models. 
 
For the data up to Week 26, the weighted GEE with and without covariates lead to similar 
conclusions.  We conclude that there is a significant interaction between week and the sertraline 
arm compared to the placebo arm (the p-value is small and almost significant for the weighted GEE 
without covariates).  The interaction between week and the hypericum arm compared to the 
placebo arm was not significant.  Only 4 samples converged in the doubly robust estimator that 
included covariates in the missing data model.  These results are not presented.  The logistic 
regression without covariates had slightly better convergence and 19 of the 200 samples converged.  
The results of the doubly robust estimator could be biased because such a large number of 
bootstrap samples are excluded and we did not consider it further here. 
6.4.5 Conclusion of MAR analysis 
It was reasonable to assume that the data might be MAR; thus the multiple imputation, likelihood-
based analysis, Bayesian analyses, pattern-mixture model using ACMV identifying restrictions 
(discussed in Section 6.5.1.3 with the MNAR models) and inverse probability weighting performed 
under MAR assumptions could be valid or reasonable approaches (Table 6.15).  Up to Week 8, 
where most data were observed, the multiple imputation, likelihood-based analysis, Bayesian 
analysis and inverse probability weighting gave similar results.  We concluded from this that the 
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interaction between week and sertraline compared to placebo was significant, and the interaction 
between week and hypericum compared to placebo was not. 
 
Analysing data up to Week 26, where the majority of the data were missing, the multiple 
imputation results differed from the results with likelihood-based and Bayesian methods.  The 
multiple imputation chain did not reach a stationary distribution and autocorrelation existed 
between the imputations from Week 10 onwards.  For this reason, we believed that the results of 
the multiple imputation up to Week 26 should be interpreted with caution.  If we only considered 
the likelihood-based, Bayesian and weighted GEE methods, we concluded that there was a 
significant interaction between week and sertraline compared to placebo, but not between week and 
hypericum compared to placebo.  
 
Table 6.15: Summary of findings in all MAR sensitivity analyses 
 Interaction week and 
sertraline arm 
Interaction week and hypericum 
arm 
 Estimate p-value Estimate p-value 
Data up to 8 weeks     
Likelihood-based methods -0.24 0.05 0.03 0.79 
Multiple imputation -0.23 0.08 0.01 0.95 
Bayesian analysis (Prior set 1) -0.54 Significant -0.02 Not significant 
Inverse probability weighting (doubly 
robust without covariates) 
-0.30 0.04 -0.06 0.68 
Weighted GEE with covariates -0.13 0.41 -0.04 0.80 
Data up to 26 weeks     
Likelihood-based methods -0.10 0.07 -0.04 0.48 
Multiple imputation -0.04 0.59 0.10 0.24 
Bayesian analysis (Prior set 1) -0.50 Significant 0.06 Not significant 
Weighted GEE with covariates -0.16 0.02 0.01 0.94 
 
We concluded that the sertraline arm was superior to the placebo arm in treating depression.  The 
same was not observed for the hypericum arm.  We could thus conclude that hypericum was not 
superior to placebo, in a clinical trial where a standard anti-depressive (sertraline) was found to be 
superior to placebo.  This changed the interpretation of the clinical trial substantially from what 
was concluded previously, where missing data were ignored in the analysis (Hypericum Depression 
Trial Study Group, 2002).   
 
We were interested in Estimand 1, as described by the National Research Council (2010).  The 
methods used attempted to impute or otherwise include data up to Week 8 for all participants 
randomised, therefore enabling Estimand 1.  However, the assumption was made that participants 
who dropped out continued to adhere to treatment in the same way as they did while on treatment.  
This assumption was not completely unrealistic, since these treatments were available and 
participants could continue to obtain the medication outside of the study setting.  It was also 
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possible that participants who discontinued study visits could obtain other rescue medication or 
take no medication whatsoever, which would invalidate this assumption. 
 
If the aim was to estimate drug efficacy, one is also interested in Estimand 3.  It is unlikely that the 
data collected in this trial would enable one to estimate Estimand 3, the difference in outcome 
improvement if all participants tolerated and adhered to treatment.  There was simply too much 
non-adherence due to drop-out.  An estimate for this estimand can be calculated by only including 
data while participants were adhering to treatment and then inferring future profiles using this data.  
This was not done.  Estimand 6 can more realistically be obtained than Estimand 3, in which case, 
the methods discussed in Carpenter et al. (2013) would be useful.  Estimand 6 is estimated using a 
weighted average of the treatment effect at endpoint in those who adhered to study medication and 
the treatment effect in those who discontinued study medication.  The placebo arm is then used to 
estimate the treatment effect in participants who discontinued study medication in the active 
treatment arm.   
 
The analysis including all data up to Week 26 does not answer any well-defined research question 
or address any estimand of interest.  Data are collected up to Week 8 in all participants who do not 
drop out, and from Week 10 data are collected only for participants who responded to treatment.  
During the analysis data are imputed or simulated for the participants who did not respond 
according to the patterns observed up to that time point.  The results depend more on the treatment 
of the missing data than on what was observed.  A more useful analysis may be to only analyse the 
data from Week 8 to Week 26 in those participants who responded at Week 8.  This would then be 
a conditional analysis; given that a participant responded at Week 8, what is the continued 
treatment effect from Week 10 to Week 26.  This is what was done in Sarris et al. (2012), who 
handled missing data after Week 10 by LOCF and not by appropriate methods.  This is a 
randomised comparison any more.  This conditional analysis needs to be done taking missing data 
into account, since only a small number of participants who entered the continuation phase 
completed the entire study to Week 26; 28 (57.1%) in the sertraline arm, 24 (63.2%) in the 
hypericum arm and 27 (64.3%) in the placebo arm.   
 
This data set highlights a major problem with the missing data techniques.  Even though the 
methods exist to analyse data under MAR assumptions and these methods can easily be 
implemented in standard software, the methods do not perform well, and might not converge or 
reach stationary distributions when the majority of data are missing.  Sparse dropout patterns also 
create problems during the analysis of data.  
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6.5 Analysis of HAM-D score under MNAR assumptions  
6.5.1 Pattern-mixture models  
The patterns of missing data are given in Table 6.2.  The first challenge when using pattern-mixture 
models is to determine how the various dropout patterns should be grouped.  Three different 
dropout variables were defined.  In the first model dropout was a binary variable created to indicate 
whether a participant completed the study or not.  Dropout was assigned a value of zero if the study 
was completed and a value of one if the study was not completed (Model 1 and Model 3).  In 
Model 1 data up to Week 8 only were considered and in Model 3 data up to Week 26 were 
considered.  In addition, a second dropout variable was created with three categories, completing 
the entire study, being regarded as a treatment failure at Week 8 and discontinued from the study 
and dropped out of the study for any other reason.  This model (Model 2) was fitted using data up 
to Week 26.  Table 6.16 gives the number of participants in each of the categories of missing data. 
 
Only 24.1% of participants completed the study up to 26 weeks, while 72.1% of participants 
completed the first 8 weeks of the study.  In Model 2 the largest group was the participants who 
dropped out of the study (Table 6.16). 
 
Table 6.16: Number of participants in each of the categories of missing data 
 Sertraline, n = 111 Hypericum, n = 113 Placebo, n = 116 
Model 1: Binary dropout variable for study up to 8 weeks  
Completed 79 (71.2%) 82 (72.6%)  84 (72.4%)  
Dropped out 32 (28.8%) 31 (27.4%) 32 (27.6%) 
Model 2:  Three dropout categories (up to 26 weeks)  
Completed study 31 (27.9%) 24 (21.2%) 27 (23.3%) 
Treatment failure at Week 8 27 (24.3%) 40 (35.4%) 38 (32.8%) 
Dropout 53 (47.7%) 49 (43.4%) 51 (44.0%) 
Model 3: Binary dropout variable for entire study (up to 26 weeks)  
Completed 31 (27.9%) 24 (21.2%) 27 (23.3%) 
Dropped out 80 (72.1%) 89 (78.8%) 89 (76.7%) 
 
Table 6.17 gives the estimated β-coefficients for each of the patterns of missing data.  We assumed 
an unstructured covariance matrix in all cases.  With some of the models, especially the models 
with dropout, the models did not converge because the Hessian matrix was not positive definite.  A 
heterogeneous compound symmetry covariance matrix was assumed for the dropouts in Model 1 
and Model 3.  The heterogeneous compound symmetry assumes the same correlations between 
observations at any two pairs of times, while allowing unequal variances at the different time 
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Table 6.17:  Estimates and standard errors of the different patterns of missing data 
 Model 1 (data up to 8 weeks) Model 3 (data up to week 26) 
 Completed Dropped out Completed Dropped out 
Effect Estimate SE Estimate SE Estimate SE Estimate SE 
Intercept 22.86 0.29 22.18 0.50 21.53 0.53 22.70 0.34 
Sertraline (ref: placebo) 0.42 0.44 0.54 0.68 0.25 0.67 0.41 0.45 
Hypericum (ref: placebo) -0.23 0.37 0.82 0.75 0.88 0.68 0.46 0.47 
Week -1.18 0.10 -0.94 0.29 -1.91 0.06 -1.53 0.09 
Interaction week and treatment 
(sertraline compared to placebo)  
-0.20 0.13 -0.63 0.44 0.09 0.05 -0.19 0.08 
Interaction week and treatment 
(hypericum compared to placebo) 
-0.01 0.13 0.02 0.41 0.06 0.05 0.05 0.08 
Week squared     0.05 0.002 0.07 0.01 




at Week 8 
Dropout  
Effect Estimate SE Estimate SE Estimate SE   
Intercept 21.53 0.53 23.06 0.50 22.11 0.70   
Sertraline (ref: placebo) 0.25 0.67 -0.01 0.62 -0.51 0.96   
Hypericum (ref: placebo) 0.88 0.68 0.23 0.77 0.12 0.96   
Week -1.91 0.06 -1.39 0.21 -2.18 0.16   
Interaction week and treatment 
(sertraline compared to placebo)  
0.09 0.05 -0.24 0.14 -0.14 0.14   
Interaction week and treatment 
(hypericum compared to placebo) 
0.06 0.05 -0.07 0.14 0.26 0.16   
Week squared 0.05 0.002 0.11 0.02 0.09 0.01   
SE: Standard error 
 
In Model 3 the Hessian matrix was not positive definite when either an unstructured covariance 
matrix or a heterogeneous compound symmetry matrix was assumed for the participants who 
dropped out.  This was despite this pattern containing almost half the participants, therefore the 
convergence problems were not caused by small sample size.  This model was fitted using an 
autoregressive matrix, which was appropriate, since the visits were spaced at equal intervals.  MAR 
models assume the slope of the HAM-D scores over time is the same across patterns, however the 
slopes differed by dropout pattern for all the models fitted.  
6.5.1.1 Pattern-mixture models using random-effects mixed models 
Procedure MIXED in SAS was used to fit the model with HAM-D score as the dependent variable.  
Independent variables included the fixed, categorical effects of treatment, dropout, and the dropout 
by treatment interaction, as well as the continuous effect of time.  The time by treatment and 
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dropout by time and dropout by treatment interaction and the three level interaction of dropout, 
treatment and time were included.  Adding a term for time squared improved the fit of the model 
since it was not a linear pattern.  An unstructured covariance matrix was used to model the within 
participant errors.  Parameters were estimated using REML with the Newton–Raphson algorithm.  
Asymptotically exact standard errors were obtained.  Denominator degrees of freedom were 
estimated using the Kenward-Roger correction (Kenward & Roger, 1997).   
 
The regression equation for the pattern-mixture model with a binary dropout variable 
(Model 1 and Model 3)   - =  β? + βH + β9S +  βt +   (βH+ β9S)t  + βD + βtD + βQ9 +  βDH + β9DS  + (βH+ β9S)tD +  ε1 
 
Regression equation for pattern-mixture model with three dropout categories (Model 2) - =  β? + βH + β9S + βt + (βH+ β9S)t + βC + β9W +  (βC + β9W)t +
βQ9 + βCH + β9WH +  β9CS + β99WS + (βCH + β9WH + β9CS +
β99WS )t  + ε1 
where C= 1 if completed, 0 otherwise; W= 1 if participant was a treatment failure at Week 8 and 
terminated from the study, 0 otherwise 
 
For Models 1 and 3, a binary variable for dropout was added to a longitudinal model as a main 
effect and as interactions with the variables treatment and week.  This allowed one to examine the 
degree to which dropouts differed from completers in terms of the outcome variable.  The main 
effect of dropout was not significant in Model 1, but significant in Model 3.  The degree to which 
the dropout pattern moderated the influence of other model terms was investigated by looking at 
interactions with the dropout pattern.  The interaction of dropout and week was significant, but the 
interaction of treatment and dropout was not significant in either Model 1 or 3. 
 
In Model 2, the missing data variable was not a binary variable, but consisted of three patterns.  
The effect of the missing data pattern was significant.  The interaction of dropout and week was 
significant, but the interaction of treatment and dropout was not significant in any of the models.  
In Model 1 the only significant interaction was the interaction between week and dropout.  
Although the pattern-mixture model fitted can be simplified by excluding some non-significant 
interactions from the model, we did not exclude any interactions.  The interaction between 
treatment and dropout was retained, since the p-value was less than 0.10, even though it was not 
below 0.05.  The interaction between week and treatment was also retained, since this is the 




Table 6.18: F-test of fixed effects for models including all two way interactions and a 
three way interaction between treatment arm, dropout and week, adjusted for all 
other variables and interactions in the model  
Effect Degrees of freedom F-value p-value 
 Numerator Denominator  
Model 1: Binary dropout variable, data up to 8 weeks    
Treatment 2 205 3.85 0.02 
Week 1 292 286.6 <0.001 
Week2 1 280 72.3 <0.001 
Dropout 1 348 0.22 0.64 
Interaction week and treatment 2 165 1.14 0.32 
Interaction between week and dropout 1 418 11.3 0.001 
Interaction between treatment and dropout 2 235 2.52 0.08 
Interaction between week, treatment and dropout 2 293 1.93 0.15 
     
Model 2:  Three dropout categories (up to 26 weeks)     
Treatment 2 186 0.04 0.96 
Week 1 187 1473 <0.001 
Week2 1 77 704 <0.001 
Dropout 2 239 4.71 0.01 
Interaction week and treatment 2 204 2.88 0.06 
Interaction between week and dropout 2 215 85 <0.001 
Interaction between treatment and dropout 4 179 1.02 0.40 
Interaction between week, treatment and dropout 4 184 2.55 0.04 
     
Model 3: Binary dropout variable for entire study (up to 26 weeks)   
Treatment 2 112 0.19 0.83 
Week 1 105 1221 <0.001 
Week2 1 74 528 <0.001 
Dropout 1 165 4.90 0.03 
Interaction week and treatment 2 138 4.16 0.02 
Interaction between week and dropout 1 145 51.4 <0.001 
Interaction between treatment and dropout 2 111 1.92 0.15 
Interaction between week, treatment and dropout 2 137 4.48 0.01 
 
The trajectory for mean HAM-D scores over time was different for participants who dropped out 
and participants who completed the study.  For participants who completed the study there was 
little difference between the treatment arms.  Amongst dropouts the sertraline arm showed 
continued improvement, while the placebo and hypericum arms did not.  A visual examination of 
the observed and fitted means indicate that the models fit well in all treatment arms for the 
completers.  For those who dropped out, the model did not fit well for the sertraline arm (Figure 




        
 
Figure 6.19:  Hamilton depression scale by dropout pattern, Model 1 with data up to 
Week 8.  Squares indicate observed data and lines indicate predicted data. 







Figure 6.20:  Hamilton depression scale by dropout pattern, Model 3 with data up to 
Week 26.  Squares indicate observed data and lines indicate predicted data. 
  
A) Completed 
B) Dropped out 
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Table 6.19:  Hamilton depression scale, fitted as pattern-mixture model  
Effect Model 1 
Binary dropout 
variable, 8 weeks 
Model 2 
 Three dropout 
categories, 26 weeks 
Model 3 
Binary dropout 
variable, 26 weeks 
 Estimate SE p-value Estimate SE p-value Estimate SE p-value 
Intercept 22.54 0.29  22.26 0.37  22.62 0.50  
Sertraline (ref: placebo) -0.48 0.39 0.22 0.15 0.50 0.77 -0.32 0.67 0.63 
Hypericum (ref: placebo) 0.65 0.42 0.13 0.67 0.55 0.23 -1.01 0.70 0.15 
Week -2.33 0.16 <0.001 -1.77 0.08 <0.001 -1.74 0.07 <0.001 
Interaction week and 
treatment (hypericum 
compared to placebo)  
0.02 0.13 0.88 0.22 0.11 0.045 -0.05 0.06 0.42 
Interaction week and 
treatment (sertraline 
compared to placebo) 
-0.15 0.13 0.25 -0.10 0.10 0.36 -0.03 0.06 0.59 
Dropout -0.25 0.56 0.66    0.09 0.57 0.87 
Complete compared to 
dropout 
   0.30 0.62 0.63    
Failure compared to 
dropout 
   0.86 0.57 0.13    
Interaction week, dropout 0.93 0.29 0.001    0.40 0.09 <0.001 
Complete compared to 
dropout 
   -0.25 0.09 0.01    
Failure compared to 
dropout 
   0.84 0.13 <0.001    
Week squared 0.14 0.02 <0.001 0.06 0.002 <0.001 0.05 0.002 <0.001 
Interaction hypericum, 
dropout 
-0.17 0.80 0.83    1.51 0.81 0.06 
Complete compared to 
dropout for hypericum 
compared to placebo 
   -1.68 0.89 0.06    
Failure compared to 
dropout for hypericum 
compared to placebo 
   -0.29 0.83 0.73    
Interaction sertraline, dropout 1.36 0.75 0.07    0.34 0.77 0.66 
Complete compared to 
dropout for sertraline 
compared to placebo 
   -0.49 0.82 0.55    
Failure compared to 
dropout for sertraline 
compared to placebo 
   -0.19 0.80 0.81    
Interaction hypericum, week, 
dropout 
-0.22 0.41 0.59    0.12 0.12 0.31 
Complete compared to 
dropout for hypericum 
compared to placebo 
   -0.17 0.12 0.18    
Failure compared to 
dropout for hypericum 
compared to placebo 
   -0.30 0.19 0.11    
Interaction sertraline, week, 
dropout 
-0.80 0.42 0.06    -0.20 0.11 0.09 
Complete compared to 
dropout for sertraline 
compared to placebo 
   0.15 0.12 0.19    
Failure compared to 
dropout for sertraline 
compared to placebo 
   -0.12 0.18 0.51    




Figure 6.20 shows the fitted curves and the observed data for Model 3.  Because values decrease 
sharply from baseline to Week 8 and level out after that, the quadratic model overestimates values 
slightly prior to Week 10 and fits well after Week 10 for completers.  The fit for dropouts is not 
good, especially in the placebo arm.  This did not improve if an interaction term between week 
squared and treatment was included.   
 
Population estimates, averaging over the missing data patterns, were calculated for the fixed effects 
using the following formula: >"B =  ∑  6̧rDv   In Model 1 the sample proportions, rD, of completers 
and dropouts were 0.72 and 0.28, respectively.  In Model 2 the sample proportion  of completers 
was 0.24, the proportion of failures at Week 8 was 0.31 and the proportion of dropouts was 0.38.  
In Model 3 the sample proportions, rD, of completers and dropouts were 0.76 and 0.24, 
respectively.  The average estimates for >" 0 is given in Table 6.20. The corresponding standard errors 
were calculated using the methodology from section 3.3.2.1.   
 
Table 6.20: Population averaged estimates and standard errors of pattern mixture 
model using random-effects mixed model for Hamilton depression scale 
 
Model 1 




categories, 26 weeks 
Model 3 
Binary dropout variable 
for entire study, 26 weeks 
Effect 3̀0 Standard error p-value 3̀0 Standard error p-value 3̀0 Standard error p-value 
Intercept 22.66 0.25 <0.001 22.60 0.25 <0.001 22.65 0.38 <0.001 
Sertraline (ref: placebo) -0.24 0.36 0.51 -0.03 0.34 0.94 -0.28 0.52 0.58 
Hypericum (ref: placebo) 0.43 0.38 0.27 0.04 0.36 0.91 -0.61 0.54 0.27 
Week -1.38 0.19 <0.001 -1.70 0.15 <0.001 -1.66 0.08 <0.001 
Interaction week and 
treatment (sertraline 
compared to placebo)  
-0.38 0.15 0.01 -0.10 0.07 0.17 -0.08 0.05 0.12 
Interaction week and 
treatment (hypericum 
compared to placebo) 
-0.002 0.15 0.99 0.09 0.07 0.18 -0.02 0.05 0.68 
Week squared    0.06 0.002 <0.001 0.05 0.002 <0.001 
 
According to Model 1, which uses data up to Week 8, the improvement in the sertraline arm was 
significantly different from the improvement in the placebo arm over time, whereas the 
improvement in the hypericum arm over time was not statistically significantly different from the 
improvement in the placebo arm.  Models 2 and 3, which used data up to Week 26 did not find 
either treatment arm to lead to improved depression scores over time compared to placebo.  In this 
analysis, HAM-D scores after dropout were extrapolated.  These extrapolations and criticism 




6.5.1.2 Pattern-mixture models using multiple imputation 
We implemented pattern-mixture models using multiple imputations as described in Section 
5.5.1.2.  Different values of δ, which indicates the association between HAM-D score and dropout, 
were assumed for participants who dropped out and those who completed the study.  Imputations 
were restricted to be between 0 and 33, which are valid scores on the HAM-D questionnaire.   
 
Table 6.21: Multiple imputation of HAM-D scores using a pattern-mixture 
approach, data up to Week 8 
 Sertraline arm Hypericum arm Placebo arm p-value* 
 Mean Standard error Mean Standard error Mean Standard error  
Assuming decrease in HAM-D score for participants who dropped out  
Model 1: δ for dropout = 0.5, σ = 1   
Week 1 19.5 0.53 20.0 0.51 18.9 0.47 0.34 
Week 2 16.2 0.74 18.2 0.67 17.6 0.57 0.15 
Week 3 14.5 1.47 17.0 1.11 17.2 0.87 0.14 
Week 4 12.7 2.51 15.6 1.93 15.3 1.52 0.40 
Week 6 10.5 4.33 13.8 3.26 13.9 2.79 0.53 
Week 7 7.4 6.84 11.2 5.36 11.1 4.99 0.68 
Week 8 4.5 10.09 8.1 8.17 10.0 7.82 0.40 
Model 2: δ for dropout = 0.25, σ = 1   
Week 1   19.6   0.53     20.0 0.51 18.9 0.46 0.32 
Week 2 16.4 0.74 18.3 0.68 17.6 0.56 0.20 
Week 3 15.1 1.55 17.3 1.16 17.2 0.87 0.25 
Week 4 13.8 2.66 16.2 2.01 15.5 1.50 0.60 
Week 6 12.4 4.53 14.8 3.39 14.5 2.78 0.72 
Week 7 10.4 7.23 12.8 5.55 12.0 4.93 0.87 
Week 8 9.0 10.67 10.5 8.55 11.6 7.85 0.60 
Assuming increase in HAM-D score for participants who dropped out   
Model 3: δ for dropout = -0.5, σ = 1  
Week 1 19.6 0.53 20.1 0.51 18.9 0.47 0.30 
Week 2 16.7 0.74 18.6 0.67 17.8 0.56 0.29 
Week 3 15.9 1.55 18.0 1.15 17.6 0.73 0.38 
Week 4 15.5 2.67 17.5 2.01 16.2 0.95 0.78 
Week 6 15.5 4.55 17.1 3.40 15.6 1.40 0.88 
Week 7 15.3 7.26 16.7 5.55 13.9 2.20 0.99 
Week 8 16.2 10.71 16.5 8.56 14.4 3.10 0.78 
Model 4: δ for dropout = -0.25, σ = 1   
Week 1 19.6 0.53 20.1 0.51 18.9 0.46 0.31 
Week 2 16.6 0.74 18.5 0.67 17.7 0.56 0.26 
Week 3 15.6 1.55 17.8 1.15 17.5 0.87 0.33 
Week 4 14.9 2.66 17.1 2.0 16.1 1.50 0.72 
Week 6 14.5 4.54 16.3 3.39 15.8 2.78 0.83 
Week 7 13.7 7.24 15.4 5.54 14.3 4.94 0.95 
Week 8 13.8 10.68 14.5 8.54 15.2 7.86 0.72 
 
Means and standard errors calculated from the multiple imputed values for each of these models 
are given using data up to Week 8 (Table 6.21) and using data up to Week 26 (Table 6.22).  The 
cross-sectional results are not to be compared to the longitudinal model, but the means over time 
are helpful in describing the implications of the different assumptions made to non-statisticians.  
The cross-sectional summaries allow one to illustrate whether an assumption implies increasing or 
decreasing means.  Models 1 and 2 assume a decrease in HAM-D score for participants who 
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dropped out, while Models 3 and 4 assume an increase in HAM-D score for participants who 
dropped out.   
 
None of the four models fitted with data up to Week 8 showed a significant effect of either 
treatment arm over placebo at any of the weeks.  Neither assuming that participants who dropped 
out improved or that participants who dropped out worsened, led to the conclusion that there is a 
significant effect of treatment at any visit.   
 
When the data up to Week 26 were fitted, this method used a lot of computing power and was 
slow.  The multiple imputations were fast to do, but fitting each of the mixed models took time.  
Since 50 models had to be fitted, it took almost 2 hours to run each of the models on a standard 
computer.  The models fitted with the data up to Week 8 required less computer resources to be 
fitted.    
 
The models fitted using all data up to Week 26 were more problematic than the models fitted using 
the data up to Week 8 (Table 6.22).   The models fitted lead to negative estimates of HAM-D 
scores, which are not possible, from Week 14, onwards.  This was corrected by truncating the 
estimated values at 0 and 33.   
 
The problem with this method of handling MNAR missing data, is that the decrease in HAM-D 
score assumed after drop out accumulates over time and therefore the assumption made about δ 
influences the later weeks post dropout much more than the earlier weeks.  From Week 10 onwards 
more values are missing than observed, meaning that the assumption made about the value of δ 
plays a larger role in the results than the actual data observed for the later visits.   
 
Models 5 and 6 assumed that HAM-D scores decreased after dropout.  This is a fairly illogical 
assumption to make, since a substantial number of the dropouts at Week 8 are because of lack of 
response.  If it is not plausible to assume that HAM-D scores will decrease after dropout, it is not 
helpful to fit such a model.  This model is included here for comparison purposes, but should not be 
used to analyse this data.  The standard errors are also very large for the later weeks.  This means 
that variability is increased over time, making all estimates less reliable.  This is due to the fact that 




Table 6.22: Multiple imputation of HAM-D scores using a pattern-mixture 
approach, data up to Week 26 
 Sertraline arm Hypericum arm Placebo arm p-value* 
 Mean Standard error Mean Standard error Mean Standard error  
Assuming decrease (improvement) in HAM-D score for participants who dropped out  
Model 5: δ for dropout = 0.1, σ = 1   
Week 1 19.5 0.52 20.0 0.51 18.9 0.46 0.32 
Week 2 16.5 0.71 18.4 0.68 17.6 0.56 0.23 
Week 3 15.2 1.28 17.5 1.01 17.3 0.83 0.20 
Week 4 14.3 1.91 16.6 1.42 15.8 1.21 0.53 
Week 6 13.4 2.52 15.7 1.88 15.2 1.87 0.61 
Week 7 12.1 3.18 14.5 2.57 13.3 2.75 0.81 
Week 8 11.6 3.68 13.3 3.20 13.4 3.52 0.76 
Week 10 10.6 5.89 13.9 6.47 13.7 6.67 0.76 
Week 14 10.4 7.36 12.3 8.27 14.1 8.59 0.77 
Week 18 10.9 8.55 13.8 9.84 12.5 9.99 0.92 
Week 22 12.5 9.50 13.2 10.61 14.1 10.79 0.92 
Week 26 12.3 10.24 14.1 11.09 14.8 11.26 0.89 
Model 6: δ for dropout = 0.25, σ = 1   
Week 1 19.5 0.52 20.0 0.51 18.8 0.46 0.32 
Week 2 16.5 0.71 18.3 0.68 17.6 0.56 0.21 
Week 3 15.1 1.27 17.4 1.00 17.2 0.83 0.18 
Week 4 14.0 1.89 16.4 1.38 15.7 1.19 0.50 
Week 6 13.0 2.49 15.4 1.82 14.9 1.83 0.58 
Week 7 11.7 3.13 14.1 2.47 13.0 2.69 0.79 
Week 8 11.1 3.64 12.8 3.07 13.0 3.48 0.75 
Week 10 9.8 5.79 12.9 6.29 12.9 6.60 0.76 
Week 14 9.5 7.19 11.0 7.86 13.0 8.49 0.78 
Week 18 9.8 8.40 12.5 9.55 11.3 9.80 0.92 
Week 22 11.2 9.38 11.6 10.26 12.9 10.8 0.91 
Week 26 10.9 10.13 12.4 10.73 13.4 11.25 0.88 
Assuming increase (worsening) in HAM-D score for participants who dropped out   
Model 7: δ for dropout = -0.05, σ = 0.5  
Week 1 19.5 0.52 20.1 0.50 18.9 0.46 0.32 
Week 2 16.6 0.60 18.4 0.59 17.7 0.54 0.19 
Week 3 15.4 0.86 17.6 0.78 17.3 0.70 0.08 
Week 4 14.4 1.34 16.7 1.09 15.9 0.87 0.40 
Week 6 13.6 1.90 15.9 1.42 15.2 1.34 0.51 
Week 7 12.4 2.49 14.7 1.97 13.4 1.98 0.79 
Week 8 11.9 3.04 13.6 2.55 13.6 2.71 0.72 
Week 10 11.0 4.63 14.8 4.69 14.2 4.92 0.68 
Week 14 10.5 5.92 12.8 6.59 14.6 6.78 0.68 
Week 18 11.4 7.32 15.1 8.17 12.1 8.33 0.96 
Week 22 13.6 8.28 14.0 9.38 14.7 9.44 0.94 
Week 26 13.5 9.25 15.6 9.86 15.9 10.2 0.88 
Model 8: δ for dropout = -0.25, σ = 0.5   
Week 1 19.6 0.52 20.1 0.50 18.9 0.46 0.31 
Week 2 16.7 0.60 18.5 0.59 17.7 0.54 0.22 
Week 3 15.6 0.86 17.8 0.77 17.4 0.70 0.10 
Week 4 14.8 1.33 17.1 1.09 16.1 0.87 0.45 
Week 6 14.2 1.91 16.4 1.45 15.6 1.35 0.57 
Week 7 13.3 2.50 15.5 2.01 14.0 2.00 0.83 
Week 8 13.0 3.05 14.5 2.62 14.4 2.70 0.75 
Week 10 12.7 4.63 16.5 4.69 15.7 4.87 0.69 
Week 14 12.8 6.01 15.3 6.85 16.7 6.64 0.68 
Week 18 14.2 7.34 17.9 7.93 15.0 8.40 0.95 
Week 22 16.6 8.17 17.4 9.44 17.6 9.23 0.94 




Table 6.23:  Multiple imputation of HAM-D scores using a pattern-mixture approach, 
results of mixed model  
 Data up to 8 weeks 
Model 1 
δ for dropout = 0.5 
Data up to 8 weeks 
Model 2 
δ for dropout = 0.25 
Data up to 8 weeks 
Model 3 
δ for dropout = -0.5 
Parameter Estimate SE p-value Estimate SE p-value  Estimate SE p-value 
Intercept 22.48 0.25  22.58 0.25  22.74 0.28  
Sertraline (ref: placebo) -0.11 0.33 0.75 0.46 0.34 0.18 -0.12 0.43 0.78 
Hypericum (ref: placebo) 0.77 0.37 0.04 0.73 0.36 0.05 0.51 0.39 0.19 
Week -1.77 0.18 <0.001 -1.98 0.21 <0.001 -1.33 0.29 <0.001 
Interaction week and 
treatment (sertraline 
compared to placebo)  
-0.44 0.26 0.09 -0.63 0.23 0.01 -0.30 0.52 0.56 
Interaction week and 
treatment (hypericum 
compared to placebo) 
0.15 0.23 0.51 0.34 0.28 0.23 0.08 0.41 0.85 
 Data up to 8 weeks 
Model 4 
δ for dropout = -0.25  
Data up to 26 weeks 
Model 5 
δ for dropout = 0.1 
Data up to 26 weeks 
Model 6 
δ for dropout = 0.25 
 Estimate SE p-value Estimate SE p-value  Estimate SE p-value 
Intercept 22.72 0.28  22.43 0.54  22.41 0.53  
Sertraline (ref: placebo) -0.11 0.44 0.80 -0.01 0.72 0.98 -0.01 0.68 0.99 
Hypericum (ref: placebo) 0.52 0.39 0.19 0.50 0.77 0.52 0.48 0.81 0.55 
Week -1.33 0.29 <0.001 -1.42 0.44 0.002 -1.47 0.42 0.001 
Interaction week and 
treatment (sertraline 
compared to placebo)  
-0.32 0.54 0.55 -0.07 0.53 0.90 -0.08 0.52 0.88 
Interaction week and 
treatment (hypericum 
compared to placebo) 
0.07 0.41 0.86 -0.004 0.45 0.99 -0.02 0.47 0.96 
Week squared    0.04 0.01 <0.001 0.04 0.005 <0.001 
 Data up to 26 weeks 
Model 7 
δ for dropout = -0.05 
σ = 0.5 
Data up to 26 weeks 
Model 8 
δ for dropout = -0.25 
σ = 0.5 
 
 Estimate SE p-value Estimate SE p-value    
Intercept 22.46 0.57  22.51 0.59     
Sertraline (ref: placebo) -0.01 0.67 0.98 -0.02 0.64 0.98    
Hypericum (ref: placebo) 0.26 0.84 0.76 0.30 0.86 0.73    
Week -1.42 0.39 0.001 -1.24 0.44 0.01    
Interaction week and 
treatment (sertraline 
compared to placebo)  
-0.06 0.51 0.90 -0.05 0.46 0.91    
Interaction week and 
treatment (hypericum 
compared to placebo) 
0.05 0.43 0.90 0.07 0.39 0.87    
Week squared 0.04 0.01 <0.001 0.04 0.01 <0.001    
SE: Standard error 
 
None of the models fitted up to Week 8, neither those assuming an improvement in HAM-D scores 
post drop-out nor those assuming a worsening in HAM-D scores post drop, had a significant 
interaction between week and the hypericum treatment arm compared to the placebo arm.  
Model 2, which assumed a small decrease in HAM-D score in participants who dropped out had a 
significant interaction between week and the sertraline arm compared to the placebo arm.  All the 




These models used multiple imputation to impute missing HAM-D scores.  The imputed values 
were changed according to the pattern assumed.  Differences between these results and the models 
fitted under multiple imputation can be attributed to the assumptions made about the unobserved 
data. 
6.5.1.3 Pattern-mixture models using identifying restrictions  
Multiple imputation was used to create a data set that included only monotone missingness before 
the identifying restrictions were utilised to impute the missing data.  We imputed 70 data sets using 
each of the identifying restrictions.  A model was fitted to the pattern-specific identifiable densities.  
Estimates were calculated over all patterns where the required components were observed, and the 
conditional distributions of the unobserved outcomes given the observed ones were calculated.   
This is described in more detail in Section 5.5.1.3. 
 
Imputed data were truncated at 0 and 33 respectively to ensure that only valid HAM-D scores were 
generated.  If the truncation was not done some of the HAM-D scores imputed were less than 0, 
especially at the later weeks.  Only a small fraction of the imputed values were affected by this.  
After the imputations using identifying restrictions, the data were analysed using the same methods 
as with multiple imputation.    
 
Table 6.24: The number of participants in each pattern 
Week Sertraline Hypericum Placebo 
 Up to Week 8 Up to Week 26 Up to Week 8 Up to Week 26 Up to Week 8 Up to Week 26 
Baseline 7 7 9 9 4 4 
1 10 10 2 2 1 1 
2 2 2 2 2 6 6 
3 2 2 3 3 5 5 
4 7 7 5 5 6 6 
6 4 4 10 10 10 10 
8 79 35 82 49 84 47 
14  5  6  5 
18  8  3  5 
26  31  24  27 
 
Small numbers of participants had a last visit at Weeks 7, 10 and 22.  This meant that those patterns 
were sparse and the models could not be fitted for those weeks.  This was circumvented in the 
analysis by combining these time points with other time points.  This means for example that a 
participant who had a last visit at Week 7 was combined in the same pattern with participants who 




This model differed from the model using multiple imputation in Section 6.4.2 in the variables 
included during imputation.  In the previous models, several baseline covariates were included in 
the imputers’ model.  In this imputer’s model only the observed outcomes are included.  Because 
the analysis and imputation is done by pattern, it is more elaborate than previous models.  Where 
patterns are sparse, the imputation and modeling in some of the patterns may not be efficient.     
 
Table 6.25: HAM-D scores over time, pattern-mixture model with identifying 
restrictions using data up to Week 8 
 ACMV CCMV NCMV 
Effect Estimate SE p-value Estimate SE p-value  Estimate SE p-value 
Intercept 22.28 0.18  22.26 0.18  22.31 0.19 HA 
Sertraline (ref: placebo) 0.08 0.26 0.75 0.11 0.26 0.67 0.11 0.27 0.68 
Hypericum (ref: placebo) 0.31 0.25 0.22 0.31 0.25 0.22 0.34 0.26 0.18 
Week -1.15 0.09 <0.001 -1.14 0.08 <0.001 -1.09 0.14 <0.001 
Interaction week and 
treatment (sertraline 
compared to placebo)  
0.08 0.12 0.53 0.08 0.12 0.47 -0.16 0.18 0.38 
Interaction week and 
treatment (hypericum 
compared to placebo) 
0.13 0.11 0.24 0.13 0.10 0.21 0.03 0.14 0.82 
SE: Standard error 
 
Under both the analysis up to Week 8 and Week 26 we concluded that there was no significant 
interaction of week and either treatment arm compared to placebo using the ACMV model.  The 
pattern-mixture model using ACMV identifying restrictions gave different results from the other 
MAR methods; for both the analysis using data up to Week 8 and using data up to Week 26.  This 
method gave less reliable results because some of the patterns were sparse, as can be seen in Table 
6.24, and we based our conclusions on the other methods used.   
 
The ACMV model, which is valid under MAR assumptions, and the CCMV model, which is valid 
under MNAR assumptions, had similar results.  If most participants completed, as is the case here, 
then borrowing information from the completers is not very different from borrowing information 
from the available cases.  The NCMV identifying restriction gave different results (Table 6.25), 
because information was borrowed from the closest neighbour.  Comparing the ACMV results to 
the CCMV and NCMV results indicates how results differ if MNAR assumptions rather than MAR 
assumptions are made.  As can be seen from Figure 6.21, all the treatment arms followed a similar 
pattern over time.  The NCMV model estimated a lower HAM-D score for each of the treatment 
arms than the other identifying restrictions, while the models using the ACMV and CCMV 




With both the MNAR models, namely the CCMV and the NCMV models, we conclude that there 
is no difference between the sertraline and placebo arm or between the hypericum and placebo arm 
in the change in mean HAM-D score over time.   
 
Figure 6.21: Models fitted using identifying restrictions, HAM-D scores over the first 
8 weeks  
 
Table 6.26: HAM-D score over time, pattern-mixture model with identifying 
restrictions using data up to Week 26 
 ACMV CCMV NCMV 
Effect Estimate SE p-value Estimate SE p-value  Estimate SE p-value 
Intercept 22.10 0.40  22.20 0.40  22.19 0.35  
Sertraline (ref: placebo) 0.49 0.63 0.44 0.52 0.63 0.42 0.32 0.49 0.51 
Hypericum (ref: placebo) 0.45 0.44 0.31 0.41 0.43 0.35 0.34 0.43 0.44 
Week -1.11 0.20 <0.001 -1.11 0.18 <0.001 -1.28 0.31 <0.001 
Interaction week and 
treatment (sertraline 
compared to placebo)  
0.18 0.13 0.17 0.16 0.11 0.16 0.05 0.19 0.78 
Interaction week and 
treatment (hypericum 
compared to placebo) 
0.12 0.10 0.25 0.11 0.09 0.24 -0.01 0.14 0.94 
Week squared 0.02 0.01 0.01 0.02 0.01 0.007 0.03 0.01 0.003 
SE: Standard error 
 
Using all the data up to Week 26, also lead to the conclusion that there was no significant 
interaction between week and either the sertraline or hypericum treatment arm compared to placebo 
(Table 6.26).  For the sertraline and hypericum arms lower mean HAM-D scores were obtained 
Legend: 
Pink: ACMV restriction 
Blue:  CCMV restriction 
Black:  NCMV restriction 
□: Sertraline arm 
o: Hypericum arm 
∆: Placebo arm 
For example:  Pink line with 




with the NCMV identifying restrictions than with the other restrictions.  In the placebo arm the 
three different models had similar mean HAM-D scores until Week 18, after which the NCMV 
identifying restriction model had higher mean HAM-D scores than the other two models (Figure 
6.22).  
 
Figure 6.22: Models fitted using identifying restrictions, HAM-D scores over 26 weeks  
6.5.2 Selection models 
Selection models were fitted in a Bayesian framework under several different assumptions about 
the missing data mechanism.  The reason for using Bayesian methods to fit the selection models 
was discussed in Section 5.5.2.  The model for the observed data was the same as the model fitted 
under MAR.  The same uninformative prior distributions were used as in the MAR case.  The 
model and prior distributions are given in Section 6.4.3 and are summarised in Table 6.27. 
 
In addition, a model for missingness was added, taking the form 
m1 ~ Bernoulli(p1), logit$p1& =  θ? + ∆y1 
where = is a binary missing value indicator for .  This model allowed the missingness to 
depend on the value that would have been observed.  A flat prior was specified on the scale of G 
by specifying a logistic(0, 1) prior for H? in all sets.  The prior distributions specified for ∆ were: 
Legend: 
Red: ACMV restriction 
Blue:  CCMV restriction 
Black:  NCMV restriction 
□: Sertraline arm 
o: Hypericum arm 
∆: Placebo arm 
For example:  Pink line with triangle is 
ACMV model, placebo arm. 
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Prior Set 1:  ∆ ~ Normal(0, 10 000) distribution 
Prior Set 2: ∆ ~ Normal(1, 100)  
Prior Set 3: ∆ ~  Normal(1, 10).   
 
A second MNAR model was fitted where the model of missingness had the following form:   
]STUQ G =  H? +  H,, + H9( − ,,). 
This model allowed the missingness to depend on the previous HAM-D score and the change in 
HAM-D score from the previous visit to the one where the missing data occurred.  The prior 
distributions assigned were:  
Prior Set 1:  H? ~ logistic(0,1) and H, H9 ~ Normal(0, 10 000) 
Prior Set 2: H?, H, H9 ~ Normal(0, 100) 
Prior Set 3: H?, H, H9 ~Normal(0, 10) 
 
A third MNAR model was fitted where the model of missingness had the following form:   
]STUQ G =  H? +  H + H9Ô + HÂ 
This model allowed the missingness to depend on the HAM-D score that would have been 
observed, while allowing for a different mechanism in each treatment arm by including the HAM-
D score by treatment arm interaction.  The prior sets were: 
Prior Set 1: H?~ logistic(0,1), H, H9 , H ~ Normal(0, 10 000)  
Prior Set 2: H?, H, H9 , H ~ Normal(1, 100)  
Prior Set 3: H?, H, H9 , H ~ Normal(1, 10)  
 
Many other models for non-random missingness could be fitted, depending on the assumptions 




Table 6.27: Hamilton depression score posterior means, standard deviations and 
credible intervals according to Bayesian analysis for data up to Week 8 
 Substantive model:  
Prior Set 1 
β ~ Normal(0, 10 000), 
Ω~Wishart(I,5) 
I: Identity matrix, 
Substantive model:  
Prior Set 2 
β ~ Normal(0, 1000), 
Ω~Wishart(A,5) 
A: diag(0.1, 0.1, 0.1, 0.1, 0.1 
Substantive model:  
Prior Set 3 
β ~ Normal(0, 10), 
 Ω~Wishart(A,5) 
A: diag(10, 10, 10, 10, 10), 
MNAR model 1: m1 ~ Bernoulli(p1), logit$p1& =  θ? + ∆y1 
 MNAR model 1: Prior Set 1 H? ~ logistic(0,1), 
∆ ~ Normal(0, 10 000) 
MNAR model 1: Prior Set 2H? ~ logistic(0,1), 
∆ ~ Normal(0, 100) 
MNAR model 1: Prior Set 3  H? ~ logistic(0,1),  
∆ ~ Normal(0, 10) 
Effect Mean SD 95% credible 
interval 
Mean SD 95% credible 
interval 
Mean SD 95% credible 
interval >?  22.55 0.29 21.98; 23.13 22.55 0.29 21.98; 23.13 22.36 0.29 21,78; 22.93 > 0.20 0.42 -0.62; 1.02 0.20 0.42 -0.62; 1.02 0.38 0.42 -0.46; 1.21 >9  0.57 0.41 -0.22;1.37 0.57 0.41 -0.22;1.37 0.75 0.40 -0.03; 1.54 >  -1.13 0.11 -1.35; -0.90 -1.12 0.11 -1.35; -0.90 -1.13 0.11 -1.36; -0.90 >  -0.28 0.15 -0.58; 0.02 -0.28 0.15 -0.58; 0.02 -0.27 0.15 -0.57;0.03 >  -0.01 0.15 -0.30; 0.29 -0.01 0.15 -0.30; 0.29 -0.004 0.15 -0.30; 0.29 
∆ 0.03 0.03 -0.02; 0.08 0.03 0.03 -0.02; 0.08 0.03 0.03 -0.02; 0.08 H?  -4.41 0.51 -5.47; -3.46 -4.41 0.51 -5.47; -3.46 -4.40 0.51 -5.45; -3.45 
MNAR model 2:   m1 ~ Bernoulli(p1), ]STUQ G =  H? + H,, +  H9( − ,,) 
 MNAR model 2: Prior Set1 H? ~ logistic(0,1), H, H9 ~ Normal(0, 10 000) 
MNAR model 2: Prior Set 2  H?, H , H9~ Normal(0, 100) MNAR model 2: Prior Set 3 H?, H, H9 ~Normal(0, 10) 
>?  22.6 0.31 22.0; 23.2 22.6 0.31 22.0; 23.2 22.4 0.30 21.8; 22.98 > 0.15 0.42 -0.68; 0.97 0.15 0.42 -0.68; 0.97 0.33 0.42 -0.48; 1.17 >9  0.49 0.41 -0.32; 1.29 0.49 0.41 -0.32; 1.30 0.67 0.41 -0.13; 1.46 >  -1.10 0.12 -1.33; -0.88 -1.10 0.12 -1.33; -0.88 -1.1 0.12 -1.33; -0.87 >  -0.33 0.15 -0.63;-0.03 -0.33 0.15 -0.63;-0.03 -0.33 0.15 -0.63;-0.03 >  -0.03 0.16 -0.33; 0.28 -0.02 0.15 -0.32; 0.27 -0.02 0.15 -0.32; 0.28 H?  -3.96 0.42 -4.82; -3.15 -4.12 0.43 -4.99; -3.30 -4.05 0.43 -4.93; -3.23 H  0.04 0.02 0.003; 0.09 0.05 0.02 0.01; 0.10 0.05 0.02 0.01; 0.09 H9  0.01 0.03 -0.05; 0.06 0.01 0.03 -0.05; 0.06 0.01 0.03 -0.04; 0.06 
MNAR model 3:  ]STUQ G =  H? +  H + H9Ô + HÂ  
 MNAR model 3: Prior Set1 H? ~ logistic(0,1), H, H9, H~Normal(0,10 000) 
MNAR model 3: Prior Set 2H? ~ logistic(0,1), H, H9, H~Normal(0, 100) 
MNAR model 3: Prior Set 3 H? ~ logistic(0,1), H, H9, H ~ Normal(0, 10) >?  22.59 0.30 21.99; 23.19 22.58 0.30 21.99; 23.15 22.38 0.29 21.8; 22.95 > 0.14 0.43 -0.70; 0.99 0.16 0.42 -0.65; 0.98 0.33 0.41 -0.47; 1.13 >9  0.49 0.41 -0.31; 1.30 0.51 0.40 -0.27; 1.31 0.68 0.40 -0.10; 1.48 >  -1.12 0.12 -1.35; -0.88 -1.11 0.12 -1.35; -0.88 -1.12 0.12 -1.35; -0.88 >  -0.31 0.16 -0.63; -0.01 -0.32 0.16 -0.62; -0.01 -0.31 0.16 -0.62; 0.004 >  -0.01 0.15 -0.32; 0.29 -0.01 0.16 -0.32; 0.30 -0.01 0.15 -0.31; 0.29 H?  -4.19 0.46 -5.14; -3.36 -4.26 0.48 -5.25; -3.39 -4.27 0.49 -5.31; -3.36 H  0.03 0.03 -0.02; 0.08 0.03 0.03 -0.01; 0.09 0.04 0.03 -0.02; 0.09 H9  -0.01 0.02 -0.04; 0.03 -0.01 0.02 -0.04; 0.03 -0.01 0.02 -0.05; 0.03 H  -0.04 0.02 -0.09; 0.001 -0.04 0.02 -0.10; 0.001 -0.04 0.02 -0.09; -<0.001 >? Intercept;  > Sertraline arm (ref: placebo arm);  >9 Hypericum arm (ref: placebo arm);  > Week, > Interaction between week and treatment arm (sertraline compared to placebo) > Interaction between week and treatment arm (hypericum compared to placebo) 
MNAR: Missing not at random, SD: Standard deviation   
 
Using the data up to Week 8, the results of the three Bayesian MNAR models differed slightly from 
the results of the MAR Bayesian model.  The absolute size of the estimated coefficient for the 
interaction between week and sertraline compared to placebo was smaller under the MNAR models 
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than under the MAR model.  In Models 2 and 3 this was statistically significant.  In Model 1, the 
upper boundary of the 95% credible interval was close to 0, indicating that the interaction had a 
small p-value.  In all three MNAR models, the interaction between week and the hypericum arm 
compared to placebo was not significant using any of the sets of prior distributions and the 
estimated coefficient was close to 0.  The choice of prior set also did not influence the results 
appreciably (Table 6.27).   
 
The same MNAR models were also fitted using the same sets of prior distributions with all the data 
up to Week 26.  These models were difficult to fit using some of the other methods because the 
majority of the data were missing.  When using all the data up to Week 26, the effect of sertraline 
over time was not statistically significant and we could not conclude that participants in the 
sertraline arm improved more than participants in the placebo arm.  The effect of hypericum over 
time was also not statistically significant (Table 6.28).  The size of the interaction coefficients 
differed a lot between the various models.  Prior Set 2 had different results from the other prior 




Table 6.28: Hamilton depression score posterior means, standard deviations and 
credible intervals according to Bayesian analysis for data up to Week 26 
 Substantive model:  
Prior Set 1 
β ~ Normal(0, 10 000), 
Ω~Wishart(I,5) 
I: Identity matrix, 
Substantive model:  
Prior Set 2 
β ~ Normal(0, 1000), 
Ω~Wishart(A,5) 
A: diag (0.1, 0.1, 0.1, 0.1, 0.1 
Substantive model:  
Prior Set 3 
β ~ Normal(0, 10), 
 Ω~Wishart(A,5) 
A: diag (10, 10, 10, 10, 10), 
Effect Mean SD 95% credible 
interval 
Mean SD 95% credible 
interval 
Mean SD 95% credible 
interval 
MNAR model 1: m1 ~ Bernoulli(p1), logit$p1& =  θ? + ∆y1 
 MNAR model 1: Prior Set 1 H?,∆ ~ Normal(0, 10 000) MNAR model 1: Prior Set 2  H? ~ logistic(0,1), 
∆ ~ Normal(0, 1000) 
MNAR model 1: Prior Set 3  H? ~ logistic(0,1),  
∆ ~ Normal(0, 10) >?  21.87 0.36 21.19; 22.6 22.24 0.40 21.4; 22.97 22.86 0.35 21.18; 22.58 > 0.70 0.45 -0.20; 1.56 0.34 0.48 -0.57; 1.32 0.66 0.44 -0.20; 1.51 >9  0.86 0.44 0.01; 1.75 0.72 0.64 -0.42; 2.01 0.88 0.41 0.09; 1.70 >  -1.88 0.21 -2.20; -1.38 -1.60 0.12 -1.83; -1.37 -1.98 0.50 -2.84; -1.39 >  0.27 0.18 -0.12; 0.58 -0.05 0.11 -0.26; 0.17 -0.14 0.14 -0.41; 0.14 >  0.28 0.20 -0.12; 0.61 -0.11 0.13 -0.37; 0.14 -0.01 0.13 -0.23; 0.26 > 0.04 0.003 0.04; 0.05 0.05 0.004 0.04; 0.05 0.10 0.06 0.04; 0.20 
∆ 0.03 0.02 -0.01; 0.07 0.03 0.02 -0.004; 0.08 0.03 0.02 -0.01; 0.08 H?  -4.41 0.41 -5.30; -3.68 -4.53 0.40 -5.45; -3.79 -4.50 0.41 -5.34; -3.74 
MNAR model 2:   m1 ~ Bernoulli(p1), ]STUQ G =  H? + H,, +  H9( − ,,) 
 MNAR model 2: Prior Set 1 H?  ~ logistic(0,1), H, H9 ~ Normal(0, 10 000) 
MNAR model 2: Prior Set 2  H?, H, H9 ~ Normal(0, 100) MNAR model 2: Prior Set 3 H?, H, H9 ~ Normal(0, 10) 
Effect Mean SD 95% credible 
interval 
Mean SD 95% credible 
interval 
Mean SD 95% credible 
interval >?  22.39 0.45 21.35; 23.12 22.59 0.29 22.02; 23.16 21.99 0.51 21.06; 22.89 > 0.16 0.54 -0.78; 1.34 -0.05 0.40 -0.83; 0.74 0.53 0.58 -0.55; 1.62 >9  0.46 0.53 -0.52; 1.53 0.41 0.39 -0.35; 1.19 0.87 0.72 -0.44; 2.12 >  -1.65 0.33 -2.67; -1.33 -1.51 0.11 -1.76; -1.31 -1.57 0.13 -1.82; -1.30 >  -0.02 0.13 -0.28; 0.28 -0.03 0.10 -0.21; 0.18 -0.03 1.11 -0.26; 0.20 >  0.04 0.14 -0.23; 0.37 0.05 0.11 -0.14; 0.30 0.03 0.15 -0.26; 0.31 > 0.06 0.03 0.04; 0.16 0.04 0.003 0.04; 0.05 0.04 0.004 0.04; 0.05 H?  -2.27 0.60 -2.79; -0.24 -2.53 0.17 -2.87; -2.19 -2.49 0.18 -2.85; -2.13 H  0.01 0.03 -0.10; 0.04 0.02 0.01 0.003; 0.04 0.02 0.01 -0.001; 0.04 H9  0.06 0.02 -0.003; 0.10 0.06 0.02 0.03; 0.10 0.05 0.02 0.004; 0.09 
MNAR model 3:  ]STUQ G =  H? +  H + H9Ô + HÂ  
 MNAR model 3: Prior Set 1 H? ~ logistic(0,1), H, H9, H~Normal(0,10 000) 
MNAR model 3: Prior Set 2 H?, H, H9, H~Normal(0,1000) MNAR model 3: Prior Set 3 H?,H, H9, H ~ Normal(0, 10) 
Effect Mean SD 95% credible 
interval 
Mean SD 95% credible 
interval 
Mean SD 95% credible 
interval >?  22.34 0.39 21.53; 23.03 21.93 0.4 21.11; 22.73 22.06 0.38 21.3; 22.78 > 0.21 0.48 -0.7; 1.19 0.61 0.49 .-0.36; 1.59 0.49 0.47 -0.41; 1.41 >9  0.67 0.48 -0.25; 1.63 1.18 0.55 0.10; 2.26 0.95 0.46 0.05; 1.87 >  -1.55 0.13 -1.79; -1.31 -2.01 0.32 .-2.73; -1.44 -1.58 0.13 -1.84; -1.35 >  -0.05 0.14 -0.35; 0.19 0.24 0.23 .-0.16; 0.59 -0.02 0.11 -0.23; 0.22 >  0.07 0.15 -0.23; 0.33 0.35 0.27 .-0.13; 0.77 0.10 0.13 -0.14; 0.36 > 0.04 0.003 0.04; 0.05 0.06 0.04 0.04; 0.18 0.04 0.003 0.04; 0.05 H?  -4.25 0.39 .-5.05; -3.53 -4.3 0.42 .-5.20; -3.55 -4.42 0.41 -5.26; -3.66 H  0.04 0.02 .-0.003; 0.09 0.04 0.03 .-0.002; 0.10 0.05 0.02 0.01; 0.10 H9  -0.02 0.02 .-0.06; 0.02 -0.02 0.02 .-0.06; 0.03 -0.02 0.02 -0.06; 0.02 H  -0.09 0.03 .-0.16; -0.03 -0.08 0.03 .-0.16; -0.03 -0.09 0.03 -0.15; -0.03 >? Intercept;  > Sertraline arm (ref: placebo arm);  >9 Hypericum arm (ref: placebo arm),  > Week, > Interaction between week and treatment arm (sertraline compared to placebo) > Interaction between week and treatment arm (hypericum compared to placebo);  >: Week squared 
MNAR: Missing not at random, SD: Standard deviation   
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6.5.3 Shared-parameter models 
Longitudinal HAM-D score and time to dropout were jointly modelled, with shared random effects, 
conditional upon which they are independent.  It is assumed that an underlying individual 
characteristic, such as disease process, influences both changes in HAM-D score and whether a 
participant drops out of the study.  The measurement error terms for the longitudinal model are 
assumed to be independent and to follow a normal distribution with mean 0 and variance C9.  
Dropout is modelled through a linear effect of the treatment variables, intercept and a random 
disturbance term in a time to event model.  The baseline hazard function follows a Weibull 
distribution.  The connection between HAM-D score and time to dropout is accomplished via the 
shared random effects U and V, which have mean 0 and the parameters L and L rescale their 
variances to account for the different scales of HAM-D score and the time variable.  A Cholesky 
parameterisation of the random effects covariance matrix was used to ensure positive definiteness.  
Initial values of the parameters play an important role in whether the model converges and 
reasonable estimates of the initial values were estimated by fitting the longitudinal model using the 
SAS procedure MIXED and the survival model using the SAS procedure LIFEREG separately.   
 
Model with shared random intercept, U, and random slope, V, between the survival and the 
longitudinal sub-models:   
Survival sub-model:  ℎ(Q) =  ℎ?(t)exp [L? + LS1 + L9H1 + LU  + LV   
where ℎ?(t) is the baseline hazard function and follows a Weibull distribution. 
Longitudinal sub-model:  - = > + U + >9Q + VQ + >S1 + >H1 + >S1Q + >H1Q  +  A 
for data up to Week 8.  The data up to Week 26 were fitted using the same models, with the 
addition of >Q9  in the longitudinal sub-model.  
 
Model with shared random intercept, U, between the survival and the longitudinal sub-models:  
Survival sub-model:  ℎ(Q) =  ℎ?(t)exp [L? + LS1 + L9H1 + LU  
where ℎ?(t) is the baseline hazard function and follows a Weibull distribution 
Longitudinal sub-model:  - = > + U + >9Q + >S1 + >H1 + >S1Q + >H1Q +  A 
for data up to Week 8.  The data up to Week 26 were fitted using the same models, with the 




Table 6.29: Joint model for HAM-D score over time and time to dropout: Data up to 
Week 8 
 Intercept linkage Intercept and linear slope 
linkage 
Effect Parameter Estimate Standard 
error 
p-value Estimate Standard 
error 
p-value 
Longitudinal sub-model        
Intercept > 20.98 0.47 <0.001 20.95 0.37 <0.001 
Week >9 -1.17 0.05 <0.001 -1.15 0.08 <0.001 
Sertraline (ref: placebo) > -0.22 0.67 0.741 -0.18 0.53 0.737 
Hypericum (ref: placebo) > 0.81 0.66 0.223 0.78 0.52 0.137 
Interaction week and 
treatment (sertraline compared 
to placebo) 
> -0.16 0.077 0.042 -0.17 0.12 0.154 
Interaction week and 
treatment (hypericum 
compared to placebo) 
> 0.07 0.076 0.380 0.06 0.12 0.600 
Time to dropout sub-model        
Intercept survival model only L? 5.53 13.10 0.673 6.18 15.04 0.681 
Sertraline (ref: placebo) L 0.70 19.97 0.972 0.95 23.41 0.968 
Hypericum (ref: placebo) L9 0.73 20.58 0.972 0.98 22.78 0.966 
Intercept shared L 0.002 1.22 0.999 0.02 1.64 0.990 
Slope shared L    0.58 10.53 0.956 
 
From the joint model with intercept linkage we concluded that the interaction between week and 
the sertraline arm compared to the placebo arm was statistically significant.  The interaction 
between week and the hypericum arm compared to the placebo arm was not significant.  In the 
joint model with shared intercept and slope neither of the interactions between treatment arm and 
week was significant.  Although the interaction between week and the hypericum arm was 
significant in the joint model with random intercept and not in the joint model with random 
intercept and slope the actual estimates were similar in the two models.  The standard error was 
larger in the model with random intercept and slope.  This model also used more degrees of 
freedom to estimate all the parameters (Table 6.29).   
 
The results for the survival sub-model were similar in the two models.  The shared intercept (L) 
estimate was close to 0 in both joint models and not significant in both models, indicating that 
baseline HAM-D score did not influence dropout time.  The positive shared slope indicated that 
participants with larger linear increase in HAM-D score also had an increase in dropout time, but 
this was not statistically significant.  
 
The substantive model fitted in these joint models is not the same as the substantive model fitted in 
the other sections because SAS cannot fit such a joint model.  The joint model that can be fitted 
with current SAS capabilities was fitted.  In order to compare the joint model under MNAR with 
the appropriate substantive model, and highlight the differences between fitting a joint model and 
just fitting a longitudinal model, a MAR model was fitted with the same formulation as the 
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longitudinal sub-model in the joint model.  These models incorporate the repeated measures of 
each participant by including a participant specific random intercept and a participant specific 
random intercept and slope, respectively.  These models were fitted with a compound symmetry 
covariance matrix and are given in Table 6.30.   
 
Table 6.30:  MAR longitudinal model with random subject specific effects: 
comparable to the longitudinal sub-model in Table 6.29: Data up to Week 8 
 Intercept linkage Intercept and linear slope 
linkage 
Effect Parameter Estimate Standard 
error 
p-value Estimate Standard 
error 
p-value 
Longitudinal sub-model        
Intercept > 21.00 0.47 <0.001 20.94 0.24 <0.001 
Week >9 -1.17 0.05 <0.001 -1.16 0.10 <0.001 
Sertraline (ref: placebo) > -0.21 0.67 0.757 -0.27 0.35 0.447 
Hypericum (ref: placebo) > 0.76 0.67 0.254 0.76 0.35 0.030 
Interaction week and 
treatment (sertraline compared 
to placebo) 
> -0.16 0.08 0.041 -0.15 0.15 0.332 
Interaction week and 
treatment (hypericum 
compared to placebo) 
> 0.07 0.08 0.363 0.07 0.15 0.658 
 
There is very little difference between the β-estimates and p-values between the joint model and the 
longitudinal model only (Table 6.29 and Table 6.30).  The same conclusions are drawn.  The 
deviations from MAR assumed by the joint model do not change the conclusions.   
 
The joint model using data up to Week 26 found that the interaction between week and the 
sertraline arm compared to the placebo arm was significant in the model with intercept and slope 
linkage.  It was not significant in the model with intercept linkage only.  Neither of the models had 
a significant interaction between week and hypericum compared to placebo.  None of the 




Table 6.31: Joint model for HAM-D score over time and time to dropout: Data up to 
Week 26 
 Intercept linkage Intercept and linear slope 
linkage 
Effect Parameter Estimate Standard 
error 
p-value Estimate Standard 
error 
p-value 
Longitudinal sub-model        
Intercept > 20.92 0.44 <0.001 20.97 0.39 <0.001 
Week >9 -1.42 0.04 <0.001 -1.41 0.06 <0.001 
Sertraline (ref: placebo) > -0.22 0.62 0.718 -0.07 0.55 0.903 
Hypericum (ref: placebo) > 1.17 0.62 0.057 0.87 0.55 0.117 
Interaction week and 
treatment (sertraline compared 
to placebo) 
> -0.05 0.03 0.118 -0.17 0.08 0.039 
Interaction week and 
treatment (hypericum 
compared to placebo) 
> 0.02 0.04 0.520 0.03 0.08 0.673 
Week squared > 0.04 0.002 <0.001 0.05 0.002 <0.001 
Time to dropout sub-model        
Intercept survival model only L? 7.42 4.95 0.135 7.30 7.26 0.316 
Sertraline (ref: placebo) L -0.80 4.76 0.867 1.05 7.81 0.894 
Hypericum (ref: placebo) L9 -0.84 4.92 0.865 1.06 7.86 0.893 
Intercept shared L -0.11 0.39 0.782 -0.07 0.90 0.938 
Slope shared L    0.91 12.22 0.941 
 
Table 6.32:  MAR longitudinal model with random subject specific effects: 
comparable to the longitudinal sub-model in Table 6.29: Data up to Week 26 
 Intercept linkage Intercept and linear slope 
linkage 
Effect Parameter Estimate Standard 
error 
p-value Estimate Standard 
error 
p-value 
Longitudinal sub-model        
Intercept > 21.19 0.44 <0.001 20.82 0.24 <0.001 
Week >9 -1.43 0.04 <0.001 -1.38 0.10 <0.001 
Sertraline (ref: placebo) > -0.53 0.62 0.392 0.08 0.32 0.795 
Hypericum (ref: placebo) > 0.90 0.62 0.146 0.91 0.33 0.006 
Interaction week and 
treatment (sertraline compared 
to placebo) 
> -0.05 0.03 0.152 -0.26 0.14 0.066 
Interaction week and 
treatment (hypericum 
compared to placebo) 
> 0.03 0.04 0.444 0.02 0.14 0.915 
Week squared > 0.04 0.002 <0.001 0.06 0.002 <0.001 
 
As with the data up to Week 8, we also fitted the longitudinal model only in order to compare the 
joint model to a MAR model with the same substantive model (Table 6.32).  The results do not 
seem to differ substantially between the joint model and the similar longitudinal model only.  The 
only noteworthy difference is for the interaction between week and hypericum treatment compared 




The joint models deviate from the MAR models by allowing the longitudinal profiles and the 
missingness process to share random effects.  The models need to be interpreted conditional on 
these random effects.  Shared-random effects models relate a participant’s propensity to show an 
increase or decrease in HAM-D score with his or her propensity to miss a visit, while selection 
models directly model the probability of a missed visit as a function of HAM-D score.   
6.5.4 MNAR conclusions 
No unequivocal conclusion can be drawn from the MNAR models fitted, because many MNAR 
models could be fitted and the data holds no indication as to which of the models are more 
appropriate.   
 
Using data up to Week 8, the sertraline arm showed a significant improvement over the placebo 
arm according to a pattern-mixture model fitted using random effects mixed models for each 
pattern of missing data.  The multiple imputation pattern-mixture models assuming an 
improvement in HAM-D score after dropout also showed reduced depression scores over time in 
the sertraline arm compared to the placebo arm, but models assuming a decrease in depression 
scores after drop-out did not find a significant difference between the sertraline and placebo arms.  
Pattern-mixture models fitted using CCMV and NCMV identifying restrictions did not show 
significant improvement over time in the sertraline arm.  Two of the three MNAR Bayesian 
selection models found significant improvement over time in the sertraline arm compared to the 
placebo arm.  A joint model with shared intercept also had a significant result for the interaction 
between week and the sertaline arm compared to the placebo arm.  In most models the size of the 
estimated interaction coefficient was similar to the size of the coefficient under the MAR models.  
None of the MNAR models fitted, found a significant interaction between week and hypericum 
compared to placebo over the first 8 weeks.  The interaction coefficient was close to 0, as in the 
MAR case (Table 6.33).   
 
Fitting models using all the data up to Week 26 was problematic.  From week 10 and onwards there 
were more missing data than observed data.  Many models fitted poorly to this data or had 
problems converging.  Using all the data up to Week 26, only one of the MNAR models found a 
significant interaction between week and the sertraline arm compared to placebo, this was the joint 
model with shared intercept and slope linkage.  No significant interaction between week and the 








week and sertraline arm 
Interaction between week 
and hypericum arm 
  Estimate p-value Estimate p-value 
Pattern-mixture model      
Pattern-mixture model using random-effects mixed 
models for each of the patterns of missing data 
(Model 1) 
-0.38 0.01 -0.002 0.99 
Pattern-mixture models using multiple imputation     
Model 1: δ for dropout = 0.5  -0.44 0.09 0.15 0.51 
Model 2: δ for dropout = 1  -0.63 0.01 0.34 0.23 
Model 3: δ for dropout = -0.5  -0.30 0.56 0.08 0.85 
Model 4: δ for dropout = -1  -0.32 0.55 0.07 0.86 
Pattern-mixture models using identifying restrictions     
CCMV  0.08 0.47 0.13 0.21 
NCMV  -0.16 0.38 0.03 0.82 
Selection models      
Bayesian MNAR model 1  -0.28 NS -0.01 NS 
Bayesian MNAR model 2  -0.33 Sign -0.03 NS 
Bayesian MNAR model 3  -0.31 Sign -0.01 NS 
Shared parameter models      
Joint longitudinal and time to event model 
with intercept linkage 
 -0.16 0.04 0.07 0.38 
Joint longitudinal and time to event model 
with intercept and slope linkage 
 -0.17 0.15 0.06 0.60 
Sign = significant, NS = not significant 
 
Using data up to 26 weeks, the majority of data were missing and the effect of the assumption 
made about missing data compounded with each subsequent missing value.  This means that at the 
later time points the assumptions made about the MNAR pattern of the missing data had a larger 
effect on the model fitted than the data observed.   
 
As with the MAR analysis, we were interested in Estimand 1.  To estimate this estimand data are 
needed on all participants at the planned end of the trial.  All the MNAR methods made 
assumptions about the missing data process in order to extrapolate or impute, by using for example 
multiple imputations, the data that was not observed.  If we wanted to estimate drug efficacy, we 





Table 6.34: Summary of findings in MNAR sensitivity analyses up to Week 26 
 Interaction between week 
and sertraline arm 
Interaction between week 
and hypericum arm 
 Estimate p-value Estimate p-value 
Pattern-mixture model     
Pattern-mixture model using random- effects 
mixed models for each of the patterns of missing 
data 
    
Model 2: Three dropout categories -0.10 0.17 0.09 0.18 
Model 3:  Binary dropout -0.08 0.12 -0.02 0.68 
Pattern-mixture models using multiple imputation  
Model 5: δ for dropout = 0.5 -0.07 0.90 -0.004 0.99 
Model 6: δ for dropout = 1 -0.08 0.88 -0.02 0.96 
Model 7: δ for dropout = -0.5 -0.06 0.90 0.05 0.90 
Model 8: δ for dropout = -1 -0.05 0.91 0.07 0.87 
Pattern-mixture models using identifying restrictions  
CCMV 0.16 0.16 0.11 0.24 
NCMV 0.05 0.78 -0.01 0.94 
Bayesian models     
Bayesian MNAR model 1 0.27 NS 0.28 NS 
Bayesian MNAR model 2 -0.02 NS 0.04 NS 
Bayesian MNAR model 3 -0.05 NS 0.07 NS 
Shared parameter models     
Joint longitudinal and time to event model 
with intercept linkage 
-0.05 0.12 0.02 0.52 
Joint longitudinal and time to event model 
with intercept and slope linkage 
-0.17 0.04 0.03 0.67 
Sign = significant, NS = not significant 
 
As mentioned previously, because so much data were missing, it might have been better to analyse 
the data from Week 10 to Week 26 in a conditional way.  In such a conditional analysis, the 
question addressed is; given that participants responded to treatment at Week 8, what was the 
continued effect of treatment arm up to Week 26.  In this instance, there was still a lot of missing 
data and this analysis would need to take missing data into account.  As it is currently presented, 
these analyses should be interpreted with extreme caution and it does not address any well-defined 
estimand of interest.   
6.6 Conclusion 
In contrast to the SAPiT study discussed in Chapter 5, this study had missing data by design.  
Participants who did not show adequate response by Week 8 were not enrolled in the continuation 
phase of the study.  This type of study design was encouraged by Carpenter et al. (2002).  
However, this study illustrates that this design should be used with caution.  Because of the large 
amount of missing data introduced by design the standard statistical methods break down and the 
analysis could not be performed validly.   
 
The multiple imputation analysis did not reach a stationary distribution and autocorrelation existed 
between the imputations from Week 10 onwards, making the analysis invalid.  Valid analyses, if 
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the unverifiable assumptions about missing data were correct, were the direct likelihood analysis 
(assuming MAR) and the pattern-mixture analysis (assuming MNAR) and the Bayesian analyses 
(assuming MAR and MNAR).   
 
In this study, the goal was to determine the short term effect of the intervention at Week 8, and to 
confirm that a positive response at Week 8 is maintained over a longer time period.  An objective 
was also to provide safety data with longer use.  Since neither of the interventions was superior to 
placebo, the continuation phase data were not needed, nor analysed in the original paper.  If the 
interventions were more effective, less missing data should have resulted by design.  However, if 
the interventions were more effective, it is possible that the placebo arm could have a lot of missing 
data, while the active arms have less missing data.  This could still create problems with valid fit of 
models, at least in the placebo arm.  The wisdom of a design such as this, from a statistical 
viewpoint, is questionable.  From an ethical viewpoint, this design is very attractive, since 
participants are not kept on a regimen that is not working for a long time.  A better compromise 
between the ethics and statistics is to allow the study clinicians to initiate participants on a rescue 
treatment at any time it is deemed clinically necessary.  Participants are not discontinued from the 
study and data collection continues when rescue treatments are started.   
 
The data collected allow one to get the conditional response over time, given that the participant 
entered the continuation phase and to have safety data with prolonged use; but it is not possible to 
calculate the unconditional effect of either of the drugs at 26 weeks.  In this instance it did not 
matter because the drug was found to have no effect at 8 weeks, which implied that there was also 
no scientific interest in the effect at 26 weeks.  Because of non-random exclusion of participants, 
the comparability of the three treatment arms after Week 8 is not equivalent to a randomised trial.  
At best, this provides an observational study about the longer term effects of the drugs.  Any 
efficacy analysis in this continuation phase should be interpreted with caution.   
 
A different study design, where all participants enter an open label safety extension, regardless of 
response in the active phase, could also be employed.  This design was used in the studies of 
Prucalopride for the treatment of constipation (Camilleri et al., 2008; Tack et al., 2009).  This 
design enable one to collect long term safety data, and maybe even long term efficacy data, without 
inducing missing data by design.  This study has been analysed using proper missing data 
techniques (Janssens et al., 2012).   
 
The conclusion drawn in the original paper was that there was no difference between either the 
hypericum arm and placebo or the sertraline arm and placebo.  This was taken to mean that the 
study results were inconclusive.  Although it showed that hypericum was no better than placebo, it 
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also did not find the expected difference between sertraline and placebo (Hypericum Depression 
Trial Study Group, 2002).  The same was found when the continuation data were analysed, and the 
placebo effect was again noted and discussed (Sarris et al., 2012).  We re-analysed the data using 
methods that are appropriate with missing data.  We fitted various models using different 
assumptions about the missing data and various analysis methods.  Under this extended sensitivity 
analysis we draw a different conclusion.   
 
Some of our conclusions are similar to the original analysis, but both the MAR and some of the 
MNAR analyses lead to the conclusion that sertraline is significantly better than placebo in 
reducing depression symptoms over 8 weeks.  No difference was found between hypericum and 
placebo in any of the analyses.  This implies that the conclusion reached 10 years ago could be 
amended to state that hypericum does not seem to provide any benefit over placebo, in a trial where 
the active control did provide a benefit over placebo in some of the sensitivity analyses; thus 
concluding that this herbal remedy should not be recommended for the treatment of depression.  
Although this study gives only weak evidence of the efficacy of sertraline (in some of the models 
under some of the assumptions about missing data), there was absolutely no evidence that 
hypericum was superior to placebo under any reasonable assumption about missing data.  This 
illustrates the point that not taking account of missing data in the analysis could introduce bias and 
lead to incorrect results.   
 
This re-analysis of the data and sensitivity analysis adds to the field of applied statistics by showing 
how a proper analysis of data taking missing data into account can lead to different results than a 
more naïve analysis.  Careful sensitivity analysis, or even re-analysis of data taking proper 
assumptions into account, brought novel insight; or even contradictory insight to the question 
regarding the effectiveness of St John’s Wort in the treatment of depression.   
 
Adjusting the analysis to take missing data into account does not imply changing the proposed 
estimate of effectiveness.  The measure of effectiveness reported in the original paper was change 
from baseline to Week 8.  We analysed the interaction between treatment arm and time under MAR 
and MNAR assumptions.  In general multiple imputation allows any measure of effectiveness, 
since the analysis of choice is done in the second step.   
 
The analysis was done with standard statistical software, using resources that should be available to 
most researchers.  The availability of software is no longer a reason not to do the proper principled 





Conclusions and discussions 
7.1 Implication for practice 
 
Missing data is an active area of research in theoretical statistics.  Many methodological advances 
have been made in recent years.  New text books on missing data are appearing regularly.  Two text 
books on missing data were published in each of 2010 (Enders, 2010; Tsiatis, 2010), 2011 
(Bethlehem, Cobben, & Schouten, 2011; Drukker, 2011) and 2012 (Graham, 2012; Tan, Tian, & 
Ng, 2012).  In the first two months of 2013, two text books on missing data have appeared 
(Carpenter & Kenward, 2013; Mallinckrodt, 2013). 
 
Although methods to handle missing data have been in development for the last 30 years, it is still 
not part of mainstream statistical methods training.  It is unlikely that an undergraduate university 
course in statistics would include extensive training in the handling of missing data.  Most non-
statistical users of statistical methods and non-statistical medical researchers are still likely to 
ignore missing data or analyse participants with complete data only.  Missing data are simply 
excluded from the analysis.  This is compounded by the default setting in many statistical programs 
that exclude missing observations (SAS Institute Inc., 2004), therefore doing a complete case 
analysis unless the user overrides the defaults.  An exception to this is most longitudinal procedures 
that do an analysis of the available cases by default.  This enables direct likelihood and direct 
Bayesian analyses.   




About ten years ago, it was common practice to analyse clinical trials using LOCF.  This is 
changing in favour of more appropriate methods.  Inappropriate methods, such as single 
imputations and LOCF are still being used; although the recommendations advice against these 
(Carpenter et al., 2004; Mallinckrodt et al., 2001; Molenberghs & Kenward, 2007; Molenberghs et 
al., 2004).   
 
The ignorance about the correct methods to analyse missing data are shown in a recent paper where 
three methods for the analysis of missing data are tested using simulated data:  the three methods 
were complete case analysis, single imputation and multiple imputation (Groenwold et al., 2012).  
Of these three methods only multiple imputation is regarded as an unbiased method to analyse 
MAR data (Carpenter & Kenward, 2007).  The conclusion reached in that publication was that 
complete case analysis with covariate adjustment should be used more often.  This is simply 
wrong, as pointed out by Liublinska and Rubin (2012) in a response to the paper.   
 
Some of the methods of missing data analysis are hard to use and definitely not mainstream or 
likely to be.  Some of the methods make lots of assumptions, require programming skills or 
knowledge of advanced statistical techniques.  But some of the methods are easy to use, available 
in standard software and should be familiar to most statisticians; especially likelihood-based 
methods, such as those based on mixed models. 
 
The major hurdle to the implementation of missing data methods is not the methodology or 
availability of software anymore.  The major hurdle is rather a lack of awareness of the problems 
posed by missing data.  Many researchers do not see excluding data as a problem.  Many 
researchers exclude participants with missing data or missing outcomes from the data set prior to 
bringing the data set to a statistician.  Unless the statistician is specifically vigilant and asks about 
missing data or excluded observations the statistician is unlikely to realise that bias might be 
present and that missing data issues should be addressed during the analysis of the data.  Some 
researchers replace participants with missing data, thus creating a complete data set, which also 
poses a problem.     
 
This lack of awareness of the importance of missing data is slowly changing.  A large impetus in 
this direction might come from journals publishing medical research and the results of clinical 
trials.  I am aware of at least two prominent journals that focus on the handling of missing data 
during the peer review of submitted papers.  One is the Annals of Internal Medicine.  The 
guidelines for authors has a section on missing data where they specifically require authors to 
report the frequency of missing variables and how the analysis handled missing data.  They also 
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say that an LOCF analysis should not be used.  To quote from the guidelines for authors:  
“Appropriate methods for handling missing data include imputation, pattern-mixture (mixed) 
models, and selection models. Application of these methods requires consideration of the patterns 
and potential mechanisms behind the missing data.” (American College of Physicians, 2012).  Our 
research group has recently submitted a paper to this journal and the majority of comments 
received focused on the handling of missing data and requested a sensitivity analysis.  Of interest, 
this medical journal has a statistics deputy editor, six statistical associate editors and two statistical 
consultants; this could be the reason they are focusing on missing data.  
 
The second is the New England Journal of Medicine, which published an update to their policies 
regarding missing data in response to a report by the National Research Council (Ware et al., 
2012).  The change in policy included a need to justify the use of complete case analyses and single 
imputation.  Weighted estimating equations, multiple imputation or model based methods are 
preferred.  Sensitivity analyses might be required if missing data are substantial.  Authors are 
required to describe the rationale for the choice of models as well as details of the models fitted.  
The journal of Clinical Pharmacology and Therapeutics also covered the handling of missing data 
recently (O'Neill & Temple, 2012).   
 
If prominent journals such as the Annals of Internal Medicine and the New England Journal of 
Medicine require submissions to handle missing data adequately, researchers and statisticians will 
be forced to become familiar with standard methodology for the analysis of missing data.  This is a 
giant step in the right direction.   
 
Authors, and especially expert panels (CHMP, 2010; Little et al., 2012; National Research Council, 
2010), are quick to point out that the problem of missing data should not primarily be addressed at 
the analysis stage.  They focus also on the design and conduct of clinical trials as important in 
reducing the amount of missing data.  This is definitely an area to focus on in an attempt to 
improve clinical trials.  More research into missing data methodology might not improve clinical 
trials as much as more guidelines to researchers on methods to design clinical trials in a way that 
will reduce missing data in the first place.   
 
Sensitivity analyses are seen as an important element of any analysis when a large amount of data 
are missing.  However, no clear guidelines are available for sensitivity analyses (Ware et al., 2012).  
The most useful sensitivity analyses would probably include modelling a MNAR model, which 
uses much more complicated methods than the likelihood-based methods that can be used when 
data are assumed to be MAR.  An area where innovation is needed is the development of guidelines 
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for sensitivity analyses and the development of software that would be able to easily, without too 
much statistical programming by the user, do MNAR analyses.    
 
What lessons could be learnt about the application of missing data techniques from the SAPiT 
study?  Maybe the most discouraging lesson is that, although it seemed from the data that the 
missing data process was probably not ignorable, and several models under different assumptions 
were fitted, the conclusions were similar to the conclusions under a naïve model.  In the end the 
more complicated analyses did not change the interpretation that one would have arrived at if a 
simple likelihood-based analysis was fitted.  Thus, taking account of the effect of missing data did 
not change the conclusions in this instance.   
 
The St John’s Wort data were difficult to analyse because such a large proportion of the data was 
missing.  In the original article published using this data, data were only analysed up to 8 weeks, 
before most of the data were missing (Hypericum Depression Trial Study Group, 2002).  The 
conclusion drawn at 8 weeks was that hypericum was not efficacious, thus obviating the need to 
analyse the follow-up data.  However, had it been necessary to analyse the follow-up data, it might 
not have been possible to do any useful analysis, other than a conditional analysis, namely looking 
at the outcomes given that a participant entered into the follow-up phase.  The St John’s Wort study 
highlighted the shortcomings of most of the missing data methods once a substantial proportion of 
the data is missing.  This is a significant weakness, since missing data are more likely to lead to 
bias and becomes more important the more missing data there is.  Even in instances where missing 
data are MNAR, the final results will probably be fairly unbiased as long as there is a small amount 
of missing data.  This means that missing data techniques becomes more difficult to use, exactly 
when they are more needed.  Statistical methodological research could therefore focus on cases 
where substantial amounts of data are missing and find optimum methods for these instances.  It 
would also be helpful to know what the maximum amount of missing data is that a specific method 
can reliably handle.    
 
Bayesian data analysis methods are not often used in the analysis of clinical trial data.  This is also 
changing and Bayesian methods are being used more readily.  In the SAPiT trial, the Bayesian 
models were easy to apply and gave results fairly similar to the likelihood-based methods.  
Bayesian analyses could provide a very usable framework in which to deal with missing data, since 
Bayesian methods can be applied when data are incomplete in much the same way as when data are 
complete.  Some of the likelihood-based methods had computational problems with models that did 
not converge.  Bayesian methods are much more robust and could be fitted in all instances in this 
thesis.  This means that Bayesian models could be a viable alternative in certain settings where the 




In summary:  The theoretical development of missing data techniques is light years ahead of the 
application of missing data techniques in everyday use.  At a minimum researchers should be aware 
of the bias that could be introduced by missing data and should report on the missing data present 
in their data and what effect this could have on the results.  It is unlikely that routine analyses will 
include more advanced missing data techniques such as pattern-mixture models and selection 
models soon.  However, likelihood-based methods, and to a lesser extent Bayesian methods, are 
easily available and provide a valid, easy to use analysis if the missing data mechanism is MAR.   
 
The latest buzzword is sensitivity analysis, but there is no clarity on the requirements for a 
sensitivity analysis.  It is logical that a sensitivity analysis should include models that assume both 
MAR and MNAR missing data.  However, MNAR models are much more complicated and make 
several assumptions and could probably not be fitted by the ‘average’ researcher without additional 
training in statistical programming or missing data methodology.  It might also require advanced 
statistical knowledge to understand how to translate practical assumptions about the missing data 
into statistical elements of the models fitted.  This makes the requirement for sensitivity analysis 
rather onerous to apply in most contexts.  In practice a sensitivity analysis may be done, but may 
not really include all relevant alternative models.  A sensitivity analysis could also never be 
exhaustive, since several alternative assumptions could be made and several models could be fitted 
under these assumptions.  This means that even when a sensitivity analysis is presented, it might 
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The extension of the delta method in Section 3.3.2.1 to four groups  
 
For four groups, say A, B, C and D, let the population weights be r, r , rp and rq and  r + r + rp + rq = 1, 
so that  rq = 1 − (r + r  + rp). 
The parameters for each of the patterns are > , >¡, >h  and >2.  Let  = (r ,  r ,  rp , > , >¡,  >h ,  >2) 
and as in the two group case, let  T() = r>  + r>¡ + rp>h + rq>2 




£¤KLM(rD) oSK ¡ oSK hoSK ¡ KLM(rD) oSK¡hoSK h0000
oSK¡h0000
KLM(rDp)0000
     
0 0           0             00 0           0             00KLM(>B )000




where oSK ¡= cov(rD, rD), oSK¡h= cov(rD, rDp), oSK h= cov(rD, rDp). 
 
The assumption is made that the four dropout status groups are independent, therefore the 
covariances between the β’s are 0.  However, the proportions rD, rD and rDp are not independent 
and the covariances are not 0 in that case.  The required derivatives are: (")3  = >  − >2  (")¹  = >¡ − >2  (")  = >h − >2  (")4  = r  (")5  = r  (")6  = rp  ()7  = 1 − (r + r + rp ). 
VVg$0&Z =  V>B  − >B2 ,  >B¡ − >B2 , >Bh − >B2 ,  π­,  π®,  π½, ²1 − (π­ + π® + π½)³ZV(θ6) µ¶T(")¶H · 
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= V$>B  − >B2&KLM(rD) + $ >B¡ − >B2&oSK ¡ + $ >Bh − >B2&oSK h ,$>B  − >B2&oSK ¡ + $ >B¡ − >B2&KLM(rD) + $ >Bh − >B2&oSK¡h  ,$>B  − >B2&oSK h +  $>B¡ − >B2&oSK¡h +  $ >Bh − >B2&KLM(rDp),
rKLM$>B &, rKLM$>B¡&, rpKLM$>Bh&, KLM$>B2&²1 − (π­ + π® + π½)³Z µ¶T(")¶H · = $>B  − >B2&9KLM(rD) +  $>B  − >B2&$ >B¡ − >B2&oSK ¡ + $>B  − >B2&$ >Bh − >B2&oSK h+ $>B¡ − >B2&$ >B  − >B2&oSK ¡ + $ >B¡ − >B2&9KLM(rD)+ $>Bh − >B2&$>B¡ − >B2&oSK¡h + $>B  − >B2&$>Bh − >B2&oSK h+ $>B¡ − >B2&$>Bh − >B2&oSK¡h+$>Bh − >B2&9KLM(rDp) + r9KLM$>B &+  r9KLM$>B¡& + rp9KLM$>Bh& + ²1 − (π­ + π® + π½)³9KLM$>B2& = $>B  − >B2&9KLM(rD) +  2$>B  − >B2&$ >B¡ − >B2&oSK ¡ + 2$>B  − >B2&$ >Bh − >B2&oSK h+ $ >B¡ − >B2&9KLM(rD) + 2$>Bh − >B2&$>B¡ − >B2&oSK¡h+$>Bh − >B2&9KLM(rDp)+ r9KLM$>B & + r9KLM$>B¡& + rp9KLM$>Bh& + ²1 − (π­ + π® + π½)³9KLM$>B2& 
 oSK ¡ = oSK¡  = oSK(rD, rD) = −rrc  oSK h = oSKh  = oSK(rD, rDp) = −rrpc  oSKh¡ = oSK¡h = oSK(rD , rDp) = −rprc  
KLM(rD) =  r(1 − r)c  
KLM(rD) =  r(1 − r)c  
KLM(rDp) =  rp(1 − rp)c  
  
If oSK ¡, oSK h ,  oSKh¡, var(rD) var(rD) and var(rDp) are replaced in VVg$0&Z  above the variance 
is estimated by the following: 
 KLM VT$"0&Z = (>B  − >B2)9 rD(1 − rD)c −  2 rDrDc $>B  − >B2&$>B¡ − >B2& − 2 rDrDpc $>B  − >B2&$>Bh − >B2&
+ (>B¡ − >B2)9 rD(1 − rD)c − 2 rDprDc $>Bh − >B2&$>B¡ − >B2& +  (>Bh − >B2)9 rDp(1 − rDp)c+ rD9KLM$>B & + rD9KLM$>B¡& + rDp9KLM$>Bh& +  [1 − (rD + rD + rDp)9KLM(>B2) 
 
This formulation of the equation is not in the most natural form to fit the model.  The following 




As above:  r + r + rp+ rq = 1, 
so that rq = 1 − (r + r+ rp) 
and 3̀ = T() = r>  + r>¡ + rp>h + rq>2 
which can also be written as  T() = r>  + r>¡ + rp>h + [1 − (r + r + rp)>2. 
A change is made by defining >¡ = >  + >∆ >h = >  + >∆9 and >2 = >  + >∆ 
with >∆ indicating how group B differs from group A, >∆9 indicating how group C differs from 
group A and >∆ indicating how group D differs from group A then   
 T(") = 3̀ = r>  + r>¡ + rp>h + rq>2 = r>  + r(>  + >∆) + rp(>  + >∆9) + [1 − (r +  r +  rp)(>  + >∆) = r>  + r>  + rp>  + >  − (r +  r + rp)(>  + >∆) + r>∆ + rp>∆9 + >∆ = >  + r>∆ + rp>∆9 + rq>∆ 
 







£¤ var(>B ) cov(>B , >B∆) cov(>B , >B∆9)cov(>B , >B∆) var(>B∆) 0cov(>B , >B∆9)cov(>B , >B∆)000
00000
var$>B∆9&0000
     
cov(>B , >B∆) 0           0                      0                       0 0           0                                    0var$>B∆&000


















= var$>B & + r cov$>B , >B∆& + rp  cov$>B , >B∆9& + rq  cov$>B , >B∆& + rcov$>B , >B∆& + π®9var$>B∆& +rp  cov$>B , >B∆9& + π½9var$>B∆9& +  π99var$>B∆& + >∆9var(rD) + rq  cov$>B , >B∆& +2>∆>∆9 cov(rD , rDp) + 2 >∆>∆ cov(rD , rDq) +  >∆99var(rDp) ++ 2>∆9>∆ cov(rDp , rDq)+ >∆9var(rDq) 
 var(>B) = var(>B  + r>B∆ +  rp>B∆9 +  rq>B∆) =  var$>B & + var$π® >B∆& +  var$rp>B∆9& + var$rq>B∆& + 2cov$>B , r>B∆& + 2cov$>B , rp>B∆9&+ 2cov$>B , rq>B∆& + 2cov$r>B∆, rp>B∆9& + 2cov$r>B∆, rq>B∆&+ 2cov$rp>B∆9, rq>B∆& 
Since the covariance between >B∆, >B∆9 and >B∆ is 0: =  var$>B & + π®9var$>B∆& +  r½9var$>B∆9& + r99var$>B∆& + 2rcov$>B , >B∆&+ 2rpcov$>B , >B∆9& + 2rqcov$>B , >B∆& 
 
Combining var(>B) and V(0) gives the following: 
;(") < E$0& ;(") <.= var$>B& + >∆9var(rD) + 2>∆>∆9cov(rD, rDp) + 2>∆>∆cov(rD , rDq) +>∆99var(rDp) + 2>∆9>∆cov(rDp , rDq) + >∆9var(rDq) 
= var$>B& +  >∆9 π®(1 − π®)
N
− 2>∆ >∆9 π®π½
N
− 2>∆ >∆ π®π9
N
+ >∆99 π½(1 − π½)
N
− 2>∆9 >∆ π½π9
N




This means that the variance can be calculated in standard statistical software by calculating the 
variance for >B  using the estimate statement and then adding the contribution to the variance made 
by the other terms; >B∆ , >B∆9 and >B∆ are available as standard output and π®, π½ and π9 can be 






Definition of variables used in SAS code 
 
Variable Description Coding 




Time point in study 1 = baseline 
2 = 6 months 
3 = 12 months 
4 = 18 months 
5 = 24 months 
Pointsquared Point2 (quadratic time effect)  
Treatment Arm randomised to 1 = early integrated treatment arm 
2 = late integrated treatment arm 
3 = sequential treatment arm 
Dummyearly Dummy variable indicating 
belonging to early treatment arm 
0 = Does not belong to early treatment arm 
1 = Belongs to early treatment arm 
Dummylate Dummy variable indicating 
belonging to late treatment arm 
0 = Does not belong to late treatment arm 
1 = Belongs to late treatment arm 
Dropout Variable indicating dropout category Dropout is coded differently in different 
models.  In the case of a binary dropout 
variable, it would be  
0 = Completed the study 
1 = Dropped out of the study 
Cd4count CD4+ count   
CD4Square Square root of CD4+ count  
Cd4at6  CD4+ count at 6 months  
Cd4at12  CD4+ count at 12 months  
Cd4at18  CD4+ count at 18 months  
Cd4at24 CD4+ count at 24 months  
Sqr_cd4atx Square root of CD4+ count at x 
months 
 
Logvl Log10 of viral load at baseline  
Who WHO status at baseline 0 = WHO stage 1,2 or 3 
1 = WHO stage 4 
Baselinecd4 CD4+ count at baseline CD4+ count divided by 50 
Age Age at baseline in years  
Gender Gender 0 = male 
1 = female 
Historytb History of tuberculosis at baseline 0 = no history of tuberculosis 
1 = history of tuberculosis  
Extrapul Presence of extra-pulmonary 
tuberculosis 
1 = extra pulmonary tuberculosis present 
0 = extra pulmonary tuberculosis not 
present 
MDR Presence of multidrug resistant 
tuberculosis  
1 = multidrug resistant tuberculosis 
detected 









Code for the identifying restriction from Section 5.5.1.3 
 
data growth4; 
 set dataset; 
 array trt_t[*] trt1t1 trt1t2 trt1t3 trt1t4 trt1t5 trt2t1 trt2t2 trt2t3 trt2t4 trt2t5 trt3t1 trt3t2 trt3t3 trt3t4 trt3t5  ;   
 do k=1 to 15; 
  trt_t[k]=0; 
 end; 
  
    if treatment = 1 and t = 1 then trt1t1  = 1; 
    if treatment = 1 and t = 2 then trt1t2  = 1;  
    if treatment = 1 and t = 3 then trt1t3  = 1;  
    if treatment = 1 and t = 4 then trt1t4  = 1;  
    if treatment = 1 and t = 5 then trt1t5  = 1;  
 
    if treatment = 2 and t = 1 then trt2t1  = 1; 
    if treatment = 2 and t = 2 then trt2t2  = 1;  
    if treatment = 2 and t = 3 then trt2t3  = 1;   
    if treatment = 2 and t = 4 then trt2t4  = 1;  
    if treatment = 2 and t = 5 then trt2t5  = 1;  
 
    if treatment = 3 and t = 1 then trt3t1 = 1; 
    if treatment = 3 and t = 2 then trt3t2  = 1;  
    if treatment = 3 and t = 3 then trt3t3  = 1;  
    if treatment = 3 and t = 4 then trt3t4  = 1;  
    if treatment = 3 and t = 5 then trt3t5  = 1;  
run; 
 
step 1: estimate model parameters given monotone missing data, by pattern; 
%macro step1; 
%do t=1 %to 5; 
proc mixed data=growth4 asycov; 
 where last_t=&t and t<=&t;   * last_t was created earlier as the last visit where data were observed ; 
 class pid t; 
 %if &t=1 %then model cd4square = trt1t1 trt2t1 trt3t1/ noint solution covb ddfm=kr;; 
 %if &t=2 %then model cd4square = trt1t1 trt1t2 trt2t1 trt2t2 trt3t1 trt3t2/ noint solution covb ddfm=kr;;     
 %if &t=3 %then model cd4square = trt1t1 trt1t2 trt1t3 trt2t1 trt2t2 trt2t3 trt3t1 trt3t2 trt3t3/ noint solution 
covb ddfm=kr;; 
 %if &t=4 %then model cd4square = trt1t1 trt1t2 trt1t3 trt1t4 trt2t1 trt2t2 trt2t3 trt2t4 trt3t1 trt3t2 trt3t3 
trt3t4/  
      noint solution covb ddfm=kr;; 
 %if &t=5 %then model cd4square = trt1t1 trt1t2 trt1t3 trt1t4 trt1t5 trt2t1 trt2t2 trt2t3 trt2t4 trt2t5 trt3t1 trt3t2 
trt3t3 trt3t4 trt3t5/  
      noint solution covb ddfm=kr;; 
 repeated t / subject=pid type=un;    
 
 ods output solutionf=beta_point_&t;  * estimates; 
 ods output covb=beta_covar_&t; * precision; 
ods output covparms=alpha_point_&t; * estimates...; 
 ods output asycov=alpha_covar_&t; * precision; 
run; 








* step 2: impute data under ACMV; 
%macro step2( data=,         /* data set used in 'step 1'                        */ 
 subject=,      /* subject indicator                                */ 
 time=,         /* time indicator                                   */ 
 last_time=,    /* indicator of last observed y within each subject */ 
 y=,            /* target variable                                  */ 
 x=,            /* predictor variable(s)                            */ 
 nimputation=,  /* number of imputations                            */ 
 seed=,         /* seed used for multiple imputations               */ 
 restrictions=  /* identifying restrictions: CCMV, NCMV, or ACMV    */); 
 
proc sql noprint; 
 select count(distinct &last_time) into :ntp from &data; %let ntp=%left(&ntp); * number of all patterns or 
timepoints; 
 select count(distinct &last_time)-1 into :nt from &data; %let nt=%left(&nt); * number of incomplete 
patterns; 
 select count(distinct &subject) into :n from &data; 
 %do t=1 %to &ntp; 
 select count(distinct &subject) into :n&t from &data where &last_time=&t; 
 %end; 
 %do t=1 %to &ntp; 




* 1. read data; 
data _orig;  






%do t=1 %to &ntp; * loop over all patterns; 
 
use _orig(where=(&last_time=&t)); * only select subjects with incomplete data; 
read all var{&subject &last_time &time &y &x 
} into data&t; 
%end; 
 
* 2. read models: beta and alpha data sets; 
%do t=1 %to &ntp; * loop over all patterns; 
 
use beta_point_&t(drop=effect stderr df tvalue probt); * only select the estimates; 
read all into beta_point_&t; 
use beta_covar_&t(drop=row effect); 
read all into beta_covar_&t; 
use alpha_point_&t(drop=covparm subject); 
read all into alpha_point_&t; 
use alpha_covar_&t(drop=row covparm); 
read all into alpha_covar_&t; 
%end; 
 
* 3. construct the conditional distributions and draw from them; 
create _done var{ 
_imputation &subject &last_time &time &y}; 
 
%do imputation=1 %to &nimputation; * start of multiple imputation loop; 
 
 call randseed(&seed+&imputation,1); 
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 * sample beta and alpha from their estimated sampling distribution, as is customarily done in multiple 
imputation; 
 %do j=2 %to &ntp; 
  beta_&j=t(randnormal(1,t(beta_point_&j),beta_covar_&j)); 
  do until (ok); * ensure that each alpha is positive definite; 
   temp=t(randnormal(1,t(alpha_point_&j),alpha_covar_&j)); 
   alpha_&j=j(&j,&j); 
   k=0; 
   do j=1 to &j; 
    do i=1 to j; 
     k=k+1; 
     alpha_&j[i,j]=temp[k]; 
     alpha_&j[j,i]=alpha_&j[i,j]; 
    end; 
   end; 
   ok=1; 
   do r=1 to &j; 
    ok=ok & det(alpha_&j[1:r,1:r])>0; * Sylvesters criterion; 
   end; 
  end; 
 %end; 
 
 %do t=1 %to &nt; * loop over incomplete patterns; 
 
  call symput('ni', char(nrow(data&t))); 
 
  %do i=1 %to &ni %by &ntp; * loop through subject * timepoint blocks; 
 
   y=data&t[&i:%eval(&i+&ntp-1),4]; * these are the outcomes for 1 subject; 
   x=data&t[&i:%eval(&i+&ntp-1),5:ncol(data&t)]; * these are the covariates for 1 subject; 
 
   %do s=%eval(&t+1) %to &ntp; * loop through missing timepoints s for subject i; 
 
    start=&s; 
    stop=&ntp; 
    if "&restrictions"="CCMV" then start=&ntp; * for CCMV, start=stop=T, index j=T will be fixed (see 
below); 
    if "&restrictions"="NCMV" then stop=&s; * for NCMV, start=stop=s, index j=s will be fixed (see 
below);; 
    call symput('start', char(start)); 
    call symput('stop', char(stop)); 
 
    y1=y[1:%eval(&s-1)]; * y1 only depends on s; 
    y2given1=j(%eval(&stop-&start+1),1); * initiate y2given1; 
    w=j(nrow(y2given1),1); * initiate w; 
    %do j=&start %to &stop; * j>=s -- for CCMV j=T, for NCMV j=s; 
     * the choice of beta and alpha depends on j -- for CCMV/NCMV index j is fixed, for ACMV j is running 
from s to T; 
     beta=beta_&j; 
     alpha=alpha_&j; 
     * the below only depends on j through beta and alpha; 
     mu=x[,1:nrow(beta)]*beta; 
     mu1=mu[1:%eval(&s-1)]; 
     mu2=mu[&s]; 
     alpha11=alpha[1:%eval(&s-1),1:%eval(&s-1)]; 
     alpha12=alpha[1:%eval(&s-1),&s]; 
     alpha21=alpha[&s,1:%eval(&s-1)]; 
     alpha22=alpha[&s,&s]; 
     if det(alpha11)>0 then do; 
      y2given1[%eval(&j-&start+1),1]=mu2+alpha21*inv(alpha11)*(y1-mu1); 
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      w[%eval(&j-&start+1),1]=&&p&j*(det(alpha11)**-0.5)*exp(-0.5*(t(y1-mu1)*inv(alpha11)*(y1-mu1))); 
     end; 
     else do; * catch exception: if the conditional variance is not positive then give a low weight to y2given1; 
      y2given1[%eval(&j-&start+1),1]=mu2; 
      w[%eval(&j-&start+1),1]=0.0001; 
     end; 
    %end; 
    if nrow(w)=1 then y[&s]=y2given1[1,1]; 
    else do; 
     abs=w#(1/sum(w)); * ensure that weights sum up to 1; 
     cum=j(nrow(abs),1); 
     do u=1 to nrow(w); 
      cum[u]=sum(abs[1:u]); * ensure that weights become cumulative; 
     end; 
     ranu=ranuni(&seed+&imputation); 
     select=1; 
     do u=2 to nrow(w); 
      if ranu>cum[u-1] & ranu<=cum[u] then select=u; 
     end; 
     y[&s]=y2given1[select,1]; 
    end; 
 
   %end; * end of loop through missing timepoints s for subject i; 
 
   data&t[&i:%eval(&i+&ntp-1),4]=y; 
 
  %end; * end of loop through subject * timepoint blocks; 
 
  impdata=impdata // data&t[,1:4]; 
 
 %end; * end of loop over incomplete patterns; 
 
 alldata=impdata // data&ntp[,1:4]; * add completers; 
 alldata=j(nrow(alldata),1,&imputation) || alldata; * add imputation index; 
 setout _done; 
 append from alldata; 
 free impdata alldata; * clear these matrices; 
 
%end; * end of imputation loop; 
close _done; 
quit; * end of proc iml; 
 
* 4. write data; 
proc sql; 
 create table &data._&restrictions as 
 select b._imputation, a.*, b.&y as _&y._&restrictions 
 from _orig a, _done b 
 where a.&subject=b.&subject and a.&time=b.&time 
 order by _imputation, _sorting; 
quit; 
data &data._&restrictions; 
 set &data._&restrictions; 
 if &y=. then &y=_&y._&restrictions; 





%step2(data=growth4, subject=pid, time=t, last_time=last_t, 
 y=cd4square, x= trt1t1 trt2t1 trt3t1 trt1t2 trt2t2 trt3t2 trt1t3 trt2t3 trt3t3 trt1t4 trt2t4 trt3t4 trt1t5 trt2t5 trt3t5 , 
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 nimputation=70, seed=999, restrictions=ACMV); 
 
* truncate imputed data;  
 data growth4_acmv; 
   set growth4_acmv; 
      if y gt 35 then y = 35; 
  if y lt 0 and y gt . then y = 3; 
  t2 = t; 
  tsquare = t*t; 
run; 
 
* step 3: estimate model parameters given imputed data; 
 
proc mixed data=growth4_acmv asycov; 
 by _imputation; 
 class pid t treatment; 
 model y = treatment t2 treatment*t2 tsquare/ solution covb ddfm=kr; 
 repeated t / subject=pid type=un; 
 
 ods output solutionf = mix_acmv covb = mixcovb; 
run; 
 
ods output close; 
 
data mixparms2; 
  set mix_acmv;  
  _imputation_ = _imputation; 
 
  if effect="treatment" and treatment=1 then effect="TRT1";  
  if effect="treatment" and treatment=2 then effect="TRT2";  
  if effect="t2*treatment" and treatment=1 then effect="TRT1_WEEK"; 
  if effect="t2*treatment" and treatment=2 then effect="TRT2_WEEK";  
  if effect="treatment" and treatment=3 then effect="TRT3";  
run; 
 
  proc mianalyze parms=mixparms2 ; 
      modeleffects Intercept t2 TRT1 TRT2 TRT1_WEEK TRT2_WEEK tsquare; 
   run; 
 





Code for pattern-mixture model using multiple imputation in Section 5.5.1.2 
 
/*  Macro name: Modify 
Parameters 
Data= Name of original data set 
Imp= Name of imputed data set 
Out= Name of Output data set 
Var= List of variables as used in Var statement for MI 
Deltadrop and deltadead= The amount to decrease imputed value by 
S= SD for Normal distribution from which Change is 
sampled with mean Delta for each imputation 
Trx= Name of variable holding treatment classification  
n = number of variables used to impute*/ 
 
%macro modify(data= ,imp= ,out= , var =, deltadrop=, deltadead= ,s= ,trx=, n = ); 
%local i n; 
 
* Get number of elements in the Var List as macro variable n; 
%let i=1; 
%let txt=%scan(&var, &i, %str( )); 
%do %while(%length(&txt)) ; 
%let i=%eval(&i +1); 
%let txt=%scan(&var, &i, %str( )); 
%end; 




array My_Var[1:&n] &Var; 
array My_Ind[1:%eval(&n+1)] My_Ind1-My_Ind&n No; 





do i= &n to 1 by -1; 







retain My_Row 0; 





create table Temp3 as 
select A.*, B.* 
from Temp2 A left join Temp1 B 
on A.My_Row = B.My_Row 
order by _imputation_, &Trx; 
quit; 
 
* My_Ind=1 if data is Real; 






by _imputation_ &trx; 
 
array My_Var[1:&n] &Var; 
array My_Ind[1:&n] My_Ind1-My_Ind&n; 
drop My_Row Change i My_ind1-My_Ind&n; 
retain deltadrop deltadead; 
 
* Change allows us to build up delta within the subject; 
 
if first.&trx then do; 





do i=1 to &n; 
 
* If it is imputed then increase Change by delta; 
if My_ind[i]=0 then do; 
    if dropoutdead = 1 then change = change + deltadrop; 








/*  Multiple imputation  */ 
proc mi data = dataset out = full nimpute = 50 seed = 1 round = 1 1 1 1 0.001 . maximum = 1000 1000 1000 
1000 8  
  minimum = 1 1 1 1 0; 
  em initial = cc; 
  MCMC nbiter=5000 niter=5000; 
  mcmc impute = full chain = single timeplot (mean(sqr_cd4at6 sqr_cd4at12 sqr_cd4at18 sqr_cd4at24))  
        acfplot (mean (sqr_cd4at6 sqr_cd4at12 sqr_cd4at18 sqr_cd4at24)); 
  var  sqr_cd4at6 sqr_cd4at12 sqr_cd4at18 sqr_cd4at24 logvl who baselinecd4 age gender historytb extrapul 
mdr ; 
  by treatment; 
run;   
 





  set bbb; 
    cd4at6kwa = sqr_cd4at6*sqr_cd4at6; 
    cd4at12kwa = sqr_cd4at12*sqr_cd4at12; 
    cd4at18kwa = sqr_cd4at18*sqr_cd4at18; 
    cd4at24kwa = sqr_cd4at24*sqr_cd4at24; 
run;     
 
proc sort; by _imputation_ treatment; run; 
 
/*  Estimate treatment effect at final time point using each imputed data set   */ 
 
proc univariate data=full2 NOPrint; 
   var cd4at6kwa cd4at12kwa cd4at18kwa cd4at24kwa; 
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   output out=outuni mean= cd4at6 cd4at12 cd4at18 cd4at24 stderr= Scd4at6 Scd4at12 Scd4at18 Scd4at24  
       n = ncd4at6 ncd4at12 ncd4at18 ncd4at24; 
   by _Imputation_ treatment; 
run; 
 
PROC SORT; by treatment; 
 
proc glm data=full2 ; 
   model cd4at6kwa= treatment/inverse; 
   by _Imputation_; 
   ods output ParameterEstimates=glmparmssix 
    InvXPX=glmxpxisix; 
quit; 
 
*  etc for each time point ; 
 
/*  Some data manipulation steps to create dataset in correct format to use with proc MIXED  */ 
 
proc mixed data = fulla method = reml; 
  class pid treatment point ; 
  model col1 = point2 treatment point2*treatment pointsquared/ solution covb ddfm = kr ; 
  repeated point / subject = pid type = un group = treatment; 
  by _imputation_;  
  ods output solutionf = mixparms covb = mixcovb; 
run; 
ods output close; 
 
data mixparms2; set mixparms;  
if effect="treatment" and treatment=1 then effect="TRT1";  
if effect="treatment" and treatment=2 then effect="TRT2";  
if effect="point2*treatment" and treatment=1 then effect="TRT1_WEEK"; 
if effect="point2*treatment" and treatment=2 then effect="TRT2_WEEK"; run;  
run; 
 
   data mixcovb2; set mixcovb;     
if effect="treatment" and treatment=1 then effect="TRT1";  
if effect="treatment" and treatment=2 then effect="TRT2";  
if effect="point2*treatment" and treatment=1 then effect="TRT1_WEEK"; 
if effect="point2*treatment" and treatment=2 then effect="TRT2_WEEK";  
rename col3=TRT1; 
rename col4=TRT2; 
rename col6=TRT1_WEEK;  
rename col7=TRT2_WEEK;  
rename col1= intercept; 
rename col2 = point2; 
rename col9 = POINTSQUARED; 
run; 
 
proc mianalyze parms=mixparms2 covb=mixcovb2; 
modeleffects intercept point2 TRT1 TRT2 TRT1_WEEK TRT2_WEEK POINTSQUARED ; 
test1: test trt1+TRT1_WEEK= trt2+ TRT2_WEEK/mult; run; 
 
proc mianalyze data=outuni ; 
   modeleffects cd4at6 cd4at12 cd4at18 cd4at24; 
   stderr Scd4at6 Scd4at12 Scd4at18 Scd4at24; 








proc mianalyze parms=glmparmssix xpxi=glmxpxisix;  
modeleffects Intercept treatment; 
run; 
 
*  etc and repeat for all time points ; 
%mend; 
 
title1 'dropout = 0.5 and dead = 1'; 
%modify(data=dataset, imp=full, out=bbb, var= sqr_cd4at6 sqr_cd4at12 sqr_cd4at18 sqr_cd4at24, 
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